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The need to increase ADRD research participation has become more pressing as the 
prevalence of ADRD increases. Nearly 70,000 Oregonians and 7 million people in the 
United States live with ADRD, and this number is expected to increase by 200% by 2050 
without identification of an intervention to halt its increase. Developing mechanisms for 
effective care and treatment depends on implementing research with numerous 
participants. Historically, ADRD research programs have had difficulty recruiting and 
enrolling individuals into studies for a variety of reasons. Given low recruitment rates, the 
interest in researching and evaluating effective strategies to recruit specifically for ADRD 
research has increased.  
 This dissertation asks “What are the factors affecting clinical research 
enrollment among individuals with ADRD?” This study has three specific aims: Aim 
1: Identify organizational, system, and policy factors that impede or enhance clinical 
research enrollment among people with ADRD within the Portland metro area; Aim 2: 
Describe personal factors that persuade or dissuade individuals with ADRD from 
enrolling in clinical research; and Aim 3: Develop motivational strategies and policy 
recommendations based on the findings from Aims 1 and 2.   
 Semi-structured interviews were conducted in two phases with ADRD clinicians, 
researchers, advocates, people living with ADRD, and caregivers. A community advisory 
board (CAB) comprised of clinicians, researchers, advocates, people with dementia, 





CAB helped develop recruitment and dissemination strategies, modify protocols, and 
interpret findings. All protocols were approved by the Portland State University 
Institutional Review Board.  
 Nine clinicians, researchers, and advocates who were employees or volunteers 
with health, research, and advocacy organizations of varying sizes and structures were 
interviewed in Phase 1. Several findings emerged from the interviews. Federal policy 
attempts to streamline research studies have not resulted in the intended outcomes at the 
local level. People with ADRD and caregivers have a lack of awareness of research 
opportunities. In some cases, this was due to lack of provider knowledge; in others, it was 
due to organizational directives to not discuss this topic or a provider’s personal 
preference. Research opportunities are not shared in places where people with ADRD and 
their caregivers are likely to congregate. Interviewees were often hesitant to join 
community collaborations or formal partnerships, and many were weary of including 
people with ADRD in their advisory boards. 
 In Phase 2, twelve dyads of people with ADRD and their caregivers (n=24) were 
interviewed. Many interviewees were unaware of dementia studies, which was surprising 
as many interviewees were recruited from organizations with rich knowledge of research 
opportunities. One’s perceived value of ADRD research did not increase their likelihood 
of joining a study. Many caregivers either did not have or did not want to use limited free 
time to be a study partner; however, several caregivers noted that they would participate 





education, or respite. A substantial number of interviewees indicated they avoid research 
because it involves taking study drugs. 
 The Robert Wood Johnson Foundation’s Culture of Health Action Framework 
was used to conceptualize motivation strategies and reflect elements that describe 
research participation among people with dementia. Six strategies were identified to 
improve dementia clinical research participation: 1) Identify and promote local 
champions for ADRD clinical research participation; 2) Promote policies and processes 
that incentive cross-sector collaboration; 3) Recognize caregivers as full research 
participants; 4) Include people with ADRD and caregivers in the research design process; 
5) Offer alternative options to reduce participation burden; 6) Evaluate and improve 
relationships between healthcare/research staff and patients/participants. These strategies 
can be used in conjunction with the Culture of Health Action Framework as a roadmap to 
form organization-community partnerships, facilitate motivation and empowerment, give 
decision-making power to people with ADRD and promote a local culture of research.  
 This study contributed to the literature by providing contextually relevant factors 
affecting clinical research participation as well as providing recommendations to improve 
recruitment. Further, this study successfully demonstrated that including people with 
dementia and caregivers on an advisory board can be effective, and the use of a CAB 
improves the study design and interpretation of findings. Through the findings and 
conclusions of this study, the potential exists to increase research participation in 
Portland, OR, and can be contextually relevant in other geographic areas where ADRD 
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In preparing this dissertation, Chapters 4, 5, and 6 were written as independent, free-
standing papers. After the successful defense of this dissertation, these three chapters will 
be edited and submitted independently for publication. Due to this formatting, there is 





CHAPTER 1: INTRODUCTION 
 
Nearly seven million people in the United States live with Alzheimer’s disease and 
related dementias (ADRD), costing the nation over 290 billion dollars per year in direct 
health and long-term care costs (National Institute on Aging [NIA], 2018; Alzheimer’s 
Association, 2019a). Given the rapidly aging population, this number will exceed 8 
million by 2025, and 18 million by 2050 (Alzheimer’s Association, 2019a). ADRD is a 
neurodegenerative, progressive, terminal disease and is the only top ten cause of death 
without a treatment, prevention, or cure (NIA, 2016). Many medical professionals, 
policymakers, and those affected by the disease agree that rapidly increasing ADRD 
prevalence rates (and subsequent rising costs) coupled with the lack of clinical solutions, 
is creating a medical, economic, and emotional crisis (Gates, 2017; Collins et al., 2018; 
NIA, 2019; Alzheimer’s Association, 2019a; Gates, 2019).  
 To combat this crisis, the U.S. Congress allocated 2.8 billion dollars for ADRD 
research in 2019 with the goal of finding solutions for prevention or treatment by 2025 
(Alzheimer’s Association, 2019b). Advancements in ADRD research are in part 
contingent on research participation by large numbers of participants (Rollin-Sillaire et 
al., 2013; Law, Russ, & Connolly, 2014, Grill & Galvin, 2014; Black et al., 2018; NIA, 
2018; Gates, 2019, Gilmore-Bykovskyi et al., 2019). To effectively utilize this historic 
funding, efforts to increase participation in clinical trials are needed. The National 
Institutes of Health (NIH) recognized this need and has allocated funding for studies that 





Additionally, the NIA released a national strategy for improving research participation in 
ADRD studies in October 2018 (NIA, 2018).  
 The national strategy provides strong recommendations; however, two gaps 
persist. First, the national strategy is not a comprehensive list of barriers and facilitators; 
the NIA recommend continued research on identifying more factors affecting 
participation (NIA, 2018).  Second, these recommendations were developed by working 
groups of ADRD clinicians, researchers, and advocates; the voice of individuals with 
ADRD was not included. Including people with ADRD in research. However, including 
the voice of people with ADRD is one of the recommendations from this strategy (NIA, 
2018). Additionally, there have been calls from academics and advocates to do so (Iliffe, 
McGrath, & Mitchell, 2013; McGrath, 2017; Kremer, 2017; Gitlin, Maslow, & Khillan, 
2018; Gilmore-Bykovskyi et al., 2019).  
This chapter begins with a description of ADRD and the challenges to recruit 
clinical trial participants. This is followed by the problem statement, the research 
question and an outline of the conceptual and theoretical frameworks. The chapter 
concludes with the purpose and significance of the study and a succinct summary, setting 
up the overall research for the dissertation. 
 
Background 
Before articulating the reasons why efforts to improve ADRD clinical research 
recruitment are needed, a brief overview of ADRD is provided here. This is followed by 





friends, family, and the health and long-term supports and services (LTSS) sectors. 
Lastly, challenges to recruiting clinical research participation are discussed.  
Alzheimer’s disease and related dementias (ADRD) 
  Dementia is a syndrome resulting in a loss of cognitive and behavioral functions. 
There are several forms of dementia with varying symptoms; however, the primary 
diagnostic signs are the loss of core mental and brain functions (such as language skills, 
problem-solving, and cognition) and the ability to perform everyday activities (NIA, 
2016).  
 The most common form of dementia is Alzheimer’s disease (AD), which accounts 
for 60-80% of all cases of dementia (NIA, 2016). AD is an “irreversible, progressive 
brain disorder that slowly destroys memory and thinking skills and, eventually, the ability 
to carry out the simplest tasks” (NIA, 2017). Common symptoms include loss of 
language, spatial issues, impaired decision-making, behavioral changes, and a decline in 
every day abilities (NIA, 2017). Though not a form of dementia, mild cognitive 
impairment (MCI) is included in discussions of dementia and memory loss (Roberts & 
Knopman, 2013). MCI results in a less severe case of memory loss and does not result in 
behavior or personality changes, however, individuals with MCI are a significantly 
higher risk of developing AD as compared to those with normal cognitive function (NIA, 
2017).  
In addition to AD, there are several other forms of neurodegenerative, progressive 
dementias that are included in the definition of ADRD. Dementia with Lewy bodies 





(Zweig & Galvin, 2014; Gomperts, 2018). People with DLB exhibit more gait and 
movement symptoms as well as more extreme behavioral issues, such as delusions and 
hallucinations, in its early stages as compared to those with AD (Zweig & Galvin, 2014; 
Gomperts, 2018). Another form, frontotemporal dementia (FTD), presents with 
significant behavioral changes and more muscle deterioration, including speech and 
language functioning, and loss of spatial awareness (Snowden, Neary & Mann, 2002; 
Hernandez, Fernandez, Tarraga, Boada, & Ruiz, 2017). People with FTD also experience 
memory loss early on, but it becomes more prominent in later stages as compared to AD 
or DLB (Snowden et al., 2002; Hernandez et al., 2017). Vascular dementia is caused by a 
loss of blood flow to the brain, most frequently due to strokes, with symptoms extremely 
similar to AD (Love, 2005; Kalaria, Alinyemi, & Ihara, 2016). However, this dementia 
can be prevented or halted provided there is a cessation of the vascular events (Love, 
2005; Kalaria, et al., 2016). Lastly, when individuals experience symptoms characteristic 
of more than one type of dementia, they are considered to have mixed dementia 
(Schneider, Arvanitakis, Bang, & Bennett, 2007).  
Virtually everyone with ADRD will require LTSS due to the disease’s debilitating 
and progressive symptoms. Long-term supports and services include a variety of 
supports, such as in-home respite care, day centers, community-based residential care, 
and nursing homes. ADRD significantly contributes to the 339 billion dollars in annual 
national LTSS costs, two-thirds of which are covered by Medicaid and Medicare (Colello 
& Talaga, 2015). These high costs are concerning to many individuals and families as 





Medicare can only be used for 100 days of nursing home care, which is typically reserved 
for severe cases of ADRD (Kaiser Family Foundation, 2016). Depending on the scope of 
state policies, Medicaid may be utilized for LTSS but is contingent on the providers’ 
willingness to accept Medicaid (NORC, 2014). Those who are higher-income may be 
able to afford private-pay LTSS; however, middle-income individuals find themselves 
spending down their assets on private-pay LTSS until they become eligible for Medicaid 
(Hudson, 2014).  
Though not the only factor, the high cost of LTSS leads to many families of 
people with ADRD taking on caregiving roles. Over 20% of the 34.2 million Americans 
providing unpaid care to an adult age 50 or older are caring for someone with ADRD 
(National Alliance for Caregiving & AARP Public Policy Institute, 2015). These 
informal caregivers perform more tasks than their non-ADRD caregiving counterparts 
(National Alliance for Caregiving & AARP Public Policy Institute, 2015). These tasks 
include: daily activities such as bathing, dressing, and toileting (referred to as activities of 
daily living [ADLs]); independent living skills such as managing money, housekeeping, 
and meal preparation (referred to as instrumental activities of daily living [IADLs]); 
medical/nursing tasks such as injections and tube feedings; and other key activities such 
as communicating with healthcare professionals and advocating on the affected person’s 
behalf. Additionally, people of color are significantly less likely to utilize LTSS for a 
variety of reasons, including stigma within their culture, discrimination from healthcare 
system, language barriers, access, and the belief that nothing could be done (Chin, 





also suffer from more adverse health outcomes as compared to their non-ADRD 
caregiving and non-caregiving counterparts, costing the United States an additional 11 
billion dollars annually (Kelly, McGarry, Georges, & Skinner, 2015).  
Currently, there is no prevention, treatment, or cure for ADRD. Studies have 
shown that a healthy lifestyle, being educated, and being socially connected to others 
lowers the risk of ADRD, but there is no proven prevention that removes the risk 
completely (Mergenthauler, Lindauer, Dienel, & Meisel, 2013; Pool et al., 2016; Yates, 
Ziser, Spector, & Orrell, 2016). There is one group of drugs that treat cognitive 
symptoms, but the treatment is a short-term, ranging from six months to a year 
(Yanniopoulou & Papegeorgiou, 2013; Alzheimer’s Association 2018a). ADRD clinical 
research has a near 100% failure rate, partly due to interventions that have not worked; 
but also because studies have been postponed or terminated due to low enrollment rates 
(Cummings, Morstorf, & Zhong, 2014; Grill & Galvin, 2014; NIA, 2018). 
Several organizations, including the Alzheimer’s Association, the Leaders 
Engaged on Alzheimer’s Disease (LEAD) Coalition, and the NIA have called for action 
to increase ADRD clinical research enrollment (Iliffe, McGrath, & Mitchell, 2013;  
Kremer, 2017; Alzheimer’s Association, 2018; NIA, 2018). However, increasing 
recruitment requires individuals with ADRD to be willing and able to participate, and 
many barriers stand in the way. 
The challenge of recruiting ADRD clinical research participants 
 Many individuals affected by medical conditions, including ADRD, report an 





opportunities to help others (English, Lebovitz, & Griffin, 2010; Law et al., 2014; 
Anderson, Borfitz, & Getz, 2018). Despite these reports, clinical research participation 
rates continue to be low (English et al., 2010; Law et al., 2014; Mahon et al., 2016; 
Anderson et al., 2018; NIA, 2018; Gates, 2019). This is due to a variety of policy, 
system, organizational, and personal factors. These factors are described in detail in 
Chapter 2, but a few are described briefly below.  
One common sentiment from interested individuals is that they are unaware of 
how to seek or receive information about opportunities to join clinical research (Sood et 
al., 2009; Law et al., 2014; Anderson et al., 2018; NIA, 2018). Individuals often expect to 
hear about studies from their primary care provider and are more likely to participate 
when these providers inform them due to their trusting relationship. However, individuals 
may be more likely to hear of opportunities from media advertisements, which are less 
trusted (Friedman, Foster, Bergeron, Tanner & Kim., 2015; Anderson et al., 2018).  
Second, when designing research studies, investigators adhere to federally-
dictated ethical and clinical practices that align with policies enforced through their 
institutional review boards (IRBs). For example, the IRB at Oregon Health & Sciences 
University (OHSU), an academic health center which conducts ADRD research, adheres 
to international regulations on good clinical and ethical practices, federal regulations 
implemented by the U.S. Department of Health and Human Services, the NIH, the FDA, 
and Oregon laws and regulations (OHSU, 2017). All research studies are designed to 
meet these regulations to ensure that risk of harm to research participants is minimized, 





comorbidities or prescribed contraindicated medications (Grill & Galvin, 2014; Adams, 
Caffrey, & McKevitt, 2015). This negatively impacts people with ADRD; most are over 
65 and are more likely to encounter one of these confounding issues than people under 65 
(Rollin-Sillaire et al., 2013; Grill & Galvin, 2014; Law et al., 2015). Additionally, many 
ADRD clinical research studies require the participation of study partners to ensure the 
person with ADRD attends appointments and adheres to study protocols, a role typically 
taken on by the primary informal caregiver of the person with ADRD (Rollin-Sillaire et 
al., 2013; Black, Taylor, Rabins & Karlawish, 2018). Study partners attend clinical 
research appointments and ensure that the person with ADRD adheres to study 
requirements (Rollin-Sillaire et al., 2013; Black et al., 2018). Though study partners are 
necessary to ensure the safety of people with ADRD and the validity of the study, this 
requirement further limits the pool of eligible participants to those with a caregiver who 
is willing and able to act as a study partner (Karlawish et al., 2008; Watson, Ryan, 
Silverberg, Cahan, & Bernard, 2014; Grill & Galvin, 2014; Cary, Rubright, Grill & 
Karlawish. 2015; Black et al., 2018).  
Furthermore, study sponsors, who fund the research and may be from the 
government, nonprofit, or private sectors, may have a role in designing the studies and 
can require additional stipulations as long as they adhere to ethical and clinical 
regulations (Califf, 2006; Rollin-Sillaire et al., 2013; Banzi, Camaioni, Tettamanti, 
Bertele, & Lucca, 2016; Cummings, Lee, Mortsdorf, Ritter & Zhong, 2017). For 
example, despite more than one-third of all ADRD cases occurring in people aged 85 or 





2015 were over the age of 85 (Banzi et al., 2016). Many studies limit eligibility to 
individuals 85 or younger, posing a barrier to individuals who may be otherwise healthy 
and eligible to participate in a clinical research, further limiting the pool of available 
recruitees. To address this barrier, the NIH revised the guidelines that allowed for 
arbitrary age exclusion; as of January 2019, clinical research, barring scientific or ethical 
reasons, can no longer exclude potential recruitees based on age (NIH, 2017a). However, 
it is unclear how strictly this policy has been interpreted to date, and it may need to be 
monitored closely to ensure it is being implemented appropriately. 
Additionally, there are significant disparities across population groups in clinical 
research enrollment due to a variety of multi-level barriers. People of color are less likely 
to participate in clinical research despite being more likely to be diagnosed with ADRD 
(Danner et al., 2011; Williams, Meisel, Williams & Morris, 2011; Alzheimer’s 
Association, 2018a; Gilmore-Bykovskyi et al., 2019). This could be due to a variety of 
reasons, such as distrust in the investigators, a lack of partnerships with local community 
organizations, advertising by recruiters in venues with high populations of white men, 
such as academic health centers and universities, or a lack of study partner (Danner, 
Darnell, & McGuire, 2011; Mahon et al., 2016, Black et al., 2018).   
This background highlights the importance of developing a national, 
comprehensive ADRD prevention or treatment strategy by 2025 and the necessity of 
increasing clinical research recruitment efforts. Though many individuals with ADRD 
may want to participate in clinical research, they may be dissuaded due to lack of 





the lack of availability or interest of their care partner. Further, some individuals with 
ADRD may not be interested in participating, due to apathy, distrust, or lack of 
motivation. The national strategy released by the NIA in October 2018 provides 
recommendations to remove barriers and enhance facilitators to ADRD research 
participation but recognizes that they do not provide a comprehensive list of strategies 
and more research needs to be conducted (NIA, 2018). Furthermore, this research was 
conducted with ADRD clinicians, researchers, advocates, and caregivers. Though they 
provide important insights, particularly as the policy, system, and organizational level, 
the voices of those with ADRD were not included. Thus, strategies developed by drawing 
on the expertise that those living with ADRD offer are missing. 
 
Statement of Problem 
Leaders within the healthcare system recognize that developing partnerships and trusting 
relationships with community members will improve access to healthy lifestyle options 
and motivate individuals to take control of their own health (Selby, Beal, & Frank, 2012; 
The Robert Wood Johnson Foundation, 2016; Weil, 2016; Tillman, 2017; Gelmon, 
Bouranis, Sandberg, & Petchel, 2018). Many health organizations have begun to utilize 
the Culture of Health Action Framework, established by the Robert Wood Johnson 
Foundation in 2014, as a reference point and are improving community health outcomes 
through their multi-sector partnerships (McCullough & Leider, 2016; The Robert Wood 
Johnson Foundation, 2018). Clinical research institutions pioneer new interventions for 





healthcare delivery, such as primary care and mental health, in terms of community 
outreach and collaboration (English et al., 2010; Adams et al., 2015; Mahon et al., 2016). 
In recent years, the NIH and the Patient-Centered Outcomes Research Institute (PCORI) 
have created formative efforts to increase community outreach and collaboration to 
improve clinical research design, recruitment, and outcomes for ADRD research (PCORI, 
2013; NIH, 2018). 
Even with the drive to find an ADRD cure or treatment by 2025, as well as the 
funding to support efforts, investigators continue to struggle to recruit and retain 
participants into ADRD clinical research (Rollin-Sillaire et al; Law et al., 2014; Watson 
et al., 2014; Grill & Galvin, 2014; NIA, 2018; Gates, 2019). Without an adequate number 
of participants, ADRD clinical research is postponed or terminated, decreasing the 
chances of reaching the goal of finding an ADRD prevention or treatment strategy by 
2025. In recent years, more work has been conducted to determine facilitators and 
barriers to clinical research subject enrollment, leading to recommendations to improve 
recruitment (Sood et al., 2009; English et al., 2010; Adams et al, 2015; Carlisle et al., 
2015; Mahon et al., 2016; NIA, 2018; Gilmore-Bykovskyi et al., 2019). Some of this 
literature focuses on ADRD research (Danner et al., 2011; Williams et al., 2011; Rollin-
Sillaire et al., 2013; Law et al., 2014; Grill & Galvin, 2014; Watson et al., 2014; Black et 
al., 2018; NIA, 2018; Gilmore-Bykovskyi et al., 2019). However, there is little published 
literature that evaluates if these recommendations have been implemented or improved 









The research study answered a single question: What factors affect clinical research 
enrollment among people with ADRD? To answer this overarching question, this study 
had three aims:  
 Aim 1: Identify organizational, system, and policy factors that impede or enhance 
clinical research enrollment among people with ADRD;  
 Aim 2: Describe personal factors that persuade or dissuade individuals with 
ADRD from enrolling in clinical research; and  
 Aim 3: Develop motivational strategies and policy recommendations based on the 
findings from Aims 1 and 2.  
 
Conceptual and Theoretical Frameworks  
Based on a review of the clinical research and ADRD literature, this research used the 
Culture of Health Action Framework, developed by the Robert Wood Johnson 
Foundation in 2014 to encourage collaboration between the health and social sectors 
(Robert Wood Johnson Foundation, 2016). According to the conceptualization of the 
framework, health providers will partner with local nonprofits and private organizations; 
these partnerships then will work with communities to define their needs and the 





(Robert Wood Johnson Foundation, 2016). Partners then redesign programs, even if they 
had been previously successful, to better meet community needs and achieve the Culture 
of Health Action Framework goals (Weil, 2016). When compared with other 
communities, those with high-density multi-sector networks supporting health 
improvement activities will have better health outcomes (McCullough & Leider, 2016). 
The Culture of Health Action Framework is a useful way to conceptualize motivation 
strategies and reflect elements that describe current and future research participation 
among people with ADRD, because many of the factors affecting clinical research 
participation can be categorized into the four action areas, as illustrated in Figure 1.1.  
 







Source: Robert Wood Johnson Foundation, 2016 
 
 This framework is rooted in concepts of civic engagement, where community 
members contribute individually and collectively to better their community. Civic 
engagement requires knowledge of opportunities to improve the community, values to 
determine what is best for the community, and motivation to become civically engaged 
(Chandra et al., 2016).  
Civic engagement 
Civic engagement embodies the notion that community members contribute 
individually and collectively in order to better their communities. Civically engaged 
individuals work together and develop their knowledge, skills, values, and motivation to 
make a difference in their community by promoting its quality of life (Ehrlich, 2000).  
Civic engagement scholars have conducted research to determine ways to foster civic 
engagement, finding that organizations, governments, and policies influence the 
community’s ability and likelihood to participate in civic engagement activities (Bellah, 
Madsen, Sullivan, Swidler, & Tipton, 1991; Denhardt & Denhardt, 2003; Vigoda-Gadot 
& Cohen, 2004, Chandra et al., 2016). Local community initiatives that foster values of 
education, participation, and community member involvement, such as the collaborative 
partnerships described by the Culture of Health Action Framework, empower individuals 
to become stakeholders in their community and increase their civic participation (Bellah 






Treating community members as stakeholders is imperative to fostering 
relationships and future collaboration (Sood et al., 2009; Law et al., 2014; Mahon et al., 
2016; PCORI, 2017). This is evident in the clinical research sector; current and potential 
participants cite failure to disseminate research results and updates as a reason for not 
participating in future opportunities (Law et al, 2014; Mahon et al., 2016). It is also 
important to recognize historical contexts of previous relationships between community 
members, policymakers, and organizations. Organization and government leaders often 
assume that community members will enter into a partnership because it could be 
beneficial, but due to a history of bad relations or culture, they may not engage (Bellah et 
al., 1991; Denhardt & Denhardt, 2003; Danner et al., 2011; Williams et al., 2011). 
Examples of this dichotomy are evident in the clinical research sector. For example, 
members of the African American community, who are twice as likely as Caucasians to 
be diagnosed with ADRD, are less likely to take part in research because of egregious 
acts such as the Tuskegee Syphilis Study and concerns that researchers do not have the 
community’s best interests in mind (Corbie-Smith, Thomas, Williams, & Moody-Ayers, 
1999; Danner et al., 2011; Brown et al., 2013). However, when clinical research 
organizations take the time to establish a relationship that builds trust and respect and 
provide full information about study opportunities in a clear, understandable manner, 
African Americans are more likely to partner with that research organization (Huang & 
Coker, 2010; Williams et al., 2011; Danner et al., 2011; Frew, Archibald, Hixson, & del 





Organizational, policy, and methodological theories and approaches 
Aspects of several organizational, policy, and methodological theories are evident 
in the Culture of Health Action Framework. Organizational theories that pertain to this 
framework fall within the school of open rational systems (Scott, 1987). Theories in this 
school emphasize that organizations are means to a predetermined end but recognize the 
influence the environment has on organizational structures. Contingency theory asserts 
that the best way to organize is contingent on the nature of the environment (Galbraith, 
1973; Mintzberg, 1983). In this case, the nature of the environment refers to the needs of 
the community and regulations that prohibit or support its needs. Williamson’s 
transaction cost theory suggests that every transaction between two parties is subject to a 
cost (Williamson, 1975). Restructuring the clinical research organization could further 
reduce the transaction costs for individuals with ADRD (Califf et al., 2006; Adams et al., 
2013; Mahon et al., 2016).  
Policy feedback theory (PFT) and social construction theory can explain policy 
processes. Skocpol's work on PFT illustrates that policies created during one time period 
affect policies created in future time periods through transformed state capacities and 
changes in social groups and their political goals and capabilities (Skocpol, 1992). In her 
Policy Feedback for Mass Publics framework, Mettler highlights how resources and 
interpretive effects that stem from policies can affect civic predisposition and capabilities, 
ultimately influencing civic engagement (Mettler, 2002). PFT is influenced by social 
construction theory, which posits that policies are contingent on policymaker and societal 





Finally, the Culture of Health Action Framework also utilizes community-
engaged research approaches. Using community-engaged research, community members 
and academics collaborate and develop research and decision-making processes that best 
address the needs of the community (Wallerstein & Duran, 2008). Community-engaged 
research recognizes that despite a common misconception that research is objective, it is 
not, and it often cannot be. All individuals have different lived experiences, leading to 
unique perspectives (Habermas, 1963/1974). To establish partnerships, these unique 
perspectives need to be identified, brought to the table, and discussed. In community-
engaged research, professionals recognize and accept the significant power differences 
between the community and themselves and the effects power differences have on 
participation behavior. By treating everyone as an equal partner with equal power, 
knowledge is fully disseminated, empowering the community and mitigating power 
dynamics (Freire, 1968/1972; Foucault, 1980).  
Furthermore, community-engaged research can enhance the study’s rigor, 
relevance, and reach (Balazs & Morello-Frosch, 2013). Rigor can be enhanced when the 
community directs researchers to use data collection methods that best addresses their 
needs, asserting that the research design is appropriate for the questions being asked. 
Additionally, member-checking, where community members provide feedback of the 
results that confirm or challenge the investigator’s analysis and takeaways from 
interviews, further enhances scientific rigor by asserting the study’s generalizability 
(Creswell, 2000; Goldblatt, Karneili-Miller, & Neumann, 2011). Relevance can be 





addition, the study’s process and findings are disseminated in ways that are most relevant 
to the community (e.g. pamphlets with clear, concise language). Reach can also be 
enhanced through dissemination to community members, and can also lead to community 
testimony to policymakers, potentially resulting in policies beneficial to the community 
(Balazs & Morello-Frosch, 2013).  
This study’s methodology reflects this approach. For instance, this study’s process 
was facilitated by a community advisory board (CAB) comprised of people with ADRD, 
family caregivers, older African Americans, researchers, clinicians, and advocates. The 
CAB assisted with recruitment and interview protocol design, engaged in member-
checking and interpretation of analyses, and brainstormed dissemination strategies. Their 
collaboration ensured that the research design is rigorous and relevant to people with 
ADRD by modifying study questions to ask what was most meaningful and pertinent to 
people with ADRD. The CAB also developed strategies to ensure that findings and 
recommendations were disseminated beyond the academic realm.  
 
Purpose and Significance of the Study  
This study drew upon the expertise of people with ADRD to determine relevant strategies 
to improve ADRD clinical research participation rates. It contributes insights to the 
current knowledge base surrounding factors affecting clinical research recruitment and 
emphasizes motivational strategies among individuals with ADRD. Additionally, this 
dissertation is the first to use a civic engagement approach to study clinical research 





this specific field. Furthermore, this study obtained information from both academic and 
community stakeholders through CAB membership and interviews and supported calls by 
advocates and academics to include the people with ADRD as research partners (Tanner, 
2012; LEAD Coalition, 2017; Kremer, 2017; NIA 2018; Gitlin et al., 2018; Gilmore-
Bylovskyi et al., 2019). Lastly, it aligns with the NIA’s national strategy to conduct more 
research on factors affecting ADRD clinical research participation and fills an important 




ADRD prevalence rates will continue to rise as the aging population grows. The efficacy 
of an intervention to prevent, treat, or cure ADRD can only be tested through clinical 
research, which will only be successful if individuals with ADRD are motivated to 
participate and strategies backed by evidence from people with ADRD are developed. 
Strategies have been identified by ADRD clinicians, researchers, and advocates, but not 
by the people with ADRD themselves. By identifying their needs, this research study 
served as the first stage in that process. In Chapter 2, a review of the literature that 






CHAPTER 2: REVIEW OF THE LITERATURE 
 
Chapter Organization 
This chapter presents a review of the literature that provides the foundation for the study. 
The follow topics are discussed: 
1. Introduction: the case for identifying facilitators and barriers to ADRD clinical 
research participation. 
2. An overview of ADRD including its pathology, prevalence, current treatment, 
supports and services, and research directions.  
3. A review of ethical guidelines that have shaped clinical research, including 
seminal guidelines, national NIH regulations, facilitators and barriers related to 
general clinical research participation, and factors related to ADRD research 
participation. 
4. Discussion of the theories and frameworks that pertain to this study, including 
organizational theories within the school of open rational systems, policy process 
theories, civic engagement approaches and the Culture of Health Action 
Framework. 
5. Literature synthesis and conclusion. 
 
Introduction 
In most developed nations, individuals no longer die from acute conditions such as 





(World Health Organization [WHO], 2017). As more people survive to old age, and the 
national and global population grows to record numbers, the number of ADRD cases has 
drastically increased and will continue to do so over the next few decades. Globally, over 
46 million people were diagnosed with dementia in 2015, costing an estimated 816 
billion dollars (Prince et al., 2016).  
WHO declared ADRD a public health crisis in 2012 and released their response 
plan in 2017 (WHO, 2017). Among their priorities is the need for innovative research and 
a specific call for collaboration between academic institutions and engaged stakeholders, 
including people with ADRD, to find prevention strategies, treatment options, and/or a 
cure for people with ADRD (WHO, 2017). The NIA followed the next year, releasing 
their National Strategy for Increasing Participation in Alzheimer’s Disease and Related 
Dementias Research in October 2018. Their four overarching goals are: 1) increase 
awareness and engagement; 2) build and improve research infrastructure; 3) engage local 
communities and support participants; and 4) develop an applied science of recruitment 
(NIA, 2018). As described in Chapter 1, two important actions should be taken to further 
improve this national strategy: continue research to identifying barriers, facilitators, and 
recommendations to improve research participation and develop strategies used that draw 
upon the expertise of people living with ADRD. This research study does both. 
 
Overview of ADRD 
This section summarizes the literature and current knowledge surrounding ADRD.  





ADRD family, including their history, epidemiology, diagnosis and treatment.  
Current services and supports for individuals with ADRD are then discussed, focusing 
mostly on long-term supports and services (LTSS). This section concludes with an 
overview of current ADRD research, including the progress that has been made in some 
areas, the stagnancy in others, and current and future pathways that ADRD researchers 
are taking in their investigations. This review of the literature is necessary to provide a 
foundation for the context of this dissertation research. In order to study ADRD clinical 
research recruitment and retention, one must first consider why discovering ADRD 
prevention strategies and treatment options is a high global priority. 
ADRD subtypes 
Dementia symptoms have been written about since ancient times, and subtypes of 
dementia were distinguished in the late 1800s; however, ADRD was not commonly 
researched nor written about until the 1970s (Boller & Forbes, 1998). With the exception 
of familial Alzheimer’s disease (AD) and vascular dementia, there is still no known cause 
of ADRD. More is known, however, about each dementia’s unique pathology. 
Alzheimer’s disease: AD’s pathology consists of two types of protein buildups in the 
brain: amyloid plaques and neurofibrillary tangles (Villemagne et al., 2013). It is not 
clear how these buildups affect the brain, but researchers do know that the tangles inhibit 
the protein from carrying out their typical tasks. Other pathological signs include brain 
inflammation, caused by immune cell attempts to remove the protein buildups, and brain 
atrophy due to cell loss (NIA, 2017). A rarer form of Alzheimer’s disease, affecting less 





precursor proteins or presenilin 1 and/or 2 proteins (Bekris, Yu, Bird, & Tsang, 2010). 
Individuals with these genetic mutations will develop AD sometime between their 30s 
and 50s (Goldman, Hahn, & Bord, 2011). There are currently 5.8 million people 
estimated to be living with AD in the United States and an additional 1 million living 
with related dementias, including frontotemporal, Lewy body, vascular, and mixed 
dementias( (Knopman & Roberts, 2011; Plassman et al., 2007; Zweig & Galvin, 2014; 
NIH2019a, 2018; Alzheimer’s Association, 2019a;). However, there is speculation that 
this number is actually much higher, given the number of people who are misdiagnosed 
or do not receive a diagnosis (Boustani, Peterson, Hanson, Harris, & Lohr, 2003; 
Bradford, Kunik, Schutlz, Williams & Singh, 2009; Lang et al., 2017).  
Dementia with Lewy bodies: The pathological diagnostic sign of dementia with Lewy 
bodies (DLB), Lewy bodies, are deposits comprised mainly of alpha-synuclein proteins 
that abnormally develop in brain cells (Gomperts, 2016). First discovered in Dr. Alois 
Alzheimer’s lab by Frederick Lewy in 1912, DLB was classified as its own subtype of 
dementia in the 1990s and its clinical criteria were most recently updated in 2015 
(Gomperts, 2016; McKeith et al., 2017). Like AD, it is difficult to assess the true number 
of people with DLB; due to its similar symptomology and pathology, many cases are 
misdiagnosed as AD or Parkinson’s disease and are not properly diagnosed as DLB until 
autopsy (McKeith et al., 2017). 
Frontotemporal dementia: Frontotemporal dementia (FTD) is another dementia 
commonly misdiagnosed as AD. The symptomology of one subset of FTD, Pick’s 





However, it was assumed to be AD, and it was not until more research comparing the two 
dementias was conducted in the 1980s that FTD was distinguished as its own subtype 
(Neary, Snowden, Northen, & Goulding, 1988; Snowden et al., 2002). Pathologically, 
FTD is very similar to AD, except all protein build-ups occur strictly in the frontal and 
temporal lobes (Alzheimer’s Association, 2018a). Clinically, FTD presents with 
behavioral and movement symptoms before cognitive symptoms. Approximately 60,000 
people live with FTD in the US, most of whom are diagnosed between the ages of 45-64 
(Galvin, Howard, Denny, Dickinson, & Tatton, 2017). The age range is in part why the 
socioeconomic burden is greater for people with FTD than AD as they are often in their 
top wage point in their life and may be caring for young children at home (Galvin et al., 
2017; The Association for Frontotemporal Degeneration, 2018). Furthermore, because of 
their age and behavioral and movement symptoms, people with FTD are often 
misdiagnosed with a behavioral or movement disorder (FTD Association, 2018). 
Vascular dementia: Vascular dementia was first recognized as a dementia subtype in the 
late 1800s but was not assigned clinical criteria until the 1990s (Battistin & Cagnin, 
2010). It is the second most prevalent dementia in the United States and Europe and the 
most prevalent in Asian countries, accounting for nearly 50% of all reported dementias in 
Japan and China (Battistin & Cagnin, 2010). Vascular dementia is caused by restricted 
blood flow to the brain due to strokes or other vascular events, leading to damaged 
vessels and brain lesions that result in symptoms similar to AD (Love, 2005; Alzheimer’s 
Association, 2018b). Slightly more than one in four people who have a stroke develop 





Mixed dementias: Mixed dementias do not have their own pathology; rather, they are a 
combination of two distinct subtypes of dementia. Generally, mixed dementia cases are 
comprised of pathology of AD, the most common form of dementia, and vascular 
dementia, the second most common type of dementia (Schneider, Arvanitakis, Bang, & 
Bennett, 2007).  
Diagnosis, risk factors and prevention, and treatment 
  This section discusses factors affecting a clinical diagnosis of ADRD, risk factors 
and prevention of ADRD, and treatments for ADRD. 
Diagnosis: Proper diagnosis of ADRD is crucial in order to treat symptoms early and 
obtain appropriate services and supports. However, a recent global meta-analysis of 23 
studies found that 26,807 out of 43,446 (61.7%) cases of dementia were originally 
undetected, with the prevalence in North America slightly higher than the global average 
at 27,328 (62.9%) cases (Lang et al., 2017). The study also found that rates of undetected 
diagnosis were higher when the individual was male, younger than 70, or had seen a 
general practitioner rather than a specialist (Lang et al., 2017). The underreporting of 
diagnoses may also be due to therapeutic nihilism, where clinicians fail to diagnose with 
patients with dementia because of their belief that nothing could be done (Aminzadeh, 
Molnar, Dalzier, & Ayotte, 2012). Additionally, many people chose not to seek a 
diagnosis for their symptoms due to the stigma and fear of having a chronic, terminal 
illness (Chin, Negash, & Hamilton, 2011; Grill & Galvin, 2014; Millenaar et al., 2016; 





Until recently, ADRD could not be confirmed until autopsy. PET scans are now 
being used outside of research studies to identify plaque buildup consistent with 
Alzheimer’s disease and can give a confirmatory diagnosis of Alzheimer’s disease 
(Rabinovici et al., 2019). This poses interesting problems as people become diagnosed 
before clinical symptoms manifest, but an investigation of this is outside the scope of this 
dissertation. Probable ADRD is typically diagnosed using neurocognitive assessments, 
such as the Mini Mental State Exam (MMSE) or the Montreal Cognitive Assessment 
(MoCA). The MMSE is best used to distinguish between healthy cognitive functioning 
versus impaired functioning, whereas the MoCA is used for distinguishing between mild 
impairment seen in MCI and early-stage AD (Trzepacz, Hochstetler, Wang, Walker, & 
Saykin, 2015). Though Caucasian individuals are more likely to be diagnosed at earlier 
stages, African Americans are significantly more likely to develop ADRD (Danner et al., 
2011; Williams et al., 2011; Chin et al., 2011; NIA, 2018).  
Biologically, ADRD disparities could be due to higher prevalence of 
cardiovascular diseases and diabetes and/or genetics polymorphisms, abnormal changes 
in genetic material, that are unique to or more prevalent in individuals of African descent 
(Chin et al., 2011).Screening African Americans for ADRD can be more ambiguous. The 
MMSE has a high rate of false positives among African Americans (Stephenson, 2001; 
Chin et al., 2011). Additionally, providers who administer the MMSE may have racial 
bias (Stephenson, 2001; Wood, Giuliano, Bignell, & Pritham, 2006; Chin et al., 2011). 
African Americans more often receive delayed and/or inadequate health services (Chin et 





normal aging and find dementia to be a more stigmatizing disease as compared to white 
adults (Espino & Lewis, 1998; Roberts et al., 2003; Connell, Roberts, McLaughlin, & 
Akinleye., 2009; Chin et al., 2011). Additionally, there is mistrust of the medical 
community by African Americans, further leading to delayed or lack of care (Katz et al., 
2009; Chin et al., 2011).  
Risk factors and prevention: The three biggest risk factors for developing ADRD are 
old age, family history, and the APOE gene (Lautenschlager, et al., 1996; Mahley & Rall, 
Jr., 2000; Herbert, Weuve, Scherr, and Evans, 2013). These risk factors are not 
modifiable; however, they do not automatically result in ADRD. Scientists have 
identified several modifiable factors that will lower ADRD risk, including cardiovascular 
diseases (CVD), being physically active, a heart-healthy diet, having formal education, 
and being socially and mentally engaged. CVD, including stroke, hypertension, and high 
cholesterol, impact brain health because the brain uses much of the body’s oxygen and 
energy, both carried through blood (Mergenthaler, Lindauer, Dienel, & Meisel, 2013). 
Thus, scientists suggest engaging in heart-healthy activities to prevent CVD and reduce 
risk of developing ADRD. This includes being physically active, which increases blood 
flow to the brain, eating a heart-healthy diet that limits sugar and saturated fats, and not 
smoking (Blondell, Hammersley-Mather, & Veerman, 2014; Morris et al., 2015; 
Hardman, Kennedy, MacPherson, Schoeley, & Pipingas, 2016).  
 Having more formal education and working in intellectually stimulating 
occupations reduces risk (Sando et al., 2008; Pool et al., 2016). Additionally, being 





(Wang, Karp, Windblad & Fratiglioni, 2002; Yates, Ziser, Spector, & Orrell, 2016). 
Lastly, associations between ADRD and head trauma have been found, especially in 
cases of younger-onset dementia (Plassman et al., 2000; Gardner & Yaffe, 2014); the 
Alzheimer’s Association suggests individuals protect their heads through seatbelt and 
helmet use and fall-proofing homes (Alzheimer’s Association, 2019a).  
Treatment: AD is the only form of ADRD with FDA-approved medications. The 
treatment does not provide relief of the disease itself, but simply offers symptom 
management. Medications to treat cognitive symptoms include galantamine, 
rivastigmine, donepezil and memantine (Yanniopoulou & Papegeorgiou, 2013). The first 
three are primarily used for mild to moderate cases of AD, and the last is used for 
moderate to severe cases (Yanniopoulou & Papegeorgiou, 2013). Often, treatment delays 
the progression of cognitive symptoms for six to twelve months, though it is ineffective 
for some (Yanniopoulou & Papegeorgiou, 2013; Alzheimer’s Association 2018d). The 
second group of medications, which include antidepressants, anxiolytics, and 
antipsychotics, are for behavioral changes associated with AD (Yanniopoulou & 
Papegeorgiou, 2013; Canevelli et al., 2016). These medications are often prescribed “off-
label,” meaning that the medication has not been approved for this specific use (Canevelli 
et al., 2016). There is also controversy surrounding the practice of prescribing off-label 
medications for behavioral symptoms of ADRD as they are often prescribed before non-
clinical interventions are attempted (Canevelli, et al., 2016). 
There are no FDA-approved medications for related dementias. DLB is treated 





Association, 2018e). Antipsychotics are not prescribed as many people with DLB have 
experienced life-threatening side effects (Lewy Body Dementia Association, 2015; 
Alzheimer’s Association, 2018e). FTD is pharmacologically treated with antidepressants 
and antipsychotics; some clinicians also prescribe medications for AD and Parkinson’s, 
but they are not frequently found to be effective (Penn Frontotemporal Degeneration 
Center, n.d.). Vascular dementia is treated with AD medications as well as hypertension, 
high cholesterol, and diabetes medications to lower risk of vascular dementia-causing 
cardiovascular events (Mayo Clinic, 2014).  
Current services and supports for ADRD 
 Given the nature of ADRD, LTSS are utilized when the disease progresses. LTSS 
include in-home services (such as personal care and respite), adult day care, community-
based care (CBC) which includes residential care (RC), assisted living facilities (AL), 
and memory care facilities (MC), and nursing homes.  In Oregon, Medicaid can be 
utilized for all LTSS, but is contingent on the providers’ willingness to accept Medicaid. 
Those individuals who are higher-income can afford private-pay LTSS; middle-income 
individuals must spend down their assets on private pay LTSS until they become eligible 
for Medicaid. Oregon Project Independence, overseen by the Oregon Department of 
Human Services and jointly run by regional Area Agencies on Aging and service 
providers, offers in-home services, such as personal care and respite, for non-Medicaid- 
eligible adults, with no age restriction for those with an ADRD diagnosis, for a $5.00 
annual fee plus a monthly sliding scale fee. However, residential LTSS is generally 





In Oregon, roughly 25% of AL residents, 50% of RC residents, and virtually all 
MC residents have dementia (Carder, Tunalilar, Elliot, & Dys, 2017). The average 
monthly rates for Oregon’s CBCs are $3,667 for ALs, $3,770 for RCs, and $5,410 for 
MCs (Carder et al., 2017). Though 79% of CBCs accept Medicaid, just 41% of residents 
pay with Medicaid (Carder et al., 2017). This low percentage rate is partially attributed to 
ineligibility, it could also be attributable to geographic disparity: CBCs are typically 
located in areas with higher levels of education and income (Stone, 2011; Carder et al., 
2017). In Oregon, one in five nursing home residents has ADRD (Mendez-Luck, Luck, 
Larson, & Dyer., 2017). More than one-fifth of Oregon counties, all of which are rural 
and low-income, do not have nursing homes (Mendez-Luck et al., 2017). People with 
ADRD who utilize residential LTSS may have to live far distances from their known 
environment. 
Many people with ADRD solely rely on informal caregivers due to cultural or 
financial reasons. Compared to non-caregiving peers, caregivers are at risk for stress, 
insomnia, fatigue, depression, anxiety, stress-related illnesses, and their own diagnosis of 
dementia (Norton et al., 2010; /NAC/AARP, 2015). These risks are even greater for 
caregivers of people with ADRD, who perform more ADLs, IADLs, medical care, and 
key activities than their non-ADRD caregiving counterparts. The burdens of caregiving 
may affect their caregiving abilities, and those with high caregiver burden are more likely 
to place the person with ADRD in the first available CBC or nursing home rather than 
proactively searching for residences that best meet their needs and preferences (Ball et al. 





Caregiver Program, federally funded by the Older Americans Act and directed by Area 
Agencies on Aging, provides caregiver education and respite opportunities, as does 
Oregon Project Independence (Oregon Department of Human Services, 2015; Oregon 
Department of Human Services, 2017). The Alzheimer’s Association also provides 
caregiver support programs and referrals to local services.    
 In a survey of African, Hispanic and Asian American ADRD family caregivers, 
many perceived caregiving as a personal responsibility that does not require seeking help 
or felt stigmatized seeking services both within their community and the healthcare 
system. In some cases, their partners with ADRD did not want to seek help, which their 
caregivers respected (Chin et al., 2011; Aranda, 2017). However, many did not seek help 
due to experiences of discrimination in the health system, language barriers, uncertainty 
about receiving help, or belief that nothing could be done (Chin et al., 2017; Aranda, 
2017). This lack of help is significant given their higher prevalence of ADRD in minority 
communities: they are at higher risk of negative consequences of caregiving yet receive 
the least amount of support from the health and long-term-care systems. 
 At the 2017 ADRD Research Summit in Bethesda, Maryland, Aranda (2017) 
offered several strategies for improving dementia care for disadvantaged groups, 
including:  
“a) investing in diversity-focused research on care, services, and supports; b) 
coordinating public awareness and outreach efforts with culturally-tailored brain 
health messaging and information on health, LTC, and community-based 
services; c) improving quality and access to care, services, and supports in 
multiple languages, for at-risk or underserved groups, geographical regions, etc.; 
d) growing the enrollment of underrepresented groups in clinical trials and 
services research through recruitment strategies and study designs that better 





diverse provider and scientific workforce to address delays in diagnosis, improve 
treatment, and quality care, supports, and services; f) decreasing the gap in 
translation of research to sustained practice based on the latest findings in 
dissemination, implementation, and improvement sciences; and g) examining 
large-scale policies that promote person-, family-, and community-centered care 
across multiple systems, educational, employment-workplace; economic, health 
and LTC, environmental, immigration, etc.” (Aranda, 2017). 
Employing these strategies may improve access, utilization, and trust of LTSS 
among minority communities. Trust-building and strengthening the relationship between 
these communities and the LTSS sector may carry over to all health and research sectors; 
however, it would require similar efforts from those sectors. 
Research progress 
 In the 1990s, efforts in ADRD research increased upon the realization that Baby 
Boomers would begin to age in the next decade. During this decade, investigators 
established three principles to guide their research: ADRD is heterogeneous, its onset can 
occur up to 40 years before “clinical manifestation,” and interventions needs to target the 
pathophysiological, symptomatic, and social aspects of the disease (Khachaturian, 1998).  
Two decades later, investigators have begun to distill these three principles into 
more focused areas. At the 2016 ADRD Summit in Maryland, research priorities included 
a) improving diagnostic skills; b) more effective dialogue, programs, and partnerships 
between the NIH and nongovernment organizations; c) address health disparities; d) 
initiate more clinical trials for DLB, particularly for diverse populations; e) create 
international research trial networks for FTD; and f) learn more about the association 





ADRD clinical trials have the highest failure rate of any disease at 99.6%, which 
is due to lack of efficacy as well as slow or failed participant recruitment (Cummings et 
al., 2014; Cummings et al., 2017). Clinical research investigators instead have shifted 
focus from treatment to diagnostics and prevention. Researchers have identified 
biomarkers, such as amyloid beta peptides measured in cerebral spinal fluid and blood, 
that could be used to diagnosis ADRD before clinical symptoms emerge (Ahmed et al., 
2014; Nabers et al., 2018). One encouraging study presented at the 2017 Alzheimer’s 
Association International Conference (AAIC)  suggested one-third of dementia cases 
could be prevented if nine lifestyle factors (active hypertension treatment, more 
childhood education, exercise, maintenance of social engagement, management of 
hearing loss, reduction of tobacco use, and diabetes, depression, and obesity 
maintenance) were addressed (Livingston et al., 2017). AAIC 2018’s plenary session 
highlighted a potential breakthrough: an amyloid anti-body being tested in a clinical trial 
has substantially reduced pathological and clinical symptoms of early AD (Swanson et 
al., 2018). The study has moved to Phase 3 to test the antibody’s safety and efficacy 
(Clinicaltrials.gov, 2019). There were no data from any large clinical trials presented at 
AAIC in 2019. Instead, presenters highlighted findings from diagnostic and preventive 
studies, which centered around biomarkers, imaging, and technology (Bowman Rogers, 
2019; Fagan, 2019; McCaffrey, 2019).  
Some pharmaceutical companies have halted their ADRD research to focus on 
other efforts, prompting speculation that they dropped out to pursue more profitable 





Despite this reduction in funding and study opportunities, academic and government 
research centers, in addition to remaining pharmaceutical companies, such as Biogen and 
Eisai, are still funding and conducting clinical research and are actively recruiting 
participants (Pickett, 2018, DeStrooper, 2018; Alzheimer’s Association, 2018b). Biogen 
renewed a previously halted trial and applied for FDA approval for a new treatment, 
aducanumab, after new analyses showed some improvement among participants who 
received the drug (Biogen, 2019).  
In March 2018, the NIA began crowdsourcing public ideas for ADRD research 
participation with the goal of developing and implementing national strategies to 
facilitate recruitment (Masliah, 2018). As of December 2019, Congress had allocated 28 
billion dollars to ADRD with the goal of finding a prevention or treatment by 2025 
(Alzheimer’s Association, 2019b).  
Conclusion 
The debilitating progressive nature of ADRD, the toll on informal caregivers 
(particularly among people of color) and the health system, and the lack of a prevention 
or cure reinforces the WHO and U.S. Congress’s goal. In order to improve the odds of 
reaching the Congress’s 2025 deadline, efforts to improve research participation are 
needed. The next section discusses this aspect further. 
  
Clinical Research 
Clinical research determines the safety and effectiveness of interventions, including 





research, prospectively assigns subjects to an intervention in order to evaluate its effects 
on human subjects (NIH, 2017b). Clinical trials consist of four phases, described below 
in Table 2.1. 
Table 2.1 Overview of Clinical Trial Phases  
Phases Definition 
Phase 1 The safety of an intervention is assessed over several months among 20-100 
healthy volunteers or people with the condition being studied. 
Phase 2 The intervention’s efficacy is assessed across hundreds of individuals over 
several months to two years. 
Phase 3 The intervention’s effectiveness, benefits, and range of adverse reactions are 
tested across hundreds to thousands of people over one to four years. 
Phase 4 The intervention has been approved by the FDA and can be purchased by the 
general public, but studies are still conducted to compare it to other 
interventions, its long-term effects on health and quality of life, and its cost-
effectiveness. 
 
 In order to successfully find a prevention or treatment by 2025, thousands of 
individuals with ADRD must be willing and able to participate in clinical research. 
Additionally, efforts to improve ADRD clinical research recruitment and retention must 
be balanced with good ethical and clinical regulatory adherence, organizational 
structures, and the community’s needs. To articulate why the balance is needed, and how 
to achieve that balance, this section is divided into four parts. First, ethical guidelines for 
conducting human subject research are discussed. This is followed by a description of 
current national clinical research regulations. Next, barriers and facilitators to clinical 
research participation are identified and categorized as policy, system, organizational, 






Ethical guidelines pertaining to clinical research  
 Underlying the duty to protect all participants, and especially those “vulnerable to 
coercion or undue influence”, is the concern for the protection of human research subjects 
(45 CFR 46, 2018, p. 9).  This section describes clinical research guidelines that aim to 
protect the health and safety of participants. It begins with an overview of two early 
guidelines for safety and ethical standards in human subject research: the Nuremberg 
Code and the Declaration of Helsinki. The section then moves into a discussion of two 
unethical research studies that occurred despite these guidelines, and the subsequent 
policy actions amid public outrage.  
The Nuremberg Code: The first of three standards protecting the rights of human 
subjects in biomedical research is The Nuremberg Code (The Nuremberg Code, 1947). 
Established to ensure that the horrific ordeal that individuals subjected to research during 
the Holocaust never occurs again, it stresses the importance of voluntary and informed 
consent: 
“The voluntary consent of the human subject is absolutely essential. This means 
that the person involved should have the legal capacity to give; should be so 
situated as to be able to exercise free power of choice, without the intervention of 
any element of force, fraud, deceit, duress, over-reaching, or other ulterior form of 
constraint or coercion; and should have sufficient knowledge and comprehension 
of the elements of the subject matter involved as to enable him to make an 
understanding and enlightened decision.” (The Nuremberg Code, 1947, p. 1). 
Under these terms, the only individuals able to consent to participation in research are 
adults with the cognitive capacity to understand the purpose, risks, and benefits of a 
study. Additionally, a participant’s decision to enroll must be an autonomous one, free of 





would not be able to participate in research due to potential diminished cognitive capacity 
and concerns of coercion.  
The Declaration of Helsinki: The 1964 Declaration of Helsinki was the first position 
statement to promote the use of a healthcare proxy for a person unable to give informed 
consent, provided that the research conducted focuses specifically on the benefit to the 
person’s disease or disability and is of minimal risk. The Declaration proclaims that “it is 
the mission of the doctor to safeguard the health of the people. [The doctor’s] knowledge 
and conscience are dedicated to the fulfilment of this mission” (World Medical 
Association, 1964, p. 1). This statement sets the precedent that the individual enrolling in 
the study is a patient first and a participant second. The guidelines also stipulate that a 
person with ADRD could participate in research so long as there is a potential of a direct 
benefit (World Medical Association, 1964). 
It is important to note that despite these ethical standards, unethical research has 
continued on occasion. In 1966, Henry K. Beecher, a physician and medical ethicist, 
published "Ethics and Clinical Research," which described 22 cases of unethical research. 
One notable example is a 1963 case of an immunologist injecting cancer cells into 22 
Jewish Chronic Disease Hospital residents in Brooklyn, NY, many of whom had 
dementia and were Holocaust survivors, without voluntary informed consent (Beecher, 
1966; Arras, 2008). The investigator, Chester Southam from the Sloan-Kettering Institute 
for Cancer Research, in 1963 wanted to determine if the human immune system could 





for not injecting himself by stating, "Let’s face it, there are relatively few skilled cancer 
researchers, and it seemed stupid to take even the littlest risk" (Langer, 1964, p. 49).    
One notable example not included in Beecher's article was the Tuskegee Syphilis 
Study, which began in 1932. What was supposed to be a six-month study on Black men 
living with syphilis in rural Alabama became a 40-year study on the pathology of 
untreated syphilis. Researchers not only withheld curative antibiotics from study 
participants after they became available in the 1950s, but also conspired with local health 
centers and the military to ensure that participants did not receive penicillin (Jones, 
1993). Despite ethical concerns raised by the medical community, it was not until a US 
Public Health Services whistleblower contacted an Associated Press reporter in 1972 that 
this study was publicized and subsequently ended after public outcry (White, 2000).  
After numerous Congressional hearings on clinical research in the United States, 
the National Research Act was passed in 1974. The Act established the National 
Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research [hereafter referred to as The Commission], creating ethical guidelines for 
human subject research and institutional review boards (IRBs) such as The Belmont 
Report and 45 CFR 46 (The Commission, 1979; Rice, 2008). 
The Belmont Report: The Commission gleaned their clinical research standards from 
three ethical principles: respect for persons, justice, and beneficence. They released their 
ethical guidelines, known as The Belmont Report, which safeguards the right to 
autonomous and informed decision making and stresses the importance of protecting 





Commission, 1979). It also ensures that researchers will equally distribute the maximum 
benefit and least amount of risk and harm to every patient without exploiting any 
vulnerable people or groups. The Belmont Report notes the necessity for research that 
may benefit society despite not providing a direct benefit to the individual involved (The 
Commission, 1979). The Commission specifically references research with children, 
stating: “effective ways of treating childhood diseases and fostering healthy development 
are benefits that serve to justify research involving children -- even when individual 
research subjects are not direct beneficiaries” (The Commission, 1979, p. 5). Similarly, 
one could infer that it is ethical for people with ADRD to participate in clinical research 
for societal benefit, such as finding effective ways to treat ADRD, despite not receiving 
an individual benefit. 
Each of the guidelines provided more flexibility than the one beforehand while 






Table 2.2: Ethical Guidelines in Clinical Research 
Guideline Year Key Contribution Relevance to ADRD Research 
The Nuremberg 
Code 




People with ADRD are unable to 
participate in clinical research.  
Declaration of 
Helsinki 
1963 Subjects can enroll via 
proxy consent so long 
as the research is 
directly beneficial and 
is of minimal risk. 
People with ADRD can participate 
in directly beneficial, minimal risk 




1979 Subject can enroll via 
proxy consent so long 
as the research benefits 
society. 
People with ADRD can participate 
in minimal risk studies if they 
have a study partner and the study 
would benefit those with ADRD. 
 
 The Nuremberg Code safeguarded against exploitative experiments and 
fraudulent acts disguised as medical research, but it also blocked those who could not 
give informed consent from receiving beneficial treatment that they could only get 
through research participation. The Declaration of Helsinki remedied that by allowing 
proxy permission for those who are unable to give consent; however, it forbids 
enrollment by proxy into research unless the research was directly therapeutic and of 
minimal risk, though neither term is defined (World Medical Association, 1964). The 
Belmont Report amends this by allowing proxy enrollment in studies that may not 
provide a direct benefit but will be beneficial to the population affected by the same 
ailment as a whole and is of low risk (The Commission, 1979).   
National clinical research regulations  
 Since the 1970s, the US has actively regulated clinical research, primarily to 





(OHRP) “provides clarification and guidance, develops educational programs and 
materials, maintains regulatory oversight, and provides advice on ethical and regulatory 
issues in biomedical and behavioral research” (OHRP, n.d., p. 1). 45 CFR 46, a 
regulation promulgated by the Department of Health & Human Services (HHS) fulfills 
OHRP’s responsibilities by ensuring the safety of individuals participating in human 
subject research. However, these rules do not provide guidance for studies that involve 
participants with ADRD, stating: “the HHS regulations are silent on the consent 
procedures specific to subjects with impaired decision-making capacity, for example, as a 
result of trauma, mental retardation, some forms of mental illness, or dementia, whether 
temporary, progressive, or permanent” (OHRP, 2017, p. 10). Investigators and research 
funders have the ability to create their own procedures, provided they align with good 
ethical and safety standards, and can differ from clinic to clinic. One result of this means 
that a person with ADRD may not be eligible for a study at their local clinic but could be 
eligible if they lived elsewhere (Friedman et al., 2015; Mahon et al., 2016). The varying 
eligibility criteria contributes to the low participation rates in ADRD clinical research, 
making it more challenging to discover a possible prevention or treatment by 2025. 
 Several policies have been implemented in recent years to encourage a larger 
scope of studies, participants, and collaboration. Federal rules established as directed by 
the NIH Inclusion Act of 1993 require NIH-funded research studies to: ensure inclusion 
of women and minority subpopulations; incorporate valid analyses of subpopulation 
groups in Phase 3 trials; not exclude participation based on cost; and initiate recruitment 





mandate that inclusion should be discussed in the research design plan, allow for 
exclusion if there is a clear and compelling reason for it, and require that valid analyses 
are submitted to ClinicalTrials.gov (NIH 2000; NIH, 2017c). Unfortunately, this only 
applies to NIH-funded studies and does not apply to the majority of ADRD clinical trials, 
as over 65% are funded by biopharmaceutical companies (Cummings et al., 2017).  
 The NIH modified its definition of a clinical trial in 2014 to “a research study in 
which one or more human subjects are prospectively assigned to one or more 
interventions (which may include placebo or other control) to evaluate the effects of 
those interventions on health-related biomedical or behavioral outcomes” (NIH, 2014, p. 
1). This expands the definition to include any study that involves human participants and 
tests a health-related intervention provided that participants are prospectively assigned to 
the intervention. The 21st Century Cures Act, which stresses transparency of clinical 
research processes and outcomes as well as access, privacy, and confidentiality for 
participants, was signed into law in December 2016 (P.L. 114-255, 2016). This policy has 
led to the creation and modification of several additional policies.  
In June 2016, the NIH passed a final rule that allows for a single IRB review of 
NIH-funded multi-site studies and requires investigators and research staff of NIH-
funded trials to complete Good Clinical Practice (GCP) training to “assure the safety, 
integrity, and quality of clinical trials” (NIH, 2016b, p. 1). In January 2017, the NIH 
enacted a policy addressing the transparency and dissemination of clinical trial results. 
Under this policy, investigators (apart from Phase 1 studies and studies without FDA 





first participant enrollment and publish their findings within one year of trial completion 
(NIH, 2016c). Previously, investigators were only required to post their publications on 
NIH-funded studies to PubMed Central.  
In September 2017, the NIH changed its confidentiality policy. Rather than 
requiring investigators to apply for certificates of confidentiality (COCs) to protect their 
participants’ sensitive information, COCs are automatically distributed by the HHS 
Secretary for studies receiving federal funding (NIH, 2017d). Under this rule, disclosure 
of identifiable, sensitive information may only be made if: required by other federal, 
state, or local laws (e.g. communicable disease reporting); necessary for the medical 
treatment of the individual; the individual consents; or, for other scientific research that 
adheres to federal human subject regulations (NIH, 2017d).  
In November 2017, the NIH announced its partnership with Open Researcher and 
Contributor Identification (ORCID), a nonprofit organization where researchers sign up 
to network and share information, reporting, and analyses. According to the NIH’s 
Deputy Director for Extramural Research, the goal of this collaboration is to “make it 
easier for the scientific community to create measures and incentives for better scientific 
researchers such as openness, rigor, and impact” (Lauer, 2017, p. 1).     
Most relevant to ADRD clinical research, NIH now prohibits investigators from 
excluding potential participants due to age without good justification (NIH, 2017a). This 
Inclusion Across the Lifespan Policy specifically cited studies that focus on cancer 
research as reasons for why this rule was necessary: for example, over one third of cancer 





over age 75 (Hurria et al., 2014). This also positively impacts people with ADRD, 
particularly those above 85 and younger than 65, because studies must now include 
individuals whose ages are most affected by these diseases. Despite over one-third of 
people with ADRD being over age 85, just 8% of ADRD clinical research participants 
between 2000 and 2015 were 85 or older (Banzi, Camaioni, Tettamanti, Bertele, & 
Lucca, 2016). Additionally, ADRD clinical research frequently limits eligibility to those 
65 and older (Clinicaltrials.gov, 2018). This is particularly important to those with early-
onset familial AD, who are more motivated to participate in clinical research yet more 
likely to be excluded by age (Schneider, 2010; Strobel, n.d.). Additionally, this only 
applies to NIH-funded studies and is not applicable to the majority of ADRD trials. 
 
Barriers, Facilitators, and Strategies Influencing Clinical Research Participation 
In order to identify ADRD-specific barriers, facilitators, and strategies influencing 
clinical research participation, one must first identify factors affecting general clinical 
research participation. The discussion of barriers, facilitators, and strategies is divided 
into four subsections: policy, system, organizational, and personal. This is followed in 
each case with a subsection on ADRD-specific factors and a summarizing conclusion. 
Policy 
 Governmental and institutional policies are intended to ensure the safety of 
participants and the quality of the study. However, these policies affect capacity to 
participate in clinical research. For instance, integrity of data collection and monitoring of 





detrimental effects on study expenditures and reduce funding allocated to participant 
recruitment and retention without evidence of the intended safety and quality benefits 
(Califf, 2006; Kramer, Smith, & Califf, 2012; Hemminki, 2016). As compared to the UK, 
Canada, and Finland where IRBs are run by the government nationally or by local 
municipalities, many U.S. research institutions have their own IRBs to determine which 
research studies take place and how (Hemminki, 2016). Though rigid national laws do 
not permit flexibility and case-by-case decision making, Hemminki (2016) is concerned 
by high costs in USA and the lack of ethical considerations of research purposes and 
dissemination of results. She argues that the time spent auditing and checking procedural 
formalities does not make research more ethical, and, in fact, the rules, procedures, and 
cost may deter clinicians from conducting research (Hemminki, 2016). This aligns with 
Kramer and his colleagues' (2012) review of clinical research impediments in the United 
States.  
 Though the scope of the IRB has expanded over the last three decades as 
pharmaceutical companies began funding more studies, there is no evidence that the 
safety and quality of clinical research has improved with the additional oversight (Dilts & 
Sandler, 2006; Kramer et al., 2012). For example, Dilts & Sandler (2006) cited one 
single-site oncology study that required 29 checks by 11 different people in order to be 
IRB approved, yet the IRB and investigators were unable to verify if the safety or quality 
of the research had been improved by those extra checks. The NIH has taken steps to 
reduce bureaucratic practices, such as permitting a single IRB review and approval for a 





done to further enhance and advance clinical research (Hudson, Lauer, & Collins, 2016; 
NIH 2017d).  
Despite U.S. requirements to disseminate results of clinical trials via PubMed 
Central and ClinicalTrials.gov, there are still issues of transparency and respect of 
participants. Investigators of NIH-sponsored studies do not need to disseminate results 
outside of the aforementioned, nor are they required to use clear and concise language.  
Thus, results are formatted as they would be for a peer-reviewed publication, not for the 
average participant, and are rarely disseminated to the participant directly. 
ClinicalTrials.gov is difficult to browse, though NIH directors plan to improve its 
formatting, featurability, and findability (Hudson et al., 2016). This directly contradicts 
what participants want; researchers have found that dissemination of results is so 
important to participants that, if they did not receive study updates, they would not enroll 
in a study again (Sood et al., 2009; Law et al., 2014). Disseminating results directly to 
those involved in research is frequently recommended in the literature (Israel et al., 2008; 
Carlisle et al., 2015; Mahon et al., 2016). 
System  
 System-level factors include the interactions among research organizations, health 
and social organizations and the community. A significant aspect of their interactions 
involves the community within and between sectors. When communities are not active 
participants in these interactions, this may result in overlooked opportunities and barriers 
to research enrollment. For example, community members may not be aware that 





Watson, Ryan, Silverberg, Cahan, & Bernard, 2014; Mahon et al., 2016; Anderson et al., 
2018). Lack of awareness of clinical research opportunities plays a large role in the 
diminished participation rates, though a large number of surveyed individuals say that 
they would participate if they knew of research opportunities (English et al., 2010; Grill 
& Galvin, 2014; Anderson et al., 2018). There is a disconnect between where research 
organizations assume community members will hear about studies, and where 
community members assume they will hear about research studies. Most assume their 
providers will inform them, but many clinicians do not involve themselves with clinical 
research but are more likely to learn of them through media advertisements (Friedman et 
al., 2015; Anderson et al., 2018). Additionally, though research studies are often posted 
on clinical research websites, many individuals report being unaware of, or not knowing 
how to find, clinical research opportunities on the internet (Sood et al., 2009; English et 
al., 2010; Kramer et al., 2012).  
 Some clinicians may not view research as a necessary piece of their clinical 
practice; others are concerned about increasing their risk of being sued or utilizing 
limited resources such as time, money, and workforce (Sugarman, Getz, Speckman, 
Byrne, & Emanuel, 2005; European Science Foundation, 2011; Kramer et al., 2012). In 
many schools, medical students are not properly trained in clinical research methods nor 
aware of clinical research opportunities at their academic medical center (Rahman et al., 
2011, Kramer et al., 2012, Meador, 2015). Consequently, there are fewer physicians 
acquainting themselves with current clinical research, resulting in fewer opportunities to 





Research organizations that are housed within, or partner with, healthcare 
providers may have access to patient data from an electronic health record (EHR) system. 
However, nonstandard nomenclature or not entering medical data in the same format, 
term, or entry area of the EHR may lead to gaps and overlook of potential participants 
(Califf, 2006; Richessen & Krischner, 2007; Kramer et al., 2012). Mahon and colleagues 
suggested adding a checkbox in the EHR to allow providers, if given permission by their 
patients, to permit researchers to access their records and contact them about clinical 
research opportunities (Mahon et al., 2016). A more passive option is to post flyers or 
brochures around a clinic to inform clinic patients of local research opportunities (Mahon 
et al., 2016).  
The NIA’s (2018) National Strategy to Increase Alzheimer’s Disease and Related 
Dementias Clinical Research Participation aims to recruit more people of color into 
research. In order for this to be successful, institutionally racist policies and practices 
needs to be recognized and mitigated. Structural or institutional racism, defined as 
“differential access to the goods, services, and opportunities of society by race,” is a 
significant systemic barrier to the inclusion of people with color (Jones, 2000, p. 1212; 
Freeman et al., 2017).  
Structural racism is well-known in the criminal justice and housing sectors, but 
also appears in the health and clinical research sectors (Delgado & Stefanic, 2001; 
Freeman et al., 2017). One example is the need for a diagnosis of ADRD, a frequent 
eligibility criterion for ADRD studies. Though African Americans have a higher 





stages of diseases, due to lack of access, transportation, language barriers, a lack of 
cultural competency, cultural beliefs about dementia and medicine, and real and 
perceived discrimination (Chin et al., 2011; Bonds & Lyons, 2017). This delayed 
diagnosed results in a missed opportunity to participate due to low cognition scores (Chin 
et al., 2011; Grill & Galvin, 2014; NIA, 2018). Other examples include requiring people 
to visit the clinic (which can exclude people of color who live too far away as a result of 
redlining and gentrification), failure to engage with African Americans because of 
assumptions that will not participate, and excluding cultural practices, such as collaborate 
decision making with friends and family members (Huang & Coker, 2010; Chin et al., 
2011; Danner et al., 2011; Penberthy et al., 2012; Frew Archibald, Hixson, & del Rio, 
2011; Grill & Galvin, 2014; Johnson et al., 2015; Mahon et al., 2016; Freeman et al., 
2017). 
One mechanism to recognize and reduce these barriers is to analyze policies and 
practices using Critical Race Theory (CRT). CRT recognizes that a racist person does not 
need be present in order for racism to exist and persist within a system; many policies and 
practices are embedded in white privilege and supremacy (Delgado & Stefancic, 2001). 
Additionally, CRT invokes the notion that identity and oppression is multi-dimensional, 
and intersectionality of gender, class, and nationality, as well as others, affect a person’s 
disempowerment in various settings (Delgado & Stefancic, 2001). CRT requires self-
reflection and community engagement with marginalized populations for praxis to be 





Community engagement among research, health, and social sectors can facilitate 
clinical research recruitment and retention (Frew et al., 2011; Grill & Galvin 2014; 
Watson et al., 2014; Mahon et al., 2016; Inungu et al., 2017; Gilmore-Bykovskyi et al., 
2019). Community-engaged strategies result in the research organization’s familiarization 
of target populations’ risk behaviors, which are essential to inform effective prevention 
strategies as they can both affect and inform research design, recruitment, and retention 
(Voytek et al., 2011; Luzi et al., 2011; Inungu et al., 2017).  
When research organizations partner with local health providers and social 
groups, they promote trust between the community and themselves (Gifford et al., 2002; 
Frew et al., 2011; Mahon et al., 2016; Inungu et al., 2017). For example, when 
neighborhood-based HIV medical and treatment programs and HIV support groups and 
services encouraged participation in an HIV-vaccine research, the likelihood of 
participation among members of a HIV-prevalent community increased (Frew et al., 
2011). Recognizing and reducing other structural barriers, such as transportation and 
geographic distance, also facilitates community member buy-in and subsequent 
participation, (Giffords 2002; Frew et al., 2011; Mahon et al., 2016, Inungu et al., 2017; 
Croff et al., in press). Among marginalized communities, the CRT practices of self-
reflection and community engagement is found to enhance trust and likelihood of 
research participation (Huang & Coker, 2010, Frew et al., 2011; Grill & Galvin, 2014; 







 Organizations and study sponsors frequently implement their own policies in 
order to adhere to good clinical and ethical standards. However, they may inadvertently 
cause barriers to clinical research recruitment and retention. For example, many research 
organizations’ IRBs take several weeks or months to review applications, grants, and 
contract reviews, despite no proof that this extra time improves the quality of their 
studies, delaying research for long periods of time (Dilts & Sanders, 2006; Kramer et al., 
2012). Additionally, study funders, such as pharmaceutical companies, can impose 
additional risk-averse practices including 100% source-document verification and on-site 
monitoring without quality improvement evidence (Kramer et al., 2012). To combat these 
high cost practices, research organizations could provide non-local study sponsors with 
data that are protected and accessible and discuss through video conference.  
Additionally, research institutions that are also academic or health centers do not 
always emphasize clinical research as a necessary skill. Students and new faculty may not 
be trained in clinical research or interpretation of randomized clinical trial results, and 
clinical research may be disincentivized in favor of basic research or general practice 
(Nathan & Wilson, 2003; Windish, Huot, & Green, 2007; Kramer et al., 2012). Studies 
conducted in the U.S. and the E.U. found that study eligibility criteria can severely 
restrict the enrollee pool of a research, making it difficult to obtain an adequate number 
of participants within the proposed time frame (Kramer, 2012; Adams et al. 2015; Mahon 
et al., 2016). Though the protocols aim to protect human subject safety, there are cases of 





comorbidities or medications, to avoid risk or delay of FDA approval (Kramer et al., 
2012).   
Communication facilitates clinical research decision-making ways that both 
increase and decrease likelihood of enrollment (Burke, 2014; Jenkins & Fallowfield, 
2015). An organization’s recruitment strategy may serve as a barrier to research 
participation. Monson and colleagues (2012) found that individually identifying and 
inviting people to participate in a study and offering a lengthy pamphlet on the study’s 
information does not provide potential participants with enough comprehensible evidence 
to make a fully informed decision to participate or not. When utilizing group 
presentations to discuss clinical research, 92% of attendees later enrolled in the study 
(Monson et al., 2012, 288). This recruitment strategy has been especially effective with 
minority populations (Williams et al., 2011; Heller et al., 2014).  
Actions that research organizations take to exemplify their gratitude or respect of 
the participant also affects the decision to participate in clinical research. For instance, 
90% of subjects in a study on research participation values stated they wanted to be 
informed of study results after the research had been completed, and over two-thirds 
found this to be such an important indicator of the research institution’s respect for them 
that they stated they would never participate in clinical research studies again if they were 
not informed (Sood et al, 2009, 244). These findings are consistent with other studies 
(Law et al., 2014; Anderson et al., 2018). African Americans’ willingness to participate 
in research is facilitated by community trust building, outreach, and community 





The discrepancy between what clinical research staff perceive they are doing 
versus what they actually do varies greatly. For instance, a large majority of staff 
recruiting HIV+ participants believed they actively recruited Black, Hispanic, and female 
individuals, yet felt most effective when interacting with white men (King et al., 2007). 
Staff also admitted to avoiding non-English speakers and active intravenous drug-users 
and did not directly market to racial and ethnic minority group members; staff reported 
they did so because they received penalties for loss-to-follow up and these population 
groups were more likely to drop out (King et al., 2007). This is consistent with other 
studies that failed to actively recruit African Americans (Uybico, Pavel, & Gross, 2007; 
Huang & Coker, 2010). This highlights an example of personally mediated racism, 
defined by Jones (2000) as differential assumptions or actions against others based on 
their race, whether intentional or not. The authors speculated that missed appointments 
might be due to lack of transport, ability to take off work, or child care, while avoidance 
of non-English speakers may be due to lack of translated materials and bilingual staff 
(King et al., 2007). King and colleagues (2007) suggested improving the diversity of 
providers and staff, using translated materials, and increasing community-based research 
as ways to improve trust between research teams and targeted participant groups. 
Despite higher rates of chronic disease diagnosis and mortality rates and inclusive 
regulatory mandates, less than 10% of African Americans participate in clinical  research  
(Owens, Jackson, Thomas, Friedman, & Hebert, 2013; Perez-Stable, 2018). When Owens 
and colleagues (2013) interviewed African American adults about their perceptions for 





they would not enroll. African American men and women more often referred to clinical 
research as “experiments,” and African American men were more likely to refer to 
participants as “guinea pigs” (Owens et al., 2013). When Corbie-Smith and her team 
(1999) interviewed African Americans in a Southern state, the interviewees 
overwhelmingly viewed research as beneficial to themselves and society but believed 
research institutions do not have their best interests in mind. One example cited by 
respondents was the use of informed consent forms; they believed that the forms were not 
actually for the participant’s safety but rather to protect the investigators from legal 
action (Corbie-Smith et al., 1999). Due to their experiences with institutional racism, as 
well as community effects from the Tuskegee Syphilis Study, the respondents expect 
“dishonesty” and “conspiracy” from research organizations (Corbie-Smith et al., 1999).  
Dialogue and education between research organizations and the African American 
community can mitigate some of the distrust (Danner et al., 2011; Owens et al., 2013). 
However, it does not automatically increase participation; after a 4-week clinical research 
education workshop with African Americans, there was no significant change in 
likelihood of participating in clinical research, but they were more likely to cite concerns 
of time commitments rather than fear or mistrust (Owens et al., 2013).  
 Researchers’ perceptions of African Americans also affect participation rates. 
African Americans are more likely to be deemed ineligible according to study criteria as 
compared to their white counterparts (Schneider et al., 1997; Chin et al., 2011; Penberthy 
et al., 2012). When investigators from Virginia Commonwealth University analyzed 





African American and White cancer patients were similarly excluded due to 
comorbidities and cancer-related characteristics, but African Americans were 
significantly more likely to be excluded from the study due to perceived/documented 
incapacity to provide informed consent and expected noncompliance (Penberthy et al, 
2012).   
Personal 
 Though studies have found that many individuals would hypothetically participate 
in clinical research, willingness does not correlate with actual enrollment (Buchbinder et 
al., 2004; Grill & Galvin, 2014; Inungu et al., 2017). Many individuals cite time 
commitments and scheduling issues, distance, and need for more information as reasons 
why they could not enroll (Penberthy et al., 2012; Owens et al., 2013; Gollhofer et al., 
2015; Friedman et al., 2015). Others cite ambiguity of informed consent, fear of side 
effects, and fear of randomization (e.g. receiving a placebo) for why they would not 
consider participation (Penberthy et al., 2012; Owens et al., 2013; Friedman et al., 2015). 
Financial incentives, ease of transportation, receiving more information about studies, 
and partnering with trusted community leaders are frequently cited ways to improve the 
likelihood of participating (Brown et al., 2013; Golhoffer et al., 2015; Friedman et al., 
2015, Mahon et al., 2016; Anderson et al., 2018; Croff et al., in press).  
In addition to mistrust of research organizations, African Americans faced 
significant barriers to participating, wanting to make decisions collaboratively with 
family and recommendations against participating from family members and friends as 





willingness to participate, and those who have participated, cite altruism, benefit to 
themselves or someone they know, and financial incentives (such as free healthcare or 
stipends) as reasons they want to participate (Owens et al., 2013; Friedman et al., 2015; 
Gollhofer et al., 2015).   
This evidence illuminates that though an individual has the final say in 
participating in clinical research, their decision is heavily influenced by a variety of 
factors. Decisions made in policy, system, and organizational spheres directly or 
indirectly affect the capacity for a person to enroll in a research study, and also their 
motivation to do so.   
ADRD-specific facilitators and barriers to participation 
 Individuals with ADRD face additional barriers to research participation. 
Approximately 10-27% of people with ADRD are eligible to participate in research due 
to comorbidities, incompatible medications, low cognition scores, and frailty (Grill & 
Galvin, 2014). Additionally, study partners are required to participate with the individual 
with ADRD to ensure protocol adherence and appointment attendance, further 
complicating the process due to their own reasons for not being able to participate 
(Karlawish et al., 2008; Watson et al., 2014; Grill & Galvin, 2014; Cary et al., 2015; 
Black et al., 2018). Though these barriers may differ from those of general clinical 
research, drawing upon the literature from other populations with similar barriers could 
assist with identifying further facilitators.  
Adult children are more likely to serve as caregivers whereas spouses are more 





general consensus among individuals with ADRD and study partners that proxy consent 
is appropriate, and most patients cede decision-making to their study partner (Karlawish 
et al., 2008). However, study partners make proxy decisions based on reasons aside from 
previously expressed preferences, including direct benefit to the person with ADRD, 
altruism, and caregiver support and education (Karlawish et al., 2008; Cary et al., 2015; 
Black et al., 2018). Study partners are more likely to agree to participation if they 
perceive the research as safe (Cary et al., 2015). Caregiver burden is not associated with 
refusal; in fact, many study partners perceive their role as an extension of caregiving 
responsibilities (Black et al., 2018). Common study partner barriers and facilitators to 
participation are similar to the general clinical research barriers (e.g. mistrust, direct 
benefit, travel), but also include unique reasons. For example, a barrier may be the 
emotional distress of not knowing answers or the realization of ADRD progression, 
whereas a facilitator may include caregiver support or education (Black et al., 2018). 
Individuals with intellectual disability (ID) are another community that have very 
low research participation rates, and often require a study partner (Lennox et al., 2005; 
Feldman, Bosett, Collet, & Burnham-Roisa, 2013). When Lennox and colleagues (2005) 
conducted a study with individuals with ID, they found that study partners, both family 
members and care staff members, were not enrolling in the studies due to burden of care, 
burnout, and mistrust of the research staff. The team consulted with a community 
advisory board, comprised of adults with ID, parents of children with ID, support 
workers, an occupational therapist, and a professional advocate, to develop strategies for 





“insider” within an organization that serves adults with ID to call prospective participants 
to provide information about the study. Additionally, public information sessions were 
held to provide more details, answer questions, and establish a relationship with ID 
community members. Using these two strategies, recruitment and participation 
significantly improved.  
Reasons for not participating within the ID community were similar to the 
experiences of people with ADRD. Family caregivers of people with ID commented that 
they did not have much financial or personnel support, and any additional time constraint, 
such as participation, was not a priority (Lennox et al., 2005). People with ID, their 
informal caregivers, and care workers also reported perceptions of discrimination by 
specialists and hospitals and may perceive research staff as an extension of that 
workforce (Lennox et al., 2005). Additionally, nearly 90% of the adults with ID eligible 
for the study required study partners due to their lower IQ scores, leading to the potential 
for refusal due to study partner dissent (Lennox et al., 2005; Feldman et al., 2014). 
Though ethically necessary to protect people with low cognition, requiring study partners 
also denies individuals who may have wanted to participate but are banned from 
inclusion without one. Lennox and his team (2005) recommended the use of participatory 
research strategies to allow the person with ID to be more of a partner than a participant.  
To further promote inclusion of ID community members in research, academics, 
advocates and individuals with ID suggest modifications and accommodations, including: 
extra time, one-on-one support, taking breaks, simplifying the language in the informed 





comprehension (Lennox et al., 2005; Feldman et al., 2014; Nicolaidis et al., 2015; 
McDonald et al., 2016). 
A provider’s lack of time, cognitive assessment training, and knowledge of 
research opportunities to accurately refer eligible patients to ADRD research hinders 
likelihood of participation (Grill & Galvin, 2014; Watson et al., 2014). As discussed in a 
previous section, not having a proper diagnosis in the first place inhibits the ability to 
participate in a clinical research. Churches and other religious institutions often serve as 
community centers for those with religious ties and may serve as another trusted source 
in addition to a provider. In a survey of clergy leaders about their church’s dementia-
friendliness, most churches reported dementia-inclusive events and practices such as 
shared meals, games, and frequent event reminders. However, the leaders also noted that 
they did not know where to find dementia resources or where to refer patrons to (Plunkett 
& Chen, 2016). The investigators suggested networking with churches to develop 
programs that better serve patron needs (Plunkett & Chen, 2016). A partnership between 
a research organization and a religious institution may establish trust between the two and 
facilitate recruitment. 
In St. Louis, one Alzheimer’s Disease Research Center (ADRC) has utilized 
many previously discussed motivators and strategies to improve research participation 
among African Americans with ADRD. The African American Outreach Satellite 
program (Satellite) works with the St. Louis Alzheimer's Disease Research Center to 
provide home-based assessments, dementia diagnoses and services, and recruitment 





their 25+ year history, they have developed sustainable relationships with older African 
American adults, caregivers, and community leaders as well as health care providers and 
local Area Agencies on Aging (Williams et al., 2011). Satellite’s work with an African 
American advisory board, the Alzheimer's Association, local clergy and religious groups, 
and other community partners helped establish and implement a variety of outreach 
strategies to increase African American recruitment in ADRD clinical research (Williams 
et al., 2011). Over a ten-year period, African American participation rates increased from 
8.6% to 19%, comparable to the St. Louis population rates (Williams et al., 2011). 
Conclusion 
 Scientists, the health and LTSS workforce, and policymakers expect an 
exponential increase in ADRD diagnoses in upcoming years, and hope for a prevention or 
treatment within the next seven (Collins et al., 2018; Alzheimer’s Association, 2018a; 
Gates, 2017). Despite significant funding and calls for research participation, ADRD 
clinical research enrollment remains low due to a variety of policy, system, 
organizational, and personal factors. Ethical guidelines and clinical policies have been 
put in place to ensure that participants are allowed to participate in studies for individual 
and collective good but are protected from harm. However, for people with ADRD, this 
has led to significant restriction of opportunities. The literature review highlighted the 
barriers of requiring a study partner, but also offered strategies to improve participation 
and the use of modifications that can be utilized and promote inclusiveness for 





Many of the system and organizational level barriers center on communication, or 
lack thereof, between and among different communities, organizations, and sectors. 
Furthermore, structural racism has led to health and research participation disparities 
among African Americans. Identifying these barriers is the first step, addressing them is 
the second. Using the CRT approach, removing these barriers requires self-reflection and 
community engagement with mitigate power structures and emancipate African 
Americans from structural racism. It is a long, arduous process, but is imperative to 
ensure that the community with the highest prevalence of ADRD has the same 
opportunities to participate and is not impeded by former and current actions from 
medical and research organizations. As exemplified by the Satellite program in St. Louis, 
when efforts are made to listen to and include all members from various directions, the 
ability to significantly increase recruitment and retention of individuals with ADRD into 
clinical research is possible. The next section elucidates some of the theories and 
frameworks that support those efforts. 
 
Theories and Frameworks That Pertain to This Study 
This section of the literature review provides an overview of the organizational theories 
and policy frameworks that are relevant to this study. The first section begins with a 
discussion of relevant organizational theories. These theories, transaction cost and 
contingency theory, fall into the school of open rational systems. The next section 
describes the social construction framework and policy feedback theory, two relevant 





connects it to the concept of research participation. Finally, the last section identifies and 
describes a framework that incorporates elements of civic engagement and the 
organizational and policy theories: the Robert Wood Johnson Foundation’s Culture of 
Health Action Framework. 
Organizational theories 
 Clinical research organizations are currently structured to adhere to both national 
and international good ethical and clinical regulations and practices, but also to meet the 
needs of the investigators and research staff in order to achieve the goal of finding a 
prevention strategy or treatment of ADRD by 2025. These regulations and practices, 
while important, are not flexible towards environmental needs such as the preferences or 
needs of people with ADRD. Additionally, some health and social sectors factors that 
further impede or facilitate an individual with ADRD’s likelihood and ability to 
participate in research, such as time for a provider to discuss research opportunities, are 
outside of the research organization’s control. Based on the body of literature reviewed, 
ADRD research organizations would benefit from a design that maintains the rigidity 
needed to meet their goals but also provides flexibility based on environmental needs and 
influences. Organizational theories that best describe the shift that research organizations 
should strive for are those within the school of open rational systems theory (Scott, 
1987). Theories in this school assert that organizations are a means to a predetermined 
end but recognize the influence that environments can have on staff roles and decision-





Transaction cost theory: Pioneered by Williamson (1975), transaction cost theory 
suggests that every transaction between two parties (both within and among organizations 
or groups) is subject to a cost. The theory has four components that are heavily based on 
market principles. Uncertainty reflects environmental changes that are outside the control 
of the organization, and potentially cause market instability (Williamson, 1975). Small-
numbers bargaining refers to the power parties have over a contract (Williamson, 1975). 
This can include the number of organizations or customers available to the party, or the 
routines or expectations that are expected from the agreement. Bounded rationality refers 
to the imperfect information surrounding the members or transactions, as well as the 
cognitive or emotional barriers to perfect knowledge (Williamson, 1975). Bounded 
rationality can result in opportunism, where one employee or community member is at 
the mercy of the other (Williamson, 1975). Bounded rationality and opportunism are 
affected by uncertainty and small numbers bargaining.  
Though this theory revolves around economics, it can be applied to the 
relationship between the research organization and people with ADRD, where the 
transaction is participating in a research study. Uncertainty includes unawareness about 
the study process, or inability to learn more about research post-participation. Small 
bargaining is affected by the fact that it is completely voluntary to enroll, so the 
participant has the power to not join a study or drop out at any point. Bounded rationality 
includes the perspectives of the study, such as historical and perceived grievances against 
the research community. Opportunism includes that fact that the participant is at the 





(Williamson, 1975). When these components, and the subsequent transaction cost, are too 
high to enter into a transaction, the organization benefits from a hierarchical structure to 
reduce uncertainties and small numbers bargaining. However, this organizational 
structure does not guarantee that the transaction cost will be at the optimal level to reach 
an agreement. Currently, the transaction cost is too high for many people with ADRD 
despite mitigating factors through the hierarchical structure, as evident though the lack of 
participation. Adjustments could be made within the research organization to further 
reduce the transaction costs for the future research participant.  
Contingency theory: Another relevant organizational theory is contingency theory, 
which states that the best way to organize is dependent, or contingent, on the nature of the 
organization’s environment (Galbraith, 1973). Lawrence and Lorsch (1967) specify that 
the structural function of the organizational subunits and the differentiation and mode of 
larger organization integration must align with the needs of the environment. Structured 
protocols can and should still exist within the research institution but should allow for 
flexibility as necessary to meet the organizational goals of increasing research 
participation and ability to restructure as necessary.  
Mintzberg builds upon contingency theory to explore how bureaucratic 
organizations can develop environmentally-influenced rigid structures and create a more 
efficient organization. In Structure in Fives: Designing Effective Organizations, 
Mintzberg (1983) describes five categories of the organization as is illustrated in Figure 
2.1. The operating core includes the frontline staff who perform direct support tasks 





comprises the executive staff members who are responsible for the entire organization. 
They directly supervise staff, ensure the organization adheres to its mission, and meet the 
needs of external stakeholders who have control over the organization. The middle line 
includes middle management staff who perform tasks related to supervision of the 
operating core, supervision from the strategic apex, and communication through vertical, 
horizontal and external channels. The technostructure staff support production through 
training, designing and planning, but do not perform production work themselves. Lastly, 
the support staff focuses on tasks unrelated to production, but support the organization in 
other ways, such as legal counsel or cafeteria staff.   
 
Figure 2.1 Mintzberg’s Model of Organizational Structure 
 
 
Source: Mintzberg, 1983, p. 11 
 Mintzberg (1983) further specifies five coordinating mechanisms. With mutual 
adjustment, coordination exists within the same level of hierarchy through informal 
communication. With direct supervision, higher level staff is responsible for lower level 
staff. Furthermore, there is the standardization of processes (specified tasks), outputs 





Mintzberg also describes design parameters and structural parameters. Design parameters 
include role specialization, behavioral formulation, training and indoctrination; structural 
parameters include unit size, unit grouping, action planning and control systems.  Every 
individual within the organization is internally influenced by these structures, 
mechanisms, and parameters. 
Mintzberg’s interpretation of contingency theory can be illustrated within the 
context of the proposed research study. Research assistants, usually at the forefront of 
recruiting, consenting, and enrolling individuals into studies, serve as the operating core. 
Investigators who design, secure funding, and lead the research serve as the strategic 
apex. Research coordinators manage and implement the studies, supervise research 
assistants, are supervised by investigators, and serve as middle line employees. IRB 
members, who ensure that research studies adhere to clinical and ethical regulations, 
serve as the technostructure. Research administrators who keep up to date with policies 
and procedures and handle back-end operations, also serve in this capacity. Lastly, 
support staff encompasses a large swath of research organization employees, including 
legal counsel, front desk staff, janitorial staff, and cafeteria workers. 
Three of the five coordinating mechanisms -- mutual adjustment, direct 
supervision, and standardization of procedures -- are self-explanatory and do not need 
specific research examples. Specific outputs may include obtaining informed consent, 
study completion, and dissemination. Standardization of skills may include research 





parameters, including friendliness and number of office employees, may differ from 
place to place but may influence the individual and the organization as a whole. 
 Given the tight hierarchy and number of regulations that must be adhered to (e.g. 
NIH and hospital-specific policies), it is difficult to completely redesign roles and 
structures of middle- and upper-level staff. However, the investigators could begin to 
include community members as external stakeholders whose needs should be considered 
in regard to the organization’s mission. Research coordinators can communicate with 
external stakeholders, encouraging capacity building, and ensure that research assistants 
adhere to new internal policies based on external stakeholder needs.  
At the operating core, several structures can be modified to increase clinical 
research participation, depending on the environment. For instance, the research 
assistant’s skills could expand to incorporate personality traits and require greater 
comprehension of study background, methods and goals in order to explain to 
participants why being in the study is of value to them. Similar duties and responsibilities 
are found in service industries; operating core staff (e.g. customer service representatives) 
personalities and knowledge about products and organizational values frequently 
determine a customer’s decision to conduct business with an organization. Similarly, 
research assistants are the first point of contact for potential research participants and are 
required to obtain informed consent. Without a friendly demeanor and comprehensive 
knowledge about the study, eligible individuals may be dissuaded from participating, 





Policy frameworks and theories 
 Two policy frameworks, social construction framework and policy feedback 
theory (PFT), are applicable to ADRD clinical research participation.  
Social Construction Framework: The social construction framework can be used to 
elucidate the power that people with ADRD wields in society. This theory posits that 
policies are contingent on policymaker and societal interpretations and values (Schneider, 
Ingram, & deLeon, 2014). Policy designs (e.g. benefits, rules, problem definition) affect 
perceptions of target groups (e.g. people with ADRD), culture, and policymaking 
dynamics, culminating in future policy designs (Schneider et al., 2014). Benefits and 
burdens are allocated to target groups based on their political power, and their social 
construction (Schneider et al., 2014). Policies have consequential effects on society's 
attitudes towards target groups and the group’s political participation (Schneider et al., 
2014). At the same time, the policy effects influence both policymakers and society’s 
decision-making and selection of future policy elements (Schneider et al., 2014). Changes 
in the target population’s political power and social construction result in changes in 
public and personal perceptions, leading to policy change and further changes in the 
target population’s material and interpretive effects, political power, and social 
construction (Schneider et al., 2014).   
According to the framework, there are four categories of target groups, derived 
from political power and societal perceptions. The first category encompasses the 
Advantaged, who are positively viewed and powerful. The second includes Contenders, 





viewed and powerless. The fourth, Dependents, are positively viewed yet powerless.  
Examples of this framework in action are evident within the older adults’ group and their 
transition from one category to another. 
Older adults were considered Dependent for most of the 20th century. Many 
policies that provided benefits, such as Social Security and the Older Americans Act, 
were met with little resistance because of the older adults’ positive image and 
powerlessness in society (Hudson & Gonyea, 2014). Estes’ work on the Aging Enterprise 
highlights the Dependent category that older adults were grouped into prior to the 1980s, 
at which point the Reagan administration decentralized programs established by the 
Older Americans Act, and local and state governments took charge of resource allocation, 
planning, and service delivery (Estes, 1980). When resources were threatened, older 
adults became more politically active; as their advocacy groups became more vocal and 
gained more resources, they became one of the most powerful players in society and have 
successfully shifted to an Advantaged target population (Hudson & Gonyea, 2014). In 
fact, twenty-five years after Estes’s work was published, the director of the AARP 
encouraged businesses to focus their marketing efforts on the aging population, boasting 
that their independence and wealth could boost the economy if they are targeted with age-
friendly products (Moody, 2004). Though the perceptions of the elderly population at 
large have shifted, older individuals with cognitive impairment still reside in the 
Dependents category. Policy designs and public perception haves deemed them worthy of 





making. This is evident within the research sector as study partner consent is required in 
order to move forward with participation. 
Policy Feedback Theory: Policy Feedback Theory (PFT) can be used to conceptualize 
the motivation strategies for research participations. Skocpol (1992) coined “policy 
feedback” as the fourth of four hypotheses in her “Policy-Centered Analytical 
Framework of American Social Provisions.” She suggests that policies implemented in 
Time Period One establish policy feedback through transformed state capacities (further 
defined by her as “administrative possibilities for official indicatives in the future and 
affect later prospects for policy implementation") and changes in social groups and their 
political goals and capabilities (Skocpol, 1992, p. 58). This policy feedback paves the 
way for policies implemented in Time Period Two. This is important because it captures 
the idea that a group’s goals and capabilities both influence its preference for future 
policies.   
One year later, Pierson expanded on Skocpol’s work with his 1993 article “When 
Effect Becomes Cause.” His framework introduced three actors affected by feedback: a) 
government elites, b) interest groups, and c) mass publics, as well as the two mechanisms 
of feedback effects affecting these actors: a) resource and incentive effects and b) 
interpretive effects (Pierson, 1993). Resource and interpretive effects shape the actors’ 
political behaviors while the interpretive effects convey information and meaning to 
them. Pierson’s work is seminal because it transformed policy feedback from a term to a 





future research directions that future PFT scholars could take. Two scholars who have 
made considerable leaps in the PFT realm are Suzanne Mettler and Kristen Goss. 
Mettler’s policy feedback for mass publics: Mettler (2002) has produced the most work 
on PFT to date, which largely focuses on civic engagement by community members, or 
what she refers to as mass publics. She established key components of civic engagement 
centered around Pierson’s mechanisms of policy feedback, as shown in Figure 2.2.  
Figure 2.2 Policy Feedback for Mass Publics: How Policy Affects Civic Engagement  
 
 
Source: Mettler & Welch, 2004, p. 511  
 Mettler argues that payments, goods, and services establish resource effects, 
which affect civic capacity, or “aptitude, ability, or faculty to participate” (Mettler, 2002, 
p. 352). Resource effects also influence civic predisposition, defined as “the perceptions 
of their role in the community, their status in relation to other citizens and government, 
and the extent to which a policy has affected their lives” (Mettler, 2002, p. 352). Civic 
predisposition is also affected by the interpretive effects established through rules and 
procedures. Ultimately, both an individual’s civic capacity and predisposition affect their 
civic engagement. 
 Mettler’s framework can be applied to individuals with ADRD’s likelihood of 





potential benefits and risks of participating and contributing to society, education about 
and information on participation, and monetary compensation, all of which can affect 
both the ability an individual has to participate and their likelihood of participating. Their 
predisposition is also susceptible to rules and procedures, such as a rule to disseminate 
research updates and findings summaries to participants. Using Mettler’s framework, 
policy changes can be made from the organizational level rather than the government 
level. A systematic review conducted by Newington and Metcalfe (2014) found several 
facilitators to increase participation rates. In addition to providing lay summaries to the 
participants, which has been discussed at length already, examples include: providing 
information on clinical studies at local community organizations, reducing the number of 
times a participant needs to travel to the study site, and having a good relationship with 
the participant’s caregiver and clinician (Newington & Metcalfe, 2014).  
 On its own, Mettler’s framework provides a good starting point for evaluating 
policy effects on clinical research participation rates. However, it does not capture the 
effects from societal influence and organizational policies. In order to capture the effects 
that these variables have on clinical research participation among people with ADRD, a 
supplemental policy framework is needed.  
Goss’s multi-level policy feedback process: Goss’s framework centers around the belief 
that society-level organizations are “vital to notions of individual’s place in polity” 
(Goss, 2010, p. 122). She referred to these influences as “the organizational level” and 





influence the organization level in five ways, which in turn influence an individual’s civic 
engagement (Goss, 2010, p. 120):   
1. Government policies “structure the political orientation of civil society by 
stimulating the development of certain types of groups and strategies, while 
constraining others, with implications for the range of participatory opportunities 
afforded to individuals.”  
2. Second, they “alter the capacity of civil society groups, including resources and 
political learning, to channel civic engagement towards non-political strategies of 
social improvement.”  
3. Third, government policies “affect the framing of strategies in a way that might 
influence mass attitudes about the optimal form that civic engagement should 
take.”  
4. Fourth, government policies “define civic membership” and “forge political 
community in ways that encourage rights-based advocacy over communitarian 
notions of public service.”  






 Figure 2.3 Multi-Level Process Feedback  
 
Source: Goss, 2010, p. 124 
 The numerous ways that policy shapes civic engagement through civil society 
also resonate with clinical research participation. A summary of how policies shape 
clinical research participation follows, based upon the literature review: 
1. Government policy structures the organizational level: As previously mentioned, 
the U.S. Congress has allocated over 2 billion dollars to the NIH specifically for 
ADRD research for the period. The NIH in turn determines how many grants they 
award to ADRD research organizations, as well as how much funding is allocated 
per grant. The amount of funds and the number of grants accepted drastically 
influences the studies an organization can conduct, the length of time they have to 
conduct the research, the number of research staff they can hire, and the 
compensation they can offer a research participant. Additionally, NIH policies, 
such as inclusion policies and 21st Century Cures Act (2016), affect inclusion and 
review criteria, data collection and analysis, and dissemination (NIH, 2017c). 
2. Government policy affects capacity of groups at organizational levels: In addition 





increase or decrease grant funding for interest groups and nonprofit service 
providers, such as the Alzheimer’s Association. Aside from offering educational 
and networking resources to ADRD individuals, caregivers, and professionals, 
they also provide a database for ADRD clinical research opportunities. Policies 
that decrease or underfund interest groups and nonprofits result in decreases in 
resources available to the organizations, and ultimately affect those who utilize 
these organizational resources.  
3. Government policy frames the organizational level’s predisposition: Interpretive 
effects from government policies not only affect individual predisposition to 
participate in clinical research, but also a group’s predisposition to discuss or 
recommend opportunities to individuals. Organizations that want to increase 
ADRD clinical research participation are likely to discuss and recommend 
opportunities with people with ADRD. However, as previously mentioned, many 
individuals do not know where to obtain information about clinical research but 
expect to find out about research opportunities from their providers. Current 
policies hinder a provider’s predisposition to discuss and recommend clinical 
research, such as a lack of time and reimbursement. Though clinicians can bill for 
a number of services, discussion of clinical research is not one of them 
(Fernandopulle, 2015).  
4. Policies define membership, forge community relationships and promote 
advocacy: Just as belonging to a civic engagement group influences attitudes of 





influenced in the same manner. Participants are proud to contribute to science and 
the quest for medical breakthroughs, even if they do not receive a therapeutic 
benefit themselves. Some research organizations, such as the OHSU Layton 
Aging and Alzheimer’s Disease Center and the University of Washington 
Memory and Brain Wellness Center, offer community events and support groups 
for research participants or refer them to local government and community 
organizations, fostering relationships with other individuals with ADRD (OHSU 
Brain Institute, 2018; University of Washington, 2018). Moreover, both 
organizations and interest groups advocate for policies that promote research 
participation. The advocacy at the organizational level in turn provides 
individuals with greater capacity and predisposition to participate.  
Civic engagement  
 Civic engagement embodies the notion that community members contribute 
individually and collectively in order to better their communities. Civically engaged 
individuals work together and develop their knowledge, skills, values, and motivation to 
make a difference in their community by promoting its quality of life (Ehrlich, 2000). 
Civic engagement in American society has gradually declined during the last half of the 
20th century (Putnam, 2000); however, when crises affect a community, such as a terrorist 
attack or natural disaster, civic engagement rates increase as measured by voting, 
discussing political affairs, and volunteering to mobilize community building efforts, 
including political campaigns and blood drives (Putnam, 2000; Sander & Putnam, 2010). 





civic engagement in times of stability. They have found that organizations, governments, 
and policies influence the community’s ability and motivation to participate in civic 
engagement activities (Bellah et al., 1991; Denhardt & Denhardt, 2003; Vigoda-Gadot & 
Cohen, 2004; Chandra et al., 2016). This section primarily describes civic engagement 
research conducted in the public administration realm but includes other examples from 
higher education and health services. Their compatibility with ADRD research is woven 
in throughout. 
Civic engagement in public administration: In The Good Society, Bellah and his 
colleagues suggest that a public commitment to building a) institutions, b) family support, 
c) quality education, and d) self-respecting work empowers individuals to participate and 
serve as community stakeholders (Bellah et al., 1991). These values can also be translated 
to the clinical research realm: a public commitment to building supportive regulations 
and initiatives for research institutions, supports for people ADRD and their caregivers, 
quality education on clinical research history, purpose, and opportunities, and treating 
research participants as respective, collaborative partners could empower individuals to 
act as stakeholders and participate in clinical research. Thus, a civic engagement 
framework is relevant to this research.  
Similarly, public administration scholars Vigoda-Gadot and Cohen (2004) suggest 
moving away from the idea of viewing community members as subjects or voters; 
instead, the government should treat community members as customers and be 
responsive to their needs. They suggest that the best way to do so is by forming and 





local private, nonprofit and volunteer organizations, local initiatives that foster 
democratic education and participation and involvement, and community members’ 
innovative ideas for problem-solving (Vigoda-Gadot & Cohen, 2004). These partnerships 
can enhance community involvement in the government and “generate(s) commitment to 
a healthy public service, proper understanding of what is right and what is wrong in 
managing public organizations, and education towards constructive participatory 
democracy” (Vigoda-Gadot & Cohen, 2004, p. 14).  
Denhardt  and Denhardt (2003) advocate for a public administration governing 
style that encourages civic engagement by including community members as active 
stakeholders, distinguishing themselves from older styles such as “old public service” and 
“new public management” where community members are treated as beneficiaries or 
customers. In “old public service”, politics is separated from administration, and public 
organizations are organized in hierarchies to ensure “greatest possible efficiency in their 
operations,” with limited citizen involvement (Denhardt & Denhardt, 2003, pp. 6-7). 
From there stems “new public management” which relies on market mechanisms (e.g. 
competition, contracting) and is supported by rational choice and managerialism, in 
which business and public sector success relies on management quality and 
professionalism (Denhardt & Denhardt, 2003). A newer wave of public administration, 
known as “New Public Service”, positions community members and public officials to 
work together to define and to address common problems in a cooperative and mutually 
beneficial way. The “New Public Service” incorporates the following seven lessons 





1. Serve citizens1, not customers: The public interest is the result of a dialogue about 
shared values rather than the aggregation of individual self-interest. Therefore, 
public servants do not merely respond to the demands of “customers,” but rather 
“focus on building relationships of trust and collaboration with and among 
citizens” (Denhardt & Denhardt, 2003, p. 45). Though self-interest plays a role, 
the shift to thinking democratically has greater benefits for both society and its 
individuals.  
2. Seek the public interest: In the New Public Service, public servants aim to 
encourage community members to think about their shared values with each 
other, further develop those values, and increase their capacity to help the public 
interest. To do so, trust must exist between government and community members. 
3. Value citizenship over entrepreneurship: In the New Public Service, it is not 
enough for the administrators to create and implement policies; they must also 
continually engage with the community to recreate and rearticulate public values. 
Community members actively participate by defining and managing the 
processes.   
4. Think strategically, act democratically: In the New Public Service, community 
engagement and community building are part of implementation. Government 
leaders and public servants must first show that they are open, accessible, and 
                                               
1 Denhardt & Denhardt use the term “citizens”; I choose to use the term “community members” as it 
recognizes and includes non-citizens living in the community. When direct quotes are used, the term 





responsive, and can create opportunities that incentivize the community to 
collaborate on various programs. 
5. Recognize that accountability isn’t that simple: In the New Public Service, public 
administrators are responsible for taking “political authority seriously” in addition 
to their “obligations with respect to the duties of others as well as the role of the 
responsible public servants in policy formulation and implementation” (Denhardt 
& Denhardt, 2003, p. 134). This means that leaders are elected or appointed to 
their positions based on their values and expertise, however, their policy decisions 
must result from a participatory process that includes administrative supervisors 
and community members. Ultimately, public servants are accountable to 
everyone.    
6. Serve rather than steer: In the New Public Service, leaders share their 
responsibilities, are value-based, and recognize that their role is to serve the 
community, not own them. Public administrators must view their role as 
responsible participants who share power, work with people, and broker solutions.  
7. Value people, not just productivity: In the New Public Service, “public 
organizations and the networks in which they participate are more likely to be 
successful in the long run if they are operated through processes of collaboration 
and shared leadership based on respect for all people” (Denhardt & Denhardt, 
2003, p. 155). Rather than attempting to control behavior, management processes 
are established and modified based on the needs, values, interests and input from 





our commitment to democratic ideals and the trust of others” (Denhardt & 
Denhardt, 2003, p. 165). This means that in order to expect community members 
to be committed to democratic ideals and trust their government and community, 
the government must include them as partners and provide the same trust and 
respect that they strive for.   
Civic engagement scholars have also identified the flawed assumption that some 
community members will forget past negative, and often egregious, relationships to forge 
new ones that may produce a benefit (Bellah et al., 1991; Denhardt & Denhardt, 2003). 
This is also evident in the clinical research sector. For example, members of the African 
American community are more likely to be diagnosed with ADRD, yet less likely to 
participate in clinical research for previously discussed reasons (Danner et al., 2011; 
Gilmore-Bykovskyi et al., 2019). However, when clinical research organizations take 
time to establish a relationship that builds trust and respect and provide full information 
about study opportunities in a clear, understandable manner, African Americans are more 
likely to enroll in their studies (Gifford et al., 2002; Danner et al., 2011; Inungu et al., 
2017; Gilmore-Bykovskyi et al., 2019). 
Civic engagement in higher education: Civic engagement scholarship has also emerged 
from the field of higher education. Traditionally, higher education implored and 
motivated students to expand their minds and improve their community. In the mid-20th 
century, many universities began to offer or require service-learning courses, where 
students apply what they have learned in the classroom directly to the community, most 





& Pollack, 2001). Additionally, college campuses became hotbeds for student protests of 
policies and norms that negatively impacted their community (Lounsbury & Pollack, 
2001).  
By the turn of the century, scholars asserted that higher education had shifted 
towards courses and student opportunities that may result in better, higher-paying jobs 
rather than community engagement and societal benefit (Kerr, 1994; Boyer, 1996; 
Battistoni & Longo, 2011; Saltmarsh & Hartley, 2011). Universities’ ideas of knowledge 
were viewed through an academic lens, impeding a view of the public’s understanding 
(Mathews, 2000). Furthermore, institutionalization gradually shifted control and 
resources away from students to people with formal power and bureaucratic authority on 
campus (Lui, 1996). Saltmarsh & Hartley (2011) identify several ways in which higher 
education has undermined its democratic processes. First, faculty pursued narrow 
specialties, which advance theories but do little to address social problems. Second, 
corporatization of universities had created a dissonance between programs and shaping 
other practices. This means that as majors and programs became more specialized 
towards career aspirations, there became less of a focus on general education, 
consequently segregating students by major. Third, a crisis in undergraduate teaching and 
decontextualized learning occurred, where many professors unduly influenced students 
without providing relevant experiences. Fourth, there was a sense of civic disengagement 
and hibernation in that universities did not teach students to be citizens. Lastly, there was 
a lack of “general reciprocal learning;” instead of being guided by Freire’s advocacy of 





faculty arrived at the idea that student knowledge was not legitimate as compared to 
faculty knowledge (Botye, 2008).  
Since then, academic institutions have worked to revert back to the civically 
engaged ways of the mid-century. For example, Widener University in Pennsylvania 
requires their physical therapy students to engage in service-learning by providing blood 
pressure screenings to low-income seniors and working pro bono at a local safety clinic 
(Palombaro et al., 2017). Compared with students who did not participate in service 
learning, the physical therapy students became more civically minded over the course of 
their program (Palombaro et al., 2017). Other higher education institutions have remained 
civically engaged. For example, the West Philadelphia Improvement Corps (WEPIC), a 
school-community-university partnership, has been in existence since 1985 (Benson, 
Harkavy & Puckett, 2011). In this partnership, the University of Pennsylvania works with 
two local high and middle schools to motivate and teach youth to revitalize their 
communities. Over the past three decades, they have established adult education classes, 
job training, drug prevention programs, and community outreach (Campus Connect, 
2016). The WEPIC partnership exemplifies another concept of civic engagement in 
higher learning, knowledge mobilization, discussed in the Culture of Health section.  
Similarly, Portland State University (PSU) has established sustainable 
partnerships with many community organizations and members since the mid-1990s 
(Holland & Gelmon, 1998). These partnerships are sustainable in part due to mutually 





measured by both university and community standards, and consistent capacity building 
and evaluation (Holland & Gelmon, 1998).  
Saltmarsh & Hartley (2011) believe that for higher education to shift towards a 
civically engaged approach, local stakeholders must be included and values of 
“inclusiveness, participation, risk sharing and reciprocity in public problem solving, and 
an equality of respect for the knowledge and experience that everyone involved 
contributes” need to be invoked (Saltmarsh & Hartley, 2011, p. 18). Battistoni & Longo 
(2011) suggest that students need to be part of the conversation, but also suggest a change 
in the way that civic engagement is conceptualized, taught, and practiced. They suggest 
three values be added to the traditional civic engagement framework. The first is the 
student voice, which allows students to define civic and political engagement for 
themselves and contribute to campus decision making on the issues that affect and matter 
to them. The second is the practice of direct participation by providing or finding 
opportunities to practice civic engagement planning, development, and implementation. 
The third is motivation. These authors stress that it is not enough to have the skills to 
become civically engaged; students need to be motivated to become civically engaged. 
To advance these student-centered models of civic engagement, universities must 
empower students to define civic issues and public work, create opportunities for longer-
term engagement, and reconstitute faculty-student relationships where faculty can be seen 
as mentors and students can be seen as colleagues. The inclusion of these three values 






As in higher education, the research organization has similarly undermined 
democratic processes. Investigators have specialties, advancing knowledge in their 
narrow field without addressing barriers to research participation (Kramer et al., 2012. 
The research organization has also become corporately influenced. Different 
organizations offer different studies, restricting geographic access to potential 
participants, studies typically recruit younger white males, and bureaucracy exists within 
the research organization (Kramer et al., 2012; Freidman et al., 2016; Mahon et al., 2016; 
Banzi et al., 2016; Perez-Stable, 2018; NIA, 2018). Research staff may unduly influence 
potential participants in their decision to participate because of their demeanor towards 
and relationship with potential participants (King et al., 2007; Penberthy et al., 2012; 
Brown et al., 2013). Further, until recently, research organizations did not engage with or 
seek out the expertise of research participants, resulting in a lack of shared knowledge 
(Williams et al., 2011; Selby, Beal, & Frank, 2012; Johnson et al., 2015; NIA, 2018). 
However, like higher education, research organizations are currently working 
towards a more civically engaged approach to research through community involvement. 
As previously mentioned, the NIH asked for public comment on ways to improve 
research participation. Additionally, the NIH has promoted funding for investigators who 
seek to work with communities and build partnerships to improve clinical research 
diversity, recruitment, and retention (NIH, 2018). Involving the voices of people with 
ADRD may help define what research issues are most imperative to them and allows 
them to be involved in the decision-making process. The practice of direct participation 





processes of the research study. Finally, the research organization can motivate 
individuals with ADRD by empowering them to play an active role in research, creating 
long-term opportunities to facilitate engagement, and enhancing the relationship between 
the research organization staff and people with ADRD where they would be treated as 
colleagues. 
Civic engagement in health services: Since the turn of the century, civic engagement 
approaches have become more utilized in the health services. The most prominent feature 
of civic engagement in health services is the Patient-Centered Outcomes Research 
Institute (PCORI). PCORI created by Congress through the Affordable Care Act in 2010 
to ensure that comparative effectiveness research “guided by patients, caregivers, and the 
broader healthcare community” and that research is being conducted to determine choices 
and outcomes that are most meaningful to patients (Selby et al., 2012, p. 583; PCORI, 
2017). Rather than simply enrolling patients into community engaged research studies, 
patient-engaged research views patients and family members as stakeholder and members 
of the research team. Some of their tasks include: a) identifying topics and formulating 
research questions; b) identifying study populations and choosing interventions, 
comparers, and outcomes; c) developing and implementing strategies for recruitment and 
retention; d) conducting and monitoring the study; e) analyzing data and interpreting 
findings; and f) disseminating results (PCORI, 2017).  
 A review of patient engagement studies conducted by Esmail and her colleagues 
(2015) found that patient engagement leads to better quality research, patient 





between patients and researchers, and continued engagement in research. However, they 
also noted a gap in evaluations of patient engagement, particularly for long-term 
outcomes (Esmail, Moore, & Rein, 2015). Community Research Partners, an online 
database, connects research organizations and patients together, and provides resources 
for research organizations on a variety of topics, including community-engaged research, 
health disparities, and translation and dissemination (Community Research Partners, 
2012).   
Similar to public administration and higher education, civic engagement has been 
increasingly incorporated in health services at the state and clinic level. When Oregon 
developed its coordinated care organization (CCO) system, it included community voices 
at the start of the design process. In thirteen months, the state held over 90 public forums 
across the state to discuss its plans, learn what each community wanted from a state 
healthcare system, and how this could be achieved in their local area (Wentz, 2017). Each 
CCO has a community advisory board, comprised of a Medicaid-insured majority to 
ensure the patient voice is heard and included within the policymaking process (Stout et 
al., 2017). In addition, community members serve on a variety of other state health care 
advisory boards and all are invited to attend open meetings (Tillman, 2017). Furthermore, 
the state Health Equity Policy Committee includes and ensures that voices of underserved 
community members, such as people of color, immigrant and refugees, and people from 






Civic engagement is also becoming more common at the clinic level. Many 
clinics in Oregon, especially those that participate in the state’s Patient Centered Primary 
Care Home (PCPCH) program, establish patient and family advisory councils (Gelmon, 
Wallace, Sandberg, Petchel, & Bouranis, 2016). In these councils, clinic patients and 
family members provide feedback on both positive and negative experiences and offer 
suggestions to improve workflow processes, quality, and care (Gelmon et al., 2016). 
When creating this program, the Oregon Health Authority established a council 
comprised of providers, patient advocates, insurers, policymakers, and major medical 
societies to help determine standards that clinics should be required to meet (Smith & 
Merrithew, 2017). Their interdisciplinary input crafted the program to be community-
focused by, for example, working with community partners to determine the best 
neighborhood resources to manage their patient populations’ diabetes (Smith & 
Merrithew, 2017). Additionally, as previously mentioned in the LTSS section, shared-
decision making is frequently invoked, so providers, patients, and family members (if the 
patient includes them) collaboratively develop the patient’s care plan. Providers utilize 
their medical expertise to determine what the best course of action is, while the patient 
and family bring the expertise of determining what they are willing and/or able to do. 
Furthermore, shared decision-making and deliberation often includes a discussion of 
community resources, such as social services, that are easily accessible to the patient and 
their family (Gelmon et al., 2016). These additional collaborations enhance the capacity 





How health services incorporate civic engagement, and how it can be applied to ADRD 
clinical research, is discussed in more detail in the next section. 
Many of the elements of civic engagement and recommendations for enhancing 
engagement, including empowerment, enhanced communication, reaching out to 
community members, and shared decision making and collaboration, not only apply to 
research participation, but are also frequently suggested within the peer-reviewed 
literature, as previously cited. These elements and recommendations are also some of the 
features with the Culture of Health Action Framework. Though aimed towards health 
services, this framework could be applied to the research sector and is also relevant to 
this research. 
The Culture of Health Action Framework 
 The Culture of Health Action Framework was developed by the Robert Wood 
Johnson Foundation in 2014 and encourages collaboration across the health and social 
sectors (Weil, 2016). In the framework's conceptualization, health providers partner with 
local nonprofits and private organizations; these partnerships then work with 
communities to define their needs and the measures that matter most to them to improve 
population health, wellbeing, and equity (Weil, 2016). Partners then design and redesign 
programs, even if they had been previously successful, to better meet community needs 
and achieve the Culture of Health Action Framework goals of improving community 
health, wellbeing, and equity (Weil, 2016). When compared with other communities, 
those with high-density multi-sector networks supporting health improvement activities 





The Culture of Health Action Framework has four action areas, as illustrated in 
Figure 2.4: 
Figure 2.4: The Culture of Health Action Framework   
 
 
Source: The Robert Wood Johnson Foundation, 2016 
Action Area 1. Make health a shared value:  In their focused article on this action area, 
Chandra and her colleagues discuss how individuals and communities view their health 
and wellbeing, and debate whether the community is expected to advocate for health 
improving policies, environments, and services (Chandra et al., 2016). They articulate 
that there are several challenges to a Culture of Health in the United States. This includes 
conversations that focus on cost control and containment rather than health and 





policy issues, and the lack of equity as an analyzed metric (Chandra et al., 2016). In order 
to combat these three challenges, the Robert Wood Johnson Foundation recommends 
three changes be made before communities can view health as a shared value. First, there 
must be a shift in mindsets and expectations of what individuals consider health and 
wellbeing, with an emphasis on group benefits and opportunities. Individuals must view 
health as shared and expected, not a function of economic privilege. Mindsets and 
expectations can shift by stressing the benefits of equitable health opportunities, but also 
require group-level empowerment in order to push for social change (Chandra et al., 
2016). Secondly, health as a shared value requires a sense of community identity. 
Whether it is perceived or not, individuals and community are interdependent given their 
sense of community membership, belonging, and shared experiences. When community 
members recognize and act upon their solidarity, they are able to better mobilize and 
enhance their ability to thrive, be healthier, and drive change. Lastly, making health a 
shared value requires the knowledge of civic engagement skills, values, motivation, and 
opportunities within that community (Chandra et al., 2016).  
Many individuals affected by medical conditions, including ADRD, want to 
participate in related clinical research for both altruistic and potentially therapeutic 
reasons; however, many are unaware of how to seek or receive information about 
research opportunities (English et al., 2010; Law et al., 2014; Mahon et al., 2016; 
Anderson et al., 2018). As previously mentioned, many expect to hear about 
opportunities from their trusted provider or community leader; however, they are more 





newspaper (English, et al., 2010; Law et al., 2014; Mahon et al., 2016; Anderson et al., 
2018). The literature on political participation, blood donation, and knowledge transfer 
also offers factors that increase motivation (Lee, Piliavan, & Call, 1998; Brady et al, 
1999; Law et al., 2003; Sojka & Sojka, 2008; Beyerland & Bergstrand, 2016).  
Individuals are more likely to become politically involved if they frequently 
discuss political issues and freely share their views (Beyerland & Bergstrand, 2016). 
They are also more likely to participate in civic activities if they are being asked by their 
partner, parent, child, or a member of their community or religious congregation 
(Beyerland & Bergstrand, 2016). Having a close relationship with a blood donor also 
facilitates blood donation; for these reasons, Sojka and Sojka suggest the “bring a friend” 
approach, which may be translated to research participation (Lee et al., 1999; Sojka & 
Sojka, 2008). Given concerns of fear, anxiety, and pain during the blood donation 
process, donors need more personal reasons to compensate for the risk, including general 
altruism or knowing a blood recipient (Lee et al., 1999). Additionally, people who 
identify themselves as blood donors are more likely to continue being a blood donor (Lee 
et al., 1999; Sojka & Sojka, 2008). Similarly, individuals who participate in research tend 
to do so for altruistic reasons and are more likely to view themselves as research 
participants (Owen et al., 2013; Friedman et al., 2015; Gollhofer et al., 2015; Anderson et 
al., 2018). 
 Knowledge transfer is another helpful way to inform communities about research 
studies. Information from researchers is translated to communities, which requires 





trusted messenger would be, how the message should be transmitted, and the effects the 
message should have (Lavis et al., 2003). Knowledge transfer can be used to directly 
solicit community members to participate, which increases motivation for political 
involvement, blood donation, and research participation (Brady, Schlozman, & Verba, 
1999; Law et al., 2014; Beyerland & Bergstrand, 2016). 
Action Area 2. Foster cross-sector collaboration to improve well-being: Three drivers 
of cross-sector collaboration, as articulated in the Culture of Health Action Framework 
include: a) number, breadth, and quality of successful cross-sector partnerships; b) 
adequacy of investment in these partnerships; and c) adoption of policies to support the 
partnerships (Towe et al., 2016). High quality cross-sector partnerships occur through 
stakeholder commitment, community buy-in, and advocacy to establish meaningful 
collaboration among stakeholders. Stakeholders should research returns on investments, 
how funding mechanisms can be shaped to address equity, how partners will engage, and 
how partnership sectors apply and benefit from these collaborations (Towe et al., 2016). 
Initiatives to create cross-sector collaborative can be formulated at local, state, and 
federal levels and require collaboration across multiple agencies.  
The Satellite program in St. Louis exemplifies how high-quality cross-sector 
partnerships can lead to participatory processes and outcomes. A federal grant from the 
NIA in 1992 provided the financial initiative to establish the program, and over several 
years, they developed partnerships with local clergy, the Alzheimer’s Association, 
government offices, senior centers, libraries, and African American community 





numerous types of investments, including federal grants and philanthropic contributions 
(Williams et al., 2011). Policies were created to maintain their partnerships and achieve 
their goals, such as the establishment of an African American ADRD research advisory 
board in 2004 (Williams et al., 2011). Satellite has achieved their primary goal of 
removing research participation inequity among the African American community in St. 
Louis; their success has led to the development of similar programs in California, 
Wisconsin, Kentucky, and New York (Williams et al., 2011; NIA, n.d.).  
The higher education and civic engagement literature offer best practices for 
fostering cross-sector collaboration. With knowledge mobilization, partnerships are 
“shaped by the organizations engaged in the production, brokerage, dissemination, and 
uptake of the research knowledge, [and] in turn, are embedded in broader social contexts 
that influence priorities, opportunities, and demands for research knowledge” (Sa, Li, & 
Faubert, 2011, p. 504). It is collaborative and facilitated by organizational resources and 
norms. Systematic collaboration among partners, faculty incentives and rewards, and 
programmatic changes enhance the strength of the partnerships and the influence of 
knowledge mobilization on resource allocation and opportunities for the community. The 
NIH’s May 2018 announcement of funding opportunities to promote diversity, 
recruitment, and retention through collaborative partnerships may serve as a gateway to 
knowledge mobilization in ADRD research. Receiving an NIH grant is a financial and 
academic incentive for investigators, who may then implement programmatic changes 





as well as influence resource allocation and opportunities based on the expertise of the 
participants and study partners. 
Civic engagement scholars state that partnership requires greater cooperation with 
volunteer, community, and private-sector organizations, as well as state and municipal 
initiatives that foster values of education, participation, and citizen involvement (Bellah 
et al., 1991; Vigoda-Gadot & Cohen, 2004). These values empower individuals to 
become stakeholders in their community, increasing participation. Treating community 
members as stakeholders is imperative to fostering relationships and future collaboration; 
current and potential participants cited failure to disseminate research results and updates 
as a reason for not participating in future opportunities (Sood et al., 2009; Law et al., 
2014; Mahon et al., 2016).  
Action Area 3. Create healthier, more equitable communities: Improving physical 
environments, social and economic conditions, and policies that facilitate coalition-
building and improvement projects will enhance opportunities for healthier and equitable 
communities (Dubowitz et al., 2016). However, the Robert Wood Johnson Foundation 
suggests that progress in this action area needs to be made before new processes can be 
implemented. First, the complexity of causality of poor health outcomes must be 
recognized. Dubowitz and colleagues exemplify this challenge with a grocery store: 
simply adding a grocery store in a neighborhood may improve the neighborhood’s 
quality, but not improve healthy eating (Dubowitz et al., 2016). Individuals living in the 
neighborhood may prefer to purchase food from other locations, may not be able to 





adequate structural supports, such as sidewalks or street lights, that would allow them to 
safely walk to the store. Second, new governance structures may need to be created to 
sustain action. Opportunities exist in cross-silo government approaches but rely on 
elected and appointed executive officials to identify, develop, and maintain them. If 
officials are not supportive, opportunities may not come to fruition. Last, creating 
healthier and more equitable communities requires mobilizing broad coalitions amid 
political polarization (Dubowitz et al., 2016). Problem framing plays a significant role in 
decision-making, and opportunities may result from framing social determinants as 
equally complementary to the role of individual choice in health outcomes, rather than 
viewing them as siloed factors. When health sectors partner with community members as 
well as local government and organizations, all stakeholder may begin to recognize the 
complex causality of health outcomes due to social determinants and individual choice 
and develop solutions that align with the community’s needs.  
 Similarly, the reasons why people with ADRD chose to participate in clinical 
research or not are complex as participation requires both capacity and predisposition to 
participate. Just as adding a new grocery store in a neighborhood does not automatically 
improve health outcomes, offering a new research opportunity does not necessarily 
improve recruitment and retention. As previously discussed in the clinical research 
section, there are a myriad of factors that impede or facilitate an individual’s ability and 
motivation to participate in research. Collaboration among the research sector, people 





facilitators, and solutions to increase participation (Grill & Galvin, 2014; Mahon et al., 
2016; Kremer, 2017).  
 The New Public Service public administration style may serve as an example as it 
encourages collaboration among community members and public officials to define and 
address common problems, including physical environment and social and economic 
conditions, in a cooperative and mutually beneficial way (Denhardt & Denhardt, 2003). 
Public servants aim to motivate community members to think about their shared values 
within their community, further develop those values, and increase their capacity to help 
each other; with every open conversation, steps are taken to establish a trusting 
relationship between the community and the public servants (Denhardt & Denhardt, 
2003). In the New Public Service, public servants view their role as responsible 
participants who share power, work with people, and broker solutions (Denhardt & 
Denhardt, 2003). Values are continuously redefined and revised by the community, and 
public servants implement policies based on those continually redefined values. The 
Culture of Health Action Framework also recognizes this necessity; stakeholders from 
health and other sectors work with the community to identify their needs and values and 
develop programs that align with them. Programs are designed and redesigned as needed, 
and like New Public Service, capacity, trust, and relationships among all stakeholders are 
strengthened as the partnerships share power, work together, and develop solutions.  
 New Public Service can influence the relationships among community members 
and research organizations. Organizations often assume that individuals will enter a 





they will avoid it, as exemplified in the previous discussion on African American 
participation in clinical research. However, if the organization takes the time to establish 
a relationship to build trust and respect and provide full information about study 
opportunities in a clear, understandable manner, they are more likely to participate in 
research (Danner et al., 2011, Frew et al., 2011; Grill & Galvin, 2014; Mahon et al., 
2016, Inungu et al., 2017). Ultimately, removing the power dynamics and valuing the 
expertise that people with ADRD have reduces the inequities among stakeholders, which 
will lead to identifying problems and solutions that are needed to reduce inequities, 
remove barriers, and improve ADRD clinical research participation. The Patient-
Centered Outcomes Research Institute (PCORI) funds 13 studies that focus on dementia 
and cognitive impairments (PCORI, 2020a). One of these studies includes people with 
ADRD as stakeholders. LiveWell, a dementia service provider in Connecticut (PCORI, 
2019), received a two-year award to increase the capacity of people living with dementia 
and their caregivers and reduce barriers to their engagement in patient-centered research 
(LiveWell, 2018). Although this is a sign of a shift in recognizing the expertise of people 
with ADRD, the small number of dementia and cognitive impairment patient-centered 
studies pales in comparison to the 89 PCORI-funded studies focusing on cancer or the 
133 studies focusing on mental and behavioral health (PCORI, 2020b; PCORI 2020c).   
Action Area 4. Strengthen health services and systems: Drivers that strengthen the 
integration of health services and systems include access, balance and integration, and 
consumer experience and quality. Access to health services and systems requires 





office hours and culture (Martin et al., 2016). Balance refers to how resources are 
prioritized and allocated between and within health and social sectors, whereas 
integration refers to the meaningful connections that are made between sectors (Martin et 
al., 2016). Consumer experience and quality is relevant to the Triple Aim (Berwick, 
Nolan, & Whittington, 2008) as one goal of the Culture of Health Action Framework is to 
improve the community’s health and experience while also lowering costs (Martin et al., 
2016). 
Integrating medical care, public health, and social services systems can connect 
community members to appropriate and timely information, supports, preventive 
services, and formal healthcare to improve health and wellbeing (Martin et al., 2016).  
Progress in this action area requires identifying and utilizing models that focus on 
improving access to healthcare and removing barriers such as language, office hours, 
transportation, and lack of cultural competence. Discussions on resource allocation and 
priorities, and their effects on experience and quality, are also necessary (Martin et al., 
2016).  
Individuals report being more open to clinical research participation if 
organizations are accommodating by offering flexible scheduling, fewer in-person visits 
with opportunities for video conferencing, and free or subsidized modes of transportation 
(Danner et al., 2011; Law et al., 2014; Friedman et al., 2015; Mahon et al., 2016). 
Research organizations often ignore the barriers encountered by residents of rural 
communities, who reside too far from the organization to attend appointments, and 





speaking English (King et al., 2007; Friedman et al., 2013; Grill & Galvin, 2014; Mahon 
et al., 2016). Denying access to research opportunities demotivates members of these 
communities who have ADRD.  
The primary care medical home (PCMH) literature offers examples of how health 
sectors can become more accessible, integrated and balanced, and improve consumer 
experience and quality, ultimately strengthening health services and systems. In Oregon, 
where over 70% of the primary care clinics participate in the PCPCH program, many 
provide office hours outside of the typical 9-5 workweek, and all are required to have a 
24/7 telephone line (Smith & Merrithew, 2017; Gelmon et al., 2018). Clinic leaders 
report translating materials and hiring bilingual and/or multicultural staff to better serve 
their patient populations, and care coordinators build repositories of community resources 
or work with other local health and social sector organizations to address other structural 
barriers (Gelmon et al., 2018). Coordinated care organizations highlight ways to balance 
resources between and among health and social sectors, as well as the meaningful 
connections between and among them. In Oregon, CCOs serve the Medicaid population 
and ensure that every consumer has access to physical, mental, and dental health 
providers in their local community (Oregon Health Authority, n.d.). Since CCOs work to 
foster preventive health, they partner with local government, nonprofit, and private 
organizations to provide resources to patients. For example, CareOregon, a Portland-
based managed care organization, partners with local nonprofits and private organizations 
to offer its members free nutritious food delivered to their home, cooking classes, and 





have reported that the program has made a real difference in their lives (CareOregon, 
2017). Though there are no studies that have evaluated the PCPCH program from the 
patient and family perspectives to date, clinic leaders perceive a positive difference for 
their patients (Gelmon et al., 2018). 
Conclusion: The Culture of Health Action Framework and its action areas could be 
useful for articulating strategies for motivating factors for research participation. Table 
2.3 highlights the twelve drivers and their applicability to ADRD clinical research. 
Table 2.3 Operationalization of the Culture of Health Action Framework 
Drivers Description and relevant examples 
Action Area 1: Health is a shared value 
Mindsets and 
expectations 
An emphasis is placed on group benefit and expectations; 
requires group-level empowerment to advocate for 
resources (Chandra et al., 2016). Per the Belmont Report, 
individuals may participate in clinical research to benefit 
society, even if they do not benefit directly (The 
Commission, 1979). This is true in clinical research, and 
many report participating for the benefit of the community 
(English et al., 2010; Law et al., 2014; Mahon et al., 2016; 
Anderson et al., 2018) 
Sense of community Community members are interdependent, even if they do 
not realize they are a part of a community (Chandra et al., 
2016). When they do recognize themselves as a 
community, their ability to motivate and drive change is 
enhanced (Denhardt & Denhardt, 2003; Chandra et al., 
2016). This is evident by the advocacy efforts in cancer 
survivors and the LGTBQ+ community, who were not 
previously recognized due to societal and self-
stigmatization.  
Civic engagement To become civically engaged, an individual must have the 
resources, skills, values, and knowledge of opportunities 
(Denhardt & Denhardt, 2003; Vigoda-Gadot & Cohen, 
2004; Chandra et al., 2016). Similarly, for individuals to 
participate in clinical research, they must be aware of 
opportunities to participate in research, hold participation 
in clinical research as an important value, meet the 





transportation) to be able to participate (Grill & Galvin, 
2014; Mahon et al., 2016; Anderson et al., 2017). 
Action Area 2: Fostering cross-sector collaboration to improve wellbeing 
Number and breadth 
of partnerships 
This requires stakeholder commitment, community buy-in, 
and advocacy (Towe et al., 2016). Examples of these 
partnerships include the Alzheimer’s Association, 
PreSERVE, OHSU Community Resources Coalition and 
Liaisons, and the Satellite program in St. Louis (Williams 
et al., 2011). 
Investment in cross-
sector collaboration 
This requires knowledge of the return of investments, how 
funding mechanisms address equity, and how partnerships 
apply, engage, and benefit (Towe et al., 2016). This can be 
applied through immediate knowledge transfer to all 
interested community members, research organizations, 
health and social sectors, and advocacy groups (Sa et al., 
2014; Sood et al., 2009; Law et al., 2014; Mahon et al., 
2016). If applying for an NIH grant for an ADRD clinical 
research study, investigators must now include all of this 
information (NIH, 2017c).  
Policies that support 
collaboration 
These policies can occur at local, state, or federal levels 
(Towe et al., 2016). Examples include the NIH’s 
recruitment, retention, and diversity grant, Oregon Health 
Authority’s Health in All Policies, and Multnomah 
County’s REACH program (NIH, 2018; Oregon Health 
Authority, n.d.; Multnomah County, 2018).  
Action Area 3: Creating healthier, more equitable communities 
Built environment and 
physical conditions 
Requires recognition of the causality of complexity 
(Dubowitz et al., 2016). Just as putting a grocery store in a 
former food desert does not automatically improve 
community health outcomes, ADRD research participation 
does not automatically increase if a new study is 
announced. There are environmental and physical factors 
affecting a person’s decision to participate (Grill & Galvin, 
2014; Mahon et al., 2016: Kramer, 2017).  
Social and economic 
development 
May require new government structures and policies 
(Dubowitz et al., 2016). The NIH Research Capacity 
Building, the new Director of Extramural research, the US 
Congress earmarking 2.8 billion dollars. The NIH funding 
for recruitment (Hudson et al., 2016; NIA, 2018; NIH, 
2018; Alzheimer’s Association, 2019b) 
Policy and 
governance 
May require framing social determinant policies as a 
complement to individual choice, rather than either/or 





includes allowing all, some, or none of the clinical 
research visits to occur via telemedicine or at the 
individual’s home rather than at the clinic. Engaging with 
community members can facilitate solutions (Denhardt & 
Denhardt, 2003, Grill & Galvin, 2013; Inungu et al., 2017) 
Action Area 4: Strengthening integration of health services and systems 
Access Current barriers to access to healthcare include cost and 
insurance, language and culture, transportation, office 
hours, and historical and current mistrust of the medical 
community (Martin et al.,. 2016). These barriers are all 
found in the clinical research world as well, particularly 
for the African American and ADRD communities 
(Danner et al., 2011; Law et al., 2014; Friedman et al 
2015; Mahon et al., 2016) 
Consumer experience 
and quality 
The Triple Aim: focused goal of improving the 
community’s health and experience and lowering costs 
(Berwick et al., 2008). The clinical research, advocacy, 
and health sectors has a similar goal of improving the 
experience of research participation, with the ultimate goal 
of ADRD prevention and treatment (NIH 2018, 
Alzheimer’s Association, 2018).  
Balance and 
integration 
Balance encompasses how resources are prioritized and 
allocated between health and social services; integration 
encompasses the meaningful connections made between 
the health and social sectors (Mahon et al., 2016). This 
balance and integration can be viewed in the clinical 
research sector as well with the prioritization of funding 
recruitment and retention activities versus other studies/ 
data management and retention and partnerships between 
the research organization and the community (NIA, 2018). 
 
 This framework provides opportunities for people with ADRD who have not been 
able to use their voice, by encouraging them to define their own needs and bring solutions 
to the table. A core tenet of this framework is to reduce inequities among and between 
groups. The high diagnosis and low participation rates that African Americans face could 
be addressed with this framework. The Culture of Health Action Framework can serve as 





structural racism, help research organizations conduct more outreach to motivate 
community members, and increase ADRD clinical research enrollment.  
 
Literature Synthesis and Conclusion 
The goal of finding a treatment or prevention for ADRD by 2025 is based on a variety of 
reasons, including: the expectation of ADRD prevalence as the older adult population 
drastically increases; the persistent lack of a successful prevention, treatment, or cure; 
and the high-costs, financially, physically, and emotionally, of living with or caring for a 
person with ADRD. Increasing research participation may reduce the delay or 
termination of studies that could potentially lead to a breakthrough. The need is 
persistent, as are the low participation rates; a myriad of policy, system, organization, and 
personal barriers stand in the way of capability and motivation to participate among 
people with ADRD. 
Ethical guidelines and government policies that serve to fund, conduct, and 
disseminate clinical research protect individuals with ADRD from harm, but 
inadvertently strip their decision-making abilities from them. Though there is an 
understanding that many of the rules and structures cannot be changed, research 
organizations are willing to make some accommodations to meet the needs of people 
with ADRD. Contingency and transaction cost theories, both of which promote 
environmental influence while maintaining the organization’s rigidity, best conceptualize 
how research organizations can facilitate ADRD clinical research participation. Policy 





influence mobilization of people with ADRD, best illustrate how health, social, and 
research sector organizations can work together and with people with ADRD to promote 
capabilities and motivation to participate in research. Concepts of civic engagement align 
with suggestions and recommendations described in the clinical research literature as 
strategies to mitigate system, organizational, and personal barriers. The Culture of Health 
Action Framework can be used as a roadmap to form organization-community 
partnerships, facilitate motivation and empowerment, give back decision-making power 
to people with ADRD and promote a culture of research. In Chapter 3, an approach is 
presented to illustrate how the Culture of Health Action Framework will be used, in 






CHAPTER 3: RESEARCH DESIGN AND METHODOLOGY 
 
Chapter Organization 
This chapter offers a detailed description of the dissertation’s design and methodology. It 
is organized in the following manner:  
1. An introduction of the research question, specific aims, and the rationale. 
2. An overview and rationale of community-engaged research, the approach used in 
this study. 
3. A detailed account of the study design: two phases of semi-structured interviews 
designed in collaboration with a community advisory board (CAB). 




The overall research question of this study asked: What factors affect clinical research 
enrollment among people with ADRD? The study aimed to a) identify organizational-, 
system-, and policy-level factors affecting ADRD clinical research enrollment, b) identify 
person-level factors affecting clinical research enrollment among people with ADRD, 
and c) develop motivational strategies and policy recommendations based on the findings 
from Aims 1 and 2.  
As previously discussed in Chapter 2, there are several reasons why this research 





global scale (WHO, 2017; Collins et al., 2018; Alzheimer’s Association, 2019a). The 
U.S. Congress has allocated nearly 3 billion dollars for ADRD research to find a 
treatment or prevention by 2025, and philanthropists have contributed financial resources 
towards the same goal (Gates, 2017; Alzheimer’s Association, 2019a). The multitude of 
reasons why enrollment is low was explored in Chapter 2. Due to public attention and 
funding appropriations from Congress, the conversation on recruitment rates has 
expanded from the academic literature to the NIH, investigators, and funders. For 
example, the NIA released their national strategy to improving recruitment and diversity 
in ADRD research in October 2018. They briefly identified barriers to research and 
provided recommendations to facilitate enrollment; however, people with ADRD were 
not included in their working groups (NIA, 2018). The research conducted in this 
dissertation serves as a first step in identifying barriers and facilitators to ADRD clinical 




This section provides an overview of community-engaged approaches to research.  
Principles of community-engaged research are identified and their application to this 
study is evaluated. This section ends with a rationale for why this approach was used.  
Overview of community-engaged research 
Community-engaged research encompasses a wide breadth of community 





process of working collaboratively with and through groups of people affiliated by 
geographic proximity, special interest, or similar situations to address issues affecting the 
well-being of those people” (Centers for Disease Control and Prevention [CDC], 1997, p. 
7). Various fields have contributed to the development of community engagement, 
including education and political science (Freire, 1968/1972; Bellah et al., 1991; Putnam, 
2000; Battistoni & Longo, 2011). In these fields, “civic” engagement is the commonly 
used term but is equivalent to community engagement, which is why community 
engagement is frequently referred to as civic engagement in Chapter 2. For this research, 
the term community engagement is used because it is the preferred term in the health 
services field.  
Rationale for using a community-engaged research approach 
Using community-engaged research, community members and academics 
collaborate and develop research and decision-making processes that best address the 
needs of the community (CDC, 1997). First, community-engaged research recognizes 
that despite a common misconception that research is objective, it is not, and it often 
cannot be. All individuals have different lived experiences, leading to unique 
perspectives (Habermas, 1963/1974). Because of these experiences and perspectives, 
researchers and community members have conscious and unconscious biases that can 
affect their research topics and processes. To establish partnerships, these unique 
perspectives and biases need to be identified and discussed.  
Second, in community-engaged research, academics recognize and accept a) that 





and b) the effects that real or perceived power differences have on participation behavior. 
However, this recognition must exist before power sharing can begin. When power is 
shared, community empowerment, trust, and meaningful relationships develop (Michener 
et al., 2012). 
 Third, community-engaged research can enhance study rigor, relevance, and reach 
(Balazs & Morello-Frosch, 2013). Rigor can be enhanced when the community directs 
researchers to use designs and data collection methods that best address their needs and 
questions. For example, scientific rigor and generalizability is enhanced with member-
checking, where community members provide feedback on the results that confirm or 
challenge the investigator’s findings analyses (Creswell, 2000; Goldblatt, Karneili-Miller, 
& Neumann, 2011). Though this technique is used often in qualitative research, it was 
used in this research specifically because it provided an opportunity for power-sharing by 
recognizing and utilizing the expertise that community members hold regarding this 
topic. Relevance is enhanced because the community is identifying topics and goals that 
matter most to them, rather than having topics and goals imposed on them; in addition, 
the study’s process and findings are disseminated in ways that are most relevant to the 
community (e.g. pamphlets with clear, concise language). Reach of the findings and 
community impact is also enhanced through dissemination to community members, and 
can also lead to community testimony to policymakers, potentially resulting in policies 
beneficial to the community (Balazs & Morello-Frosch, 2013). 
 The principles of community-engaged research set standards for how research can 





nine principles, as identified by Israel and her colleagues (2003) in Minkler and 
Wallerstein’s foundational text on community-based participatory research (CBPR), are 
one approach to community-engaged research, and are described below:  
1. CBPR recognizes the community as a unit of identity.  
2. CBPR builds on strengths and resources within the community. 
3. CBPR facilitates collaborative equitable partnerships in all research phases and 
involves an empowering and power-sharing process that attends to social 
inequities. 
4. CBPR promotes co-learning and capacity building among all partners. 
5. CBPR integrates and achieves a balance between research and action for the 
mutual benefit of all partners. 
6. CBPR emphasizes public health problems of local relevance and ecological 
perspectives that recognize and attend to the multiple determinants of health and 
disease. 
7. CBPR involves systems development through a cyclical and iterative process. 
8. CBPR disseminates findings and knowledge gained to all partners and involves 
all partners in the dissemination process.  
9. CBPR requires a long-term process and commitment to sustainability. 
Studies that use a CBPR approach to research design often involve community members 
to a more intensive degree, as illustrated by Figure 3.1 (Minkler & Wallerstein, 2008; 





style with community members, where the study is primarily researcher-designed but the 
community collaborates on modifications and develops dissemination strategies. The 
medium intensive approach to community-engaged research is used for two reasons: 1) 
ADRD entails progressive cognitive decline; though full partnership is infeasible, people 
with ADRD can and should collaborate to the extent of their abilities; and 2) a 
dissertation research study demonstrates that a doctoral student can conduct research 
independently in a time-constricted manner; thus, a long-term, community-led study is 
not possible. Despite their typical use for more intensive community engagement, the 
applicable guiding principles are reflected throughout the study design and adapted as 
needed. Examples are highlighted throughout this chapter. 






African American representation  
 As discussed in Chapter 2, African Americans are significantly more likely to be 
diagnosed with ADRD than any other race or ethnicity, yet significantly less likely to 
participate in clinical research for a multitude of reasons (Williams et al., 2010; Danner et 
al, 2011; Chin et al., 2011; Williams et al, 2011; Gilmore-Bykovskyi et al., 2019). This 
disparity is recognized, and the NIH has prioritized funding to reduce it and increase 
diversity in clinical research (NIH, 2018). Strategies to increase enrollment among 
African Americans with ADRD must derive from expertise that can only be provided by 
African Americans. Evidence posits that community-engaged approaches increase 
African American collaboration with academics (Williams et al., 2010; Huang & Coker, 
2010; Johnson et al., 2015; Harris, Pensa, Redlich, Pisani, & Rosenthal, 2016). For these 
reasons, older African Americans, regardless of their cognitive status, were members of 
this study’s CAB. In order to identify personal-level factors affecting ADRD clinical 
research enrollment in the African American community, the investigator attempted to 
mindfully sample African American dyads. Recruitment was conducted through the 
CAB, the OHSU Layton Aging and Alzheimer’s Disease Center, which conducts clinical 
research that specifically focuses on the African American population, and the 
PreSERVE Coalition for Black/African American Memory and Brain Health, a Portland-
based “coalition of individuals from non-profits, health institutions, and the African 
American community that seeks to improve the health of African Americans over the age 
of 55” (PreSERVE, n.d.). This study originally had a recruitment goal of 50% African 





in recruiting African Americans. The consequences of not having African Americans 
included in this research are discussed in Chapter 7. 
 
Conceptual Framework 
The Culture of Health Action Framework, previously discussed in Chapter 2, was chosen 
as a conceptual framework for several reasons. First, the framework and its action areas 
may be useful for articulating strategies to increase the ability and motivation to 
participate in ADRD clinical research. This is due to the similarities between factors 
affecting healthcare and factors affecting clinical research participation. Second, the 
voices of people with ADRD have not traditionally been included in research. This 
framework could be used to conceptualize an approach that encourages inclusion of 
people with ADRD to define their own needs and develop solutions to address structural 
barriers to participation. Third, the Culture of Health Action Framework has not yet been 
applied to the ADRD clinical research setting. Using this framework is a novel approach 
to organizing strategies to improve ADRD clinical research participation. 
 
Design 
The design of this study entailed two phases of semi-structured qualitative interviews. 
Recruitment strategies and data collection protocols were designed in collaboration with 





Use of CAB and rationale  
A CAB was established to provide formal leadership and guide study processes. 
CAB membership recruitment was facilitated through the Alzheimer’s Association, 
OHSU’s Layton Aging, and Alzheimer’s Disease Research Center, and PreSERVE. The 
CAB membership was comprised of two individuals with ADRD, two current ADRD 
family caregivers, two ADRD advocates, two ADRD clinicians/investigators, one ADRD 
research assistant, and two older African American community members, as well as a 
dissertation committee member with experience with CABs and the researcher. The CAB 
was convened three times throughout the dissertation process to guide the investigator on 
recruitment and interview protocols and member-checking. CAB community members 
received a $120 honorarium, or $30 grocery gift card per meeting, for their contributions 
to the CAB. Two originally planned meetings were condensed to one meeting; 
community members received two $30 grocery gift for collaborating in that meeting. 
These funds were reimbursed by an Oregon Partnership for Alzheimer’s Research Tax 
Checkoff grant awarded to the researcher. 
Rationale for CAB: Ian Kremer (2017), executive director of the Leaders Engaged on 
Alzheimer’s Disease (LEAD) Coalition, suggests that CABs for dementia programs 
should include persons with ADRD as they have the greatest insights for developing and 
enhancing dementia-related services. For example, the Dementias and Neurodegenerative 
Research Network (DeNDRoN) in the UK includes people with dementia in their CAB, 





because they have not experienced those barriers (Iliffe, McGrath, & Mitchell, 2013; 
Pickett, 2017). 
CAB practices and expectations: Best practices for CABs were applied at the 
formative, operational, and maintenance stages (Newman et al., 2011). In the formative 
stage, the purpose and function of the CAB and membership roles must be clarified, and 
specific membership composition and recruitment strategies should also be developed 
and confirmed by the members (Newman et al., 2011). For this CAB, membership and 
expectations were discussed and approved at each meeting (Appendices A-D), and it was 
explicit that the CAB would be for a short-term project. The recruitment for this study’s 
CAB was facilitated through the researcher’s professional network of key contacts, 
influential people who have gained access and trust with people with ADRD and older 
African Americans, and snowball sampling among involved community members.  
During the operations phase of the CAB, procedures and principles, such as 
determination of leadership, power balance, and decision-making processes, should be 
reevaluated periodically and revised as necessary (Newman et al., 2011). For example, 
Israel’s CAB with the Detroit urban community requires every member to get behind an 
idea with at least 70% of their support, whereas Nicolaidis’s CAB with the autism 
community requires full membership consensus by showing one or two fingers on a five-
finger scale (Israel et al., 2001; Nicolaidis et al., 2011). This CAB required that all 
members must be “okay” with decisions before they could move forward, meaning that 
they did not have to “love” or “like” a decision but would be okay with it taking place. 





developed CAB protocols and decision-making processes based on what worked best for 
the community members. Accommodations for people with cognitive impairment are 
adaptable within the CAB. Pickett (2017) suggests individually tailoring accommodations 
and revising as needed given the progression of the disease. Some of the strategies from 
the developmental disability literature include one-on-one sessions before meetings, extra 
time to gather and present their thoughts, and caregiver inclusion (Nicolaidis et al., 2011; 
Nicolaidis et al., 2015; McDonald et al., 2016; McDonald & Stack, 2016). Additional 
strategies, such as frequent breaks, using simpler language, and minute-long pauses 
between topic discussions for thought-processing, can be included as processes that all 
CAB members abide by (Lennox et al., 2005; McDonald et al., 2016; McDonald & 
Stack, 2016). For this CAB, the investigator spoke individually by telephone or in-person 
with members who requested the meeting that the investigator offered. Frequent breaks, 
minute-long pauses, and simple language were also used during meetings. These 
strategies and processes are included in Appendices A-D. 
In the maintenance phase, all partnership processes are evaluated, sustainability 
plans are created, and membership contributions, such as funding strategies and member 
stipends, are discussed and recognized (Newman et al., 2011; Nicolaidis et al., 2011; 
Pickett, 2017). In addition to discussing and confirming meeting expectations, each 
meeting ended with a five-minute debrief to evaluate and modify processes for future 
meetings. Because this study was a short-term project, this CAB will not continue after 
the study’s completion, but communication and relationships with members will continue 





A CAB is ultimately responsible for establishing procedures and protocols for 
data collection, analysis, and dissemination. The research should be reflective of active 
dialogue with the community. This starts with effective recruitment strategies and 
accommodation practices that work to ensure diverse members are able to participate. 
Examples are discussed in Chapter 6 and final products are included in the Appendices.  
Plunkett & Chen (2016) found that many clergy, who are opinion leaders for religious 
communities, are unsure of dementia-related resources to which they can refer their 
members. They suggest developing partnerships between community organizations and 
churches to facilitate recruitment and develop programs to better serve people with 
ADRD (Plunkett & Chen, 2016). Places of worship were not discussed by members of 
the CAB nor mentioned as a possible referral site. This limitation is discussed in Chapter 
7.   
Two-phase qualitative interviews and rationale 
 To address the first two aims of the study, presented in Figure 3.2 below, two 
phases of semi-structured interviews were used. Semi-structured interviews provided an 
opportunity to have a conversation that the interviewee could steer within the parameters 
of the interview protocol, establishing a more trusting relationship between the two 
parties (Cook, 2012). In the first stage of data collection, the investigator conducted semi-
structured interviews with nine clinicians, researchers, and advocates who serve people 
with ADRD in the Portland metropolitan area to address the first aim. These included 





treat the ADRD community, and investigators and research assistants who conduct 
research with the ADRD community. The stakeholders were recruited through the 
researcher’s professional network of contacts as well as referrals from the CAB. 
Interviewing nine key stakeholders provided the researcher with a breadth of perspectives 
until saturation was reached without hitting the threshold of researcher burden 
Figure 3.2 Dissertation Aims 
1. Aim 1: Identify organizational, system, and policy factors that impede or 
enhance clinical research enrollment among people with ADRD; 
2. Aim 2: Describe personal factors that persuade or dissuade individuals with 
ADRD from enrolling in clinical research; and 
3. Aim 3: Develop motivational strategies and policy recommendations based 
on the findings from Aims 1 and 2. 
 
In Phase 2, the semi-structured interviews were conducted with 12 dyads of individuals 
with ADRD and their caregivers who live in or participate in research based in the 
Portland metropolitan area. The dyads were recruited through the CAB and key 
informants from Phase 1. These interviews addressed both the first and second aims 
(Figure 3.2). Six of the dyads currently or previously participated in ADRD clinical 
research. The remaining six had never participated in ADRD clinical research. Twelve 
dyads were chosen because this allowed the researcher to receive a breadth of differing 
perspectives from both those who had or had not participated in clinical research. The 
caregiver and person with ADRD were interviewed separately, but the person with 





long as the caregiver remained quiet. Only one of twelve people with ADRD had their 
caregiver sit with them.  
 This approach was used for several reasons. First, in dyadic interviews, the 
relationship between two people is recognized and used as a source of information 
(Morgan, Ataie, Carder, & Hoffman, 2013; Caldwell, 2014). Second, dyadic interviews 
are frequently used when interviewing people with cognitive impairment because it 
provides them with more control of the situation, reduces the need to conform to 
preconceived notions of what the interviewer is looking for, and empowers them to 
actively participate (Morgan et al., 2013; Caldwell, 2014). Dyadic interviews were 
intentionally conducted after the Phase 1 interviews with key informants provided 
context for the Portland metro area and identified insights that may not have been 
discussed in the literature.  Phase 2 interviewees confirmed whether the findings from 
Phase 1 aligned with what people with ADRD and their caregivers perceived as barriers 
and facilitators to clinical research enrollment.  
 This interview process was guided by several of the CBPR principles. Through 
these interviews, this research recognized people living with ADRD as a unit of identity. 
Interviewing people with ADRD and their caregivers after key informant interviews 
empowered them by asking about their experiences and invited a power-sharing process 
by perceiving them as experts in their own field through confirmation or rejection of key 
informant perceptions. Recognizing their expertise further integrated and achieved a 
balance between research and action by providing research organizations, advocates, and 





participation, mutually benefitting both groups. Further, these semi-structured interviews, 
drafted in collaboration with the CAB, were designed in a way that offered the 
interviewee the ability to take the conversation in a direction that allowed them to discuss 
their most pressing issues and concerns and provided the opportunity to articulate factors 
affecting their decision to participate in clinical research.  
 
Data Collection 
The two-phase approach to semi-structured qualitative interviewing was utilized to 
address the first two aims of the study (Figure 3.2) while also confirming if the 
interviewed people with ADRD and their caregivers’ perceptions of barriers and 
facilitators to clinical research enrollment aligned with those of ADRD researchers, 
clinicians, and advocates. In this section, each phase of data collection is discussed, 
including the rationale, recruitment and interview protocols, the CAB’s involvement in 
data collection, and IRB processes. 
Phase 1 interviews with key informants 
 In the first stage of data collection, the investigator conducted semi-structured 
interviews with key informants who serve people with ADRD in the Portland 
metropolitan area to address the first aim. Key informants included professionals and 
volunteers who advocate for, clinicians who treat, and investigators and research 





Recruitment approach and development of protocols: The investigator established 
relationships with the PSU Institute on Aging, the Alzheimer’s Association, the Layton 
Aging and Alzheimer’s Disease Center (OHSU), and PreSERVE. The investigator 
emailed clinicians, researchers, and advocates who were suggested as good key 
informants by members of the aforementioned organizations. Nine key informants were 
selected based on the organization they worked for, to ensure that there was diversity in 
organizational representation in this study. These key informants were not paid. 
Interview protocols: Table 3.1 presents an overview of the domains that were addressed 
and the questions that were asked during Phase 1 and approved by the CAB. Key 
informants were asked about their experience of working with people with ADRD, their 
knowledge of clinical research, if and how they receive information about clinical 
research opportunities, dissemination of those opportunities, their perceptions of 
organizational-, system-, and policy-level factors affecting clinical research recruitment 
and retention, and suggestions for improving ADRD clinical research enrollment. The 
questions were derived from various frameworks and literature described in Chapter 2. 
The interviews were audio-recorded, transcribed and deductively and inductively coded 
for themes that addressed the first and second study aims. 
Table 3.1 Phase 1 Interview Domains 
 
Domains Questions  Derives from 
Engagement 
with people with 
ADRD 
Describe this organization and your 
role within it. 
How does your organization engage 
people with ADRD? 
Culture of Health (CoH) 
Action Area 1 
Civic engagement literature 
Policy feedback theory 











What policies or funding 
mechanisms enhance your work? 
What policies or funding 
mechanisms have made it easier or 
more difficult to engage with 
people with ADRD and/or increase 
knowledge of opportunities? 
CoH Action Areas 2 and 3  
Policy Feedback theory 
Contingency theory 
Clinical research barriers 
and facilitators literature 
Partnerships What partnerships are you involved 
in that relate to people with ADRD? 
How is this partnership funded? 
How are stakeholders involved? 
CoH Action Area 2 
Clinical research and 
community engagement 
literature 





How valued is clinical research at 
this organization? 
Describe your process for informing 
people with ADRD and their 
caregivers of research opportunities 
[or recruiting and enrolling if 
organization is a research 
organization]. How has that process 
changed since it was implemented? 
CoH Action Areas 1 and 4 
Policy feedback theory 
Contingency theory 
Civic engagement literature 
Transaction cost theory 
Clinical research barriers 




What are some factors that you 
think may facilitate recruitment? 
What about factors that impede 
recruitment? 
What are your recommendations for 
increasing ADRD clinical research 
participation? 
CoH Action Areas 3 and 4 
Policy feedback theory 
Transaction cost theory 
Social construction theory 
Critical race theory 
Clinical research barriers 
and facilitators literature 
Clinical research and civic 
engagement literature 
ADRD specific barriers and 
facilitators literature 
CAB involvement in Phase 1: The investigator created a draft of recruitment and 
interview protocols based on best practices from the academic and grey literature, and 





members were asked to draw upon their expertise to suggest changes; recruitment and 
interview protocols were modified based on their suggestions.   
Phase 2 dyadic interviews with people with ADRD and their caregivers 
The second stage of data collection also consisted of semi-structured interviews 
but included a sample of 12 dyads of individuals with ADRD and caregivers living in the 
Portland metropolitan area (n=24). These interviews addressed both the first and second 
aims. To ensure the data collected articulated the personal reasons for why people with 
ADRD members both have and have not participated in clinical research, six of the dyads 
had participated in ADRD clinical research while the remaining six had never 
participated in ADRD clinical research. 
Recruitment approach and protocols: At the end of each Phase 1 interview, key 
informants were asked if they were willing to leave a recruitment flyer in their office 
and/or to send a recruitment flyer to their mailing list and people with ADRD and their 
caregivers who they believed would be interested in participating in the study. Through 
CAB referrals, dyads were also recruited through the Memory Café hosted by 
Multnomah County (a social group for people with ADRD and caregivers) and an 
Alzheimer’s Association early-stage memory loss support group. An initial telephone 
screening was conducted with one member of the dyad to determine eligibility based 
upon the following factors: a) if they both fluently spoke English, could engage in a 
conversation, and discussed their perceived values; b) if the person with MCI or ADRD 
had a clinician-assessed diagnosis; and c) if one member of the dyad had ADRD, if they 





Although MCI is not considered a form of ADRD, clinical research studies frequently 
include people with MCI given hypotheses about the progression of ADRD, and that 
people with MCI are significantly more likely to progress to dementia (Roberts and 
Knopman, 2013; Rabinovici et al., 2019).  Each interviewee received a $25 gift card to 
the grocery store of their choice as compensation for their time.  
 It is important to note that some of the recruitment strategies influenced 
dissemination of local dementia research opportunities. In one case, the researcher was 
able to attend an Alzheimer’s Association early memory loss support group for caregivers 
and people with dementia to recruit for this study. The researcher spent a few minutes 
describing the study and shared recruitment flyers. The researcher found this to be a 
useful resource, and an opportunity for researchers to request to speak to support groups 
is listed on the Alzheimer’s Association’s webpage, so the researcher encouraged other 
researchers to contact the staff member and ask to present at the support groups. Shortly 
thereafter, the researcher was notified by the program director that support group 
facilitators had received a large number of requests and asked that the researcher no 
longer promote this resource as this was not the purpose of the support groups, and 
instead to share TrialMatch with fellow researchers as a resource for promoting their 
studies. 
 Conversely, after recruiting for this study at a county-sponsored Memory Café in 
August 2019, the program coordinator of the Memory Café advised the researcher that 
her employer could choose to help sponsor the café and share study opportunities with 





Center began a partnership with Multnomah County’s Memory Café in September 2019. 
In addition to offering a venue for sharing resources about research participation 
opportunities, the sponsorship requires a representative to help set up, clean up and 
converse with Memory Café attendees and sponsors. This requirement has resulted in 
relationships among community members, community organizations and research staff. 
Further, it has led to several initial contacts between OHSU research staff and potential 
participants. Although there is no evidence as yet indicating how many participants have 
been recruited due to this new partnership, this could be explored in the future. 
Interview protocols: Table 3.2 illustrates the domains and interview questions for Phase 
2. Dyads were asked about their first signs of ADRD or MCI, their knowledge of clinical 
research, how and if they receive information about opportunities, their perceptions of 
clinical research, their decision to enroll or not enroll in studies, and suggestions for 
improving ADRD clinical research enrollment. Questions derived from the various 






Table 3.2: Phase 2 Interview Domains 
 
Domain Questions Derives from 
ADRD 
diagnosis 
When did you first notice signs of 
MCI/dementia?  
When did you receive a diagnosis? 
CoH Action Area 4 
Clinical research barriers and 
facilitators literature 





Please describe in your own words 
what “clinical research” is. 
What do you think about clinical 
research? 
What made you decide to 
participate/not participate? 
If you have participated, what was 
your experience like? Would you 
participate again (or participate in 
another study)? 
CoH Action Areas 1, 3, and 4 
Policy feedback theory 
Clinical research barriers and 
facilitators literature  
Social construction theory 
Transaction cost theory 
Civic engagement literature 




Have you heard of clinical research 
opportunities? What about dementia 
research? 
Are there any barriers to make it more 
difficult for you to participate? What 
about things that make it easier? 
What makes you not want to 
participate? 
If you could tell research organizations 
anything to improve research 
participation, what would it be? 
CoH Action Areas 1, 3,and 4 
Policy feedback theory 
Transaction cost theory 
Contingency theory 




with Aim 1 
findings 
These are some of the 
facilitators/barriers from research 
organizations, clinicians, and 
advocates. Please tell me if you agree 
or disagree and why.  
Aim 1 findings 
 
Questions were semi-structured and based on the literature, policies, findings from the 
key informant interviews, and the CAB. The interviews were audio-recorded, transcribed 





CAB involvement: The investigator created a draft of recruitment and interview 
protocols based on best practices from the academic and grey literature as well as 
suggestions from the Phase 1interviewees. These drafts were submitted to CAB members 
before their second meeting. At the meeting, CAB members provided their expertise and 
suggest changes. Afterward, the protocols were modified based on their suggestions. 
 
IRB Processes 
The study processes were conducted per PSU’s IRB rules and regulations. 
IRB process for semi-structured interviews 
To ensure informed consent and confidentiality, before the start of the interviews, 
written informed consent by all interviewees was obtained per PSU IRB requirements. 
Informed consent provided the purpose of the interviews and let the interviewees know 
that they would be recorded but their information would be kept confidential and will not 
be traced back to them.  
Interviewees were given a six-digit alphanumeric code number and each interview 
was given a four-digit alphanumeric code. The investigator took handwritten field notes 
during the interviews. Post-interview field notes were either handwritten or audio-
recorded and transcribed after the interview. Post-interview, the hard copy was scanned, 
saved to Google Drive, a secure and password protected file storage site, and 
immediately shredded. All voice recorded field notes and interviews were transcribed as 





transcriptions of interviews and the master file containing the alphanumeric coding 
information were password protected on the investigator’s secure laptop.  
Process for IRB approval 
To prepare for PSU’s IRB approval, the investigator completed Collaborative 
Institutional Training Initiative (CITI) human subjects research training as per PSU 
requirements. After a successful dissertation proposal defense, the IRB application was 
submitted for review and approval (PSU IRB# 184814). The application included the 
IRB application and all relevant supporting documents, including recruitment materials 
for key informant and dyadic interviews (Appendices E and F), informed consent for the 
key informants, ADRD caregiver, and person with ADRD (Appendices H-J), and the 
interview protocols for the two phases of interviews (Appendices K-M). Interviews did 
not take place until the IRB application was approved. A list of factors based upon Phase 
1 findings (Appendix N) was submitted as a modification and approved by the IRB 
before Phase 2 interviews took place. As previously mentioned, the investigator did not 
need to obtain IRB approval to recruit and convene the CAB. Modifications to the 
recruitment, informed consent, and interview protocols as a result of CAB review were 
submitted for final approval by the IRB before they were administered. 
 
Analytic Processes 
Analysis of semi-structured interviews is, by nature, an iterative process where analysis is 
intertwined with data collection. Johnson and Rowlands (2014) explain the process well:  
“After several interviews, however, the interviewer begins to build a stock of 





information back to the informants in subsequent interviews, after those same 
questions have been covered...as the research develops, the interviewer should 
keep and review their own jottings and notes and review prior interviews when 
possible, or when transcripts become available…the later interviews of an in-
depth interviewing project are usually more focused on specific probes and 
verification of what has been learned in the earlier interviews” (p. 14). 
The investigator took field notes during and after each interview and analyzed them 
immediately post-interview. The approach to research, coding, and analysis is further 
described below. 
Approach to the research 
 A phenomenological approach was used for this study. In phenomenology, data is 
collected from people who have first-hand knowledge, or a lived experience, of a 
phenomenon in order to develop a better understanding of it (Creswell, 2013). In this 
study, the phenomenon is ADRD clinical research participation.  
Coding and analysis 
The codebook emerged from the interviews, but codes were informed by the 
investigator’s a priori knowledge of the literature and various theories and framework, 
including the Culture of Health. Codes included sentences or sentence fragments that 
represented data and concepts (Miles, Huberman, and Saldana, 2020).  
The study was informed by thematic analysis. In thematic analysis, deductive and 
inductive approaches can be used to identify themes from the data. (Lapadat, 2010). Most 
of the analysis was deductive, meaning the codes were analyzed with the notion that they 
may align with orienting concepts derived from the literature and theories (Miles et al., 
2020). An inductive approach was also used to code and analyze themes that did not 





from the data organically and mitigate the possibility of coding those themes based on 
current literature rather than the interviews (Lapadat, 2010). The coding process began by 
coding broad themes then coding with details. For example, if an interviewee noted they 
were unaware of ADRD clinical research opportunities, it was coded as “ability, barrier, 
awareness.” Conversely, if an interviewee described a policy that led to funding 
partnerships, it was coded as “facilitator, ability, then policy, funding, partnership.”  
The focus of the analysis was to identify factors affecting ADRD clinical research 
participation. Identified factors were compared and contrasted among interviewees and 
with organizational theories and frameworks to identify patterns, commonalities, and 
outliers. This led to several major themes and subthemes that are discussed in Chapters 4 
and 5. After identifying themes and subthemes, recommendations and strategies were 
developed and organized using the Culture of Health Action Framework, and are 
discussed in Chapter 6. 
CAB involvement 
 After analysis of transcripts from each interview phase, the findings were 
provided to the CAB. The CAB engaged in member-checking and interpretation, where 
community members reviewed the analysis to confirm or reject investigator takeaways. 
Summaries of findings were sent to the CAB one week before each of the second and 
third meetings. During the meetings, the investigator used 3M Easel pad Post-it notes 
with the findings written on them and adhered them to the wall. Members were asked to 
write their initials on color-coded Post-it notes and to add them to the findings that they 





they felt anything was missing. After this activity, each finding was discussed, with the 
information on the Post-its used to facilitate conversation. 
  
Conclusion 
The literature posits that policy, system, organizational, and personal factors play a role 
in people with ADRD’s capacity and motivation to participate in clinical research. The 
literature also suggests that the expertise of people living with ADRD must be 
incorporated to identify factors and develop strategies to improve ADRD clinical 
research enrollment. This study was designed in such a way to identify these factors 
through insights of researchers, clinicians, advocates, people with ADRD and their 
caregivers, and utilizes a community-engaged approach to enhance the rigor, relevance, 
and reach of the research. Chapters 4 and 5 discuss and synthesize the findings from the 
two phases of interviews. Chapters 6 introduces recommendations to improve ADRD 
clinical research participation using the Culture of Health Action Framework to 
conceptualize and organize them. Lastly, Chapter 7 presents conclusions, limitations, and 






CHAPTER 4: ORGANIZATIONAL, SYSTEM, AND POLICY FACTORS 
AFFECTING DEMENTIA CLINICAL RESEARCH PARTICIPATION 
 
Introduction 
Alzheimer’s disease and related dementias (ADRD) affect nearly seven million people in 
the United States, and rank in the top ten of causes of death and the most expensive 
diseases to treat, both in actual costs for treatment and care and caregiving burden 
(Alzheimer’s Association, 2019a). ADRD clinical trials have a failure rate of over 99%, 
which is due to a lack of evidence of efficacy as well as slow or failed participant 
recruitment (Cummings, Morstorf & Zhong, 2014; Cummings, Lee, Morstorf, Ritter, & 
Zhong, 2017). Numerous pharmaceutical companies (Axovant, Eli Lilly, Eisai, and 
Merck) halted their trials in the past few years after multiple study failures (Axovant, 
2018; Merck & Co; 2018; AstraZeneca; 2018). Pfizer terminated their ADRD research 
arm in 2018 (DeStrooper, 2018; Hawkes, 2018).  
 With no current prevention, treatment, or cure and an anticipated prevalence of 
over 18 million by 2050 in the United States alone, the need to find an effective 
intervention is urgent (Alzheimer’s Association, 2019a). An essential element in finding 
an intervention is ensuring that there are enough participants in clinical research studies 
to determine if proposed interventions are feasible and efficacious. ADRD clinical 
research studies have difficulty recruiting and enrolling participants. Nearly three-
quarters of people with ADRD are ineligible to participate in ADRD research (Grill & 





policy level factors, both general and ADRD-specific, affecting motivation and ability to 
join a study (Grill & Galvin, 2014; NIA, 2018). These factors, with relevant citations 
from the literature, are introduced in Table 4.1 and are described below. 
Table 4.1: Factors Affecting ADRD Research Participation 
Organizational factors System level factors 
 
Policy level factors 
 
Facilitators or barriers that 
occur within an 
organization, or between an 
organization and its 
sponsor or funder 
Facilitators or barriers that 
span two or more 
organizations 
Facilitators or barriers that 
affect organizational or 
system rules, processes, or 
activities due to created or 
enacted policies 
Data and compliance 
oversight (Califf, 2006; 
Kramer, Smith, & Califf, 
2012; Hemminki, 2016) 
Communication about 
research opportunities 
(Mahon et al., 2016; 
Anderson et al., 2018) 
Data and compliance 
oversight (Califf, 2006; 
Kramer, Smith, & Califf, 
2012; Hemminki, 2016) 
Eligibility criteria (Rollin-
Sillaire et al., 2013; Grill & 
Galvin, 2014; Adams, 
Caffrey, & McKevitt, 
2015) 
Clinician training and 
interest (Meador, 2015) 
IRB/Security protocols 
(Hudson et al, 2016) 
Recruitment strategies 
(Sood et al., 2009; Law et 
al., 2014; Mahon et al., 
2016; & Galvin, 2014; 
Friedman et al., 2015, 
Mahon et al., 2016) 
Community engagement 
(Grill & Galvin, 2014; 
Mahon et al., 2016) 
Recruitment and diversity 
policies (King 2007; 
Huang & Coker, 2010; 
Penberthy et al., 2012) 
Relationships with people 
with ADRD/caregivers 
(Williams, Meisel, 
Williams, & Morris, 2011) 
Structural elements (Grill 
& Galvin, 2014; Mahon et 
al., 2016) 
Dissemination policies 
(Israel et al., 2008; Carlisle 
et al., 2015; Mahon et al., 
2016) 
IRB/Security protocols 
(Hudson et al., 2016) 
 Funding opportunities 
(NIH, 2018)  
Community engagement 
(Grill & Galvin, 2014; 
Mahon et al., 2014)  
  
 For the purposes of this study, organization level factors are defined as facilitators 





or funder, such as a research organization and its study sponsor. System level factors are 
facilitators or barriers that span two or more organizations, such as those involving a 
research organization and a healthcare organization. Policy level factors are facilitators or 
barriers that affect organizational or system rules, processes, or activities due to created 
or enacted policies. In some cases, factors may exist at multiple levels. As Table 4.1 
illustrates, the aggregation of organizational, system, and policy factors contributes to the 
low participation rates in ADRD clinical research. Several organizational and policy 
theories can be used to conceptualize how these factors affect ADRD research 
participation. 
Organizational factors 
 From an organization level perspective, research and health organizations are 
considered open rational systems; they have structures and processes that they must 
adhere to, but can adapt to environmental needs (Scott, 1987). Contingency theory can be 
applied to better understand the structure of these organizations. Contingency theory 
posits that the best way to structure an organization is contingent on both the needs of the 
organization and its environment while recognizing some structures cannot be changed 
(Lawrence & Lorsch, 1957; Mintzberg, 1983). For example, national and organization-
wide data collection and monitoring, while necessary to ensure ethical and clinical 
regulatory compliance, account for a large proportion of study resources, minimizing 
staff time and funding allocated to participant recruitment and retention (Califf, 2006; 





 Although research organizations are unable to modify these requirements, they 
can adjust other processes to meet the needs of people with ADRD. For example, study 
partners are required to participate with the individual with ADRD to ensure protocol 
adherence and appointment attendance, ensuring further difficulty due to the requirement 
that study coordinators need to recruit twice the number of people (Karlawish et al., 
2008; Watson et al., 2014; Grill & Galvin, 2014; Cary et al., 2015; Black et al., 2017). 
Although this is something that cannot (and should not) be changed, modifications could 
be made to increase accessibility and ease of participation for caregivers, such as 
conducting interviews over the phone or offering study visits outside of traditional office 
hours to fit the caregiver’s schedule. When using contingency theory to explain these 
processes, organizations recognize that data compliance and monitoring and the need for 
study partners cannot be adjusted, other processes can be modified to better fit 
environmental or community/individual needs.  
 Often, recruitment processes are developed and implemented at the organizational 
level, or between a research team and their study sponsors. While the NIH requires their 
funded studies to include underrepresented groups, biopharmaceutical companies, which 
sponsor over 65% of Alzheimer’s disease clinical trials, do not have these requirements 
(Cummings, Lee, Mortsdorf, Ritter, & Zhong, 2017). Studies conducted in the United 
States and the European Union found that study eligibility criteria can severely restrict 
the enrollee pool of a research study, making it difficult to obtain an adequate number of 
participants within the proposed time frame (Kramer, 2012; Adams et al. 2015; Mahon et 





cases of private study sponsors requiring unsubstantiated ineligibility criteria, such as 
comorbidities or medications, to avoid risk or delay of FDA approval (Kramer et al., 
2012). Study organizations and sponsors may also impose penalties for not recruiting at 
expected levels, resulting in avoidance of underrepresented groups in research, 
particularly African Americans (King et al., 2007; Uybico, Pavel, & Gross, 2007; Huang 
& Coker, 2010). This is especially damaging for ADRD studies as African Americans are 
twice as likely to develop ADRD and more likely to be diagnosed in the later stages of 
ADRD (Chin, Negash, & Hamilton, 2011; Danner, Darnell, & McGuire, 2011; Bonds & 
Lyons, 2018). If research organizations work with study sponsors to modify their 
recruitment processes and unsubstantiated eligibility criteria and enact policies to include 
underrepresented groups, they can address environmental needs and facilitate ADRD 
clinical research participation. 
System level factors 
 Contingency theory can also be used to examine system level factors. Community 
engagement among research, health, and social sectors can facilitate clinical research 
recruitment and retention (Frew et al., 2011; Grill & Galvin 2014; Watson et al., 2014; 
Mahon et al., 2016; Inungu, Bender, & Geiber, 2017). Community-engaged strategies 
result in the research organization’s developing knowledge of target populations’ risk 
behaviors, which are essential to inform effective prevention strategies as they can both 
affect and inform research design, recruitment, and retention (Voytek et al., 2011; Luzi et 
al., 2011; Inungu et al., 2017). When research organizations partner with local health 





(Gifford et al., 2002; Frew et al., 2011; Mahon et al., 2016; Inungu et al., 2017).  
Recognizing and reducing other structural barriers, such as transportation and geographic 
distance, also facilitates community member buy-in and subsequent participation, 
(Giffords 2002; Frew et al., 2011; Burke, 2014; Mahon et al., 2016, Inungu et al., 2017; 
Croff et al., in press). Working with the community leads to greater knowledge of 
community needs, and organizational structures and processes can be modified to address 
those needs. 
 Transaction cost theory can be used to examine system level factors affecting 
ADRD research participation. In transaction cost theory, every transaction between two 
parties is subject to a cost; if the perceived cost is too high for either party, the transaction 
will not happen (Williamson, 1975). Hemminki (2016) argues that the time spent auditing 
and checking procedural formalities does not make research more ethical, and, in fact, the 
rules, procedures, and costs associated with clinical research may deter clinicians and 
organizations from conducting research. Many individuals assume that their providers 
will inform them of studies (Anderson et al., 2018), but clinicians may not view 
advocating for research participation as a necessary piece of their clinical practice or may 
view it as an unnecessary utilization of limited time, money, and workforce (Sugarman, 
Getz, Speckman, Byrne, & Emanuel, 2005; European Science Foundation, 2011; Kramer 
et al., 2012). In these cases, the transaction costs for clinicians to learn and share 
information about clinical trials may be too high for providers, which negatively affects 





Policy level factors 
 Social construction posits that policies are based on societal perceptions of groups 
of people (Schneider, Ingram, & de Leon, 2014). Changes in a group’s political power 
and social construction result in changes in public and personal perceptions, leading to 
policy change and further changes in the target population’s material and interpretive 
effects, political power, and social construction (Schneider et al., 2014). Given the low 
recruitment rates for ADRD clinical research, interest has increased in researching and 
evaluating effective strategies to recruit specifically for ADRD research. The U.S. 
Congress allocated 2.3 billion dollars for ADRD research in 2019 with the hope of 
eradicating this set of diseases by 2025, and Bill Gates has invested $50 million into his 
Dementia Discovery Fund with a specific focus on participant enrollment (Hodes, 2018; 
Gates, 2017).  
 Social construction is incorporated within another theory, policy feedback theory 
(PFT). PFT recognizes that payments, goods, rules and procedures and policies affect a 
person’s predisposition and capabilities to participate in society (Skocpol, 1992), or in 
this case, ADRD clinical research. The NIH has taken steps to reduce bureaucratic 
practices, such as permitting a single IRB review and approval for multi-site studies, yet 
NIH directors acknowledge that more work needs to be done to further reduce systemic 
and bureaucratic barriers to enhance and advance clinical research (Hudson, Lauer, & 
Collins, 2016; NIH 2016).  
 Disseminating results directly to those involved in research is frequently 





2016), yet NIH policies only require NIH-funded studies or studies of FDA-approved 
drugs or devices to disseminate their results of clinical trials via PubMed Central and 
ClinicalTrials.gov (Hudson et al., 2016; NIH, 2016b). However, these results are not 
written in lay language, and articles are often hidden behind a paywall, resulting in them 
being inaccessible to those without scientific literacy, fiscal means to purchase articles, or 
awareness of how to access articles for free. Further, researchers are still not required to 
directly update participants with the results of the study in which they participated. Thus, 
these dissemination policies are geared more towards the scientific community than study 
participants.  
 Beginning in 2016, the National Institute on Aging (NIA) convened working 
groups to identify strategies to improve recruitment and retention in ADRD studies. Their 
report was released in 2018; it emphasizes the concept of local community collaboration, 
with four key strategies: (a) increase awareness and engagement; (b) build and improve 
research infrastructure; (c) engage local communities and support participants; and (d) 
develop an applied science of recruitment (NIA, 2018). The aforementioned factors 
affecting ADRD clinical research, and the literature in general, do not incorporate 
concepts of local community collaboration. Thus, research is needed to contextualize 
how policy, system, and organizational factors affect local ADRD research participation.  
Purpose of this study  
 This study aimed to identify organizational, system, and policy level factors 
affecting ADRD clinical research participation in the Portland, OR metropolitan area. 





disease, and this number is expected to increase to 84,000 by 2025 without an 
intervention to halt its increase (Alzheimer’s Association, 2019a). This number represents 
about 9% of adults 65 and older living in Oregon, slightly less than the national average 
of 10% (U.S. Census Bureau, 2018; Alzheimer’s Association, 2019a). However, the 
actual numbers of those living with ADRD are higher because the figures cited do not 
include people under the age of 65 or with related dementias. Additionally, the number 
does not include individuals who exhibit symptoms but are un- or misdiagnosed, which 
could be as high as 60% (Lang et al., 2017) Although the research cited above describes 
these factors, it focuses on general, national factors. Although these factors certainly 
affect local ADRD research efforts, they do not speak to specific state or local factors and 
the effects of local efforts. 
 
Methodology 
This paper describes organizational, system and policy factors affecting ADRD clinical 
research participation that were identified by ADRD clinicians, researchers, and 
advocates interviewed for this study. The larger dissertation project further identified 
factors affecting the decision of a person with ADRD to participate in clinical research. 
In addition to identifying organizational, system, and policy level factors affecting 
participation in ADRD research studies, the dissertation also sought to identify personal 
factors affecting ADRD participation as well as provide recommendations to healthcare 






 To assess organizational, system and policy factors affecting ADRD clinical 
research, the investigator worked with several local health providers, researchers, 
community organizations, and a community advisory board (CAB) to identify ADRD 
clinicians, researchers, and advocates to offer expert opinions on factors affecting ADRD 
clinical research participation. Semi-structured interview questions were derived from the 
literature and various theoretical frameworks. Interviewees were ultimately selected 
based on the organization they worked for to ensure diversity in organizational 
representation. Potential clinicians, researchers, and advocates were recruited by email or 
phone. Interviewees were not paid. All protocols were reviewed and approved by the 
Portland State University Institutional Review Board (IRB #184914). 
 The investigator adopted a community-engaged approach to this research by 
identifying interviewees based on community referrals, as well as through the 
development and involvement of a community advisory board (CAB). The investigator 
chose to use a community-engaged approach to enhance study rigor, relevance, and 
reach, as well as for its strength in identifying community-specific factors and strategies 
(Balasz & Morello-Frosch, 2013; NIA, 2018).  
 A CAB was established to advise and guide study processes. CAB recruitment 
was facilitated through the NIA-Layton Aging and Alzheimer’s Disease Center (NIA-
Layton Center), the Alzheimer’s Association, and the PreSERVE Coalition for 
Black/African American Memory and Brain Health. CAB members included researchers, 





African Americans, and a member of the researcher’s dissertation committee who has 
experience working with CABs in community-based research. The 12-member CAB met 
three times during the study to guide the investigator on recruitment and interview 
protocols, interpret findings, and develop dissemination strategies. CAB community 
members were given a grocery gift card for each meeting they attended or contributed to, 
in recognition of their contributions to the CAB. 
Data collection and analysis 
 Semi-structured interviews with clinicians, advocates, and researchers were 
completed between April 2019 and June 2019. Interviewees were asked about their 
experience of working with people with ADRD; their knowledge of clinical research and 
related policies; if and how they receive information about clinical research opportunities 
and dissemination of those opportunities; their perceptions of organizational, system, and 
policy level factors affecting clinical research recruitment and retention; and suggestions 
for improving ADRD clinical research enrollment. Interviews were audio-recorded, and 
the investigator took field notes during and after each interview. Interviews were de-
identified and transcribed using transcription services (Rev.com), then uploaded to 
Atlas.ti 8.1 software for coding and thematic analysis (Scientific Software Development 
GmbH, Berlin, Germany).  
 The codebook emerged from the interviews, but codes were informed by the 
investigator’s a priori knowledge of the literature and various theories and framework, 
including the Culture of Health (Robert Wood Johnson Foundation, 2016). Codes 





Huberman, and Saldana, 2020). The coding process began by coding broad themes then 
coding with details. For example, if an interviewee described a lack of awareness of 
ADRD research opportunities, it was coded as “barrier, ability, system, awareness.” 
Conversely, if an interviewee described a policy that led to funding partnerships, it was 
coded as “facilitator, ability, policy, funding, partnership.” Most of the analysis was 
deductive, meaning the codes were analyzed with the notion that they may align with 
orienting concepts derived from the literature and theories (Miles et al., 2020). An 
inductive approach was also used to code and analyze themes that did not correspond 
with existing literature and theories to identify themes that emerged from the data 
organically and mitigate the possibility of coding those themes based on current literature 
rather than the interviews (Lapadat, 2010). The investigator was the single coder and the 
CAB interpreted findings by identifying what was most important, surprising, or missing 
in the interviews. 
 
Results 
Ten clinicians, researchers, and advocates were interviewed, with one interview removed 
from the analysis due to the interviewee discussing their experiences in a location outside 
of the study’s geographic area. Nine interviews were ultimately included in the final 
analysis. The interviewees were employed by (8) or volunteered with (1), several health, 
research, or advocacy organizations of varying sizes and structures. Table 4.2 provides 






Table 4.2: Interviewee Characteristics 
Investigator at large research organization 
Research associate at large research organization 
Research associate at small research organization 
Neurologist/investigator at large research organization 
Advocate at ADRD advocacy organization 
Support group facilitator and advocate 
Geriatrician at mid-sized health care organization 
Geriatrician at large health care organization 
Geriatrician at large health care organization 
 Table 4.3 summarizes the key findings, organized as thirteen subthemes across 
five main themes: engaging with people with ADRD; policies and funding mechanisms; 
partnerships and collaborations; clinical research as an organizational value; and 
perceptions of ADRD clinical research participation. Subthemes are discussed in detail 
below. 
 
Table 4.3: Themes and Subthemes from Interviews 
Themes Subthemes 
Engaging with people 
with ADRD 
 Organizational roles and processes 
 Alzheimer’s Association as a tool for engagement 
Policies and funding 
mechanisms 
 Industry funding 




 Community collaboration 
 Multi-site and cross-sector collaboration and 
partnerships 
 Advisory boards 
Clinical research as an 
organizational value 
 Research as a priority 
 Communication of research opportunities 




 Shift in mindsets 
 Caregivers as gatekeepers 






Theme 1: Engaging with people with ADRD 
 The two subthemes related to Theme 1 are organizational roles and processes and 
the Alzheimer’s Association. A summary of how they affect ADRD clinical research 
participation is provided at the end of this section. 
Organizational roles and processes: Two of the three local ADRD research 
organizations were included in this study (the third did not respond to requests to be 
interviewed). Both research organizations additionally serve as cognitive health clinics, 
but there was a substantial difference in the size of the two organizations. The small 
research organization opened a few years ago, had a very small number of employees and 
was not actively recruiting for studies at the time of the interview. The large organization 
has over 100 employees, has been in operation for 30 years, and was recruiting for many 
studies. Both organizations recruit participants within and outside of their regular patient 
population, as described below: 
Researcher: “Our primary way of informing them about our studies and 
enrolling them is word of mouth through our clinic. The doctors who see our 
patients often have research study discussions and they're not allowed to say, 
‘Hey, do you want to do this study?’ But they can say, ‘Are you interested in 
research?’ … Then we have certain approved flyers that we put up around. We 
also go and give community lectures [and] slide in some information about our 
studies.” 
Researcher: “We've done talks, we've had our physician do talks in the 
community before. We have done plenty of advertising, we've gone through the 
[newspaper], we have done radio advertising, but that did not work at all. The 
[newspaper] is actually where we've had the best turnout. We've done fliers and 
canvassing; it’s kind of rare as to where you can find a place where you can 
canvass nowadays. A lot of people don't want you hanging up your posters and 
things like that, so kind of rare in where we can go with that, but I don't think 
we've had anybody coming in saying that they saw it from a library poster or 





The large research organization held weekly clinic meetings where clinicians discuss 
their patients, and a coordinator is present to advise if the person with ADRD or their 
caregiver might qualify for a study. Study coordinators are involved in, or oversee, all 
aspects of their specific studies, but generally are not familiar with other studies beyond 
those to which they are assigned. However, the organization added the role of a 
recruitment coordinator who is familiar with all of the organization’s studies. This 
coordinator fields phone calls from interested community members or patients, lets them 
know which studies they may qualify for, and connects them with the appropriate study 
coordinators. Researchers regarded this recently-added position as beneficial to 
improving recruitment. 
 All of the healthcare providers interviewed served as the directors of their 
respective departments or divisions. Many of these interviewees noted that primary care 
providers often refer patients to geriatricians or neurologists in order to obtain an ADRD 
diagnosis, evaluation and treatment, and resources for both patient and caregiver: 
Healthcare provider: “There are several of the general internists who have 
learned the basics of addressing cognitive impairment. They often still want us to 
see the patient to provide more education and support. But, some of the primary 
care providers say, "Oh, you have a memory problem? Okay, we need to refer 
you." So, it's variable as to people's ability or willingness to manage patients on 
their own.” 
One provider noted that with the increase of at-home DNA testing kits, they receive 
referrals from individuals who discovered they were at higher risk for Alzheimer’s 
disease and want to be vigilant about reducing their risk or preparing for a diagnosis. 
However, the provider’s patient panel ranged from those with no cognitive impairment to 





they only work with frail older adults, over 60% of whom had a confirmed ADRD 
diagnosis. 
 Two of the nine interviewees were advocates for people with ADRD, one of 
whom held a professional role with the local chapter of the Alzheimer’s Association. The 
mission of the Alzheimer’s Association focuses on providing support groups, education, 
and resources for people with ADRD and caregivers, as well as advocacy and research. 
The second advocate was a former spousal caregiver who volunteered as a facilitator for 
ADRD support groups and held positions on advisory boards for caregiver and ADRD 
support policies in the local area.   
Alzheimer's Association: Nearly every interviewee mentioned the Alzheimer's 
Association as a primary way they either recruit people with ADRD and caregivers or 
provide education, support, and resources for them. In addition to working directly with 
people with ADRD and their caregivers, the Alzheimer’s Association also supports local 
community organizations. Their involvement was recognized as significant for one 
researcher whose work focuses on brain health and the local African American 
community: 
Researcher: “[The Alzheimer’s Association] has tables at [our] events, and the 
tables really feel like it’s for the community, whereas sometimes you might have a 
table where researchers are just trying to get people … the Alzheimer’s 
Association, they’re not doing research studies … they have these materials about 
you know, what are 10 signs of Alzheimer’s disease? What are some free online 
workshops that you can attend? Where are there caregiving classes or even just 
bringing the person you’re caring for even to the Alzheimer’s Association to the 
Portland branch and they can do art activities while you discuss with other 
caregivers? So all those types of things really feel like it’s for the community 





However, one researcher noted that they no longer collaborate with the Alzheimer’s 
Association because the study staff did not reach their target populations: 
Researcher: “[Investigator] used to be involved with the Alzheimer's Association 
and setting up booths after runs and things like that, and [investigator] just found 
that it really didn't benefit the people that needed it. So the people who were 
actually at the runs and things like that would be the younger cousin who's 
representing somebody who could benefit from the services, but they're not there, 
and then the information wasn't really being [transferred] to the people who 
really needed to hear it. So [investigator] didn't really find any benefit there for 
us or for any patients in that aspect.” 
Summary: Organizational processes and resources contributed to an organization’s 
strategies for engaging with people with ADRD. Research organizations used clinic 
records and had different ways of finding non-clinic individuals who might be interested 
in research. Having a recruitment coordinator who can refer interested individuals to the 
appropriate study has been beneficial to study recruitment. Health organization 
interviewees spoke mainly about their referral system for treating people with ADRD and 
caregivers. Some organizations had formal processes for referrals; others had more 
informal, flexible processes. The Alzheimer’s Association provided options for many of 
the organizations, who in turn were able to refer individuals to the Alzheimer’s 
Association’s resources and support groups and reach people with ADRD. However, not 
every organization had the same level of success. 
Theme 2: Policies and funding mechanisms 
 The two subthemes discussed for Theme 2 are industry funding and processes and 
policies for research recruitment. A summary of how they affect ADRD clinical research 





Industry funding: Researchers receive funding from a variety of sources, including 
nonprofits (e.g. Alzheimer's Association), government (e.g. National Institutes of Health) 
and internal funding, but industry sponsors (e.g. pharmaceutical companies) provided 
substantially more money. One researcher specifically stated that applying for non-
industry grants was not worth their time since they already receive a lot of money from 
industry sponsors. However, researchers also are required to adhere to their sponsor’s 
specific standards. All industry-funded research activities and strategies, such as 
recruitment materials, compensation for study participation, or the use of a specific MRI 
machine, are dictated by the industry sponsor and any modifications require their 
approval: 
Researcher: “Occasionally, with industry-funded trials, they're a little bit pickier 
about the kinds of advertising that we do. So any sort of patient-facing 
advertisement like a brochure or a flyer or even like a phone call, we need to have 
all of that approved by the sponsor as well as the IRB … If we don't like it, we're 
like, "Oh. Well. I don't think the patient’s really going to want to be in this trial if 
it says that." But if that's what the sponsor requires then we're kind of stuck [with] 
that. It might limit our engagement with people. We have had that happen 
before.” 
 
Researcher: “So the sponsor sends somebody to do [quality assurance testing] on 
one specific machine, so we can't even just send them to one facility, it has to 
literally be one specific machine that was [tested] by them, so that they're 
scanned under the same protocol each time on the same machine, really just 
anything to reduce variability. That would help, if we could send people to other 
places.”  
 
Researcher: “Usually, the sponsor has relationships with multiple vendors that 
we have to work with directly but we don't have contracts with directly. When I 
first started, that was nine years ago, we didn't have hardly any vendors. Maybe 
one for the MRI review or something. But, now, our latest trial has 10 vendors. 
All these different labs and PET scan review, PET scan dose ordering and MRI. 
There's a vendor for paying the subjects and there's a vendor for looking at 
photographs of subjects skin changes that are a risk factor in the trial. All kinds of 





Policies for research recruitment: There are new federal policies that focus on diversity 
in research, such as the NIH’s Inclusion Across the Lifespan policy (NIH, 2018), which 
went into effect in 2019: 
Researcher: “With the new NIH policy…you have to now say why you’re ending 
it at a certain age, your eligibility, like if you’re saying age range is between 50-
90, why are you ending at 90? ... It just seems silly that so many studies end at 90 
when that’s precisely the group that’s more likely to be affected by ADRD.” 
 
However, many interviewees were unable to identify specific policies that improve 
ADRD research participation. Other interviewees discussed policies that have been 
enacted but not utilized in the field. As previously mentioned, there was a recent NIH 
policy change to allow a single IRB for multi-site studies (NIH, 2016), but this policy 
change has not been utilized by the researchers interviewed for this study: 
Researcher: “I think institutions tend to stay within their bounds of what they're 
used to doing. One area this has clearly shown its face is in the area of trying to 
enact a uniform, a single consent process, so I won't have 20 different IRBs 
reviewing the same consent but coming up with 20 different versions. The time 
and delay that just generates practically, versus having a common agreement that 
we'll defer to one central organization. It's been aspirational. It's still not 
happening. I still see just in recent experience with multi-center projects that 
we're supposed to use a central IRB or a single IRB. In practice, it still hasn't 
happened … I think most of it is fear, it's liability.” 
Conversely, some healthcare providers described billing and Medicare policies that made 
it easier for them to see patients with ADRD: 
Healthcare provider: “There has been a change in the last five years, since we 
took on this consult model, where we realized that we couldn't be like a primary 
care clinic where a provider typically sees twenty, twenty five patients a day. That 
doesn't work at geriatrics just because they have special needs, they need more 
time. We in our consult clinic have a ninety minute visits for the initial consult 
with the provider …. Because we have these longer appointments with our coding 
has changed in that we code prolonged services, so we code by time which is 
different from what a typical primary care clinic codes for. This allows us enough 





Summary: Policies and funding mechanisms were described as playing a large role in 
affecting ADRD research participation. Policies were enacted to streamline the study 
start-up process or incentivize inclusive research, but some policies are deemed 
ineffective in practice. Industry funding offered a strong balance between having 
additional funds for research study activities, but came at a cost of additional barriers, 
potentially affecting recruitment or ability for individuals with ADRD to participate.  
Theme 3: Partnerships and collaborations 
 Three subthemes are discussed in this section: collaborating with the community, 
collaborating with non-community organizations, and advisory boards. A summary of 
how these subthemes affect ADRD clinical research participation is provided at the end 
of this section. 
Collaborating with the community: Some interviewees spoke about sharing 
information with community groups through presentations or flyers, whereas others 
described collaborations for referrals or research recruitment. One researcher worked 
with an African American community organization that serves as an advisory board for 
some of the research organization’s studies and also has a designated workflow to 
determine with which investigators to work and share resources with. Some interviewees 
articulated that any work with community groups or members was volunteer time away 
from their job; one noted that she was required to make up the time: 
Healthcare provider: “I honestly devoted hours and hours and hours to trying to 
develop processes and education. But, over time, it's been hard to remain 
enthusiastic because any time I spend working on things like that, comes out of 
my own personal time. And people don't seem to understand that I'm not funded to 
attend two to three hour long meetings. And if I spend time in a meeting, then I 






Researcher: “It is a challenge, particularly for minority research, where the key 
element to successful research in minority communities is establishing a long 
standing relationship. In order to do that, it takes resources. You can't really go 
out and fund a grant to create those relationships. It's basically volunteer time in 
a way … develop those relationships. Then hopefully they just get established, and 
then you open the door to a more formal project or study.” 
Collaborating with non-community organizations: All interviewees spoke of 
partnering with other healthcare or government agencies to provide resources for people 
with ADRD or caregivers. Additionally, researchers spoke of collaborations with other 
researchers or professional research organizations to work on projects together. As 
previously mentioned, one researcher noted that despite attempts to have one uniform 
process for these collaborations, each organization ends up following their own rules out 
of fear of liability, often resulting in delays in study start-up and recruitment. 
Additionally, collaboration with vendors led to partnerships to streamline study start-ups: 
Researcher: “There's also a new partnership that we have called the Alzheimer's 
Clinical Trial Consortium. ACTC. They are focused on helping clinical trials get 
started up a little bit faster so they're an umbrella consortium … [to] help with all 
of the startup. Because start up for a study takes so long with the negotiations and 
contracts … I would say our longest trial that went from very beginning to 
completely ready to go was one year. I would say six months at a minimum. Very 
rarely do we get a trial up and running in less than six months. There are just a 
lot of pieces and negotiations and that takes a while.” 
Advisory boards: Respondents who spoke of advisory boards had mixed feelings. Some 
felt that they provided opportunities for community empowerment and an opportunity to 
learn from the experts. Others felt they did not truly capture community needs: 
Researcher: “If we have a meeting, I make sure that we don’t have 7 
[researchers] and 3 community members on the other side of the table … we are 
conscious about power imbalance. And then we always approach them as ‘you’re 
the experts.’ So we always want to approach it as ‘we want to learn from you’ 





looking for. What if I don’t know about what they want?” … It’s them giving to 
us, when really…we want to say, ‘look, you’re the experts, help us learn from 
you.’ And so it’s putting them in a position of knowledge and, you can even say, 
empowerment. But whatever they have to tell us is what we want to hear.” 
 
Researcher: “Those are challenging, because I think they sound good, but if you 
think about it, how can one person from a community represent the community? I 
mean, you take it as input, but I think that it's hard to get the voice of a community 
from a single community representative. We've had this experience where there's 
a person from the community who is quite vocal and has a view that we're pretty 
sure is not necessarily the majority view, but they're vocal and adamant… you 
take it as input, but I think that it's hard to get the voice of a community from a 
single community representative.” 
Some respondents questioned the membership of people with ADRD on advisory boards 
given the nature of their disease: 
Healthcare provider: “Some of the people who go to the participant advisory 
council meetings, I'm sure have dementia. The biggest challenge inherent to 
dementia … is apathy … it just looks like they don't do anything. And they don't 
care about anything. And they don't say anything. Which is all true…So, I think 
having dementia itself is going to stand in your way. I mean, there are really 
exceptions. There's a person here or there who's, for whatever reason, the one out 
of four who doesn't have that syndrome predominantly.” 
 
Healthcare provider: “For the things I've done, we haven't included individuals 
with dementia … with dementia, people often lack insight, they often have enough 
memory impairment that they won't remember a previous conversation. So, you 
can't build on what you've done previously and it's just a much more limited 
interaction.” 
Only one interviewee, an advocate, described actively recruiting people with ADRD for 
their advisory boards and advocacy work: 
Advocate: “We have our own board. We have people living with cognitive 
impairment and change … They are there because they're an expert. They know 
what it means to live with this disease every single day. They know what it means 
to care for someone's disease or to watch their husband change before their eyes. 






Summary: Collaborations and partnerships affected relationships between organizations 
and people with ADRD, as well as partnerships between organizations. Some 
organizations valued the role that community members have as experts, others did not 
believe that community members are experts, or had negative thoughts. This is 
additionally true for people with ADRD -- while some thought their expertise was 
integral to the research process and decision-making, others believed that having people 
with ADRD involved was not good practice due to the nature of the disease.  
Theme 4: Clinical research as a value 
 The two subthemes discussed for Theme 4 are research as a priority and 
conversations about research opportunities. A summary of how they affect ADRD 
clinical research participation is provided at the end of this section. 
Research as a priority: For the researchers and some advocates interviewed, research 
was viewed as a high priority and incorporated in all aspects of their work:  
Researcher: “I think doing dementia clinical work day-in-day-out will burn you 
out. It certainly would burn me out immediately. Being able to do research … 
helps me feel like, well at least I'm trying to move the needle … It's not going to 
get better unless we understand how to fix it. That's why I think it's so important, 
and that's why I do it.” 
For the healthcare providers and other advocates interviewed, research was not a high 
priority because their organizations focused on providing healthcare, education, or other 
support resources. For example, one provider spoke of a research project that they 
planned to collaborate on with a research organization, but had to end their participation:  
Healthcare provider: “It's become an entirely [research organization]-based 
project because of lack of support [at healthcare organization] for the research 
components … Originally we designed it as a project that would be based in both 





It's not to say that our patients … couldn't participate but we can't recruit and 
enroll them here.” 
Conversations about research opportunities: Two of the three ADRD healthcare 
providers who do not conduct ADRD clinical research reported on organizational policies 
that banned or discouraged active sharing of information about research opportunities: 
Healthcare provider: “Because of the population that we treat, [the Centers for 
Medicare and Medicaid Services] has it in our regulations that we are not 
allowed to enroll our participants in research … And it's really because we're a 
capitated plan … we control nearly everything about our participants. So, if we 
don't approve it, and we don't transport them to it, and we don't provide it, they 
don't get it.”2 
 
Healthcare provider: “I suppose we could say, ‘There are some research 
projects over at [research organization]. If you're interested you can contact this 
person or this phone number.’ But that's on the edge of what we're supposed to 
do.” 
Conversely, many respondents from research organizations reported that providers 
typically discussed research opportunities with patients as part of their care plans: 
Researcher: At the end [of the first visit], you say, "Well, you could take this 
drug. You could do this. You really need to have this test though." Then of course 
we want to bring up, "This is a research center. If you would be interested, we 
would love to have you consider being involved in a research study." Then we 
would say, we usually have in mind what that might be based on what we've 
heard. It might be a caregiver study, it might be a drug study, it might be 
enrolling in the [organization] as a cohort person.” 
Additionally, some responses indicated that there was a large segment of community 
members who were not aware of opportunities or responsive to researchers’ recruitment 
efforts: 
Advocate: “We need to hear about it more. I mean, if I don't know about it … If I 
had some pamphlets or if [researchers] like you want to come and I introduce you 
                                               
2 Interviewee sees patients through the Program for All-Inclusive Care of the Elderly (PACE), a capitated 
comprehensive health and long-term service program for dual-eligible, frail, community-dwelling, older 





and say this is what you're doing, and if anybody wants to talk to you, meet you 
after ... I think it needs to be more of a priority. But like I said, I've never had any 
information on it.” 
 
Researcher: “It’s so easy to get the easy people, the people in our networks, and 
if our network isn’t very diverse … and the people who have been in other studies 
keep coming back, and then it’s easy to say ‘oh, well it’s too hard to get that 
population.’ I think it just means we’re not planning ahead enough, we’re not 
working hard enough, we’re not using our networking skills and community 
building to reach those people, or maybe the way we’re approaching those people 
is not the right way culturally to approach those people.” 
Summary: An organization’s perceived value of clinical research affected the likelihood 
of a conversation about clinical research opportunities and ultimately affected awareness 
and the ability to participate in research. Some organizations perceived clinical research 
to be of such low value that they have policies in place to avoid conversations, whereas 
others may consider research to be as valuable as other courses of action in a care plan. 
Interviewees also noted that there were missed conversations with many community 
members, suggesting that research organizations may need to rethink recruitment 
strategies. 
Theme 5: Perceptions of clinical research 
 Four subthemes are discussed in this section: fear, shift in mindset, caregivers as 
gatekeepers, and motivation discrepancies. A summary of how these subthemes affect 
ADRD clinical research participation is provided at the end of this section. 
Fear: Interviewees discussed knowledge of some providers appearing to be afraid to give 
an ADRD diagnosis, which could affect the ability to participate in studies that require an 





in research because it could lead to being identified as someone with ADRD, or may be 
afraid that research participation will disrupt their routines:  
Healthcare provider: “Dementia research is in the same place cancer research 
was in the 1950s. When cancer was a terminal illness, there were no treatments, 
there were no disease modifying effects, and we didn't tell people they had cancer. 
And that's exactly how it is for dementia. We don't tell people they have 
dementia.” 
 
Healthcare provider: “There is a fear factor … fear of the unknown as to what's 
going to happen to them [in the study] but also having other people know about 
their cognitive issues. We see that a lot of people who have been really high 
functioning they mask cognitive issues. There's that really, you know just coming 
out and sharing that with other people. There's a concern there.” 
Shift in mindset: Many interviewees advocated for reframing ADRD in order to remove 
the stigma around it. One suggestion included viewing ADRD and brain health as a 
public health issue rather than an individual one. Another suggested re-marketing ADRD 
similarly to what has been done in describing cancer, such as using the terms “fighters” 
and “champions” to describe people with ADRD. Yet another suggestion was to 
recognize the resilience that older adults have in the face of many medical changes, and 
challenge the notion that nothing can be done to help the individual once an ADRD 
diagnosis has been made: 
Advocate: “One of [the organization’s policy goals] is increasing public 
awareness and early detection and diagnosis around Alzheimer's disease … really 
taking a look at Alzheimer's disease that leans towards public health, that this is a 
public health crisis. It's not just a disease affecting people that are aging, but 
everybody is affected by it.” 
 
Healthcare provider: “I think on the provider's side … it's just uncertainty and 
feeling like there's nothing for them to do. So why make the diagnosis? Because 
they could be wrong. When in fact, there are things to do. Get your affairs in 






Caregivers as gatekeepers: Most interviewees described the important role that 
caregivers play as a major factor affecting research participation, given the requirement 
that study partners also participate in ADRD research: 
Researcher: “Sometimes the participant is really gung-ho and ready and wants to 
be involved and the caregiver just doesn't care, so that's really unfortunate and 
we see that often enough, where it's the caregiver dropping the ball, just not 
following through, not getting back to us for scheduled appointments, and just lost 
through follow up, basically, which is really unfortunate.” 
When asked to provide recommendations to improve ADRD research participation, many 
focused on improving the caregiver’s ability to participate in research via flexible 
scheduling and locations, or providing education or support for the caregiver: 
Healthcare provider: “If caregivers could get support … sometimes maybe 
there's a small stipend or agreement that people get from research participation. 
But sometimes it could be in terms of supporting caregivers. They might see this 
as a plus instead of just a monetary part of it.” 
Motivation discrepancies: Research coordinators and advocates found it easy to 
describe the high motivation for people to participate in research: 
Researcher: “For Alzheimer's disease studies, folks are really motivated to 
participate. They will go to great lengths to participate in our trials and, 
sometimes, we're even surprised. We're like, "Wait a second. You live two hours 
away and you're willing to come in every two weeks for six months? Wow." That's 
really surprising. But people are just so motivated to find a cure for Alzheimer's 
disease that they often say, "I don't want my children to go through this or my 
grandchildren." So they're really motivated to help us.” 
 
Researcher: “This is a demographic that is really eager to participate because 
they're worried … they’re not as good as they once were before … so I think we 
do get a lot of people who are willing to be applicable for the study but I don't 
think they're impaired like they think they are.” 
Conversely, healthcare providers found it easier to identify specific reasons why people 





Healthcare provider: “And the reality is, yes, if you are participating in a study, 
you are not really going to benefit yourself. It's about benefiting others.” 
 
Healthcare provider: “I do think that for a lot of research you can appeal to 
people's altruism. And the idea of helping other people like you. But, I'm not sure 
that that's a very significant motivator with people who have dementia.” 
One researcher noted that there are more concerns about participating in research due to 
the negative historical relationship between researchers and specific communities, so 
participants want to know that the research is giving back to their community: 
Researcher: “I send out updates all the time … where we’re saying ‘hey we got 
our abstract accepted; we’re presenting on a national scale, people in 
Washington DC are caring about the research you participated in’ and we let 
people know that that research assistants that were helping us out, ‘because of 
you participating in our study and their experience working with you in research, 
they’ve been accepted to these grad schools’ and so we just keep connected that 
way, and so that’s like ‘oh hey, you know, we have a conversation going on about 
research instead of a constant ask [of participants to do something for us].’”  
Summary: These interviews highlight that perceptions of clinical research vary from 
person to person, as do perceptions of perceptions. Fear, personal and public perceptions 
of ADRD affect motivation. Organizations also affect motivation and ability to tell 
patients about ADRD research opportunities. All of these factors affect the ability of a 
person with ADRD to participate in research. 
 
Discussion 
These five themes and thirteen subthemes illustrate organizational, system, and policy 
level factors affecting ADRD research participation. The thematic findings are discussed 
below in relation to the three levels of factors, i.e, organization level, system level, and 





Organizational factors  
 Interviewees described several organizational factors affecting ADRD clinical 
research participation, as presented in Table 4.4. These factors can be further evaluated 
using organizational theories, such as contingency theory.   
Table 4.4: Themes in Relation to Organizational Factors 
Organizational Factors Themes 
Data and compliance oversight  Engaging with people with ADRD 
 Policies and funding mechanisms 
 Partnerships and collaborations  
Eligibility criteria  Engaging with people with ADRD 
 Policies and funding mechanisms 
 Perceptions of ADRD clinical research 
participation 
Recruitment strategies  Engaging with people with ADRD 
 Policies and funding mechanisms 
 Partnerships and collaborations 
 Clinical research as an organizational 
value  
Relationships with people with ADRD/ 
caregivers 
 Engaging with people with ADRD  
 Partnerships and collaborations,  
 Clinical research as an organizational 
value 
 Perceptions of ADRD clinical research 
participation 
IRB/Security protocols  Policies and funding mechanisms 
 Contingency theory posits that organizations can modify some of their rules and 
processes to best address environmental needs (Lawrence & Lorsch, 1967; Galbraith, 
1973). Organizational roles and processes play an integral role in initial and continued 
engagement with people with ADRD. At the larger research organization, study 
coordinators generally stick to their own studies, but there is a central staff person who 





opportunities for which they may be eligible. In the smaller research organization, all 
staff worked on every study. In healthcare organizations, clinician referrals play a large 
role in diagnosis, treatment, and provision of resources to people with ADRD and their 
caregivers. Notably, there is a wide variability of primary care providers’ willingness and 
ability to discuss a possible ADRD diagnosis with their patients. Some organizations 
automatically refer a patient with cognitive impairment to another specialist, in other 
cases, primary care providers can use their own discretion. 
 Both research organizations used similar research strategies for recruitment 
through the clinic, community talks, media advertisements, and flyers, with differing 
levels of success. However, the same group is often people participating in multiple 
studies within the organization over a variety of years because they are more inclined to 
participate as compared to someone who has never participated before. The interviews 
highlight that the methods used to recruit in the Portland area need to be revisited to 
avoid re-enrolling the same network of people. Recommendations derived from the 
interviews include presentations at ADRD and caregiver support groups, making 
materials reflective and culturally responsive to the community that researchers wish to 
work with and providing additional incentives for caregivers. These recommendations are 
similar to what has been described in the literature (King et al., 2007; Uybico, Pavel, & 
Gross, 2007; Huang & Coker, 2010; Monson et al., 2012; Newington and Metcaffe, 
2014; Black et al., 2017).  
 The finding that clinical research ranks as a higher priority to research and 





was unexpected to learn that some healthcare organizations had policies in place to 
restrict conversations and discussions about clinical research. Two of the interviewees 
worked at organizations that are completely or primarily funded by federal dollars, which 
means they are more restricted in the modifications they can make to adapt to 
environmental needs. As previously mentioned, most people believe they will hear about 
research opportunities from their providers (Anderson et al., 2018), so this substantially 
influences the ability of people with ADRD to learn about research opportunities. 
 In addition to roles and processes that can be adjusted based on environmental 
needs, contingency theory is useful for articulating what cannot be changed. For example, 
researchers must adhere to IRB, security, and data compliance protocols that are 
determined by their larger organization, funder, or governing body’s policies. While this 
takes time and funding resources away from other research activities, including 
recruitment, these are processes that cannot be adjusted at the researcher or departmental 
level. Similarly, certain eligibility criteria, such as excluding those without study 
partners, those who do not have the required memory scores, or those who take 
contraindicated medications, are non-negotiable due to safety regulations. However, 
some criteria could be modified, such as age, distance from the study site, and in some 
cases, willingness to travel to the clinic, in order to address community member needs. 
System level factors  
 The schools of organizational theory of open rational systems (Scott, 1987) and 
contingency theory (Lawrence & Lorsch, 1957; Mintzberg, 1983) can also be used to 






Table 4.5: Themes in Relation to System Level Factors 
 
System level factors Themes 
Communication about research 
opportunities 
 Engaging with people with ADRD 
 Partnerships and collaborations 
 ADRD clinical research as an organizational 
value 
 Perceptions of ADRD clinical research 
participation 
Clinician training and interest  Engaging with people with ADRD 
 Clinical research as an organizational value  
Community engagement  Engaging with people with ADRD  
 Partnerships and collaborations  
 Clinical research as an organizational value 
Structural elements  Engaging with people with ADRD 
 Perceptions of ADRD clinical research 
participation 
 Non-community collaborations, such as those with other healthcare clinics, 
research organizations, or government and advocacy agencies were discussed more 
frequently than community collaborations. Some collaborations and partnerships aimed 
to enhance recruitment by streamlining the study start-up process, such as negotiating 
contracts between organizations and vendors in order to begin recruiting and enrolling 
faster. Others aim to educate the local community about clinical research, including 
ADRD studies. Interviewees from both research organizations noted that these 
partnerships had recently begun. These partnerships were developed based upon a need to 
ultimately facilitate research participation, and processes were developed to achieve this 
goal.  
 The Alzheimer’s Association can be considered at the system level, as it plays a 





multiple organizations and community settings. Many providers and researchers work 
with the Alzheimer’s Association to recruit, share information, and offer support, without 
the Association apparently asking for anything in return from community members. 
Experiences were reported as generally beneficial; however, it is important to note that 
one researcher had negative experiences tabling at the Alzheimer’s Association’s 
community events as study staff were not able to reach the study’s target population. 
However, it is also possible that the study staff needed to use different methods to reach 
these populations through the Alzheimer’s Association, such as presenting study 
opportunities at support groups (at the discretion of the group facilitator) or posting 
recruitment announcements to the support group’s mailing list. 
 Transaction cost theory can also be used to articulate system level factors. One 
example is the use of advisory boards that include community members. Many 
interviewees seemed dismissive of community representation, especially when it was 
inclusive of people with ADRD. Numerous negative symptoms of ADRD were 
discussed, negating the fact that ADRD is a progressive disease, and many people can 
participate in advisory boards at various levels, with and without accommodations, until 
they are no longer interested in doing so. This is explicitly shown through the advisory 
boards led by the Alzheimer’s Association and DeNDRoN, where the expertise of people 
with ADRD is recognized and brought in for decision-making processes (Iliffe, McGrath, 
& Mitchell, 2013; Plunkett, 2017).  
 Another example of how transaction cost affects research recruitment at the 





new NIH policy was intended to reduce time-consuming bureaucratic practices and 
streamline some study processes, yet organizations continue to use their own IRBs 
because the cost of fear and liability outweigh the possible benefits of timeliness and 
centralization. The transaction cost of using a central IRB is higher than the cost of 
continuing to use single site IRBs, so organizations make the decision to continue to use 
single site IRBs. This leads to a longer delay before recruitment, scheduling visits, and 
participation can begin. 
 A third example is the perceived motivation and ability for people to join studies. 
Researchers found that many people with ADRD and caregivers were motivated to join 
studies from an altruistic perspective of benefitting society as a whole; the benefit of hope 
and helping others is worth the cost of frequently traveling long distances or giving a lot 
of time to be part of a study. However, healthcare providers seemed to have trouble 
identifying motivations for participating in ADRD research, instead of focusing on the 
high costs of research participation. The researchers and healthcare providers perceived 
these transaction costs differently -- researchers believe the transaction cost of 
participating in research is worth the benefit, whereas healthcare providers felt the 
transaction cost was too high.  
Policy level factors 
 Social construction and PFT can help describe the policy level factors affecting 






Table 4.6: Themes in Relation to Policy Level Factors 
Policy level Factors Themes 
Data and compliance oversight  Engaging with people with ADRD 
 Policies and funding mechanisms 
 Partnerships and collaborations 
IRB/Security protocols  Policies and funding mechanisms 
Recruitment and diversity policies  Engaging with people with ADRD 
 Policies and funding mechanisms 
 Clinical research as an organizational value 
Dissemination policies  Perceptions of ADRD clinical research 
participation 
Funding opportunities   Policies and funding opportunities,  
Partnerships and collaborations,  
 Clinical research as an organizational value  
 Social construction explains the prominent role that reluctance and fear have in 
ADRD research participation. Providers are reluctant to diagnose a person with a 
progressive disease with no known prevention, treatment, or cure, and individuals may 
fear being identified as a person with ADRD due to socially constructed perceptions of 
people with ADRD.   
 Schneider et al. (2014) places socially constructed groups into four categories. 
People with ADRD would fall into the “dependent” category -- those who are positively 
viewed by society but would be considered politically powerless. Policy designs and 
public perception have deemed them worthy of benefits, but they are still viewed as 
powerless and unable to contribute to decision-making. For example, many researchers 
and healthcare providers seemed dismissive of community representation in research, 
especially when it was inclusive of people with ADRD. Numerous negative symptoms of 





people could join advisory boards with varying levels of participation, with and without 
accommodations, until they are no longer interested in doing so. However, other 
researchers and advocates who viewed people with ADRD as “experts” led to more 
decision-making opportunities, highlighting the capabilities that people with ADRD do 
have. Additionally, while some researchers may view caregivers as “contenders” who 
have decision-making capabilities but are negatively perceived, the majority of 
interviewees viewed them as “advantaged”, having positive views and recognizing their 
decision-making capabilities, which may explain why many suggested additional 
resources or incentives for caregivers to act as study partners for ADRD research.    
 Social construction may also describe the perceptions and values that are placed 
on ADRD research participation itself. Some organizations, particularly those primarily 
funded through the federal government, had policies in place to not discuss ADRD 
research opportunities or did not provide funding for research projects. They may 
perceive ADRD research as Contenders. However, advocacy groups and research 
organizations heavily promoted research opportunities, particularly the Alzheimer’s 
Association, which is the third-largest funder in the world (Alzheimer’s Association, 
2019a). This is also evident through Congress’s bipartisan decision to earmark over two 
billion dollars for ADRD research, and the NIA’s strategy for improving ADRD research 
participation (Hodes, 2018; NIA, 2018). 
 For example, Congress’s decision to provide $2.3 billion dollars for ADRD 
clinical research increases the number of grants that a research organization can 





length of time they have to conduct the research, the number of research staff they can 
hire, and the compensation they can offer a research participant. Similarly, the NIH’s 
Inclusion Across the Lifespan policy removes exclusion criteria that often restricted 
adults over the age of 85 from joining ADRD research (NIH, 2017a). This new rule 
increases the ability to participate in research for a group of people who are substantially 
more likely to be diagnosed with ADRD. Conversely, recruitment procedures that do not 
use appropriate recruitment materials or networking opportunities can negatively affect 
the ability and motivation for people of color to participate in research. The NIA’s new 
R24 grant, Examining Diversity, Recruitment and Retention in Aging Projects, provides 
funding opportunities for research organizations for relationship-building and community 
collaboration to develop recruitment strategies needed to increase the ability and 
motivation of diverse populations to participate in ADRD research (NIA, 2018).  
 PFT can also be applied to the balancing act of industry-sponsored studies. 
Organizations receive more money when funded by industry, but all activities, processes, 
and collaborations are dictated by these sponsors. This finding is important because it 
identified several barriers to recruitment. Though additional funding initially presents as a 
way to increase research participation through extra money for recruitment activities, 
several other procedures lead to a negative impact on an individual’s ability and 
motivation to participate in research. These include time delays before the study can 
begin recruitment, the time needed to send participants or test results to a specific scan or 
lab vendor, the travel delays potential participants may experience traveling to a specific 





 PFT also recognizes that policy feedback from past policies affects future policies 
(Skocpol, 1992), so it is possible that industry sponsors may modify their policies based 
on coordinator or community feedback. Policy feedback is evident in other examples of 
findings. For instance, the NIH’s policy to streamline the multi-site study start-up through 
a central IRB was created based on the feedback that studies were being delayed. 
However, with the realization that study sites are not being utilized as intended due to 
fear and liability, modifications will need to be made to ensure that fear and liability are 
combatted and the policy’s outcomes are achieved as intended. Another example is the 
NIH’s Alzheimer’s Clinical Trial Consortium, which an interviewee noted was 
established due to the long delays organizations underwent in getting studies launched 
(Balintfy, 2017).  
 
Conclusion 
The purpose of this study was to identify organizational, system, and policy level factors 
affecting participation in ADRD clinical research in the Portland, OR metropolitan area. 
This research has several important findings. One notable finding is the discussion on 
enacted policies that have not made their way to practice. Despite attempts by the NIH 
and CMS to streamline research studies by allowing a single IRB for multi-site studies 
and provide care planning to people with ADRD and their caregivers, neither of these 
policies has resulted in the intended outcomes. Researchers noted that it is difficult to 
fully implement these policies due to organizational concerns, and advocates noted that 





advantage of these policies. A second major finding is the lack of awareness that people 
with ADRD and caregivers have of research opportunities. All of the healthcare 
providers, with the exception of the dual healthcare provider/investigator, discussed the 
rarity of telling people with ADRD about research opportunities. In some cases, this was 
due to a lack of provider knowledge, but in others, it was due to organizational directives 
to not discuss or a provider’s personal preference. Further, these opportunities are not 
being shared in places where people with ADRD and their caregivers are likely to 
congregate, such as support groups or social activities for people with ADRD, or may not 
be shared in a culturally appropriate way. A third major finding is that while some 
interviewees discussed providing educational presentations and seminars to teach 
community members, they were often hesitant to join community collaborations or 
formal partnerships, and many were wary of including people with ADRD in their 
advisory boards. This appears counterintuitive to a central theme in the NIA’s strategy to 
increase ADRD research participation, that of local community collaboration (NIA, 
2018). 
 There are several limitations to this study. First, the sample size was small (n=9) 
and not fully representative of one metropolitan area. Though it was designed to be 
organizationally representative, all but one of the healthcare providers were geriatricians 
and there were no providers who specifically focused on primary care. This is because 
the investigator recruited interviewees based on referrals from key informants and 
community advisory boards, and nearly all provider referrals were for geriatricians. 





for interviews. The study also did not include interviews with local county government 
employees despite the fact that county governments in the Portland metropolitan area 
provide services for people with ADRD and caregivers. The investigator was not referred 
to county employees. These county agencies were discussed by advocates, but not by 
providers and researchers, so it is possible that the services provided by the counties are 
unknown to local health and research organizations.  
 Second, these findings are specific to the Portland metropolitan area, and while 
they may be contextually relevant for similar communities, they are not necessarily 
generalizable. Lastly, there is always the risk of bias. Interviewees may have censored 
themselves due to the audio-recording of interviews and may have focused on what they 
perceived the interviewer would want to hear, resulting in response bias. The investigator 
mitigated the likelihood of confirmation bias by writing field notes immediately after 
each interview, a conscious effort to self-assess when analyzing codes and themes, and 
CAB member-checking of analyses. Furthermore, while there are no conscious biases 
due to the researcher’s identity, it is important to acknowledge that subconscious biases 
are possible due to her identity as a female academic who is a proponent of ADRD 
research and community inclusion. 
 Several recommendations can be made based on the study’s findings. First, 
research organizations’ strategies may benefit from modifications to reflect community 
needs. Based on the interviews, this could include presentations at ADRD and caregiver 
support groups, making materials reflective and culturally responsive to the community 





This also applies to industry sponsors who may be receiving suggestions from 
coordinators or community members about best recruitment strategies but continue to 
adhere to their original processes.  
 Second, research could be enhanced by identifying why some health 
organizations have policies in place that discourage healthcare providers from speaking 
about ADRD research participation with their patients. It is important to note that this 
may be due to policies that are outside an organization’s control, such as external funding 
mechanisms. In such cases, it would be beneficial to explore why the external funders or 
policymakers perceive ADRD research in a negative manner and to determine ways to 
assuage these perceptions.  
 Third, organizations may benefit from recognizing the expertise that people with 
ADRD can offer. Rather than excluding them from conversations, people with ADRD 
can be empowered through an organization’s inclusive decision-making processes, such 
as including them on advisory boards. This inclusion may lead to a change in the social 
construction of people with ADRD.  
 Fourth, a shift in the social mindset needs to occur in order for people with ADRD 
to become empowered and reduce stigmatization of ADRD. This may be difficult to 
accomplish, but these interviews highlighted the numerous ways that the shift in mindset 
can be perceived. Social research could be conducted to identify what kind of shift would 
be most feasible and effective.  
 Fifth, funding opportunities for developing community collaborations should be 





part. The NIA offers funding opportunities for this purpose, and other opportunities may 
exist through nonprofits and philanthropies. However, only one interviewee noted that 
such a grant existed. Utilizing these opportunities can provide incentives for 
organizations to collaborate and may provide greater opportunity for people with ADRD 
and their caregivers to participate in decision-making processes.    
 Finally, caregivers should be given greater consideration in the design phase of 
ADRD research. As study partners, they are essential to research participation. 
Researchers should be willing to accommodate their schedules and needs, such as 
requiring fewer in-person visits, or provide resources or supports specific to the 
caregiver, and these efforts may help in increasing their ability and motivation to 
participate in ADRD research. 
 This research study identified organizational, system, and policy factors affecting 
ADRD research participation in the Portland metropolitan area. These were identified 
through interviews with local researchers, healthcare providers, and advocates, and the 
application of various organizational and policy frameworks to contextualize the themes 
into organizational, system, and policy level factors. Identifying how these factors affect 
the decision of a person with ADRD to participate in research is an important first step to 
increasing participation rates. Based on these factors, strategies can be developed and 
implemented to improve the ability and motivation of people with ADRD to join research 
studies in the Portland metropolitan area. This study should be repeated in a larger 
context or as pilots in other communities to determine contextual relevance and 





evaluated to determine their feasibility and effectiveness. No matter the steps, researchers 
should consider the larger picture -- this is not just about finding a way to increase 
participation in ADRD clinical research studies, but more importantly about finding a 






CHAPTER 5: PERSPECTIVES OF PEOPLE WITH DEMENTIA AND 
CAREGIVERS ABOUT DEMENTIA CLINICAL RESEARCH 
 
Introduction 
Nearly seven million people in the United States live with Alzheimer’s disease and 
related dementias (ADRD), costing the nation over 236 billion dollars (US) per year in 
direct medical costs (NIA, 2018; Alzheimer’s Association, 2019a). These numbers will 
increase as our population ages. Many healthcare professionals, policymakers, and those 
affected by these diseases agree that rapidly increasing ADRD prevalence rates (and 
subsequent rising costs) coupled with the lack of clinical solutions are creating a medical, 
economic and emotional crisis (Collins et al., 2018; Alzheimer’s Association, 2019a; 
Gates, 2017). To combat this crisis, the United States Congress allocated 2.9 billion 
dollars for ADRD research in 2019 with the goal of finding solutions for prevention or 
treatment by 2025 (Alzheimer’s Association, 2019b). Advancements in ADRD research 
are in part contingent on research participation by individuals with an ADRD diagnosis 
and their caregivers (Rollin-Sillaire et al., 2013; Law, Russ, & Connolly, 2014; Grill & 
Galvin, 2014; Black et al., 2016; Gates, 2019). To effectively utilize this historic funding, 
efforts to increase participation in ADRD clinical research are needed.  
 Individuals with ADRD face additional barriers to research participation as 
compared to research for other diseases. Only 10-27% of people with ADRD are eligible 
to participate in research due to comorbidities, incompatible medications, low cognition 





with ADRD who would be eligible to become participants before even considering the 
person’s interest in a study. Additionally, study partners are required to participate with 
the individual with ADRD to ensure protocol adherence and appointment attendance, 
further complicating the process (Karlawish et al., 2008; Watson et al., 2014; Grill & 
Galvin, 2014; Cary et al. 2015; Black et al., 2017; NIA, 2018).  
 In this paper, three frameworks are considered to better understand the barriers 
and facilitators of engagement in clinical research by people with ADRD. Two 
frameworks, transaction cost theory and principles of civic engagement, can be used to 
conceptualize factors affecting ADRD clinical research participation. A third framework, 
contingency theory, can help to describe how organizations adjust their rules and 
processes to reduce the transaction costs for potential participants in ADRD research. 
Transaction Cost Theory 
 The decision to participate in dementia clinical research can be partially explained 
by transaction cost theory; pioneered by Williamson (1975), this theory can be used to 
illustrate the financial and other costs of enrolling in a study. Transaction cost theory 
suggests that every transaction between two parties (both within and among organizations 
or groups) is subject to a cost. The decision to participate in an ADRD clinical research 
study is a transaction between a person with ADRD and a research organization, and the 
costs (both real and perceived) of the transaction affect the decision. The theory has four 
components that are based on market principles.  
 The first component, uncertainty, reflects changes beyond the control of the 





engage and recruit people with ADRD and caregivers into studies, examples include 
symptom recognition and a timely ADRD diagnosis (or lack thereof) from a healthcare 
provider. In these cases, a person may not seek out an ADRD study if their cognitive 
impairment is misdiagnosed or misattributed, which may be the case for up to 60% of all 
people with dementia (Lang et al., 2017). Uncertainty may also refer to indirect 
knowledge transfer of study opportunities from healthcare providers and community 
organizations to people with ADRD and their caregivers. For example, researchers may 
share opportunities directly with healthcare providers or community organizations, but 
how that information is shared with potential participants is outside of the researchers’ 
control. Providers, community organizations and even friends and families may choose to 
share information about study opportunities; further, they may choose to share their 
trusted opinions of the research or research organization, which may be positive or 
negative. Again, these decisions and opinions are outside the control of the research 
organization(s).  
 The second component, small numbers bargaining, refers to the power parties 
have over a contract (Williamson, 1975). This may include the number of organizations 
or customers available to the party, or the routines or expectations that are expected from 
the agreement. From the participants’ perspective, a researcher’s small numbers 
bargaining includes eligibility criteria and structural elements such as the time spent to 
participate and the distance traveled for study appointments. From the researcher’s 
perspective, the participant’s and study partner’s small numbers bargaining includes their 





 The third component, bounded rationality, refers to imperfect information 
surrounding the members or transactions, including any cognitive or emotional barriers 
affecting a person’s ability to understand that knowledge (Williamson, 1975). Bounded 
rationality includes perceptions of research or motivation to enroll (or not enroll) in a 
study. For example, although studies may be available, a person with ADRD or caregiver 
may or may not be aware of them. Alternatively, a person who is averse to taking 
medication may not be inclined to look for studies if they perceive them to all require 
taking a study drug.  
 Bounded rationality can lead to the last component, opportunism, or acting in self-
interest (Williamson, 1975). For ADRD research, potential participants may feel that 
researchers are taking advantage of their circumstances (having a diagnosis of ADRD) 
because they must be willing to engage in all study activities. Additionally, the person 
with ADRD’s availability to participate is contingent on their caregiver’s ability and 
motivation to participate, potentially leading to additional dependence upon the caregiver. 
Transaction cost theory illustrates why many people with ADRD do not 
participate in research -- the transaction costs are often too high for people with ADRD 
and/or their caregivers. In some of these cases, the costs are beyond the control of both 
the research organization and the potential participants. In other cases, the people with 
ADRD and their caregivers have weighed the costs to be higher than the benefits of 
joining a study. Understanding the decisions of people with ADRD and study partners to 







 A second framework, civic engagement, describes how ability and motivation 
affect civic engagement -- the notion that community members contribute individually 
and collectively in order to better their communities (Mettler, 2002). Common examples 
of such contributions include donating blood, participating in neighborhood associations, 
or voting. Similarly, many people participate in clinical research with the intent of 
helping others (Law et al., 2014; Anderson, Borfitz & Getz, 2018). Although there are 
costs to participate in research, including the time spent on study activities and distance 
traveled, as well as the costs of the study intervention, the motivation to contribute to the 
common good may supersede these negative aspects and make the transaction costs more 
acceptable. Figure 5.1 depicts how the decision to be civically engaged is developed and 
how civic engagement is applied to ADRD clinical research participation.  
Figure 5.1 Policy Feedback for Mass Publics: How Policy Affects Civic Engagement  
 
Source: Mettler & Welch, 2004, p. 511 
 Mettler (2002) states that payments, goods, and services establish resource 
effects, defined as behaviors shaped by resources and incentives, which affect civic 
capacity, or the ability to be civically engaged. In the clinical research realm, these 





studies (Karlawish et al., 2008; Golhoffer et al., 2015; Friedman et al., 2015, Mahon et 
al., 2016; Anderson et al., 2018). Resource effects also influence civic predisposition, 
defined as “the perceptions of their role in the community, their status in relation to other 
citizens and government, and the extent to which a policy has affected their lives” 
(Mettler, 2002, p. 352). In the clinical research contact, this can be interpreted as 
individual motivation to participate. Resource effects affecting civic predisposition may 
include altruism, financial incentives, and partnerships with trusted community leaders 
(Brown et al., 2013; Golhoffer et al., 2015; Cary et al., 2015; Friedman et al., 2015; 
Mahon et al., 2016; Black et al., 2017; Anderson et al., 2018).  
 Civic predisposition is also affected by the interpretive effects -- the information 
conveyed through policies (Mettler, 2002). Interpretive effects specific to ADRD 
research, including Congress’s earmarked funding for ADRD research and NIA grants 
specific to increasing ADRD research participation, highlight that dementia research, and 
the need to recruit for dementia research, is important (Alzheimer’s Association, 2019a; 
NIH, 2018). Interpretive effects also exist within the research organization. For example, 
if recruitment procedures are not inclusive of the needs of diverse groups, such as English 
language requirements, recruiting within a certain mile radius, or not giving presentations 
in areas that people of color frequent, they might convey messages that these 
communities are not important enough to recruit for studies, and may demotivate these 
groups of people. Ultimately, an individual’s ability and motivation both affect their 





 Various scholars have taken different approaches to encourage civic engagement 
in communities. Bellah and his colleagues (1991) suggest that a public commitment to 
building a) institutions, b) family support, c) quality education, and d) self-respecting 
work empowers individuals to participate and serve as community stakeholders. Vigoda-
Gadot and Cohen (2004) suggest moving away from the idea of viewing community 
members as subjects or voters; instead, the government (or in this context, the research 
organization) should treat community members as customers and be responsive to their 
needs. Denhardt & Denhardt (2003) advocate for a public administration governing style 
that encourages civic engagement by including community members as active 
stakeholders. 
 ADRD research organizations can apply these approaches to civic engagement 
and adapt their own policies in order to be more responsive to their community’s needs. 
In response to Bellah et al. (1991), several processes can indicate a public commitment to 
clinical research and empower people with ADRD and caregivers. First, organizations 
can share knowledge about research opportunities with people with ADRD and their 
caregivers. This could be directly through community presentations or listservs, or 
indirectly through providers’ offices. They can also provide supports for people with 
ADRD and their caregivers by offering referrals to support groups, social workers, or 
community resources for memory-loss friendly activities. Research organizations can 
ensure quality education on clinical research history, purpose, and opportunities through 





with ADRD and research participants as respected, collaborative partners by including 
them on advisory boards or in the research design process.  
 When applying Vigoda-Gadot and Cohen’s (2004) work on civic engagement to 
ADRD clinical research participation, this could translate to treating participants and 
study partners as customers and being responsive to their multiple and often complex 
health and social needs. For example, in order to increase participant enrollment, research 
organizations could introduce ways to reduce time spent in study visits and distance 
traveled to study appointments. Utilizing Denhardt and Denhardt’s (2003) civic 
engagement work to illustrate ADRD clinical research participation, indicators of civic 
engagement for people with ADRD and caregivers as active stakeholders could be 
recognized through opportunities to serve on advisory boards or participate in listening 
sessions with researchers.  
Civic engagement and contingency theory  
 In times of crisis, acts of civic engagement increase (Putnam, 2000; Sander & 
Putnam, 2010). Given the propensity of the U.S. government, philanthropists, and 
dementia advocates to refer to ADRD as a public health crisis, one would expect acts of 
ADRD research participation to increase. Unfortunately, this has not been the case, 
possibly due to the factors described above (NIA, 2018).   
 However, civic engagement scholars have found that organizations, governments, 
and policies influence the community’s ability and motivation to participate in civic 
engagement activities (Bellah, Madsen, Sullivan, Swidler, & Tipton, 1991; Denhardt & 





the same to be true for ADRD research participation as has been the case for cancer and 
HIV/AIDS, two other diseases for which the U.S. Congress has earmarked funding. 
However, the community driving forces that are behind these movements may not exist 
to the same level for ADRD. This can be due to a variety of factors, such as the stigma in 
being identified as a person with ADRD or a caregiver, the progressive cognitive decline 
associated with ADRD, and the low rates of ADRD researchers collaborating with people 
with ADRD and caregivers in the same way that researchers have learned to collaborate 
with people with cancer or HIV/AIDS (Hermann et al., 2018).  
 The U.S. government has taken measures to increase participation through 
earmarked funding for ADRD studies, a national report on improving research 
participation, and grant opportunities for researchers to develop strategies to increase 
research participation in their local communities (Alzheimer’s Association 2019a; NIA, 
2018; NIH, 2018). Research organizations can rely on contingency theory, or modifying 
rules and processes, in order to be responsive to their community’s needs to the extent 
that organizational and external policies allow. Modifying these rules and processes may 
increase the ability and motivation of people with ADRD and caregivers to participate in 
ADRD clinical research (Lawrence & Lorsch, 1967; Galbraith, 1973). Modifications can 
include extended clinic hours, study activities conducted over the phone or telemedicine, 
and/or partnering with communities of color to identify their needs and form a trusting 
relationship. Table 5.1 summarizes how each theory is applied in this study. The purpose 






Table 5.1 Theory Summary 
Theory How it Relates to ADRD Clinical Research Participation 
Transaction Cost Theory Describes the costs of participating in a study 
Civic Engagement Describes how ability and motivation affect the decision to 
participate in a study 
Contingency Theory Describes how, and to what extent, organizations can 
address the needs of people with ADRD and caregivers 
 
Purpose of this study 
 The purpose of this study is to identify barriers and facilitators to dementia 
research participation from the perspective of people with ADRD and their caregivers. In 
order to increase ADRD research participation, the NIA allocated funding for studies that 
focus on ADRD clinical research recruitment, retention, and diversity of race, ethnicity, 
gender, and socioeconomic status. Additionally, NIA released a national strategy for 
improving research participation in ADRD studies in October 2018 (NIA, 2018). The 
national strategy provides recommendations that address ADRD research participation. 
However, the national strategy does not include a comprehensive list of barriers and 
facilitators; the NIA recommended continued research on identifying more barriers and 
facilitators for ADRD research participation (NIA, 2018). Further, these 
recommendations were developed by working groups of ADRD clinicians, researchers, 
and advocates; the voice of individuals with ADRD was not included despite calls from 
academics, collaboratives, and advocates to do so (Iliffe, McGrath, & Mitchell, 2013; 
Kremer, 2017; NIA, 2018). This study contributes to the field by identifying additional 
factors affecting ADRD clinical research through the incorporation of perspectives of 








 The current study addresses one of the three aims that a larger dissertation 
research project investigates. Data reported here come from semi-structured interviews 
with 12 dyads of individuals (n=24) living with mild cognitive impairment (MCI) or 
ADRD and their caregivers. Although MCI is not considered a form of ADRD, clinical 
research studies frequently include people with MCI, as MCI is hypothesized to progress 
to ADRD (Roberts and Knopman, 2013). Dyadic interviews were employed as they 
recognize and use the relationship between two people as a source of information 
(Caldwell, 2014). Furthermore, dyadic interviews are frequently used when interviewing 
people with cognitive impairment because they provide interviewees with more control 
of the interview situation, reduce the need to conform to preconceived notions of what 
the interviewer is looking for, and empower interviewees to participate actively (Morgan, 
2008; Morgan et al., 2013). Both dyad members were given a $25 gift card to the grocery 
store of their choice. Dyads were recruited through local memory cafes, early-stage 
memory loss and caregiver support groups, and research organizations. More detailed 
information about the interview procedures is described below. All protocols were 
reviewed and approved by the Portland State University Institutional Review Board (IRB 
#184914).  
 In addition to interviewing 12 dyads, a community-engaged approach to the 





factors and strategies (Balasz & Morello-Frosch, 2013; NIA, 2018). This approach 
recognizes interviewees as experts in the field of living with MCI or ADRD, or caring for 
a family member with MCI or ADRD and including them in the development and 
involvement of a community advisory board (CAB) to advise and guide study processes. 
Further, establishing a CAB is considered a good practice in community-engaged work 
(Newman et al., 2011; Kremer, 2017). CAB recruitment was facilitated through the 
Oregon Alzheimer’s Disease Research Center, the Alzheimer’s Association, and the 
PreSERVE Coalition for Black/African American Memory and Brain Health. CAB 
membership was comprised of researchers, clinicians, advocates, individuals with 
ADRD, current and former caregivers, older African Americans, and a member of the 
researcher’s dissertation committee with experience working with CABs in community-
based research. The 12-member CAB met three times during the study to guide the 
investigator on recruitment and interview protocols, interpret findings, and develop 
dissemination strategies. CAB community members (people with ADRD, caregivers, and 
older African Americans) were given a grocery gift card for each meeting they attended 
or contributed to, in recognition of their contributions to the CAB. 
Data collection and analysis 
 Semi-structured interviews with dyads took place starting in August 2019 and 
concluding in December 2019. Dyads were eligible if they spoke fluent English and lived 
in, received care within, or participated in an ADRD clinical research study based in the 
Portland, OR metropolitan area. Additionally, people with MCI or ADRD needed to have 





provider visit within the last six months, and were able to discuss their perceived values 
of dementia clinical research. Individuals with MCI/ADRD who did not have a caregiver 
were ineligible for the study. 
Dyad members were interviewed separately. Caregivers were interviewed first in 
order to obtain detailed information about symptom recognition and diagnosis; the 
caregivers were allowed to sit in the interview of the person living with MCI or ADRD 
on the conditions that they remained quiet and the person living with MCI or ADRD 
preferred having them present. Interviewees were asked about the first signs of ADRD or 
MCI and the diagnosis experience, their knowledge of clinical research, how and if they 
received information about research opportunities, their perceptions of clinical research, 
their decisions to enroll or not enroll in studies, and suggestions for improving ADRD 
clinical research enrollment. They were also asked to review a list of factors identified in 
earlier research (see Chapter 4) and identify their level of agreement with those factors. 
This empowered people with ADRD and caregivers by asking about their experiences 
and invited a power-sharing context by recognizing them as experts.  
 Interviews were audio-recorded, and the investigator took field notes during and 
after each interview. Interviews were de-identified and transcribed using transcription 
services (Rev.com), then uploaded to Atlas.ti 8.1 software for coding and thematic 
analysis (Scientific Software Development GmbH). The codebook emerged from the 
interviews, but codes were informed by the investigator’s a priori knowledge of the 
literature and various theories and framework. Codes included sentences or sentence 





coding process began by coding broad themes then coding with details. For example, if 
an interviewee noted they did not have time to participate in ADRD clinical studies 
described lack of awareness, it was coded as “ability, barrier, time.” Conversely, if an 
interviewee said they participated in research because they wanted to help others, it 
would be coded as “motivation, facilitator, altruism.” Much of the analysis was 
deductive, meaning the codes were analyzed with the notion that they may align with 
orienting concepts derived from the literature and theories (Miles et al., 2020). An 
inductive approach was also used to code for themes that did not correspond with existing 
literature and theories to identify themes that emerged from the data organically and 
mitigate the possibility of coding those themes based on current literature rather than the 
interviews (Lapadat, 2010). The investigator was the single coder, and the CAB 
interpreted findings by identifying what was most important, surprising, or missing from 
the themes and subthemes.  
 
Results 
Semi-structured dyadic interviews were conducted with 12 dyads of individuals (n=24) 
living with MCI or ADRD and their familial caregivers. Table 5.2 provides the 
characteristics of the interviewees. Six of the dyads had never participated in dementia 
research, five were currently participating in at least one study, and one had previously 
participated in clinical trials. Of the five people with ADRD currently participating in 
research, one was in a clinical drug infusion trial, two were in separate observational 





physical health changes, one was in both a clinical trial and a community-based 
technology study, and one was a participant in a longitudinal cognitive testing cohort 
study. Ten of the 12 caregivers were spouses (50% female), and two were adult children 
(50% female). Eight of the 12 people with ADRD were diagnosed with Alzheimer’s, two 
were diagnosed with MCI, one was diagnosed with mixed dementia, and another was 
diagnosed with dementia with Lewy bodies.  
Table 5.2 Characteristics of Interviewees with ADRD and Caregivers  






Male Wife Yes Mixed 3 
Male Wife No Alzheimer’s 4 
Female Daughter No Alzheimer’s 5 
Male Wife No Alzheimer’s  5 
Female Son No Alzheimer’s 3 
Female Husband No Alzheimer’s 3 
Female Partner No Dementia with 
Lewy Body 
2 
Female Husband Yes MCI/Alzheimer’s 2 
Female Husband Yes MCI/Alzheimer’s 4 
Female Husband  Yes Alzheimer’s 1 
Male Wife Yes Alzheimer’s 4 
Male Wife Yes Alzheimer’s 3 
  
 The key findings are summarized in Table 5.3, organized into three themes and 12 






Table 5.3 Themes and Subthemes from Interviews 
Themes Subthemes 
Symptom recognition and diagnosis  Symptom recognition 
 Diagnosis 
Factors affecting the ability to 
participate in research  
 Knowledge of opportunities 
Ineligibility/withdrawal 
 Time/distance 
 Caregiver burden 
 Using the Internet 
Factors affecting motivation to be 
in research 
 Helping others 
 Living good years to the fullest 
 Caregiver support 
 Taking study drugs 
 Advisory boards 
 
Theme 1: Symptom recognition and diagnosis 
 Lack of a formal diagnosis is described in the literature as a barrier to research 
participation and was discussed frequently in the interviews (Chin et al., 2011; Grill & 
Galvin, 2014; Corriveau et al., 2017). Caregivers and people with ADRD described the 
diagnosis process in two parts: symptom recognition and receiving a diagnosis. These are 
the two subthemes discussed subsequently. 
Symptom recognition: Several caregivers stated that when they or their family members 
noticed initial symptoms, such as forgetfulness or difficulties at work, the caregiver 
assumed these symptoms were due to stress or aging. Some caregivers mentioned an “a-
ha” moment when they noticed their spouse or parent had difficulties with driving or not 
recognizing the time of day, which led them to make an appointment with their provider. 






Caregiver: “It's not like suddenly he started doing something he'd never done 
before, it's that stuff that he'd always done and every wife in the world complains 
her husband doesn't finish projects that he starts out on. It just went from being a 
four or five on a ten point scale to an eight or a nine. You're like, "Is it me? Am I 
just being way picky and hard to live with, or is there something?" 
Several people with ADRD were able to identify a specific event or several incidents 
where they recognized symptoms, such as not being able to get things done at work. 
Those who recounted substantive signs of memory changes, such as trouble driving or 
being outside and not remembering where they were, also noted that they received a 
diagnosis relatively quickly after seeking help. Others with earlier symptoms, such as one 
person who had difficulties at work or trouble with their crossword puzzles, recalled 
feelings of dismissiveness from their providers. They also stated that it took years to get a 
diagnosis: 
Person with ADRD: “I knew that there were some issues. And so I went to my 
family care physician and I said, "You know, I just can't remember things like I 
used to." And he just discounted it … So then I went and spent another few years 
after that and it just kept continuing to get worse.” 
Diagnosis: Both people with MCI did not have a confirmed Alzheimer’s disease 
diagnosis but believed they had progressed to Alzheimer’s disease based on contextual 
clues, such as the need to have Alzheimer’s to be accepted into a drug trial. Two of the 
dyads noted their diagnoses were questionable, but for different reasons: 
Caregiver: “[The neurologist] said, "Well, since it doesn't look like it's getting 
any better, probably getting worse … MRI didn't show anything," he says, "She 
has some kind of cognitive impairment." Basically, Alzheimer's [was written 
down] because he says cognitive impairment insurance companies can sometimes 
be jerks about…They won't pay.” 
 
Caregiver: “Dementia, conceivably Lewy body … The underlying observations 





hallucination, but as our separate counselor said later, he wouldn't trust anyone's 
self-reporting of a hallucination.” 
 
Though they clinically exhibit MCI symptoms, two people with ADRD noted that they 
received a diagnosis of Alzheimer’s after receiving a PET scan. One expressed 
skepticism of his diagnosis:  
Person with ADRD: “After going there for two years and being tested, she was 
ready to tell me I don't need to come back anymore because “we don't think you 
have [Alzheimer’s]. But we want to … give you a PET scan.” Well, the fellow that 
reads it couldn't see anything but [they said] the software picked it up. That 
doesn't sound like a real definite diagnosis.” 
Some dyads noted that receiving a diagnosis was somewhat positive because they could 
finally explain the changes, and in one case, resulted in the ability to complete their 
“bucket list” and focus on their creative abilities: 
Person with ADRD: “Just because you have dementia doesn't mean you've lost 
your life. In fact, it's been a breakthrough for me … Because now I do paintings 
and [I] would never have done that without [the diagnosis].” 
Others described negative interactions with their providers: 
Person with ADRD: “At first [the neurologist] was sort of dismissive, "Oh, I'm 
sure you're just being neurotic," kind of message … he comes back, he throws 
down the papers on the table and he said, "You're right! You do have a 
problem!"… It made me want to laugh. It was so shocking. But I just kind of sat 
there in stunned silence. I just thought, "Wow. Do you let all of your patients 
know the results that way?" 
 
Person with ADRD: “If you don't care anymore about your patient than [having 
the secretary call to give the diagnosis], he needs to be doing something else … 
He was so lackadaisical, like, "Geez, I've done this test for so many times”… I 
don’t know if I should [go see another neurologist]. I’m scared to go to one 
now.” 
Summary: Substantial symptoms resulted in immediate worry and concern for providers, 





person with ADRD who felt their symptoms were minimized or dismissed by providers, 
despite continued concerns, resulting in a delay in the diagnosis. In two cases, 
interviewees who received a PET scan received an early diagnosis of Alzheimer’s 
although they had only exhibited MCI symptoms. For most of those cases, caregivers felt 
that they were able to recognize unusual behaviors as symptoms now that there was a 
diagnosis that they originally misattributed to stress or age, though at least one noted that 
she noticed changes before her husband did. Several interviewees noted unprofessional 
encounters with their provider that led to uncertain diagnoses or diagnoses. Aspects of 
transaction cost theory and civic engagement are evident in this theme. A lack of 
diagnosis is beyond the control of a research organization, but without it, those with 
undiagnosed ADRD are either ineligible or not actively looking for ADRD clinical 
research opportunities. 
Theme 2: Factors affecting ability to participate in research 
 Both respondents who participated in ADRD clinical research and respondents 
that have not participated in research described similar factors affecting their ability to 
enroll in a study. These factors include knowledge of opportunities, ineligibility or forced 
withdrawal from a study, time spent and distance traveled to partake in the study, 
caregiver burden, and use of the Internet.  
Knowledge of study opportunities: Knowledge of study opportunities varied in terms of 
awareness and avenue of knowledge. Those who participated in studies learned of them 
via brochures in their neurology clinic, a friend’s referral, a referral through an 





two dyads that had participated in multiple studies, one was told of an additional study by 
their research coordinator, and another was told of a study by their neurologist. Some 
caregivers noted that they asked their clinician or support groups about opportunities, but 
either the providers/facilitators were unaware of any, or the caregivers were told to check 
their organization’s website. Some noted that they had never heard of opportunities. In 
this particular study, four of the ten dyads directly asked the investigator if they could 
provide any information about research opportunities:  
Caregiver: “I had asked our primary care physician. She did not recommend 
any particular person to contact … Then we have a friend at church who was in 
a study at [research organization] … and he knew I wanted to get [wife] in, so 
he gave me the contact person at [research organization].” 
 
Person with ADRD: “It has never come up. [They] haven't asked me. You're the 
first one ... I don't know of any other research.”  
 
Caregiver: “In these smaller communities … doctors don't automatically do 
referrals for research, for evaluations … The doctor says, "Well, looks like you 
got dementia.” That's it.” 
 
Person with ADRD: “I don't think it's come up. It's not that I'm opposed.” 
Several caregivers noted that they have heard of research opportunities but decided not to 
get in contact with the research coordinator for a variety of reasons. This is discussed 
later in this chapter. 
Ineligibility/forced withdrawal: Three of the six people with MCI/ADRD who had 
participated in clinical research noted that they were ineligible for other studies or could 
not continue in the study. The first person was not eligible because he scored too high on 
cognitive tests. The second person was not eligible because of his age. The third person 





Caregiver: “The first [study] was really sad one because [wife] got a drug ... and 
within a couple of days she just turned around and she was just sharp and full of 
energy, and it was wonderful … And then, she tested out of the group … Because 
they were only looking at a certain parameter, and she was above the parameter. 
So she tested out of the thing, and she … [was] not happy when this was taken 
away from her. It really had been a help and her friends … are saying, "Well, why 
can't they keep giving her that?" 
The person with ADRD subsequently enrolled in two other trials, both of which were 
canceled by the study sponsor before the study ended. One trial was canceled due to a 
lack of positive results; neither the caregiver nor the person with ADRD could remember 
why the second trial was canceled. 
 Of the six dyads that had not participated in ADRD clinical research, none 
reported being told that they were ineligible; however, one speculated that they might 
have been eligible: 
Caregiver: “I've put her name on a couple of different websites, where they're 
asking for research subjects, but nobody's ever contacted us. So, evidently, she 
didn't meet the criteria.” 
Time and distance: The time spent on research activities and driving distance to drive to 
attend these activities were major factors for many caregivers and people with ADRD. 
Most noted that driving to get to the various study sites affected their decision to 
participate in research: 
Caregiver: “We drive out [across town] for an optometry appointment, and have 
to drive back, and it's just like that was what really put her off to it. And me, too ... 
I mean, they had one place for CT and one place for MRI … [and then a third 
place for] optometry … [Then], she had a hearing test at another place.” 
 
Caregiver: “It'd have to be convenient if we had to [drive]. [If it was in] 
southeast [Portland] at 9:00 in the morning and it took us two hours to get there, 





One couple who drove two hours one way every four weeks to get to their study site had 
a different outlook on the time and distance they spent in the study: 
Caregiver: “It's just something we plan on. Sometimes we just go up for the day, 
sometimes we meet friends and spend the night. It's a day, you spend three or four 
hours sitting in a chair. It's not particularly painful. Sometimes I take the dog with 
us, so I take the dog for a walk. We have a little routine, we listen to “Wait Wait 
... Don't Tell Me” on the way up, or music. We have our favorite restaurants that 
we go to. So it’s not difficult at all.” 
Caregiver burden: A few caregivers noted the demands of caregiving affect the ability 
they have to participate in research: 
Caregiver: “Well, it's just that my life is just so jammed full … there's just so 
many things, that, I think, "Oh, why am I doing this? It takes time to fill out 
things. "I mean, if things get worse with [husband], I might have to just say, "I 
can't do it." 
 
Caregiver: “Doing anything is a significant effort. It takes 20 minutes to get out 
of the house, you have to get it on the count. It's just a significant effort to do 
anything other than kind of hang around the house. … [Husband] will go. He 
would just prefer not to.” 
Caregivers also noted how their responsibilities affect their ability to be in research, even 
if they were not required to drive to study sites: 
Caregiver: “Searching through a whole bunch of websites looking for research 
studies where the criteria might meet what she has, doing that is very time-
consuming … She can't drive anymore. So, I've got to take her everywhere she 
goes, which I didn't used to do… And, I've got to do a lot of things with her and 
everything that [she] used to do independently and all. What that does is put the 
time-consuming burden on me.” 
 
Caregiver: “One I thought about doing … it seemed very easy because we didn't 
have to go anywhere … But the thought of using [the technologies], it just would 
have been a headache trying to explain, "Oh, this is for this," constantly ... I'm 
already answering questions all the time, and then to add something else.”  
Using the Internet: Several caregivers noted that they did their own online research to 





Person with ADRD: “[Husband] gets online and he said, "Okay. As far as I can 
see, the best place on the West Coast to go is [research organization]." So I went 
down there and I got tested. And they confirmed, yes, I did have a problem. Then I 
was in a clinical trial down there.” 
 
Caregiver: “You get on these websites, and a lot of times they're in fairly 
scientific terms, which for the most part, yeah I can read and decipher. Most 
people can't ... To me, the ideal site would have to be a website that there'd have 
to be some other ways you can do it too in-person because not everybody is 
computer literate.” 
 
Caregiver: “One of the people at the [organization] said their website is a 
nightmare. She says … it's a nightmare to navigate, so I doubt if I would have 
looked and found [the clinical trial] there.” 
Summary: There are a variety of factors affecting the decisions of a person with ADRD 
regarding participation in ADRD clinical research, including knowledge of opportunities, 
ineligibility or forced withdrawal from studies, time and distance, their caregiver’s 
burden, and the ability to use the Internet to find research opportunities. In most cases, 
interviewees discussed these factors as barriers to research participation. Theories of 
transaction cost and civic engagement are prominently featured in these subthemes. Small 
numbers bargaining, bounded rationality, and resource effects affect a person’s decision 
to participate in ADRD research.  
Theme 3: Factors affecting motivation to participate in research  
 All interviewees believed that ADRD clinical research was essential and more 
people needed to participate in it; however, that did not necessarily mean they were 
willing to join a study. Factors derived from these interviews include the motivation to 
help others, living life to the fullest, taking study drugs, and advisory board participation. 
Motivation to help others: Nearly everyone recognized that a clinical trial would not be 





if they participated. Rather, they participated or said they would consider participating to 
help others or give back in some way. 
Caregiver: “People ask, "What's in it for me?" Sometimes, the answer is, "Well, 
they will find a cure and fix you." I think for Alzheimer's, that's not going to 
happen in her case. I think if I was diagnosed five years out, I don't know whether 
it would help me. But, it could help our kids.” 
 
Person with ADRD: “I didn't hesitate to get into clinical trials. What have I got 
to lose? And I like the feeling that even if it doesn't help me, it's contributing to 
knowledge. So for me, it's kind of giving back and hoping that maybe I'm getting 
some study drug; which I think I am.” 
 
Caregiver: “My thinking was, "This is so horrible. Something good should come 
out of it." 
 
Person with ADRD: “I always felt it was my duty to do it. And so that's why I did 
it for as long as I did … Because if I was suffering, I knew others were as well. 
And I really felt like this was a fight worth going into.” 
 
Caregiver: “If researchers could advertise that this is something that'll make you 
feel good because you're making a difference … all of us want to be doing 
something I think.” 
For some, not receiving a direct therapeutic benefit was a sufficient reason to not 
participate in available research opportunities: 
Caregiver: “Well, to be honest with you, it was a couple of factors. One is that 
it's I don't think there's going to be anything that's going to reverse it… And I 
know that it could help people in the future …. But it's like, okay, do I want to 
add on one more thing, drive up to [research organization], which is like way the 
heck up there, and for what?”  
 
Caregiver: “I don't think that there's anything to be done in our situation. We're 
working for someone else.” 
Living their life to the fullest: Several interviewees felt that having dementia was a race 
against the clock before the person with ADRD was no longer able to do what they 





had to choose between participating in a study and doing things they enjoyed, they would 
choose the latter, as illustrated in the following quotes: 
Person with ADRD: “I would prefer [a research study] not take so much time. I 
can't work on [my leisure projects] because I really feel that I don't have that 
much time [to work on those projects].” 
 
Caregiver: “There are a lot of opportunities for us to do things that enrich what 
are still good years. If it was going to be some intervention that would interfere 
with that or gobble up a lot of our time, that would be a substantial negative.” 
 
Person with ADRD: “I participated in so many studies that after eight years I 
said, "Enough … I want to have my life back." 
 
Person with ADRD: “If there'd been a two-year lag period [to get into a 
research study], we would have continued to look for other options. As it was, I 
think we did wait for a few months, but with something like Alzheimer's, where 
you sort of feel little bits of your brain chipping off, you don't want to wait 
indefinitely.” 
Taking study drugs: When interviewees were asked how they would describe clinical 
research, most defined it in terms of clinical trials — testing an intervention to determine 
if it is effective for treating or preventing a disease. For five of the 12 caregivers and five 
of the 12 people with ADRD, taking a study drug was an automatic disincentive to 
joining a study, especially if there was no guarantee that the drug would be effective. 
Some interviewees alluded to having physical difficulty swallowing pills, while others 
noted concerns about safety, effectiveness, or side effects. Very few indicated that they 
would be willing to participate in studies where safety and efficacy have already been 
established, but still had concerns about side effects:  
Caregiver: “I'm not big on any drugs so that rules out a fair amount of them.” 
 
Caregiver: “If the only research options were medication, I don't think that 






Person with ADRD: “I think you can take one pill and it interferes with the 
results of the other pill, and I'm taking about six right now.” 
 
Person with ADRD: “Well, generally, I take some medications, and I will take 
more medications in the future. But I'm not for medication particularly … unless 
somebody has advised me they are useful.” 
 
Caregiver: “[if a study coordinator tells us that] this drug has a potential for 
being really helpful, but in this stage of development, we know there are … side 
effects that will probably happen, that would be a strong negative no … We 
wouldn’t [participate], we've got enough trouble already.” 
Caregiver support: Several caregivers felt unsupported, even if they were attending 
support groups. Although they acknowledged that while it was not the researcher’s “role” 
to provide support, they noted that it could be a motivator for caregivers to join a study: 
Caregiver: “They probably know a caregiver's under a lot of pressure. So ease 
some of that pressure and you might help with participation … They could 
provide a caregiver and compensation for a couple of hours. They could have an 
activity that we could drop the person off at another time. They could help deal 
with any issues you're dealing with your person in particular. That's not their 
role, but those are useful things.” 
One caregiver noted that they report on their emotional health every week as part of their 
study participation and yearned for a response: 
Caregiver: “You know, [my survey responses] are all going into a big file in a 
computer, and you think, "Here I am pouring out my heart about how lonely I 
was”… So, if I say I'm lonely, just lend me an ear, and give me wisdom about how 
to deal with this.” 
Advisory board participation: When asked about being on an advisory board where 
caregivers and people with ADRD collaborate with researchers and staff, most 
interviewees described them as unimportant to their decision to participate in research. 
Some caregivers mentioned wanting to participate in the future but were unaware of 





interested in serving on an advisory board. One interviewee was a former neurologist 
diagnosed with Alzheimer’s, who speaks to medical students about treating individuals 
with dementia. He is also part of a research advisory board for the Alzheimer’s 
Association, but was unable to join their advocacy board due to policies regarding 
caregivers: 
Person with ADRD: “The Alzheimer's Association invited me to join an 
advocacy group; I said I'd be happy to do it but they required a partner because 
they didn't want people to travel on their own … I don't know how much longer 
I'll be able to do that, but right now that's not an issue. But that was something 
that was etched in stone … [so] they said how about a different division?”  
Notably, several people with ADRD felt that they would not be able to contribute: 
Person with ADRD: “My brain isn't doing very well. I don't think that's 
something that would help anybody with me getting confused. I don't need to help 
people when I can't [help] myself.” 
 
Person with ADRD: “I think I'm past being useful on an advisory board myself. I 
mean, I may have opinions that could be useful and people might be interested in. 
Fine. But ... I'm 80-whatever-it-is … I feel I'm too old to be useful in that regard.” 
Summary: Helping others, living life to the fullest, caregiver supports, and taking 
medications were identified as factors affecting motivation to participate in research. 
Helping others and caregiver supports were listed as positive motivators whereas living 
life to the fullest and taking study drugs decreased motivation. While advisory boards 
were generally considered neither motivating nor demotivating for most interviewees, it 
is important to recognize that several people with ADRD felt that they had nothing to 
contribute to them because they felt they could not help anyone. Theories of transaction 
cost and civic engagement are both evident in these subthemes. In some cases, the cost of 





interpretive effects of knowing that one has helped others were sufficient motivation to 
join a study. 
 
Integration of Findings and Theories 
These three themes, and the associated twelve subthemes, offer insights in understanding 
personal factors affecting the decisions of people with ADRD and their caregivers to 
participate in clinical research in their local community. Themes were similar across both 
dyads that have participated in ADRD research and dyads that have not, yet their 
decisions to participate in research were different. Civic engagement helps to explain the 
decisions of those who have participated in ADRD research, whereas transaction cost 
theory helps to explain the decisions of those who have not participated in ADRD clinical 
research. Contingency theory can be used to demonstrate how organizations can develop 
strategies to encourage people with ADRD and their caregivers to participate in research. 
Civic engagement and ADRD research participation 
 Civic engagement can be used to describe people who participate in ADRD 
clinical research due to their beliefs that their participation is valuable to better their 
community. The interviewees who participated in research, and even those who are not 
participating but wanted to, recognize that their participation will not result in a 
therapeutic benefit to help themselves, but they are doing so to help friends, family, or 
future generations, or to contribute to science. For example, one dyad noted that though 





the distance traveled is worth it in exchange for the benefit of helping others and 
potentially receiving a therapeutic benefit.  
 An application of Mettler & Welch’s (2004) framework can be used to understand 
factors increasing the likelihood of ADRD research participation, where civic capacity is 
viewed as “ability” and civic predisposition is viewed as “motivation.” In these cases, 
factors identified by the interviewees that affect their capacity, or ability, to participate in 
research include knowledge of opportunities, eligibility criteria, time and distance 
required to participate, caregiver burden, and use of the Internet. Similarly, 
predisposition, or motivation, to participate in research includes the chance to help others, 
living good years to the fullest, caregiver support, taking study drugs, and joining 
advisory boards. These factors may also compete. A person might be motivated to 
participate in ADRD research, but if they would be required to take study drugs, their 
motivation may be negatively impacted and they would choose to not join the study. 
Transaction costs and ADRD research participation 
 For many interviewees, the transaction costs of participating in research are too 
high. Specific factors are identified in Table 5.4. With regard to uncertainty, specifically 
factors that are outside of the research organization’s control, many of the caregivers and 
people with ADRD noted the lengthy time to recognize symptoms as dementia or receive 
a diagnosis from their provider. Part of this delay is due to attributing ADRD symptoms 
to stress or age rather than cognitive impairment; however, in some cases when a person 
went to their provider with concerns of memory loss, these concerns were dismissed. 





Table 5.4: Interviewees Transaction Costs of ADRD Research Participation 
Component Examples in ADRD Clinical Research  
Participation Literature 
Uncertainty  Symptom recognition and diagnosis  
Small numbers 
bargaining 
 Time spent and distance traveled 
 Eligibility criteria 
Bounded rationality  Knowledge of study opportunities 
 Using the internet 
 Living life to the fullest   
 Opinion of research benefits (direct versus non-
direct benefits) 
Opportunism  Caregiver burden 
 Study drugs 
 Small numbers bargaining, or the bargaining power that researchers, study 
sponsors, research organizations, people with ADRD, and caregivers bring to the 
transaction, was also evident in the findings. Interviewees frequently noted that in order 
to join a study, they needed to meet all requirements set up by the researchers or 
sponsors. These often included a dementia diagnosis, meeting all eligibility criteria, and 
commitment to time and travel. In many cases, people with ADRD and caregivers made 
it clear that they were not willing to adhere to those standards (and potential 
inconvenience) just to participate in a study.  
 Examples of bounded rationality were evident in the interviews. Many 
interviewees were unaware of study opportunities, even in cases when they had asked 
their doctor or signed up for dementia research registries. Some interviewees noted that in 
order to search for dementia research opportunities online, they needed a high level of 
scientific understanding as well as time to search for research or sign up for registries. 





and people with ADRD to use the Internet as a means for finding study opportunities. 
 Further, all interviewees were aware that the likelihood of receiving a direct 
intervention for MCI or ADRD from study participation was almost guaranteed to be 
unlikely. In these cases, individual beliefs about the benefits of participation differed. For 
some, the fact that participation might lead to an intervention for future generations, or at 
least contribute to science, was worth the effort. For others, the substantial unlikelihood 
of a direct therapeutic benefit equated to no benefit. In some cases, caregivers and people 
with ADRD noted that they believed that they only had a few “good years” left before the 
disease progressed too far to fully enjoy life. In these cases, they decided not to 
participate in study opportunities because this could take away from their perceived 
limited time remaining to live their lives to the fullest while they still could.  
 Examples of opportunism were also present in the findings. For several caregivers 
and people with ADRD, research opportunities that required taking a study drug was an 
automatic deal-breaker due to their dislike of taking pills or concerns of safety, 
effectiveness, interactions with other medications, and side effects.  Many caregivers also 
noted elements of opportunism when they said they had no or limited free time due to 
taking care of the person with ADRD. In those cases, the spouse or parent would not be 
able to participate in research because their caregiver was unable to do so.  
Using contingency theory to reduce transaction costs and promote civic engagement 
 By applying contingency theory, research organizations and sponsors can address 
frequently discussed barriers to participation. Research organizations could collaborate 





For instance, they could work with local healthcare providers to offer centralized 
locations for study activities, such as CT scans or hearing tests, or work with multiple site 
locations so participants could choose the site closest to them. They could also seek to 
provide more opportunities for in-home study participation or provide care services for 
those who do not want to, or cannot, drive to the research clinic or other study activity 
sites, such as working with home nurses to provide infusions instead of requiring an 
actual visit to the study site. 
 Not all of the people who did not participate in research described that the 
transaction costs were too high. In fact, there were several interviewees who said they 
had attempted to learn more about research opportunities but were not told of any studies, 
yet would happily participate if given the chance. Although the connection between 
hypothetical willingness and actual participation is not strong (Buchbinder et al., 2004; 
Burke, 2014; Grill & Galvin 2014; Inungu et al., 2017), organizations could modify their 
rules or processes to increase the likelihood of turning ability and motivation into 
participation. If a person with ADRD or a caregiver is unaware of research opportunities, 
they are unable to participate in studies. In these cases, knowledge transfer could be used 
to inform communities about research studies.  
 Information from researchers is translated to communities, such as a trusted 
healthcare provider or a community organization, which requires determination of what 
information is important to the community, who is a credible and trusted messenger, how 
the message should be transmitted, and the effects the message should have (Lavis et al., 





about a drug trial at their support groups, but more likely to share knowledge about a 
study that includes some sort of caregiver benefit. Additionally, ADRD researchers could 
refocus their recruitment efforts and focus on giving presentations in areas where people 
with ADRD and caregivers congregate. Researchers interviewed for Phase 1 of this study 
noted that they post flyers or give community presentations at senior centers. This may be 
an ideal recruitment location for healthy adults for dementia prevention studies, but not 
necessarily for the target population of those with ADRD. Researchers might instead 
focus on areas where people with ADRD and caregivers are likely to congregate, such as 
support groups, memory cafes, or respite and day centers. 
 Knowledge transfer can also be important for letting people know the differences 
between clinical research and clinical trials. Clinical research can encompass numerous 
observational studies, from cognitive assessments to neuroimaging to study of in-home 
technologies. Clinical trials could include study drugs, herbal supplements, diet, exercise, 
technology, or social engagement as the intervention. Further, potential study participants 
who are concerned about physically swallowing study drugs might be more inclined to 
participate in studies that involve infusions rather than pills. Those who are concerned 
about safety, effectiveness, or side effects may benefit from learning about the different 
clinical trial stages and may be more willing to participate in large-scale studies that test 
the effectiveness of a drug against the current standard treatment. Not all studies require 
study drugs, and potential participants could be better informed about non-drug 





 To address caregiver burden, which is a frequently cited reason for not 
participating in ADRD clinical research, research organizations and study sponsors could 
modify some of their processes to better address caregiver needs. Many of the caregivers 
noted that they would like some sort of support if they were participating, either in the 
form of respite or support when they are going through difficult times. According to these 
caregivers, organizations and sponsors could better respond to their needs and provide 
these resources. This study’s findings also suggested that research organizations could 
modify how they articulate their view of caregivers. If the participation of a study partner 
is a requirement for participation in a study by a person with ADRD, then they are 
participants, with differences in their study roles and activities. Thus, research 
organizations may consider treating study partners as participants and potentially 
compensate them for their participation (including time lost to other activities, such as 
employment). To identify specific caregiver needs, researchers could conduct focus 
groups with study partners and caregivers to identify their unique needs. 
 
Discussion 
The reasons why people with ADRD choose to participate in clinical research are 
complex, as participation requires both the ability and the motivation to participate. These 
interviews provided a unique opportunity for 12 people living with ADRD and 12 
caregivers to describe in detail the process of recognizing and being diagnosed with 
ADRD, and their decision to participate or not participate in an ADRD clinical research 





to explain factors related to ADRD clinical research participation. Transaction cost theory 
and civic engagement illustrated why people with ADRD and caregivers may not have 
the ability and/or motivation to participate in ADRD clinical research. Civic engagement 
also identified factors influencing the decision to participate. Contingency theory 
illustrated how research organizations can modify their processes and rules to address the 
needs of people with ADRD and caregivers. 
 This research has several findings. First, there is an identified lack of knowledge 
about opportunities in the local Portland area. Many interviewees had never heard of 
research opportunities. While this is discussed frequently in the literature, this was 
surprising as most of these interviewees were recruited for this study from organizations 
with rich knowledge of research opportunities. In cases where they had searched for 
study opportunities online, many interviewees noted that websites and registries were 
difficult and time-consuming to navigate and often required scientific and Internet 
literacy. Second, neither a person with ADRD nor their caregiver’s perceived value of 
ADRD research may increase their likelihood of joining a study. All interviewees agreed 
that ADRD research was important and necessary, but there were many factors--  
including time and distance, not receiving a direct benefit, concern of taking study drugs, 
and caregiver burden -- that led to a decision to not participate in a study. This aligns with 
findings from the literature that articulates the lack of a relationship between hypothetical 
and actual willingness to be in a study (Buchbinder et al., 2004; Burke, 2014; Grill & 





 Third, many caregivers either do not have the free time to join a study with their 
participants or do not want to give up their limited free time. However, several caregivers 
noted that they would take the time to participate in the study provided some sort of 
caregiver benefit to ease their burdens, such as support, education, and/or respite. The 
literature about ADRD study partners and caregivers describes caregiver support as a 
facilitator to their study participation (Karlawish et al., 2008; Cary et al., 2015; Black et 
al., 2017). Some organizations may be unable to provide supports because of a lack of 
resources or because of concerns that it may compromise the integrity of the trial. In 
these cases, coordinators can search for and recommend local caregiver supports. 
  Fourth, the number of people who avoid research because it involves taking study 
drugs was substantial among interviewees. However, there are many studies that do not 
require taking study drugs, including neuroimaging, dietary, exercise, social engagement 
and technology studies that investigate diet, or those that use technology in a person’s 
home. Fifth, providers need more education on symptom recognition and professional 
diagnosis. Many people with ADRD and caregivers noted that symptoms were initially 
dismissed. Often, it was not until more substantial symptoms presented that further 
evaluations were conducted. Further, at least two people with ADRD noted 
unprofessional diagnoses from their provider, leading to one person stating that she is 
scared to see a neurologist again.  
Recommendations 
 Several recommendations can be made based on this study’s findings. First, 





study opportunities. This may include sharing study flyers or brochures with providers or 
giving presentations at community organizations. Some interviewees in the first phase of 
this study noted the difficulty in recruiting participants from these community talks (see 
Chapter 4). More research may need to be conducted to identify why there is little 
response after presentations and what strategies can be developed to improve recruitment 
from these presentations. Knowledge of study opportunities could also be fostered by 
modifying both national and local online registries and clinical research websites. These 
sites and registries, including TrialMatch, ClinicalTrials.gov, and local research 
registries, offer a wealth of information about study opportunities but may be inaccessible 
to those who lack scientific or Internet expertise or are short of time for searches. 
Modifications may include using lay language, providing definitions to describe trials, 
and streamlining navigation and registration processes.  
 Second, researchers could advocate that study partners be treated as full 
participants, and seek sufficient funding to enable caregiver compensation for their time 
and effort. Though they engage in different study activities, such as answering 
questionnaires, driving to appointments, or ensuring the person with ADRD is adhering 
to study protocols, their participation is absolutely essential to the study. Further, their 
compensation should be provided in a manner that is most suitable to them as caregivers, 
such as caregiver education, respite, or as-needed support and advice, and also reflective 
of what the organization can feasibly provide. Researchers could budget for this 





 Third, research organizations could develop strategies to remove or reduce the 
time spent and distance traveled in order to participate in research. For example, they 
could work with study sponsors to include more secondary sites for specialty testing (e.g. 
optometry or CT scans), or work with home health agencies to avoid traveling for some 
medical procedures.  
 Fourth, researchers could highlight the benefits of helping others. Many 
interviewees noted that they participated for the ultimate benefit of others, rather than 
themselves, and they derived happiness from that. Researchers could partner with people 
with ADRD and caregivers who participate in research to share the message of what it is 
like to participate in research and discuss the benefits of being a research participant. 
These messages can also include the differences among clinical research and clinical 
trials, study drug versus non-study drug clinical trials, and clinical trial phases. 
Limitations 
 There were several limitations to this study. First, sampling bias is likely given 
that all but one of the interviewees were white individuals, and there were no African 
American participants despite targeted recruitment. This may be due to a variety of 
structural and systemic barriers. For example, one community advisory board member 
noted the hesitancy of African Americans to participate in clinical research given the 
egregious acts conducted by clinical researchers. Additionally, Oregon has a history of 
mistreatment of African Americans, racist policies and practices, and modern 
displacement of African Americans due to gentrification (Hannah-Jones, 2011; Parks, 





barriers, many older African Americans are hesitant to speak with an unknown white 
academic about their perspectives on clinical research. Additionally, the researcher had 
developed a relatively recent relationship with African American community 
organizations and had not yet established a trusting relationship.). As a result, these 
findings may or may not be relevant to African Americans with ADRD and their 
caregivers, and there may be other factors that were not explored. This limitation is 
further discussed in Chapter 7. 
 A second limitation is that these findings are specific to the Portland metropolitan 
area. However, saturation was reached through these interviews, meaning that new data 
was not adding new information to the findings (Miles et al., 2020). They may be 
contextually relevant for similar communities, but are not necessarily generalizable nor 
are they intended to be, in the quantitative sense. Rather, these findings can be 
transferable to other researchers, clinicians, or advocates in other metropolitans areas if 
they believe these findings may be applicable to their setting and specific context (Smith, 
2017). 
 Third, there is always a risk of response bias, confirmation bias, and subconscious 
bias. Interviewees may have censored themselves due to the audio-recording of 
interviews and may have focused on what they perceived the interviewer wanted to hear, 
resulting in response bias. Confirmation bias is also likely given that the investigator was 
the single coder and drew upon relevant theories and literature for analysis. The 
investigator mitigated some of this bias by writing field notes immediately after each 





engaging the CAB in member-checking and interpretation of analyses. Furthermore, 
while there are no conscious biases due to the researcher’s identity, it is important to 
acknowledge that subconscious biases are possible due to her identity as an academic 
who is a proponent of ADRD research and community inclusion, and these may have led 
to response bias, where interviewees may have answered questions in a way that seems 
more agreeable to the investigator (Kovera, 2010; Kalu & Bwalya, 2017). These biases 
are further explored in Chapter 7. 
 
Conclusion 
 This research study identified personal factors affecting ADRD research 
participation in the Portland metropolitan area. These were identified through interviews 
with local people with ADRD and caregivers, some of whom have participated in clinical 
research. Identifying how these factors affect the decisions of a person with ADRD to 
participate in research is an important first step in increasing participation rates. Given 
these factors, strategies can be developed and implemented to improve the ability and 
motivation of people with ADRD to join research studies in the Portland metropolitan 
area. This study should be repeated in a larger context or as small pilot studies in other 
communities to determine contextual relevance and generalizability for other areas. 
Further, strategies implemented by researchers, research organizations, or study sponsors 
should be routinely evaluated to determine their feasibility and effectiveness. Researchers 





treatments, or a cure for ADRD. Participation in clinical research is an important step 






CHAPTER 6: RECOMMENDATIONS TO IMPROVE LOCAL DEMENTIA 
CLINICAL RESEARCH PARTICIPATION 
 
Introduction 
The United States Congress has allocated 2.8 billion dollars annually to find a prevention 
or treatment for Alzheimer’s disease and related dementias (ADRD) by 2025 
(Alzheimer’s Association, 2019a). One critical factor in achieving this goal is recruiting 
enough people with ADRD and their caregivers who are willing and able to participate in 
clinical trials. Historically, ADRD clinical trial participation is low; only 10%-27% of 
people with ADRD are able to participate due to comorbidities, low cognition, and frailty 
(Grill & Galvin, 2014; NIA, 2018). In addition, there are numerous policy, system, 
organizational, and personal factors affecting an individual’s ability and motivation to 
participate. 
For those who are able to participate, many factors affect their motivation to 
participate. One significant factor is the requirement of a study partner, typically a spouse 
or adult child, who can attend study appointments and ensure protocol adherence (Rollin-
Sillaire et al., 2013; Black, Taylor, Rabins, & Karlawish, 2016). The necessity of a study 
partner requires that two participants need to be recruited and enrolled -- the person with 
ADRD and their caregiver partner (Karlawish et al., 2008; Watson, Ryan, Silverberg, 
Cahan, & Bernard, 2014; Grill & Galvin, 2014; Cary, Rubright, Grill, & Karlawish. 
2015; Black et al., 2016), unlike other clinical research where a study partner is not 





Many individuals affected by medical conditions, including ADRD, report an 
interest in joining relevant clinical research both for potential benefits for themselves and 
opportunities to help others (English, Lebovitz, & Griffin, 2010; Law et al., 2014; 
Anderson, Borfitz, & Getz, 2018). Despite these reports, clinical research participation 
rates are low (English et al., 2010; Law et al., 2014; Mahon et al., 2016; Anderson et al., 
2018). One common sentiment from interested individuals is that they are unaware of 
how to seek or receive information about opportunities to join clinical research (Sood et 
al., 2009; Law et al., 2014; Anderson, Borfitz, & Getz, 2018). Individuals often expect to 
hear about studies from their primary care provider and are more likely to participate 
when these providers inform them due to their trusting relationship. However, individuals 
may be more likely to hear of opportunities from media advertisements (Anderson et al., 
2018).  
Regulations intended to protect vulnerable populations may also restrict 
participation among people with ADRD. Potential study recruits with ADRD may be 
deemed ineligible for clinical trials due to comorbidities or contraindicated medications 
(Grill & Galvin, 2014; Adams, Caffrey, & McKevitt, 2015). As most people with ADRD 
are over age 65 and already treated for multiple comorbidities, recruitment is especially 
challenging (Rollin-Sillaire et al., 2013; Grill & Galvin, 2014; Law et al., 2015, Gilmore-
Bykovskyi et al., 2019).  
Furthermore, investigators and study sponsors may require additional eligibility 
criteria to manage clinical and ethical risks associated with research on older adults with 





example, despite more than one-third of all ADRD cases occurring in people aged 85 or 
older, just 8% of individuals participating in ADRD clinical research between 2000 and 
2015 were over the age of 85 (Banzi, Camaioni, Tettamanti, Bertele, & Lucca, 2016). 
Many studies place age limitations to individuals age 85 or younger due to concerns 
about complex health problems. Age restrictions pose a barrier to individuals who may be 
otherwise healthy and eligible to participate in clinical research, and further limit the pool 
of available participants. To address this barrier, the NIH recently reversed a policy 
(NOT-98-024) that allowed for arbitrary age exclusion; as of January 2019, clinical 
research, barring scientific or ethical reasons, can no longer exclude individuals based on 
age (NIH, 2017a). However, it is still unclear how strictly this policy has been interpreted 
and implemented. The NIH has invited public comments in preparation for an upcoming 
workgroup to evaluate and modify the strategy to improve recruitment and retention of 
underrepresented populations, including geriatric participants (NIH, 2019).  
The NIA recently convened working groups to identify strategies to improve 
recruitment and retention in ADRD studies. Its report was released in 2018 and 
emphasizes the concept of local community collaboration, with four key strategies: (a) 
increase awareness and engagement; (b) build and improve research infrastructure; (c) 
engage local communities and support participants; and (d) develop an applied science of 
recruitment (NIA, 2018). The aforementioned factors affecting ADRD clinical research, 
and the literature in general, do not incorporate concepts of local community 
collaboration. More research is needed to examine how local community collaborative 





Purpose of this study  
 This study aimed to identify factors affecting local ADRD clinical research 
participation in the Portland, OR metropolitan area, and specifically focused on local 
recommendations for increasing ADRD clinical research participation. Roughly 67,000 
Oregonians over the age of 65 are currently diagnosed with Alzheimer’s disease, and this 
number is expected to increase to 84,000 by 2025 without an intervention to halt its 
increase (Alzheimer’s Association, 2019b). This number represents about 9% of adults 
65 and older living in Oregon, slightly less than the national average of 10% (United 
States Census Bureau, 2018; Alzheimer’s Association, 2019). However, the actual 
numbers of those living with ADRD may be substantially higher because the figures cited 
do not include people under the age of 65 or those with non-Alzheimer’s disease 
dementia. This number also does not include individuals who exhibit symptoms but are 
un- or misdiagnosed, which can be as high as 60% of those living with dementia in 
higher-income countries (Lang et al., 2017).  
 
Conceptual Framework 
The Culture of Health Action framework provides a useful structure to conceptualize 
recommendations to improve research participation among people with ADRD because 
many of the factors affecting clinical research participation can be categorized into the 
Culture of Health Action Framework’s four action areas, illustrated in Figure 6.1. The 
Culture of Health Action Framework was introduced by the Robert Wood Johnson 





social sectors with the goal of improving population health, wellbeing, and equity (Robert 
Wood Johnson Foundation, 2016). In the conceptualization of this framework, health 
providers partner with local nonprofits and private organizations. These partnerships then 
work with communities to define their needs and the measures that matter most to them 
to improve population health, wellbeing, and equity (Weil, 2016). Partners then design 
and redesign programs to better meet community needs and achieve the Culture of Health 
Action Framework’s goals of improving community health, wellbeing, and equity (Weil, 
2016). When compared with other communities, those with high-density multi-sector 
networks supporting health improvement activities have better health outcomes 
(McCullough & Leider, 2016).   
Figure 6.1 Culture of Health Action Framework  
 
Source: The Robert Wood Johnson Foundation, 2016 
 
 There are several socioecological frameworks that may be used to articulate 





Action Framework was chosen for a variety of reasons. The Culture of Health Action 
Framework and its action areas could be useful for articulating strategies to increase the 
ability and motivation to participate in ADRD clinical research. For example, the 
knowledge of opportunities from trusted providers and community leaders, and 
partnerships among community members, multiple organizations, and government, are 
strategies recommended by researchers to encourage motivation. This framework has not 
been applied to date in an ADRD context (based upon a literature review), but it could be 
applied to illustrate opportunities for people with ADRD. Traditionally, the voices of 
people with ADRD have not been incorporated in research design; however, this 
framework could be used to conceptualize an approach that would encourage the 
inclusion of people with ADRD in order to define their own needs and develop solutions 
to address structural barriers to participation. Although there is no strong evidence that 
people with ADRD identify themselves as part of an ADRD community, community-
engaged principles can be used to include the voices of people with ADRD and their 
caregivers in research. Further, many of the factors that affect ADRD research 
participation can be contextualized using this framework and its four action areas, which 
are described in detail below.  
Culture of Health Action Framework Action Area 1: Make health a shared value 
 The Robert Wood Johnson Foundation recommends three changes be made in 
order for communities to view health as a shared value. First, there must be a shift in 
mindsets and expectations of what individuals consider health and wellbeing, with an 





expected, not a function of economic privilege. Mindsets and expectations can shift by 
stressing the benefits of equitable health opportunities, but also require group-level 
empowerment in order to push for social change (Chandra et al., 2016). Second, health as 
a shared value requires a sense of community identity. Individuals and communities are 
interdependent by virtue of their sense of community membership (or lack thereof), 
belonging, and shared experiences. When community members recognize and act upon 
their solidarity, they are able to better mobilize and enhance their ability to thrive, be 
healthier, and drive change. Lastly, making health a shared value requires the knowledge 
of civic engagement skills, values, motivation, and opportunities within that community 
(Chandra et al., 2016).  
 In this context, this means that those in a position of power, including healthcare 
and service providers, researchers, advocates, and policymakers, must share those 
resources with community members. As noted above and in Chapters 4 and 5 of this 
dissertation, individuals with ADRD may want to participate in related clinical research 
but are unaware of how to seek or receive information about opportunities (English et al., 
2010; Law et al., 2014; Mahon et al., 2016; Anderson et al., 2018). Many expect to hear 
about opportunities from their trusted provider or community leader but may be more 
likely to learn through media outlets (English, et al., 2010; Law et al., 2014; Mahon et al., 
2016; Anderson et al., 2018). Knowledge transfer, where information from researchers is 
translated to communities, can be used to make ADRD research participation a shared 
value. Knowledge transfer requires determination of what information is important to the 





transmitted, and the effects the message should have (Lavis, Robertson, Woodside, 
McLeod & Abelson, 2003). Knowledge transfer can be used to directly solicit community 
members to participate, which increases motivation for research participation (Law et al., 
2014).  
Culture of Health Action Framework Action Area 2: Foster cross-sector 
collaboration to improve wellbeing 
 There are three unique drivers to foster cross-sector collaboration. First, high-
quality cross-sector partnerships result from having a sufficient number, variety, and 
quality of partners (Towe et al., 2016). Collaborations emerge from advocacy, 
community buy-in, and commitment from the partners (Towe et al., 2016). Second, 
partners must be informed of how they are expected to engage with and benefit from 
these collaborations, how the collaborations will address equity, and what will be the 
return on investment (Towe et al., 2016). Third, these collaborations can be developed 
through local, state, and/or federal level initiatives and policies across multiple agencies 
(Towe et al., 2016). 
Cross-sector collaboration can be used to shape ADRD research and increase 
participation. The Satellite program, at Washington University in St. Louis, aimed to 
increase African American participation in dementia research. It illustrates how high-
quality cross-sector partnerships can lead to participatory processes and outcomes 
(Williams, Meisel, Williams, & Morris, 2011). A federal grant from the NIA in 1992 
provided the financial initiative to establish the program, and over several years, they 





offices, senior centers, libraries, and African American community organizations 
(Williams et al., 2011). Partnerships were sustained through numerous types of 
investments, including federal grants and philanthropic contributions (Williams et al., 
2011). Policies were created to maintain their partnerships and achieve their goals, such 
as the establishment of an African American ADRD research advisory board in 2004 
(Williams et al., 2011). Satellite achieved its primary goal of removing research 
participation inequity among the African American community in St. Louis; their success 
has led to similar programs being developed in California, Wisconsin, Kentucky, and 
New York (Williams et al., 2011; NIA, n.d.).   
The NIH’s May 2018 announcement of funding opportunities to promote 
diversity, recruitment, and retention through collaborative partnerships may serve as a 
gateway to knowledge mobilization in ADRD research (NIH, 2018b). Receiving an NIH 
grant is a financial and academic incentive for investigators, who may then implement 
programmatic changes within their research organization that establish or strengthen 
collaborative partnerships. They may also influence resource allocation and opportunities 
based on the expertise of the participants and study partners. Finally, NIH funding can 
also strengthen existing partnerships by providing funding to support collaborative 
activities. 
Culture of Health Action Framework Action Area 3: Create healthier, more 
equitable communities 
 Improving physical environments, social and economic conditions, and policies 





healthier and more equitable communities (Dubowitz et al., 2016). In order to achieve 
healthier, more equitable communities, the complexity of the causality of poor health 
outcomes must be recognized. Dubowitz and colleagues illustrate this challenge with the 
example of a grocery store: simply adding a grocery store in a neighborhood may 
improve the neighborhood’s quality, but not improve healthy eating (Dubowitz et al., 
2016). Individuals living in the neighborhood may prefer to purchase food from other 
locations, may not be able to afford the groceries, or may not have transportation to get to 
the store. Additionally, there may not be adequate structural supports, such as sidewalks 
or street lights, which help individuals to safely walk to the store.  
 New governance structures may need to be created to sustain these actions. 
Opportunities may exist when governmental departments work together (e.g. departments 
of health and transportation), but rely on elected and appointed executive officials who 
are supportive of these goals. Further, creating healthier and more equitable communities 
requires mobilizing broad coalitions amid political polarization (Dubowitz et al., 2016). 
When health sectors partner with community members as well as local government and 
organizations, stakeholders may begin to recognize the complex causality of health 
outcomes due to social determinants and individual choice and develop solutions that 
align with the community’s needs.  
 The reasons why people with ADRD choose to participate in clinical research or 
not are complex, as participation requires both capacity and predisposition. Just as adding 
a new grocery store in a neighborhood does not automatically improve health outcomes, 





retention. As previously discussed in the clinical research section, multiple factors may 
impede or facilitate an individual’s ability and motivation to participate in research. 
Collaboration among the research sector, people with ADRD, and other relevant 
stakeholders is the best way to identify barriers, facilitators, and solutions to increase 
participation (Grill & Galvin, 2014; Mahon et al., 2016; Kramer, 2017).  
 The Culture of Health Action Framework also recognizes this necessity; 
stakeholders from health and other sectors work with the community to identify their 
needs and values and develop programs that align with them.  Programs are designed and 
redesigned as needed, capacity, trust, and relationships among all stakeholders are 
strengthened as the partnerships share power, work together, and develop solutions. 
Furthermore, organizations often assume that individuals will enter a relationship if it is 
beneficial; however, if there is a history of bad relations or culture, the individuals will 
avoid the organization, as exemplified in the previous discussion on African American 
participation in clinical research. However, if the organization takes the time to establish 
a relationship to build trust and respect and provide full information about study 
opportunities in a clear, understandable manner, it may improve the likelihood that the 
person with ADRD and/or their caregiver will participate in the research (Danner et al., 
2011, Frew et al., 2011; Grill & Galvin, 2014; Mahon et al., 2016, Inungu et al., 2017).  
Culture of Health Action Framework Action Area 4: Strengthen health services and 
systems 
 Drivers that strengthen the integration of health services and systems include 





2016). Access to health services and systems requires reducing and/or removing barriers 
due to cost and insurance, language, transportation, office hours and culture. Balance 
refers to how resources are prioritized and allocated between and within the health and 
social sectors, whereas integration refers to the meaningful connections that are made 
between sectors (Martin et al., 2016). Integrating medical care, public health, and social 
services systems can connect community members to appropriate and timely information, 
supports, preventive services, and formal healthcare to improve health and wellbeing 
(Martin et al., 2016). This requires a focus on improving access to healthcare and 
removing barriers such as language, office hours, transportation, and culture. Removing 
these barriers may lead to patients’ greater participation in their own healthcare because 
their ability to participate has increased (Gelmon, Bouranis, Sandberg, & Petchel, 2018). 
Discussions on resource allocation and priorities, and their effects on experience and 
quality, are also necessary (Martin et al., 2016).  
The literature on primary care medical home (PCMH) offers examples of how 
health sectors can become more accessible, integrated and balanced, and improve 
consumer experience and quality, ultimately strengthening health services and systems. 
For example, in Oregon, where over 70% of the primary care clinics participate in the 
state’s Patient Centered Primary Care Home program, most clinics provide office hours 
outside of the typical 9-5 workweek and all are required to have a 24/7 telephone line 
(Smith & Merrithew, 2017; Gelmon et al., 2018). Clinic leaders report translating 
materials and hiring bilingual and/or multicultural staff to better serve their patient 





with other local health- and social-sector organizations to address other structural barriers 
(Gelmon et al., 2018). Though there are no studies that have evaluated the PCPCH 
program from the patient and family perspectives to date, clinic leaders perceive a 
positive difference for their patients (Gelmon et al., 2018).  
This patient-centered set of strategies could be adapted to working with people 
with ADRD. Research organizations could apply similar strategies for dementia clinical 
research participants and their study partners. Study visits and activities could be 
conducted outside of the typical 9-5 workweek, and materials, including neuropsychiatric 
tests, could be translated into various languages. Research coordinators could build 
repositories of community resources specific to dementia and caregiving needs, including 
memory cafes, caregiver education, support groups, respite, and long-term care services.  
Additionally, the NIH’s Inclusion Across the Lifespan policy removes age as a barrier 
(NIH, 2017a). This increases the ability for older adults to participate in research because 
they are no longer arbitrarily excluded from ADRD clinical research studies due to their 
age, increasing potential recruitment of people who are older. Just as removing barriers 
and providing resources through the PCMH model may increase patient participation in 
their own healthcare because of increases in ability and motivation, the same could be 
done in ADRD research to be more patient-centered and improve the conditions and 
supports for research participation of people with ADRD and caregivers.   
As described above, each of the Culture of Health Action Framework’s four 
action areas may be used to illustrate recommendations to increase ADRD clinical 





opportunities for people with ADRD and caregivers to share their expertise and develop 
solutions to mitigate barriers and increase motivation to participate.  
 
Methodology 
 The study discussed here addresses the third aim of the larger dissertation 
research project: Provide recommendations to research organizations, health clinics, and 
advocacy groups to facilitate ADRD clinical research recruitment and retention. The 
purpose of the dissertation project was to identify factors affecting the decisions of a 
person with ADRD regarding participation in clinical research. These recommendations 
are based on two prior aims: the first identified organizational, system, and policy level 
factors affecting participation in ADRD research studies, and the second identified 
personal factors affecting ADRD participation.  
Study Design 
 For the first aim of the study, the investigator worked with several local health 
providers, researchers, community organizations, and a community advisory board 
(CAB) to identify ADRD clinicians, researchers, and advocates to offer expert opinion on 
organizational, system and policy factors affecting ADRD clinical research participation. 
This study’s data collection approach used semi-structured interviews. Interview 
questions were derived from the literature and various theoretical frameworks. 
Interviewees were ultimately selected based on organizational affiliation to ensure 
diversity in organizational representation. Potential clinicians, researchers, and advocates 





 For the second aim, which examined personal factors that affect research 
participation, the investigator conducted 12 semi-structured dyadic interviews (24 
interviews total) with individuals living with mild cognitive impairment (MCI) or ADRD 
and their caregivers. Although MCI is not considered a form of ADRD, clinical research 
studies frequently include people with MCI given hypotheses about the progression of 
ADRD, the availability of new diagnostic technologies (such as PET scans) that can 
identify pathological symptoms of AD even if the person exhibits only clinical symptoms 
of MCI, and the knowledge that people with MCI are significantly more likely to 
progress to dementia (Roberts and Knopman, 2013; Rabinovici et al., 2019). Both dyad 
members were given a $25 gift card to the grocery store of their choice. Dyads were 
recruited through local memory cafes, early-stage memory loss and caregiver support 
groups, and research organizations.  
 The investigator used elements of a community-engaged approach to enhance 
study rigor, relevance, and reach, as well as for its strength in identifying community-
specific factors and strategies (Balasz & Morello-Frosch, 2013; NIA, 2018). This 
approach included recognizing the interviewees as experts in the field because of living 
with MCI or ADRD, or caring for a family member with MCI or ADRD, and including 
them in the development and involvement of a community advisory board (CAB) to 
advise and guide study processes. CAB recruitment was facilitated through the Oregon 
Alzheimer’s Disease Research Center, the Alzheimer’s Association, and the PreSERVE 
Coalition for Black/African American Memory and Brain Health. CAB membership was 





former caregivers, older African Americans, and an academic faculty with experience 
working with CABs.  
 The 12-member CAB met three times during the overall study to guide the 
investigator on recruitment and interview protocols, interpret findings, and develop 
dissemination strategies. CAB community members (people with ADRD, caregivers, and 
older African Americans) were given a grocery gift card for each meeting they attended 
or contributed to, in recognition of their work with the CAB. 
Data collection and analysis 
 Semi-structured interviews (n=9) with clinicians, advocates, and researchers took 
place between April 2019 and July 2019. Interviewees were asked about their experience 
of working with people with ADRD, knowledge of clinical research and related policies, 
if and how they receive information about clinical research opportunities, dissemination 
of those opportunities, perceptions of organizational-, system-, and policy-level factors 
affecting clinical research recruitment and retention, and suggestions for improving 
ADRD clinical research enrollment. 
 Semi-structured interviews with dyads (n=12) took place between August 2019 
and December 2019. Dyads were eligible if they spoke fluent English and lived in, 
received care within, or had participated in an ADRD clinical research study based in the 
Portland, OR metropolitan area. Additionally, people with MCI or ADRD needed to have 
a clinician-assessed diagnosis, were considered to be in the mild or moderate stages based 
on a visit with a provider within the last six months, and were able to discuss their 





separately, with caregivers interviewed first, but caregivers were allowed to be present 
during the interview of the person living with MCI or ADRD on the condition that they 
remained quiet and if the person living with MCI or ADRD preferred having them 
present.  
 Interviewees were asked about the first signs of ADRD or MCI and the diagnosis 
experience, their knowledge of clinical research, how and if they received information 
about research opportunities, their perceptions of clinical research, their decisions to 
enroll or not enroll in studies, and their suggestions for improving ADRD clinical 
research enrollment. They were also asked to review a list of factors identified in Chapter 
4 and identify their level of agreement with those factors. This empowered people with 
ADRD and caregivers by asking about their experiences and invited a power-sharing 
context by perceiving them as experts.  
 Interviews were audio-recorded, and the investigator took field notes during and 
after each interview. Interviews were transcribed and de-identified using a transcription 
service (Rev.com), then uploaded to Atlas.ti 8.1 software for coding and thematic 
analysis (Scientific Software Development GmbH, Berlin, Germany, n.d.). The codebook 
emerged from the interviews, but codes were informed by the investigator’s a priori 
knowledge of the literature and various theories and framework, including the Culture of 
Health. Codes included sentences or sentence fragments that represented data and 
concepts (Miles, Huberman, and Saldana, 2020). The coding process began by coding 
broad themes then coding with details. For example, if an interviewee noted they were 





awareness.” Conversely, if an interviewee said they participated in research because they 
wanted to help others, it would be coded as “motivation, facilitator, altruism.” Much of 
the analysis was deductive, meaning the codes were analyzed with the notion that they 
would fit into a conceptual framework (Miles et al., 2020). An inductive approach was 
also used to code and analyze themes that did not correspond with existing literature and 
theories to identify themes that emerged from the data organically and mitigate the 
possibility of coding those themes based on current literature rather than the interviews 
(Lapadat, 2010). The investigator was the single coder, and the CAB interpreted findings 
by identifying what was most important, surprising, or missing from the themes and 
subthemes. All protocols were reviewed and approved by the Portland State University 
Institutional Review Board (IRB #184914).  
Study population 
 Thirty-three interviews with healthcare providers, researchers, advocates, people 
with MCI or ADRD, and caregivers were analyzed and included in this study. In Phase 1, 
nine healthcare providers, researchers, and advocates were interviewed. Interviewees 
were employed by or volunteered with several healthcare, research, or advocacy 
organizations of varying sizes and structures. In Phase 2, interviews were conducted with 
12 dyads of individuals living with MCI or ADRD and their caregivers (n=24). The 






Table 6.1 Characteristics of Interviewees 
Category of 
Interviewee 
Number Previous participation  




Researchers 4* n/a  75% 
Healthcare providers 4* n/a 75% 
Advocates 2 n/a 100% 
Caregivers 12  50% (n=6) 50% 
People with 
MCI/ADRD 




*One interviewee identified as both a researcher and a healthcare provider 
 Six of the people with ADRD had never participated in ADRD research, and five 
were currently participating in at least one study. One was in a clinical drug trial, and two 
were participating in separate observational home-based studies that involved 
unobtrusive technologies that identify real-time changes. One was in both a clinical drug 
trial and a community-based technology study. Lastly, one was a participant in a 
longitudinal cognitive testing cohort study. The one person with ADRD who was not 
currently participating in a study had previously been in clinical drug trials. Ten of the 12 
caregivers were spouses and two were adult children. Eight of the 12 people with ADRD 
were diagnosed with Alzheimer’s disease, two were diagnosed with MCI/Alzheimer’s, 
one was diagnosed with mixed dementia (vascular dementia and Alzheimer’s disease), 
and one was diagnosed with dementia with Lewy bodies. Table 6.2 summarizes the 






Table 6.2 Characteristics of Interviewees with ADRD and Caregivers  






Male Wife Yes Mixed 3 
Male Wife No Alzheimer’s 4 
Female Daughter No Alzheimer’s 5 
Male Wife No Alzheimer’s  5 
Female Son No Alzheimer’s 3 
Female Husband No Alzheimer’s 3 
Female Partner No Dementia with Lewy 
Body 
2 
Female Husband Yes MCI/Alzheimer’s 2 
Female Husband Yes MCI/Alzheimer’s 4 
Female Husband  Yes Alzheimer’s 1 
Male Wife Yes Alzheimer’s 4 
Male Wife Yes Alzheimer’s 3 
 
Recommendations and Discussion 
Based on the analysis of the quotes from these two phases of interviews, supplemented 
by the CAB’s review and complemented from the literature, six recommendations are 
made to improve local ADRD clinical research participation: 1) identify and promote 
local champions for ADRD clinical research participation; 2) promote policies and 
processes that incentivize cross-sector collaboration; 3) recognize caregivers as full 
participants; 4) include people with ADRD and caregivers in the research design process; 
5) offer alternative options to reduce participation burden; and 6) evaluate and improve 
relationships between providers/researchers and patients/participants. These six 
recommendations can be categorized according to the four action areas in the Culture of 






Table 6.3 Culture of Health Action Areas and Corresponding Recommendations 
Action Areas Recommendations 
1. Making Health a Shared 
Value 
1. Identify and promote local champions for ADRD 
clinical research participation 
2. Foster Cross-Sector 
Collaboration to Improve 
Well-Being 
2. Promote policies and processes that incentivize cross-
sector collaboration 
3. Create Healthier, More 
Equitable Communities 
3. Recognize caregivers as full participants in the research 
process 
4. Include people with ADRD and caregivers in the 
research design process 
4. Strengthening Integration 
of Health Services and 
Systems 
5. Offer alternative options in study design to reduce 
participation burden 
6. Evaluate and improve relationships between 
providers/researchers and patients/participants 
 The following sections are presented by the Culture of Health Action Framework 
action area and include quotes from the interviews and synthesis from the literature that 
integrate the findings and relate them to the recommendations.  
Culture of Health Action Framework Action Area 1: Making health a shared value 
 Individuals are more likely to participate when they receive information from a 
trusted source (Lavis et al., 2003). Although there may not be a direct therapeutic benefit, 
people with ADRD and caregivers can discuss the benefits they have received from 
ADRD research participation, including altruism, contributing to the knowledge base, 
and potentially helping future generations. Further, information from trusted researchers, 
clinicians, and community members who have participated in ADRD clinical research 
may increase motivation to participate (Lavis et al., 2003; Grill & Galvin, 2014). 
Recommendation #1: Identify and promote local champions for ADRD clinical 





during which time the visibility of high-profile champions for ADRD awareness and 
funding has increased. In support of his mother-in-law, actor Seth Rogan co-founded a 
nonprofit, Hilarity for Charity, and testified to Congress about the necessity of funding 
ADRD research, bringing awareness to younger generations and politicians alike 
(Alzheimer’s Disease Research, 2014; Hilarity for Charity, 2019). NCAA basketball 
coaching legend Pat Summitt founded the Pat Summitt Foundation before passing away 
from younger-onset ADRD in 2016. Her legacy spurred a new ADRD research clinic in 
Knoxville, TN, and annual awareness and fundraising events at college basketball games 
during “We Back Pat” week (The Associated Press, 2016; SEC Staff, 2019). 
Philanthropist Bill Gates, whose father has Alzheimer’s disease, had led missions to 
increase ADRD research through a 50 million dollar donation, convening working 
groups, writing blogs about the need for people to participate in ADRD clinical research, 
and creating his “Part the Cloud” initiative with the Alzheimer’s Association (Gates, 
2019). 
 These high-profile champions help demonstrate the prestige champions have in 
the community and the recognition they bring to an issue. Similar to how national 
champions can spur ADRD research funding, awareness, and participation, community 
members can champion these causes at the local level. This may include people with 







Advocate: “We need to hear about it more. I mean, if I don't know about it … If I 
had some pamphlets or if [researchers] want to come and I introduce you and 
say this is what you're doing, and if anybody wants to talk to you, meet you after 
... I think it needs to be more of a priority. But like I said, I've never had any 
information on it.”  
 
Caregiver: “In these smaller communities … doctors don't automatically do 
referrals for research, for evaluations … The doctor says, "Well, looks like you 
got dementia.” That's it … if researchers could advertise that this is something 
that'll make you feel good because you're making a difference … all of us want to 
be doing something I think.” 
Efforts to champion research participation could include community events or 
presentations where individuals with ADRD or caregivers describe their reasons for 
participating. Many interviewees noted that they participated for the ultimate benefit of 
others, rather than themselves, and they derived happiness from that. Researchers could 
partner with people with ADRD and caregivers who participate in research to share the 
message of what it is like to participate in research and discuss the benefits of being a 
research participant: 
Person with ADRD: “I didn't hesitate to get into clinical trials. What have I got 
to lose? And I like the feeling that even if it doesn't help me, it's contributing to 
knowledge. So for me, it's kind of giving back and hoping that maybe I'm getting 
some study drug; which I think I am.” 
 
Person with ADRD: “I always felt it was my duty to do it … Because if I was 
suffering, I knew others were as well. And I really felt like this was a fight worth 
going into.” 
 
Caregiver: “People ask, "What's in it for me?" Sometimes, the answer is, "Well, 
they will find a cure and fix you." I think for Alzheimer's, that's not going to 
happen … But, it could help our kids.” 
Conclusion: In order to make health, or (in this context of this study) ADRD research, a 
shared value, there needs to be a shift in mindsets and expectations, level of civic 





Chandra et al., 2016). Identifying and promoting local champions for ADRD research can 
influence these three drivers. Interviewees described how they need more awareness of 
local studies to share more information and resources. Interviewees also described the 
importance of having local champions, especially people with ADRD and caregivers who 
participate in research, describe to others why they decided to participate and encourage 
community members to do the same. 
Culture of Health Action Framework Action Area 2: Foster cross-sector 
collaboration to improve well-being  
 Core values of this action area of the Culture of Health Action Framework include 
the promotion of policies and investments that support collaboration, variety in the 
number, breadth, and quality of partnerships, and knowledge of what to expect from these 
partnerships (Towe et al., 2016). This action area encourages both internal and external 
changes at the local and state levels, such as removing a policy that forces a provider to 
use personal time for collaboration activities, as well as those that discourage 
conversations with patients about study opportunities, which may usher in partnerships 
with research organizations to learn about new opportunities for patients. The NIA’s R24 
funding opportunity, Examining Diversity, Recruitment and Retention in Aging Projects, 
is an example of a federal-level investment that intends to foster cross-sector 
collaboration to improve ADRD clinical research participation (NIH, 2018).  
 Collaborations may involve partnerships that focus on research design and event 
planning to reach shared and organizational missions. They could be less formal, where 





study opportunities or to share community resources with participants. This may include 
distributing study flyers or brochures to providers or giving presentations on healthy 
aging and dementia at community organizations. Investigators from research 
organizations can use this funding to establish cross-sector collaborations with local 
community organizations, including cultural centers or religious groups, following the 
example of the Satellite program at Washington University (Williams et al., 2011). 
Additionally, funding could be used to reimburse providers and researchers who must use 
their personal time when engaging in community-based collaboration.   
Recommendation #2: Promote policies and processes that incentivize cross-sector 
collaboration: In order to promote awareness and interest in study opportunities, 
collaborative efforts between organizations must take place across sectors within 
communities. In some organizations, efforts are blocked by policies forbidding 
discussions or interactions with patients about research opportunities: 
Healthcare provider: “Because of the population that we treat, [the Centers for 
Medicare and Medicaid Services] has it in our regulations that we are not 
allowed to enroll our participants in research … And it's really because we're a 
capitated plan … we control nearly everything about our participants. So, if we 
don't approve it, and we don't transport them to it, and we don't provide it, they 
don't get it.”3 
 
Healthcare provider: “I suppose we could say, ‘There are some research 
projects over at [research organization]. If you're interested you can contact this 
person or this phone number.’ But that's on the edge of what we're supposed to 
do.” 
                                               
3 Interviewee sees patients through the Program for All-Inclusive Care of the Elderly (PACE), a capitated 
comprehensive health and long-term service program for dual-eligible, frail, community-dwelling, older 





In other cases, providers may be unaware of opportunities, resulting in patients or 
caregivers conducting their own searches for research opportunities, or simply remaining 
unaware: 
Caregiver: “I had asked our primary care physician. She did not recommend 
any particular person to contact … Then we have a friend at church who was in 
a study at [research organization] … and he knew I wanted to get [wife] in, so 
he gave me the contact person at [research organization].”  
 
Person with ADRD: “It has never come up. [They] haven't asked me. You're the 
first one ... I don't know of any other research.”  
These interviews highlight that there are organizational policies hindering conversations 
about research, which results in a lack of sharing knowledge of research opportunities. 
Interviewees also spoke of policies that have resulted in the avoidance of cross-sector 
collaboration: 
Healthcare provider: “I honestly devoted hours and hours and hours to trying to 
develop processes and education. But, over time, it's been hard to remain 
enthusiastic because any time I spend working on things like that, comes out of 
my own personal time. And people don't seem to understand that I'm not funded to 
attend two to three hour-long meetings. And if I spend time in a meeting, then I 
have to make up for that time at the end of the day later.” 
 
Researcher: “It is a challenge, particularly for minority research, where the key 
element to successful research in minority communities is establishing a long 
standing relationship. In order to do that, it takes resources. You can't really go 
out and fund a grant to create those relationships. It's basically volunteer time in 
a way … to develop those relationships.” 
Policies can be put in place to promote cross-sector collaboration, such as funding to 
develop these relationships, and funding for providers, researches, or advocates to partner 
with other organizations. Some of these opportunities exist, such as the NIA’s R24 grant 
opportunity (NIH, 2018), so more work may need to be done to highlight these 





partnerships can be redesigned to ensure that goals are being met. For example, one 
researcher described an NIH policy designed to streamline research processes during 
multi-site collaboration by allowing one central IRB to approve study protocols for all of 
the sites. According to this researcher, the policy has not achieved its intended outcome: 
Researcher: “I think institutions tend to stay within their bounds of what they're 
used to doing. One area this has clearly shown its face is in the area of trying to 
enact a uniform, a single consent process, so I won't have 20 different IRBs 
reviewing the same consent but coming up with 20 different versions … It's been 
aspirational. It's still not happening. I still see just in recent experience with 
multi-center projects that we're supposed to use a central IRB or a single IRB. In 
practice, it still hasn't happened.” 
Many interviewees described how collaborations provide benefits to their organization 
and to their patients or participants: 
Researcher: PreSERVE [Coalition, comprised of researchers, African American 
community members, and other community organization representatives] tries to 
have a balance between asking people to participate in research, but not having it 
be like ‘We’re really just having this event because we need to have you 
participate in research.’ We really try to communicate why this research is 
important to the community, what is the giveback, how is this a sustained 
relationship instead of a one-time, ‘We get from you what we need.’” 
This researcher further described how one community organization provides benefits that 
are not research-related: 
Researcher: “[The Alzheimer’s Association] has tables at [our] events … they 
have these materials about … what are 10 signs of Alzheimer’s disease? What are 
some free online workshops that you can attend? Where are there caregiving 
classes or even just bringing the person you’re caring for even to the Alzheimer’s 
Association to the Portland branch and they can do art activities while you 
discuss with other caregivers? So all those types of things really feel like it’s for 
the community.” 






Healthcare provider: “When we have a patient come in, and they have dementia 
or depression, our team works very closely with community resources, [for 
example] finding them a clinical psychologist for counseling or finding an adult 
daycare program where somebody with early dementia, a family member needs to 
go to work but needs to have them be in a safe place during the day.” 
Other researchers described new collaborations and partnerships -- one to improve 
research awareness and education in the local community and another to facilitate back-
end processes to reduce time delays: 
Researcher: “the Oregon Alliance for Clinical Research, it's made up of a few 
different sites throughout Portland … [and] is aimed at educating the population 
[about] what clinical research is and how it can help some individuals, especially 
if there's no other avenue for them to take.” 
 
Researcher: “The Alzheimer's Clinical Trial Consortium, ACTC, they help 
clinical trials get started up a little bit faster … for example, having a master 
agreement between our institution and that sponsor so that we don't have to 
negotiate all of the parts of the contracts every single time.” 
Conclusion: Action Area 2 conceptualizes how partnerships and collaborations, and the 
policies that fund and support them, can predispose to equity and further inclusion of 
community members (Towe et al., 2016). Findings from these interviews demonstrate 
how collaborations can be used to promote equity and participation. They also highlight 
how a lack of communication or collaboration reduces knowledge of opportunities within 
the community. Finally, these findings highlight how organizational and government 
policies can be used to create and remove barriers.  
Culture of Health Action Framework Action Area 3: Creating healthier, more 
equitable communities 
 This action area articulates how policies and processes may not have the intended 





action area is applied to considerations of equitable communities through the built 
environment, social and economic development and policies (Dubowitz et al., 2016). In 
the context of this research, this action area is applied through a lens that equity may be 
better achieved through the inclusion of community members with lived experiences of 
living with or caring for someone with ADRD. Community members have the expertise 
that can only be developed from living in the community, which researchers, advocates, 
and clinicians may not share. Community members should be included to achieve desired 
results—in this case, improving ADRD clinical research recruitment. Collaboration and 
equity can be encouraged by recognizing caregivers as full participants, and by including 
both caregivers and people with ADRD in research design processes. This leads to 
empowerment and motivation to create more palatable options and ideas around research 
recruitment and participation. Further, removing power dynamics by including people 
with ADRD and caregivers in the design process and valuing the expertise of people with 
ADRD reduces inequities, which may lead to identifying problems and solutions that are 
needed to reduce inequities, remove barriers, and improve ADRD clinical research 
participation.  
Recommendation #3: Recognize caregivers as full participants: Although caregivers 
engage in different study activities from the person with ADRD, such as answering 
questionnaires, driving to appointments, or ensuring the person with ADRD is adhering 
to study protocols, their participation is absolutely essential to the study, as noted by 
some researchers: 
Researcher: “Sometimes the participant is really gung-ho and ready and wants 





we see that often enough, where it's the caregiver dropping the ball, just not 
following through, not getting back to us for scheduled appointments, and just lost 
through follow up, basically, which is really unfortunate.” 
When asked to provide recommendations to improve ADRD research participation, 
interviewees often focused on improving the caregiver’s motivation to participate in 
research through education or caregiver support:  
Healthcare provider: “If caregivers could get support … sometimes maybe 
there's a small stipend or agreement that people get from research participation. 
But sometimes it could be in terms of supporting caregivers. They might see this 
as a plus instead of just a monetary part of it.” 
 
Caregiver: “They probably know a caregiver's under a lot of pressure. So ease 
some of that pressure and you might help with participation … They could 
provide a caregiver compensation for a couple of hours. They could have an 
activity that we could drop the person off at another time. They could help deal 
with any issues you're dealing with your person in particular. That's not their 
role, but those are useful things.” 
 
Caregiver: “You know, [my survey responses] are all going into a big file in a 
computer, and you think, ‘Here I am pouring out my heart about how lonely I 
was’ … So, if I say I'm lonely, just lend me an ear, and give me wisdom about how 
to deal with this.” 
As such, researchers should recognize study partners as full participants who deserve 
compensation for their time and effort. Caregiver compensation should be provided in a 
manner that is most suitable to them as caregivers, including education, respite, or as-
needed support and advice. Researchers can include funding for caregiver support staff, 
such as care coordinators or social workers, within their grants, or simultaneously involve 
them in studies that focus on caregiver health and support. This specific strategy may 
prove problematic if research organizations do not have the capacity, or there is concern 
about the integrity of a clinical trial if the study partner is receiving their own 





information about local resources (support groups and training programs, respite care, 
care coordinators or social workers who are trained to provide resources). It may also be 
worth designing a randomized clinical trial to identify the effects of caregiver support 
when a person with ADRD in enrolled in a clinical trial. 
Recommendation #4: Include people with ADRD and caregivers in the research 
design process: In the Gilmore-Bykovskyi et al. (2019) systematic review on improving 
dementia research recruitment among disadvantaged populations, it was noted that none 
of the papers that described strategies to improve research participation included bringing 
community members into the design process, and recommended researchers begin doing 
so. In this particular study, interviewees had mixed feelings on incorporating community 
members with and without ADRD. Some interviewees noted that they do not include 
community members because they pose challenges, particularly in the context of a person 
with ADRD participating in the research process: 
Researcher: “Those are challenging because I think they sound good, but if you 
think about it, how can one person from a community represent the community? I 
mean, you take it as input, but I think that it's hard to get the voice of a community 
from a single community representative. 
 
Healthcare provider: “For the things I've done, we haven't included individuals 
with dementia … with dementia, people often lack insight, they often have enough 
memory impairment that they won't remember a previous conversation. So, you 
can't build on what you've done previously and it's just a much more limited 
interaction.” 
Others viewed community members as experts, highlighting that caregivers and people 
with ADRD are the only ones with the true expertise in living with or caring with 





Researcher: “If we have a meeting, I make sure that we don’t have 7 
[researchers] and 3 community members on the other side of the table … We are 
conscious about power imbalance … We always want to approach it as ‘we want 
to learn from you’ … we want to say, ‘look, you’re the experts, help us learn from 
you.’” 
 
Advocate: “We have people living with cognitive impairment and change … They 
are [on the board] because they're an expert. They know what it means to live 
with this disease every single day. They know what it means to care for someone's 
disease or to watch their husband change before their eyes. They know what it 
means. They're an expert and that's who policymakers want to hear from.” 
One pathway to include people with ADRD and caregivers in the research design process 
may be to start with websites that are designed for finding available research 
opportunities. Several interviewees noted that the study websites that they used to search 
for trials or join a registry were difficult to navigate: 
Caregiver: “One of the people at the [organization] said their website is a 
nightmare to navigate, so I doubt if I would have looked and found [the clinical 
trial] there.” 
 
Caregiver: “[The study search websites] are probably for medical professionals 
who are used to doing it all the time. I talked to the family doctor. I say, ‘How 
come you can find this stuff and I can't?’ She says, ‘Because I do it every day, and 
I know exactly how these people think when they set these websites up … You 
don't do it every day. You're not familiar with how it works.’" 
At least one caregiver had ideas to improve online study search functionality and ability: 
Caregiver: “[The organizations] send you an email and say …. ‘Go to this 
website, fill this thing out.’ … [Then] they look at the questionnaire and they say, 
‘Okay, now if this answer was yes, then they might be a candidate,’ or that type of 
thing. They could at least establish an initial contact … Because right now, 
searching through a whole bunch of websites looking for research, studies where 
the criteria might meet what she has … doing that is very time-consuming.”  
This example illustrates how people with ADRD and caregivers provide needed expertise 





affecting their ability to search for research studies and suggested a strategy to mitigate 
that barrier.   
 When asked about being on an advisory board where caregivers and people with 
ADRD collaborate with researchers and staff, most people with ADRD and caregivers 
described these boards as not important in their decision to participate in research. Some 
caregivers mentioned wanting to join an advisory board in the future but were unaware of 
current opportunities. A small number of people with ADRD said they would be 
interested in serving on an advisory board. One interviewee was a former neurologist 
diagnosed with Alzheimer’s, who speaks to medical students about treating individuals 
with dementia. This person is also part of a research advisory board for the Alzheimer’s 
Association, but was unable to join their advocacy board due to policies regarding 
caregivers: 
Person with ADRD: “The Alzheimer’s Association invited me to join an 
advocacy group; I said I’d be happy to do it but they required a partner because 
they didn’t want people to travel on their own … I don’t know how much longer 
I’ll be able to do that, but right now that’s not an issue. But that was something 
that was etched in stone … [so] they said how about a different division?”  
Notably, several people with ADRD felt that they would not be able to contribute: 
Person with ADRD: “My brain isn't doing very well. I don't think that's 
something that would help anybody with me getting confused. I don't need to help 
people when I can't [help] myself.” 
Organizations may benefit from recognizing the expertise that people with ADRD bring 
to the table. People with ADRD can be empowered through an organization’s inclusive 
decision-making processes, such as inviting them to join advisory boards if they are 





with ADRD felt their contributions would be unhelpful, so an invitation with an 
explanation of why they are being invited might serve as a way to empower them 
personally. In doing so, this may lead to a change in the social construction of people 
with ADRD by empowering them within their community as well as increasing equity by 
having their voices and expertise included in the research design process.  
 As noted in Chapter 3 and the methods section of this chapter, a CAB was 
established for this study. In addition to professional members, the CAB included people 
with ADRD, caregivers, and older African Americans. In addition to helping develop 
study materials and interpreting the results, they provided numerous insights, such as 
using the terms “Alzheimer’s disease” and “dementia” instead of “memory loss,” 
describing how compensation is helpful but researchers need to consider how it may 
affect their benefits, and articulating what learning styles were most helpful to them (e.g. 
visual versus auditory), which led to multiple ways that knowledge was disseminated 
before, during, and after the CAB meeting. Additionally, at every CAB meeting debrief, 
the members identified what was positive about the session and what could be adjusted to 
better suit their needs.  
 Further, when provided with a list of factors affecting ADRD clinical research 
participation, which was developed based on providers, researchers, and advocates input, 
every Phase 2 interviewee provided insights on what factors were important, which were 
not, and how the list could be improved. They demonstrated that individuals with ADRD 
and caregivers have the expertise to improve study design even in cases where they 





Conclusion: The conceptualization of Action Area 3 -- creating healthier, more equitable 
communities -- is generally applied through the lens of the built environment, social and 
economic conditions, and policies (Dubowitz et al., 2016). In the context of this study, 
the lens of equity is achieved through the inclusion of people with ADRD and caregivers 
in creating policies and processes for ADRD research. Findings from interviews 
recognize the necessity of caregiver participation in ADRD research but also highlight 
the sometimes negative position they may be placed in. Recognizing caregivers as full 
participants rather than study partners offers the ability for researchers to provide the 
caregivers with some of the benefits they need and could motivate caregivers to be 
involved in research. Including caregivers and people with ADRD in the research design 
process provides opportunities to remove barriers and strengthen resources that address 
the needs of their community while encouraging participation. It also empowers people 
with ADRD and their caregivers by recognizing and respecting their expertise, further 
reducing inequities.     
Culture of Health Action Framework Action Area 4: Strengthening and integration 
of health services and systems   
 The clinical research, advocacy, and health sectors have similar goals of 
improving the experiences of people with ADRD and their caregivers as well as 
discovering an ADRD prevention and treatment (NIH 2018; Alzheimer’s Association, 
2019). This action area is conceptualized as including access to care, balance and 
integration, and consumer experience (Martin et al., 2016). In the context of ADRD 





integration of research services, and participant experience. Individuals report being more 
open to clinical research participation if organizations are more accommodating by 
offering flexible scheduling, fewer in-person visits with more opportunities for video 
conferencing, and free or subsidized modes of transportation (Danner et al., 2011; Law et 
al., 2014; Friedman et al., 2015; Mahon et al., 2016). Study opportunity knowledge could 
also be fostered by modifying both large-scale and local online registries and clinical 
research websites, as noted in Recommendation 4. These sites and registries, including 
TrialMatch, ClinicalTrials.gov, and local research registries, offer information about or 
the option to be notified about study opportunities but are inaccessible to those who are 
scientific or Internet illiterate or with limited time to navigate the cumbersome sites. The 
relationship between organizational staff and a person with ADRD and their caregiver 
often contributes to the decision to participate in research.  
Recommendation #5: Offer alternative options to reduce participation burden: 
Interviewees noted multiple factors affecting their ability and motivation to participate in 
ADRD clinical research. Time spent driving, using the internet to search for study 
opportunities, and participating in study activities were frequently discussed: 
Researcher: “So the sponsor sends somebody to do [quality assurance testing] on 
one specific machine, so we can't even just send them to one facility, it has to 
literally be one specific machine that was [tested] by them, so that they're 
scanned under the same protocol each time on the same machine, really just 
anything to reduce variability. That would help if we could send people to other 
places.”  
 
Caregiver: “We drive out [across town] for an optometry appointment, and have 
to drive back, and it's just like that was what really put her off to it. And me, too ... 
I mean, they had one place for CT and one place for MRI … [and then a third 






Caregiver: “There are a lot of opportunities for us to do things that enrich what 
are still good years. If it was going to be some intervention that would interfere 
with that or gobble up a lot of our time, that would be a substantial negative.” 
Research organizations’ strategies may benefit from modifications to reflect community 
needs. Based on the interviews, this could include presentations at ADRD and caregiver 
support groups, making materials reflective and culturally responsive to the community 
that researchers wish to work with, and providing additional incentives for caregivers. 
This also applies to industry sponsors that may be receiving suggestions from 
coordinators or community members about the best recruitment strategies but continue to 
adhere to their original processes. Willingness to accommodate their schedules and 
needs, such as requiring fewer in-person visits, reducing or removing the time spent or 
distance traveled, or providing resources or supports specific to the caregiver, may help 
in increasing their ability and motivation to participate in ADRD research. For example, 
including more secondary sites for specialty testing (e.g. optometry or CT scans), or 
working with home health agencies to reduce the number of clinic visits, could address 
travel-related burdens and may increase participation.  
Recommendation #6: Evaluate and improve relationships between providers/ 
researchers and patients/participants: In Phase 1, several interviewees described the 
fear that some providers have when encountering a person with signs of dementia: 
Healthcare provider: “I think on the provider's side … it's just uncertainty and 
feeling like there's nothing for them to do. So why make the diagnosis? Because 
they could be wrong. When in fact, there are things to do. Get your affairs in 






This sentiment was echoed by several of the Phase 2 interviewees, who noted negative 
interactions with their provider. Less obvious dementia symptoms, such as trouble 
concentrating at work, were noticed more often by the person with ADRD who felt their 
symptoms were minimized or dismissed by providers, despite continued concerns, 
resulting in a delay in the diagnosis. Several interviewees noted interactions that led to 
uncertain diagnoses or diagnoses received in an unprofessional manner: 
Person with ADRD: “I knew that there were some issues. And so I went to my 
family care physician and I said, ‘You know, I just can't remember things like I 
used to.’ And he just discounted it … So then I went and spent another few years 
after that and it just kept continuing to get worse.”  
 
Person with ADRD: “At first [the neurologist] was sort of dismissive, "Oh, I'm 
sure you're just being neurotic," kind of message … [After testing], he comes 
back, he throws down the papers on the table and he said, "You're right! You do 
have a problem!" … I just kind of sat there in stunned silence. I just thought, 
"Wow. Do you let all of your patients know the results that way?" 
Some noted that relationships with their research staff were different from their 
experiences with their providers, and had positive things to say about the staff:  
Caregiver: “The staff, research assistants, are just fantastic. They really do 
everything they can to make it easy for you.” 
 
Person with ADRD: “I can't think of anything that [research staff] can do better 
… It's just superb. It's better than even dreamed of. And they make you feel 
worthwhile … They look at me, they listen, they reflect back, they communicate 
beautifully.”  
Others noted that the relationship between their provider or research staff affected their 
decision to keep seeing them:  
Caregiver: “If [research staff] treated him or us more as a number instead of a 
person, that would definitely be a factor [in participating]. But we haven't seen 
that … these days, you go in for [a doctor’s] appointment and you feel like a 





Conversely, others were apprehensive because of previous bad experiences: 
Person with ADRD: “If you don't care anymore about your patient than [having 
the secretary call to give the diagnosis], he needs to be doing something else … 
He was so lackadaisical, like, ‘Geez, I've done this test for so many times’… I 
don’t know if I should [go see another neurologist]. I’m scared to go to one 
now.” 
These quotes exemplify how important the experience and interaction between staff and 
patient/participant is in the decision to participate in research or seek treatment. These 
interviewees had positive experiences with research staff, but that cannot be generalized 
for all ADRD research participants. 
Conclusion: In the context of ADRD research, this study conceptualizes Action Area 4 
through access to research, balance and integration of research services, and participant 
experience.  Developing alternative options to reduce participant burden provides greater 
access and integration of research services, and improves the experience and quality of 
participating in ADRD research. Similarly, the relationship between a provider or 
researchers and their patient or participant substantially influences their experience. 
Findings that do not align with the Culture of Health Action Framework 
 Two findings did not align with the Culture of Health Action Framework. The 
first involves the number of people who will not participate in research due to their 
concerns about taking study drugs. Ten of the 24 Phase 2 interviewees noted that they 
would not participate in a study that required them to take study drugs. In some cases, 
learning from local ADRD research champions, particularly those who have participated 
in drug trials, may inform people with ADRD and caregivers of the purpose, benefit, and 





a new medication that negatively impacted their health and did not want to repeat that 
experience, especially if the drug was not proven to treat their dementia. In these cases, 
the Culture of Health Action Framework would not be helpful for increasing their 
likelihood of participating in an ADRD drug intervention. However, the framework could 
still be used to improve their motivation and ability to participate in alternative types of 
ADRD research opportunities that do not require taking an investigational drug.  
 The second finding concerns the number of people who are ineligible or forced to 
withdraw from a study. Three of the 12 people with ADRD interviewed noted that they 
had been ineligible for, or withdrawn from, studies for three reasons: age, 
neuropsychological testing scores, and/or for scoring too high on screening tests after 
receiving an intervention. Additionally, one caregiver noted that she was ineligible to 
participate in an ADRD prevention study for herself because she did not have a study 
partner, despite having normal cognitive function. Of these four reasons, age is the only 
ineligibility factor that has been addressed due to a policy that promotes equity in ADRD 
research by removing arbitrary age exclusion criteria (NIH, 2017a). The other three 
exclusionary reasons are necessary to ensure study validity, intervention efficacy, and the 
overall safety and wellbeing of the participants. Because of their necessity, they are not 
likely to be adjusted or modified. 
 Despite these two findings not having a good fit with the Culture of Health Action 
Framework, the majority of the findings do fit within the framework. Thus, this 
framework remains a useful tool for conceptualizing factors and organizing 






Synthesis and Conclusion 
The goal of finding a treatment or prevention for ADRD by 2025 is contingent on having 
enough people with ADRD and study partners who are able and willing to participate in 
clinical research. For Oregonians with ADRD and their caregivers, there are many policy, 
system, organizational, and personal barriers potentially standing in the way of capability 
and motivation to participate in ADRD clinical research. However, the recommendations 
presented here may mitigate these barriers. The Culture of Health Action Framework was 
used to frame this research; these six recommendations were derived from the expertise 
of the interviewees and were then applied to this framework. They can serve as a map to 
build capacity and partnerships, recognize and mitigate barriers caused by structural 
racism, help research organizations conduct more outreach to motivate community 
members and increase ADRD clinical research enrollment. 
 There are several limitations to this project. First, the sample size is small (n=33) 
and not fully representative of one metropolitan area. However, saturation was reached 
through these interviews. These findings are specific to the Portland, OR metropolitan 
area. They may be contextually relevant for similar communities, but are not necessarily 
generalizable nor are they intended to be, in the quantitative sense. Rather, these findings 
can be transferable to other researchers, clinicians, or advocates in other metropolitans 
areas if they believe these findings may be applicable to their setting and specific context 





 Second, there is sampling bias in this study. Though Phase 1 interviews were 
designed to be organizationally representative, all but one of the healthcare providers 
were geriatricians and there were no providers who specifically focused on primary care. 
This is because the investigator relied upon referrals from key informants and community 
advisory boards, and nearly all provider referrals were for geriatricians. Further, one of 
the three local ADRD research organizations did not respond to requests for interviews. 
The study also did not include interviews with local county government employees 
despite the fact that county governments in the Portland metropolitan area provide 
services for people with ADRD and caregivers. This is because the investigator was not 
referred to county employees for Phase 1 interviews by either the CAB members or other 
key informants. These county agencies were discussed by advocates, but not by providers 
and researchers, so it is possible that the services provided by the counties are unknown 
to local health and research organizations. In Phase 2, all but one interviewee was white, 
despite efforts to recruit African Americans. Factors that specifically affect African 
Americans were not captured in this study. It is likely that a more robust discussion of 
built environments and shared values, specifically around local ADRD research studies 
that target African Americans, would have emerged from the findings if there had not 
been this bias. This sampling bias is discussed in detail in Chapter 7.  
 Confirmation and response biases also exist in this study. Interviewees may have 
censored themselves due to the audio-recording of interviews and may have focused on 
what they perceived the interviewer wanted to hear, resulting in response bias. 





upon the conceptual framework and the literature. The investigator mitigated some of this 
bias by writing field notes immediately after each interview, a conscious effort to self-
assess when analyzing codes and themes, and CAB member-checking and interpretation 
of analyses. Furthermore, while there are no conscious biases due to the researcher’s 
identity, it is important to acknowledge that subconscious biases are possible due to her 
identity as a female academic who is a proponent of ADRD research and community 
inclusion and may have affected the rapport with interviewees. The consequences of 
these biases are discussed further in Chapter 7. 
 This study contributes to the literature by providing recommendations to improve 
dementia clinical research recruitment and by providing a deep and rich understanding of 
the experiences of people with ADRD, caregivers, clinicians, researchers, and advocates. 
Additionally, these recommendations derive from the voices of interviewees and are 
organized using the Culture of Health Action Framework, applying the framework in a 
unique manner. Further, the study successfully demonstrated that including people with 
dementia and caregivers on an advisory board can be valuable, and improved the study 
design and interpretation of findings. Through this study, the potential exists to increase 
research participation at the local level to the point that it increases the national rate of 
recruitment, and ultimately helps to achieve the US Congress’s goal of finding a 
prevention or treatment for ADRD by 2025. This study should be repeated in a larger 
context or as pilots in other communities to determine contextual relevance and 
generalizability for other areas. Further, strategies implemented as a result of the 





feasibility and effectiveness. Future research related to ADRD should consider the larger 
context – these recommendations are not only about finding a way to increase 
participation in ADRD clinical research studies, but more importantly about the larger 





CHAPTER 7: CONCLUSION 
 
 This final chapter offers a detailed description of the conclusions of this 
dissertation. It is organized as follows: 
a) Restatement of the study’s purpose and a summary of the findings; 
b) Assumptions and limitations; 
c) Plans for dissemination of the findings; 
d) Implications for future research; and 
e) Conclusion.   
 
Overview of the Study Purpose and Summary of Findings 
The purpose of this study was to identify organizational, system, and policy factors 
affecting ADRD clinical research participation in the Portland, Oregon metropolitan area. 
This research question was addressed through three aims.  
 Aim 1: Identify organizational, system, and policy factors that impede or enhance 
clinical research enrollment among people with ADRD.   
Aim 1 was addressed through nine semi-structured interviews with local 
clinicians, researchers, and advocates who were identified through referrals from key 
informants and a Community Advisory Board. Organizational, system, and policy factors 
affected ADRD clinical research participation in the local community. Federal policy 
attempts to streamline ADRD research studies have not resulted in the intended outcomes 





opportunities. In some cases, this was due to a lack of provider knowledge of ongoing 
clinical research. In others, it was due to organizational directives preventing providers 
from discussing research opportunities. At times, providers preferred not to refer patients 
to research opportunities. Research opportunities were not shared in places where people 
with ADRD and their caregivers are likely to congregate, such as support groups. 
Interviewees, many of whom participated in professional partnerships, were often 
hesitant to join community collaborations or formal partnerships. This reduced the 
likelihood of building a relationship and shared resources with people with ADRD and 
caregivers.  
Many interviewees, mostly clinicians and some researchers, were wary of 
including community members, with or without ADRD, on their advisory boards. 
Reasons ranged from not receiving true representation from the community to people 
with ADRD negatively affecting the progress of the advisory board. Advocates and other 
researchers spoke positively of including people with ADRD and caregivers, noting that 
they were the only true experts because they had the lived experiences.  
Aim 2: Describe personal factors that persuade or dissuade individuals with ADRD 
from enrolling in clinical research.  
 Personal factors affecting ADRD clinical research participation in the Portland, 
Oregon metropolitan area were identified through interviews with twelve people with 
MCI or ADRD and their caregivers (n=24). Interviews explored factors affecting the 
interviewees’ ability and motivation to participate in research. Half of those interviewed 





clinician diagnosis. Several interviewees noted their provider initially dismissed their 
symptoms of ADRD, with two citing unprofessional behavior. There was a lack of 
knowledge about research opportunities in the local Portland area. Many interviewees 
were unaware of dementia studies, which was surprising as many were recruited from 
organizations with rich knowledge of research opportunities.  
 One’s perceived value of ADRD research did not increase their likelihood of 
joining a study. Many caregivers either did not have or did not want to use their limited 
free time to be a study partner; however, several caregivers noted that they would take the 
time to participate if the study provided some sort of caregiver benefit to ease their 
burden. Benefits might include listening to the caregiver’s challenges, providing or 
referring to individual therapy or support groups, caregiver education, or respite services. 
Ten of 24 Phase 2 interviewees noted that they would not participate in a study that 
required them to take an investigational drug, but all expressed willingness to participate 
in other types of ADRD studies.   
Aim 3: Develop motivational strategies and policy recommendations based on the 
findings from Aims 1 and 2.  
 The discussion of Aim 3 presented recommendations for local clinicians, 
researchers, and advocates to facilitate ADRD clinical research participation. Six 
strategies emerged from the qualitative interviews, CAB discussions, and an extensive 
review of the literature: 1) identify and promote local champions for ADRD clinical 
research participation; 2) promote policies and processes that incentivize cross-sector 





ADRD and caregivers in the research design process; 5) offer alternative options to 
reduce participation burden; 6) evaluate and improve relationships between healthcare/ 
research staff and patients/participants.  
 The Culture of Health was adapted and applied as a guiding framework to help 
conceptualize factors affecting ADRD clinical research participation and to organize the 
strategies within the framework’s four action areas. Using the Culture of Health Action 
Framework, the six recommendations can serve as a map to build capacity and 
partnerships, recognize and mitigate barriers caused by structural racism, help research 
organizations conduct more outreach to motivate community members and increase 
ADRD clinical research enrollment.  
 
Assumptions and Limitations 
As with any research, there are some assumptions and limitations that influence the 
interpretation of the findings and conclusions of this dissertation study.  
Assumptions 
 Three assumptions were made. First, the investigator correctly assumed that 
clinicians, researchers, advocates, and dyads of people with ADRD and their caregivers 
were willing to participate in semi-structured interviews. Second, there was an 
assumption that the investigator would be able to successfully recruit African Americans 
for Phase 2 of the study given her connections with organizations that work with older 
African Americans in the Portland area. The investigator was not successful; this is 





have the capacity and motivation to join a CAB. This assumption was accurate. Lastly, 
there was an assumption that the CAB would confirm the investigator’s findings. This 
also was accurate.  
Limitations 
 There are several limitations to this dissertation research, including a lack of 
African American representation, and issues of generalizability, sampling bias, response 
bias, and confirmation bias. 
Lack of African American representation: This study’s recruitment goal of 50% 
African Americans for the Phase 2 interviews was unmet; no African Americans were 
interviewed for Phase 2. Recruitment was attempted through CAB referrals to four 
African American community organizations, two OHSU African American cohort 
studies, a PreSERVE member with several friends who care for a friend or family 
member with ADRD, and by sharing flyers and attending three community events that 
catered to older African Americans. Of the four African American community 
organizations suggested by the CAB, three of the contacts did not respond and one ceased 
communication. Of the respondents from the two OHSU studies, none of the individuals 
had a clinical diagnosis of MCI/ADRD. Of the five participants that responded to an 
email from the study investigator, none were caregivers. The investigator brought flyers 
and interacted with attendees at community events. Two attendees reported being 
interested but did not respond to follow-up. Limitations due to lack of African American 
Phase 2 interviewees as well as steps to recruit and interview African Americans for 





Additional limitations: In addition to the lack of African American representation, other 
limitations must be acknowledged in interpreting study findings. This includes 
generalizability, sampling bias, response bias, and confirmation bias. 
Generalizability: This was a small pilot study in one midsized city based upon 33 
interviews, but saturation was reached in both phases of interviews. These findings are 
specific to the Portland, OR metropolitan area but may be contextually relevant for 
similar communities. They are not necessarily generalizable nor are they intended to be in 
the quantitative sense. Rather, these findings can be transferable to other researchers, 
clinicians, or advocates in other metropolitan areas if they believe these findings may be 
applicable to their setting and specific context (Smith, 2017).  
Sampling bias: Although saturation was reached, 33 interviewees are not representative 
of all of the ADRD clinicians, researchers, advocates, people with ADRD or caregivers in 
the Portland, OR area, resulting in possible sampling bias (Kovera, 2010). Phase 1 sought 
to include representation of numerous organizations by including interviewees from 
organizations of varying sizes and structures. Nine representatives from six organizations 
of varying sizes and structures were included, but the study did not include 
representatives from two local healthcare systems, independent health clinics, and one of 
the three ADRD research organizations. Had these representatives been included, it is 
possible that there would have been more discussion of different funding sources, 
community collaborations, and interactions with people with ADRD and caregivers. 
Three of the clinicians identified as geriatricians and one identified as a neurologist. Not 





provider to see a person complaining of dementia symptoms, as compared to a 
neurologist or geriatrician who has received a referral.    
 Additionally, this study did not include representatives from local county 
government offices on health and aging, who provide social services and supports for 
people with dementia and caregivers in the Portland metropolitan area. This was because 
they were not recommended by professional contacts nor by the CAB as a Phase 1 
interviewee but rather suggested as a recruiting source for Phase 2 interviews. These 
additional perspectives may have provided insights into the value of social gatherings and 
fostering a community among people with ADRD and caregivers. Representatives from 
pharmaceutical or other industry groups were not included because they do not directly 
interact with people with ADRD or caregivers. Given the leverage they have over 
research study design, their insights could provide a better understanding of their 
organizational roles and structures, funding, and decision-making processes.  
 Sampling bias is also likely in Phase 2 interviews. Phase 2 interviews included 
just 24 people with dementia and caregivers in a state with over 67,000 people diagnosed 
with Alzheimer’s disease and an estimated 200,000 caregivers (Alzheimer’s Association, 
2019a). Interviewees who had not participated in ADRD clinical research were involved 
in some type of group activity related to ADRD or caregiving, resulting in a lack of 
inclusion of people who are less connected to ADRD supports and services. This may 
have omitted insights on factors affecting their decisions regarding engaging in research 
or group supports. Working with a 100% non-African American sample versus 50% non-





interviewees, and by the CAB were not identified. African American interviewees might 
have discussed how egregious acts conducted by researchers, Oregon’s history of 
mistreating African Americans, current gentrification, and lack of formal health service 
access and utilization negatively impacts their decision to participate in ADRD clinical 
research (Hannah-Jones, 2011; Parks, 2012; Multnomah County Health Department, 
2014; Geiling, 2015; Bonds & Lyons, 2017). It also left out a robust discussion from 
African Americans who do participate in ADRD research about why they choose to join a 
study. These findings would have been useful for identifying culturally competent and 
community engagement practices to increase ADRD research participation. 
Response bias: The researcher identifies as an academic, is employed at a large research 
organization and is a proponent of research, all of which could have affected power 
dynamics between the researcher and interviewees. It could also have led to response 
bias, where interviewees may answer questions in a way that seems more agreeable 
(Kovera, 2010). For example, individuals who have negative perspectives of academics 
and research may have felt they needed to speak positively about research in order to 
please the investigator. Additionally, it is possible that stronger connections could have 
been made with interviewees whose views align with the researcher’s, which could have 
led to more sharing of details about interviewees’ perspectives, as compared to those who 
are not proponents of dementia research. Possible response bias may have led to a lack of 
robust discussion on more negative perspectives of research or relationships with 





Confirmation bias: Per Portland State University and Health System & Policy Ph.D. 
program requirements, only one researcher coded and analyzed the data. The investigator 
used the Culture of Health Action Framework as a conceptual framework and drew on 
the literature and various theories for coding and analysis. This increases the risk of 
confirmation bias, or the predisposition to value evidence that confirms preconceived 
notions and dismiss evidence to the contrary (Karson & Goodwin, 2010). It is possible 
that the investigator ignored data that did not fit with the framework or literature, and 
missed important findings. To mitigate these risks, the researcher took field notes after 
each interview to capture various emerging themes and findings, particularly those that 
were surprising and not found in the literature. Additionally, the researcher worked with 
the CAB to member-check and interpret the findings by identifying and describing what 
was interesting, surprising and/or missing.  
 Despite these limitations, the qualitative design elucidated contextual factors 
affecting ADRD clinical research participation in Portland, OR that have not been 
described elsewhere, and could not have been gleaned from quantitative analyses alone.  
 
Dissemination of the Research 
Originally, the researcher planned to host a community event so people with dementia, 
caregivers, and other interested community members could learn about findings and 
recommendations from this study. The CAB noted that caregivers and people with 
ADRD are unlikely to attend an event that was specifically held to describe the findings, 





multitude of ways to serve varying populations. The first is to join presentations that 
discuss healthy aging and dementia, such as those hosted by health clinics, advocacy 
groups, community organizations, or the local government. The second strategy is to 
speak at professional conferences that are designed for local caregivers, such as the 
McGinty Caregiver Conference. The third is to speak at professional conferences that are 
designed for local dementia professionals, such as the Oregon Gerontological 
Association. The fourth is to staff information booths at community events specific and 
non-specific to dementia, ranging from neighborhood festivals to the annual Alzheimer’s 
Walk. These recommendations are in addition to making presentations at academic 
conferences and submitting manuscripts to relevant journals. 
 
Implications for Future Research 
Findings from this dissertation suggest several topics for further research. First, this study 
could be expanded to include more interviewees in the Portland metropolitan area. 
Recruitment could be conducted through research organizations, advocacy groups, 
clinics, county offices, support groups, and memory cafes. Single or dyadic interviews 
may be resource-prohibitive due to the time and money required to conduct and analyze 
interviews with dozens of individuals. In these cases, focus groups or surveys could be 
used to build upon the findings identified in this dissertation. Strategies developed 
through this study, such as establishing local champions to promote ADRD clinical 
research participation, should be implemented, routinely evaluated and modified to fit 





 Second, pilot studies could be conducted in other communities to identify how 
contextual factors affect dementia research participation. Identifying how organizational, 
system and policy factors affect the ability and motivation of a person with dementia to 
participate in local dementia clinical research opportunities cannot be generalized to a 
larger study in a different geographic area. Larger studies can be developed after pilot 
studies, and as noted previously, strategies developed through this study should be 
implemented, routinely evaluated and modified to fit community needs and increase 
research participation. 
 Third, this study should be expanded to involve communities of color. This 
requires extensive preparation through coalition building with community leaders and the 
development of a trusting relationship with the community. As previously mentioned, 
this study attempted to focus on African Americans because of their increased likelihood 
of developing ADRD but the investigator did not successfully recruit interviewees. Based 
on suggestions from the CAB and the literature, three recruitment strategies should be 
used in a future study to include African Americans in this research. First, efforts should 
be made to reach out and work with African American churches in the local area. Many 
older African Americans attend church services, and many churches have health 
ministries that can work to promote health and reduce disparities among their 
parishioners (Levin, 1984; Holt et al., 2018). Another strategy would be to work with 
local community health clinics, such as North by Northeast, a community health clinic in 
Portland that focuses on African American health, to recruit for future studies. A third 





websites that promote African American medical professionals in Portland. A fourth 
strategy would be to contact and work with Portland’s Black-owned businesses to hang 
flyers, meeting customers, and encourage word-of-mouth referrals.  
 Other communities of color, including older Latinx, Asian Americans, and Native 
Americans, are also more likely to develop ADRD as compared to non-Hispanic white 
adults. Therefore, the specific inclusion of communities of color should be part of future 
studies. In addition to coalition building and development of a trusting relationship, this 
will require funding resources for bilingual, culturally competent staff and translation of 
materials. Strategies for recruitment from communities of color, described above, should 
be modified and applied for these other communities. 
 Fourth, studies should be conducted to determine if involving caregivers as full 
participants and providing them with caregiver supports increases recruitment and 
retention. An advisory board of current and former caregivers can identify the best 
options for what they need from the research team. Researchers may be hesitant to offer 
caregiver supports because it is difficult to ascertain if improvements are due to the study 
intervention for the person with dementia or because of the caregiver support. It could be 
beneficial to develop a randomized clinical trial where some study partners receive 
caregiver supports and others do not, and thus test if these supportive interventions 
improve retention.  
 Fifth, studies can be conducted to evaluate the success of various research 
websites and registries in recruiting new participants into studies, as well as how they can 





organization websites (e.g. a research university), through federal websites (e.g. Clinical 
Trials.gov), and local and global dementia-specific websites and registries (e.g. 
ACTNOW, Brain Health Registry, TrialMatch, Alzheimer’s Prevention Initiative). 
Evaluations can include how to define “success” (e.g. website search clicks or registry 
signups, initial contacts, screening visits, enrollments), which type of website design is 
most successful, and how to improve design and functionality of websites.  Advisory 
boards of people with ADRD, caregivers, and community members, focus groups, and/or 
surveys can be utilized to identify website strengths and weaknesses and develop 
solutions.  
There are theoretical implications of this research study. The Culture of Health 
Action Framework was applied in a novel way for ADRD clinical research. This 
framework served as a map to build capacity and partnerships, recognize and mitigate 
barriers caused by structural racism, help research organizations conduct more outreach 
to motivate community members and increase ADRD clinical research enrollment. 
Elements of transaction cost theory, civic engagement, and contingency theory can be 
used by research organizations to increase the ability and motivation of people with 
ADRD and caregivers to participate in research. Transaction cost theory describes the 
cost of participating in a study. Civic engagement describes how ability and motivation 
affect the decision to participate in a study. Contingency theory describes how, and to 
what extent, organizations can address the needs of people with ADRD and caregivers.     
 There are a number of research implications that can be directed to specific 





partner with clinics and community organizations to briefly present research 
opportunities and share flyers, particularly those that do not require study drugs. 
Researchers can also develop studies that evaluate their recruitment strategies and 
identify which are effective and which can be improved. They can also create advisory 
boards with people with ADRD and caregivers to improve recruitment and study design 
processes. Federal agencies could earmark some of the 2.8 billion dollars designated for 
dementia research to fund studies that focus on recruitment and retention. In recent years, 
the NIH and the Patient-Centered Outcomes Research Institute (PCORI) have created 
formative efforts to increase community outreach and collaboration to improve clinical 
research design, recruitment, and outcomes (PCORI, 2013; NIH, 2018). PCORI recently 
funded a two-year award to LiveWell, a dementia service provider in Connecticut 
(PCORI, 2019), to increase the capacity of people living with dementia and their 
caregivers and reduce barriers to their engagement in patient-centered research 
(LiveWell, 2018). There are many advocacy groups that advocate for this type of 
collaboration, such as the Alzheimer’s Association, Us Against Alzheimer’s, and the 
Dementias and Neurodegenerative Diseases Research Network (DeNDRoN) in England. 
ADRD research organizations have not encouraged this type of collaboration to the 
extent that advocacy groups have done, possibly due to reasons articulated in Phase 1 
interviews and described in Chapters 4 and 6.  
Advocates, healthcare providers, and policymakers can also facilitate ADRD 
clinical research recruitment. Advocates can share research opportunities with 





Healthcare providers should view research studies as another resource and include 
materials in referral or resource packets for patients, or share flyers and brochures from 
outside of their clinics in their waiting rooms. In addition to earmarking designated funds 
for recruitment studies, policy-makers can remove policies that forbid discussions of 
research and promote marketing campaigns that publicize dementia diagnoses and 
research participation.  
 
Conclusion 
The US Congress’s deadline to find a prevention or treatment for ADRD by 2025 is only 
a few years away. In addition to the billions of dollars that Congress has earmarked for 
dementia research, the NIA released a report highlighting strategies to increase ADRD 
clinical research participation (NIA, 2018). This study addressed their fourth strategy, 
developing a science of recruitment, through a first step of identifying factors affecting 
clinical research participation within the local Portland, OR metropolitan area. 
Subsequent steps for researchers and policy analysts include developing and 
implementing policies to improve research recruitment and retention, evaluating and 
modifying policies as needed to fit the needs of the community, and achieving the 
overarching goal of increasing research participation.   
 This study contributed to the literature by providing contextually relevant factors 
affecting clinical research participation as well as providing recommendations to improve 
recruitment. Further, this study successfully demonstrated that including people with 





improves the study design and interpretation of findings. Through the findings and 
conclusions of this study, the potential exists to increase research participation at the local 
level to the point that it increases the national rate of recruitment, and ultimately helps to 
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APPENDIX A: CAB WELCOME AND EXPECTATIONS 
 
Welcome to the First Community Advisory Board Meeting! 
 
Why does this Community Advisory Board exist? 
The purpose of this community advisory board (CAB) is to engage with me (Nicole) 
onPh.D. PhD research. I want to identify factors that affect a person diagnosed with 
memory loss’s decision to participate in clinical research and develop recommendations 
to make it easier for them to participate. 
 
I will do this in 4 steps. First, I will interview clinicians, researchers, and advocates of 
people diagnosed with memory loss. Second, I will interview people diagnosed with 
memory loss and their caregivers. Third, I will develop recommendations and send them 
to research organizations, health clinics, and advocacy groups to improve dementia 
clinical research participation rates based on the interview findings. Lastly, I will share 
the findings from this study with local community members. 
 
Why Are You Here? 
I come from a vein of science called community-engaged research, which believes that 
people who are impacted by something (in this case, a memory loss disorder such as 
Alzheimer’s disease) should be at the table when researching a topic that impacts them- 
not just as interviewees or subjects, but as stakeholders. Further, you have lived 
experience of living with memory loss or have cared for someone diagnosed with 
memory loss, which others do not have. You are here because you are the experts! 
 
Community-engaged research also focuses on including people whose voices have not 
been traditionally represented in research are not heard. For this research project, this 
includes people with memory loss and caregivers, and in particular older African 
Americans. Older African Americans are more likely to be diagnosed with memory loss 
and serve as caregivers, but are less likely to participate in clinical research. Furthermore, 
their voices are not frequently included so it’s important their expertise is sought out and 
included in the CAB and from the interviewees.  
  
Given the nature of a dissertation (where I prove that I can conduct research 
independently and in a timely manner), I have to take the lead in decision-making.  
However, collaboration and the principles of community-engaged research are incredibly 
important to me and influences how I plan to do research now and in the future. This 
means that I will be responsible for creating the agenda, facilitating the conversation and 






What Do I Bring to the Table? 
1. Skills to facilitate the conversation among CAB members 
2. Knowledge based on literature on memory loss and clinical research 
3. Drafts of recruitment materials and interview questions  
4. Findings from interviews 
5. Ideas to share findings from this research with community members (people 
diagnosed with memory loss, caregivers, older African Americans, etc.) 
 
What Do You Bring to the Table? 
1. Skills to think of and discuss great ideas 
2. Knowledge based on expertise in living with or caring for someone diagnosed 
with memory loss 
3. Ideas to improve recruitment materials and interview questions 
4. Identifying what’s most important from the findings based on your expertise 
5. Ideas to share findings from this research with community members (people 
diagnosed with memory loss, caregivers, older African Americans, etc.) 






The Big Picture: Why Does This Research and the CAB Matter? 
 
Source: Alzheimer’s Association, 2018 
 
Memory loss disorders such as Alzheimer’s disease and other dementias takes a social, 
financial, and medical toll on the person diagnosed, their friends and family, and their 
communities. There is no prevention, treatment, or cure, and number of people diagnosed 
and impacted by these disorders is growing fast.  
 65,000 Oregonians are diagnosed with Alzheimer’s disease. This number is 
expected to increase 30% to 84,000 by 20254. This doesn’t include people with 
other forms of dementia. 
 
Finding a preventive strategy, treatment, or cure matters to the more than 65,000 
Oregonians diagnosed with memory loss, their friends and family members, and their 
communities. In order to find an intervention, we need people with memory loss to 
participate in clinical research. However, the rates of people with memory loss 
participating are low, so we need to find out ways to improve those rates. 
 
In order to determine why people diagnosed with memory loss do or don’t participate in 
research, and to recommend ways to a) be motivated to participate and b) make it easier 
for participate, researchers need to incorporate your voices because you are the experts on 
this topic.  
 
Furthermore, including your voices in the research design process ensures that the 
research is designed in a way that will be most impactful to people diagnosed with 
                                               






memory loss, their friends and family members, and their local communities within the 
Portland metro area.  
 
Membership Responsibilities:  
1. Meeting materials are sent out at least one week prior to the meeting via email. I 
will include questions to prompt feedback. All members will review the material 
ahead of time and provide feedback at the meetings. I will send out a reminder 
email 48-72 hours before the meeting (or phone call, if preferred). 
2. If a member is unable to attend in-person, members may join the meeting through 
telephone or video-chat. Members may also submit their feedback and edits prior 
to the meeting if they cannot attend. Members can still contribute even if they are 
unable to attend all 4 meetings. 
3. All community members are paid $30 grocery gift cards for attending each 
meeting, for up to $120 total. Community members are defined as older African 
Americans, people diagnosed with memory loss, and current/former caregivers of 
people diagnosed with memory loss.  
 
Meeting Expectations: 
1. I will write up the meeting materials in a brief, clear manner. Exceptions may 
include the interview questions.  
2. If a member requests it, I will meet or chat with anyone ahead of the meeting to 
review materials and obtain their feedback. 
3. There will be 2 note-takers and time-keepers for each meeting, one for each half. 
4. At the beginning of every meeting, I will review the expectations and ask if there 
are motions to clarify or modify them.  
5. All attending members will give feedback. If changes are being made, all 
members need to be okay with the changes taking place. This doesn’t mean they 
have to love the decision, but rather than they are okay with it enough for it to 
move forward. I will ultimately make the final decision to include each change in 
the final materials.  
6. At the end of each discussion, the CAB will wait 1 minute for thought-processing 
or to make a final comment/suggestion before moving on to the next agenda item. 
7. The CAB will take breaks as needed. Any other accommodations requested by 
CAB members will be included in the CAB procedures.  







Meeting dates are based first on the availability of community members, followed by 
Dawn Richardson, Ph.D.(PhD advisor) availability, then a Doodle poll majority vote. 
 
Date and time Meeting Agenda Notes 
March 4, 2019 2-
4pm (2 hrs) 
 Introductions and overview of 
CAB 
 Review Phase 1 recruitment 
material and interview questions 
 
July 2019 (1 hr)  Interpret Phase 1 findings These two meetings can be 
combined if the CAB 
prefers to do so. 
July/August 2019 
(1 hr) 
 Review Phase 2 recruitment 
material and interview questions 
November 2019 
(2 hrs) 
 Interpret Phase 2 findings 
 Develop strategy to share 
findings with community 
members 









APPENDIX B: FIRST CAB MEETING AGENDA AND NOTES 
 
First CAB Meeting, February 4, 2019, Agenda: 
Time Agenda Item Objective 
2:00-2:10 Arrival & grab food  Get settled in 
2:10-2:20 Welcome  Describe the reasons for this CAB 
2:20-2:40 Group intro  Learn each other’s name, expertise, 
reason for joining CAB 
2:40-2:55 Expectations  Discuss CAB membership and meeting 
expectations 
 Name our CAB  
5 minute break 
3-3:24 Discuss Recruitment 
Materials 
 Enhance the recruitment list and 
materials for Phase 1 interviewees to 
send out 
1 minute for thought processing 
3:25-3:49 Discuss Interview 
Questions 
 Improve Phase 1 interview questions 
1 minute for thought processing 
3:50-4:00 Debrief  Find out what worked well in this 
meeting and communication  
 Find out what could be improved upon  
 
Note-taker 1:     Time-keeper 1: 






Bouranis Community Advisory Board- First Meeting 
Monday, February 4th, 2019, 2pm-4pm at New Seasons Market 
In attendance: [Redacted] 
Not in attendance: [Redacted] 
**********************************************************************  
 Nicole introduced herself and the subject of her dissertation 
 Find out why people either choose to or choose not to participate in research 
 She will develop recommendations to improve research participation rates 
 She will share findings from study with community members in Portland 
 Nicole represents community engaged research and that’s why she is bringing 
together people directly affected by A&D 
 She is also focused on including underrepresented groups 
Attendees: 
 [Redacted]- living with dementia.  Joined advisory board, because her husband is 
always hoping to find something new.  She’s hoping to learn something from it.   
 [Redacted]- his wife is living with dementia.  He states he’s in denial about the 
diagnosis.  Has been experiencing another family who has a dx of ALS, and in 
interacting with other caregiver support groups and doesn’t hear a lot of hope.  
Would like to find ways to help so there can be hope for caregivers. Experiencing 
frustration and depression. 
 [Redacted]- Has been involved in research about 20 years with various academic 
institutions.  His wife got sick about four years ago and he is caring for her.  
Recruits for research and wasn’t sure why he was getting so many no’s.  Has a dx 
of Parkinson’s disease.   
 [Redacted]- Program director for Alzheimer’s Association.  Invited to the group 
as an advocate for people living with AD and other dementias.   
 [Redacted]- Cared for his mother , she passed away from dementia 6 years ago.  
He began attending a support group in Tigard while caring for her, and now 
facilitates two support groups. He volunteers for the Alzheimer’s association on 
both the care and support and fundraising side.  He is currently involved in two 
clinical studies.  He is part of research because he wants to help find a cure.   
 [Redacted]- Found out about the program because they are part of an in home 
monitoring program.  She is hoping to gather more skills as a caregiver.  She 
expressed that it’s hard for her to wrap her head around the changes with her 
husband, and it’s frustrating that he isn’t who he used to be anymore.  She wants 
to help with research.  She and her husband have explored alternative treatments 
for dementia, including coconut oil. 
 [Redacted]- Living with Dementia.  He and Jerry have been married for 50 years. 
Talked about how music is helpful.  Phil’s wife brought him to the meeting.  Has 





 [Redacted]- Research assistant at the Layton center. Serves on the PreSERVE 
coalition with Nicole. Joined the advisory board because she is interested in 
Nicole’s work and how to bring more people to research.   
 [Redacted]-  Nicole’s PhD advisor, was not able to be here due to a family 
emergency. 
 [Redacted] and [Redacted] are members of the group but weren’t able to be here 
today due to schedules.  They have provided feedback on the materials. 
CAB expectations 
 Nicole will send out meeting materials in advance, members should review and 
write down feedback for the items.   
 Each member of the group will receive a $30 gift card for each meeting attended.   
 There will be note taker and time keeper for each meeting.   
 Nicole asked if each group member would let her know if there is anything that 
would help them to focus/and/or participate in meetings to let her know privately 
or share with the group.   
5 minute break, group to reconvene at 2:47 
 
Action items: 
 Recruitment email:  It was suggested that memory loss be changed to MCI, 
Alzheimer’s or other dementia.  Feedback was given that it was not clear that the 
interview with the caregiver would be separate from the person with dementia 
interview.  Nicole will work on the wording. 
 Recruitment flyer: combine first two sentences about caring for or a person with 
MCI, dementia etc.  Delete sentence with your responses to a list of factors. 
 Reviewed interview list: [Redacted] suggested [Redacted], she’s a PCP with 
house call MD.  Discussed public policy director with Alz Association 
{Redacted].  Harvey suggested someone with Multnomah County Health.  Alz 
Association facilitator.  Heidi to intro Nicole to [Redacted] with Summit.  Harvey 
suggested [Redacted] to represent veterans.   
 Review of interview questions:  [Redacted] asked about the value of clinical 
research question, requested clarification.  [Redacted] brought up clarification of 
early stage dementia for the interviews, since that is clearly outlined in the 
interview questions.  It was suggested that ADRD be spelled out at the beginning 
and then can be abbreviated after, this will be changed.  Nicole will change the 
value of clinical research to how high of a priority is clinical research.  Will fix 
typo in form.   
Debrief of meeting:   
 [Redacted] asked how the meeting location was determined.  Nicole said she 
looked for someplace free, with parking and that would allow her to serve food.  
[Redacted] suggested that earlier in the day would be better for traffic 





scheduled to have two shorter meetings in the summer, but we could combine the 






APPENDIX C: SECOND CAB MEETING AGENDA AND NOTES 
 
Date and time: Tuesday, July 9th 2019, 10am-12pm 
Location: Alzheimer’s Association Portland office  
Time Agenda Item Objective 
10:00-10:10 Arrival & grab food  Get settled in 
10:10-10:25 Introductions and 
Expectations 
 Introductions and review CAB 
expectations 
10:25-11:05 Interpret Phase 1 
findings 
 Identify what’s most important, 
surprising, and missing 
5 minute break 
11:10-11:29 Discuss Recruitment 
Materials 
 Enhance the recruitment list and phone 
script for Phase 2 interviewees 
1 minute for thought processing 
11:30-11:50 Discuss Interview 
Questions and materials 
 Improve Phase 2 interview questions 
(includes list of factors affecting 
decision to participate) 
1 minute for thought processing 
11:51-12:00 Debrief  Find out what worked well in this 
meeting and communication  
 Find out what could be improved upon  
 
Note-taker 1:     Time-keeper 1: 






Bouranis Community Advisory Board - Second Meeting 
Friday, Tuesday, July 9th 2019, 10am-12pm at the Alzheimer’s Association  
In attendance: [Redacted] 
Not in attendance: [Redacted] 
************************************************************************
Nicole reviewed expectations for participation in the CAB and clarified the participatory 
process.  
Overview of agenda provided. Introduction of the broad themes found (on posters) 
Nicole sent out summary of the findings. Asked CAB to review and provide reflections 
on the findings she’d emailed out and listed on posters.  
CAB takes time to review findings, distribute post-its, share some initial thoughts: 
- [Redacted]: a lot of work to do moving forward 
- [Redacted]: can’t think of anything not being captured (yet) 
 
Nicole leads discussion and unpacking of post-it/findings review process 
- Role of geriatrician as one of the most important factors- why? 
o [Redacted]: Gerontologist doesn’t know history of patient 
o [Redacted]: Primary care physician referred to geriatrics at VA 
o [Redacted]: Too often the PC has little to no geriatric training so getting to 
a specialist is important  
- Alzheimer Association was important for engagement & connection & resources 
o [Redacted]: Not referred to AA, but here now. Does VA work with AA? 
No one there mentioned it to us.  
o [Redacted]: Was surprised at the extent. Knows it’s a great resources, but  
o [Redacted]: We were referred to AA, went through OHSU (10 years ago) 
and used the resources there 
o [Redacted]: AA has been working w/physicians to educate on the 
importance of early diagnosis and referral, so that families will be 
provided with resources at diagnosis. Re: findings, it could be there is a 
skewed perception here, since the people sampled might be more familiar 
w/AA than others.  
- Policies & Funding Mechanisms (research activities dominated by sponsors) 
o [Redacted]: Surprising 
o [Redacted]: Surprising 
o [Redacted]: Wanted more detail 
o Nicole: Industry funding was found to drive decision making. There are 
policies for increasing diversity in research recruitment.  
o [Redacted]: Policies around research recruitment is very important, as far 
as why or why not people participate 
- Partnerships & Collaboration 
o [Redacted]: Wanted more detail; Finds important 
o [Redacted]: Surprised that community collaboration is something they’re 





o [Redacted]: This whole page could be greens for me 
o [Redacted]: Surprising that people w/ADRD not included- the thought 
process from people w/in this field is surprising 
- Clinical research as a value 
o [Redacted]: Surprising. Thinks this should be such a major priority.  
o [Redacted]: Surprising. 
o [Redacted]: The doctor should be knowing more than I do 
- Perceptions of Clinical Research 
o [Redacted]: Wants more detail 
o [Redacted]: Wants more detail.  
o [Redacted]: Surprising. I should look at home experience. There’s a study 
we’re a part of where the questions make him angry (because he can’t 
answer them).  
o [Redacted]: I have 3 organizations asking the same stupid questions.  
o Nicole: Need to reframe dementia as a public health issue; Comparison to 
cancer and how it’s been reframed. Emphasis on resiliency.  
o [Redacted]: I think it’s important that people get reprogrammed. Because 
it’s less of a thing to be ashamed of- it’s something that happens. This man 
is almost 85 years old, and 90% of the time he’s all there. People don’t 
want to talk about it. But stop-it’s ok. It should be more of a public health 
issue.  
o Nicole: Historical relationship that has damaged the relationship between 
black Americans and the medical community.  
o [Redacted]: Wanted sisters to know they were loved and cared for 




[Redacted]: Convene a meeting with the organizations to have a discussion about this 
project, and see if they’d be willing to work together, with Nicole.  
[Redacted]: How about senior centers? Potlucks, guest speakers- great way to connect 
Nicole: Would either of you be willing to connect me to your senior centers?  
[Redacted]: I know people at Tigard & Tualatin, Wilsonville too.  
[Redacted]: How will you reach people “on the edge” of Alzheimers? Might need a flyer. 
You’ve also got DHS you can work with.  
[Redacted]: - Memory cafes.  
[Redacted]: Memory café directory. And what about Next Door? Have enough people 
posting on Next Door you’d reach a lot of household.  
[Redacted]: Community Action Team. They have a finder on the pulse of where people 
are.  
 
Interview Questions Conversation 






List of Questions Conversation 
Agree/disagree? Options? 
It is a long list of factors- it feels like a lot. 
[Redacted]: use these, but divide in to 3 sections. Make print larger ([Redacted]: yes).  
[Redacted]: It’s all jammed together 
[Redacted]: Some repetitiveness, and some things that are facilitators and others that are 
barriers.  
[Redacted]: It seems like you want to know their thought process, rather than just yes/no 
[Redacted]: Might have implications for paycheck/benefits. A concern that some might 
have. 




[Redacted]: Post-its was a good exercise. Helps to know what you’re needing. 
[Redacted]: We were able to get involved. If your committee understand the concept 
here, we do have productive meetings because we know what you’re working towards.  
[Redacted]: This meeting felt a lot more productive. Felt like good work. My only 






APPENDIX D: THIRD CAB MEETING AGENDA AND NOTES 
 
Third CAB Meeting Agenda: 
Date and time: Friday, Jan 17th, 2020, 11:30am-1:30pm 
Location: Alzheimer’s Association Portland office  
Time Agenda Item Objective 
11:30-11:40 Arrival & grab food  Get settled in 
11:40-11:55 Introductions and 
Expectations 
 Introductions and review CAB 
expectations 
11:55-12:35 Interpret Phase 2 findings  Identify what’s most important, 
surprising, and missing 
5 minute break 
12:40-12:55 Discuss Six 
Recommendations 
 Identify what’s most important, 
surprising, and missing 
1 minute for thought processing 
12:56-1:20 Discuss Dissemination 
event 
 What type of event is best way to share 
findings with community? 
 What else should the event include 
(e.g. food, dancing, activity, etc.) 
 What community resources can be 
shared at event? 
 Other ways to share findings 
1 minute for thought processing 
1:21-1:30 Debrief  Find out what worked well in this 
meeting and communication  
  Future collaborations  
 
Note-taker 1:     Time-keeper 1: 







Bouranis Community Advisory Board - Third Meeting 
Friday, Jan 17, 2020 11:30-1:30 at the Alzheimer’s Association  
Attendees in person: [Redacted] 
Attendees via phone: [Redacted] 
************************************************************************ 
Review of Findings 
Theme 1: Symptom Recognition and Diagnosis 
Subtheme: Symptom recognition 
 [Redacted] thought symptom recognition was important.  A lot of people do not 
have enough knowledge to recognize symptoms.  Some people may be used to 
people doing things for them for their whole life, and it may mask symptoms as 
this seems “normal”.   
 [Redacted] found it surprising that people pass off symptoms as normal aging.  
She felt she noticed symptoms in her husband earlier.    
 [Redacted] found it surprising that symptoms were overlooked often.   
 [Redacted] had noticed that his wife had always made lists to go to the grocery 
store and she always repeated things.  Bonnie went to the neurologist due to 
forgetting students’ name.  Bonnie was diagnosed with younger onset 
Alzheimer’s. After that.   [Redacted] noticed her symptoms before anyone else.  
[Redacted] reports that she is still capable of doing everything she used to do.  It’s 
hard for her when her husband tells her that she has already said something.   
 [Redacted] marked this finding as important and a bit surprising.  He did report 
being in denial with his mom, he knew there was something wrong but didn’t 
think it could be dementia.  Availability of specialists is an issue with receiving 
dx. 
Subtheme: Diagnosis: 
 [Redacted] was surprised that doctors are not as educated as they should be on 
diagnosis.  
 [Redacted] stated that there have been a lot of efforts to educate physicians, and 
this is improving some.  Shared that GP’s are tasked with so much.  We don’t 
have great medical treatments for dementia, and that can be difficult for docs and 
this can be a reason for hesitancy with dx.  Primary care docs may have known 
patients for a long period of time, and may also be in denial.  Competing interests 
i.e. cancer and heart. 
Theme 2: Factors Affecting Ability to Participate 
Subtheme: Knowledge of study opportunities 
 [Redacted] wanted more info on how to find study opportunities.   
 [Redacted] shared that when [Redacted] was referred to go to a neurologist in 
Hillsboro.  [Redacted] was shocked that her meeting was at 9am and was 
supposed to be there 45 min.  They kept her there until 3pm, and she was a 
“mess”.  He went to get a second opinion, and she was diagnosed with MCI.  Dr. 





support.  Wants to be given lifestyle interventions instead of just drugs.  
Caregivers are dying faster than the patients.   
Subtheme: Ineligibility/forced withdrawal from study 
 [Redacted] was surprised about people not being able to be in studies, or studies 
being cancelled.  [Redacted] agreed. 
Subtheme: Time/Distance 
Subtheme: Caregiver Burden 
 [Redacted] asked about the Caregiver burden, and participant burden.  [Redacted] 
reported as a clinically normal study participant that he does feel the participant 
burden. He feels strongly that it is important to participate.   
Subtheme: Using the internet 
 
Theme 3: Motivation to Participate in Research 
Subtheme: Motivation to help others 
 [Redacted] found this important 
Subtheme: Living life to the fullest 
 [Redacted] would like to see something positive come out of research. 
 [Redacted] noted this was very important.  It resonated with her, as she has 
worked with a lot of study participants. 
Subtheme: Taking study drugs 
 [Redacted] said it was important because people are being asked to take drugs that 
have not been fully tested and do not understand side effects. 
 [Redacted] found it surprising and wondered about distrust of medical 
community.   
 [Redacted] expressed distrust of pharmaceutical industry.   
 [Redacted] talked about having a range of trials available lowest to highest risk.   
 [Redacted] shared that many commercials are pharmaceutical in nature, and side 
effects are worse than the disease.  The first thing the neurologist did was to 
prescribe medications.  Would rather have [Redacted] be happy then be drugged. 
 [Redacted] asked if dementia is genetic.  Nicole and [Redacted] shared that it can 
be. [Redacted] shared that there are also environmental and lifestyle concerns as 
well. 
 [Redacted] reported that African Americans have historicaly been taken 
advantage of in studies.   
Subtheme: Caregiver Support 
 [Redacted] said this is more disappointing than surprising. 
Subtheme: Advisory board participation 







1. Identify and promote local champions for ADRD clinical research participation 
2. Promote policies and processes that incentivze collaboration between 
organizations 
3. Recognize caregivers as full research participants 
4. Include people with ADRD and caregivers in the research design process 
5. Offer alternative options to reduce participation burden 
 [Redacted] noted it would be helpful if research staff can go to the local clinics, in 
a setting where they would feel more comfortable 
6. Evaluate and improve relationships between healthcare/research staff and 
patients/participants 
 [Redacted] brought up pharmacist education 
Sharing These Findings with the Community 
 Set up a booth at already-established community events (they don’t need to be 
specific to dementia) to share information about dementia research that people 
with dementia and caregivers that may already be attending those events 
 [Redacted] noted Talk and Tastes 
 Presentations at McGinty conference 
 People probably would not come out for a presentation that is just on this topic. 
 Future articles, presentations, writings- some CAB members would be interested 






APPENDIX E: RECRUITMENT EMAIL 
 
Hi there. 
My name is Nicole Bouranis. I’m a doctoral student at the Oregon Heath & Science 
University-Portland State University School of Public Health. I’m interested in clinical 
research for memory loss disorders. Specifically, I want to know all of the reasons why 
people diagnosed with MCI, Alzheimer’s disease, or another related dementia do or 
don’t participate in clinical research. For my dissertation, I’m planning to interview 
people who are experts on living with memory loss or caring for a family member or 
friend diagnosed with memory loss. This email is an invitation to you to participate in the 
study. 
 
Who do I want to interview? People who have been diagnosed with memory loss and 
their primary caregivers (friend or family member).   
 
What would we talk about? We would talk about the following topics: 
 When signs or symptoms of memory loss were first noticed, and the diagnosis 
experience. 
 Why people diagnosed with memory loss are or aren’t motivated to participate in 
clinical research. 
 What makes it easier or more difficult to participate in clinical research. 
How long will this interview last and where would it take place? You and your 
friend/family member would be interviewed separately. Each interview would last 
between 30-60 minutes and take place in the home of the person with memory loss (or 
another preferred location).  
 
Will I get paid for this? Yes! You and your friend/family member will each receive a 
$20 gift card to a preferred retailer. 
 
This sounds great! How can I get involved? If you are interested in learning more 
about the study or being interviewed, please contact me at Bour4@pdx.edu or XXX-
XXX-XXXX. If you are not interested, please also let me know so that I will not continue 
to contact you. 
 


































APPENDIX G: SCREENING PHONE SCRIPT  
 
Hello, is this xxxx or xxxx? 
If wrong number, thank them and hang up. 
If yes, Hi xxxx, this is Nicole Bouranis. I’m calling because you emailed [me]/[key 
informant]/ [other recruiter] about a study I’m working on, and said you might be 
interested in participating. Is that correct? 
If no, thank them and hang up.  
If yes, Is now a good time to talk? 
If no, ask when is a good time to call back, and schedule time to call back. Provide them 
contact information. 
If yes, Great. So to give you background on the study, I am a doctoral student at the 
Oregon Health and Science University - Portland State University School of Public 
Health. My research looks at the different types of factors that affect a person with 
memory loss’s ability and motivation to participate in clinical research. We hope to better 
understand what helps or gets in the way of a person’s decision to enroll in a clinical 
research study by interviewing both people who have been diagnosed with memory loss 
and their friend or family member who acts as their primary caregiver. The interview will 
ask some questions about memory loss and about clinical research.  
Through these interviews, we hope to improve access and motivation to participate, 
increase enrollment, and find a cure, treatment, or prevention for memory loss diseases 
such as mild cognitive impairment, Alzheimer’s disease and related dementias. 
Interviews should last about 90 minutes total and will be audio-recorded. The recording 
of the interview will be erased once it has been written up, and your name will not appear 
in any written documentation or any other places where the study results are shared. To 
thank you for your time, both you and your friend/family member will each receive a $20 
gift card to your preferred retailer.  
Are you still interested?  
If no, thank them and hang up. 
If yes, Great. I’d like to continue by asking you some eligibility questions. This will just 
take a few minutes. 
First, have you or your friend/family member been given a diagnosis by a doctor or other 





dementia, such as Lewy-body dementia, frontotemporal dementia (FTD), vascular 
dementia, or mixed dementia? 
If the person responds with any form of ADRD: Are you or your friend/family member 
considered to be in the early or moderate stages as per your/their last provider visit within 
the last six months? 
Second, do you and your friend/family member speak fluent English? 
Third, are you and your friend/family member able to engage in a conversation about 
your experiences with being diagnosed with [diagnosis], living with [diagnosis], and your 
perceived values about clinical research? 
Finally, will you and your friend/family member both be able to individually sign a 
consent form? 
If no to any of these questions: Unfortunately, it looks like you do not meet the eligibility 
criteria for this study. Thanks for your interest. If you know anyone who would meet the 
criteria and think they might be interested in participating, please give them my 
information and tell them to reach out to me. 
If yes, Wonderful, you and your friend/family member meet all the criteria for 
participating in the interview. One last question: have you/your friend/family member 
participated in clinical research related to memory loss previously? 
Set up a time and location for the interview. 
I’m going to send you and your friend/family member the consent forms ahead of the 
interview for your review. Do you prefer email or regular mail? What are your 
addresses/email addresses?  
Great, I’ll see you on DATE at LOCATION. I’ll call you the day before to remind you. If 
you need to postpone or cancel, please call me at XXX-XXX-XXXX or email me at 






APPENDIX H: KEY INFORMANT CONSENT FORM 
 
Portland State University 
Consent to Participate in Research 
Multi-level factors affecting clinical research enrollment among people with 
Alzheimer’s disease or related dementias (ADRD) 
Study By: Nicole Bouranis, MA, Doctoral Student, Bour4@pdx.edu 
Principal Investigator: Dr. Sherril Gelmon, Dissertation Committee Chair, 
gelmons@pdx.edu 
What is this form for?  
We invite you to participate in a research study being conducted by Nicole Bouranis, a 
doctoral student at the School of Public Health at Oregon Health & Science University 
and Portland State University. This form will explain the research study and the possible 
risks and benefits to you if you decide to participate. If you have any questions, please 
ask Nicole Bouranis. 
Why am I being asked to participate?  
You are a clinician who treats people with ADRD, an investigator or research assistant 
for ADRD clinical research, or an advocate for people with ADRD.  
What is this study about?  
This study looks at the different types of factors that affect a person with MCI, 
Alzheimer’s disease or a related dementia’s ability and motivation to participate in 
clinical research. We hope to better understand what helps or gets in the way of a 
person’s decision to enroll in a clinical research study. By doing so, we hope to improve 
access and motivation to participate, increase enrollment, and find a cure, treatment, or 
prevention for Alzheimer’s disease and related dementias. 
What will happen if I decide to participate?  
If you agree to be in the study, you will participate in an interview with Nicole Bouranis. 
This interview will take place on [DATE]. During this interview you will talk about:  
 Your and your organization’s engagement with people with ADRD. 
 Policies and funding mechanisms that affect your engagement with people 
with ADRD. 
 Partnerships that engage with or relate to people with ADRD. 





 Your perceptions of what makes it easier or more difficult to recruit people 
with ADRD into clinical research. 
The interview will be audio-taped. 
You do not have to answer any questions that you do not want to. You can end the 
interview and your participation in this study at any time. 
How long will this study take?  
This interview will last about one hour. 
What are the risks of being in this study?  
It is very unlikely that participating in this study could cause you harm as the questions 
discussed relate to organizational and policy elements, not personal experiences. There is 
also a risk of loss of privacy if the researcher fails to follow the strict rules about 
confidential information, but there are many safeguards in place to prevent this. For more 
information about risks and discomforts, please ask Nicole Bouranis. 
What are the benefits to being in this study?  
Participating in the interview may or may not be helpful to you. However, your answers 
may help make it easier to improve access for people with MCI or ADRD to participate 
in clinical research in the future.  
How will my information and data be kept private or confidential?  
When the project is complete, there will be a report of the results.  Your name or 
information that might identify you will not be in the report.  Everyone involved in the 
study will be trained to keep your information private. The recording of the interview will 
be erased once it has been written up, and your name will not appear in any written 
documentation or any other places where the study results are shared. Information from 
this study will be kept on a password-protected computer.  
Will I be paid for taking part in this study?   
No.  
Can I stop being in the study once I begin?  
You do not have to be in this research study. You have the right to change your mind 
about being in the study at any time. Your participation in this study will help researchers 
find ways to improve participation in clinical research for MCI and ADRD. 





If you have any questions, concerns, or complaints at any time about the research study, 
please contact Nicole Bouranis at XXX-XXX-XXXX or Bour4@pdx.edu. 
Who can I contact with questions about my rights as a research participant?  
If you have questions regarding your rights as a research participant, you may contact the 
Portland State University (PSU) Office for Research Integrity at (503) 725-2227 or 1 
(877) 480-4400 or email hsrrc@pdx.edu. The ORI is the office that supports the PSU 
Institutional Review Board (IRB). 
CONSENT 
You are making a decision about whether to participate in this study. By signing below, 
you indicate that you have read the information in this form, have had an opportunity to 
ask any questions and have them answered, and are agreeing to participate in the study. A 
copy of this consent form will be given to you, if you request it. 
Your signature below indicates that you have read the information provided (or the 
information was read to you). By signing this consent form, you are not waiving any of 
your legal rights as a research participant.  
____________________________ ____________________________ ___________  




This research study has been explained to the participant and all of his/her questions have 
been answered. The participant understands the information described in this consent 
form and freely consents to participate.  
_________________________________________________  
Name of Investigator/ Research Team Member (type or print)  
_________________________________________________ ___________________ 








APPENDIX I: CAREGIVER CONSENT FORM 
 
Portland State University 
Consent to Participate in Research 
Multi-level factors affecting clinical research enrollment among people with 
Alzheimer’s disease or related dementias (ADRD) 
Study By: Nicole Bouranis, MA, Doctoral Student, Bour4@pdx.edu 
Principal Investigator: Dr. Sherril Gelmon, Dissertation Committee Chair, 
gelmons@pdx.edu 
What is this form for?  
We invite you to participate in a research study being conducted by Nicole Bouranis, a 
doctoral student at the School of Public Health at Oregon Health & Science University 
and Portland State University. This form will explain the research study and the possible 
risks and benefits to you if you decide to participate. If you have any questions, please 
ask Nicole Bouranis. 
Why am I being asked to participate?  
You are a person who is a primary caregiver of someone who has been diagnosed with 
MCI, Alzheimer’s disease, or a related dementia. ADRD research requires the subject to 
have a study partner to attend appointments and make sure the person with ADRD 
adheres to study protocols. This means that your ability and motivation to participate in a 
clinical research is just as necessary as the person with MCI or ADRD. 
What is this study about?  
This study looks at the different types of factors that affect the ability and motivation to 
participate in clinical research pf a person with MCI, Alzheimer’s disease or a related 
dementia. We hope to better understand what helps or gets in the way of a person’s 
decision to enroll in a clinical research study. By doing so, we hope to improve access 
and motivation to participate, increase enrollment, and find a cure, treatment, or 
prevention for Alzheimer’s disease and related dementias. 
What will happen if I decide to participate?  
If you agree to be in the study, you will participate in an interview with Nicole Bouranis. 
Your friend or family member will also be interviewed. If they wish, you may sit in on 
their interview, but it is important that all questions in that interview are answered by the 
person with MCI/ADRD. This interview will take place on [DATE]. During this 





 When you noticed signs or symptoms of MCI/ADRD and when your friend or 
family member received an ADRD diagnosis. 
 Why you are or aren’t motivated to participate in clinical research. 
 What makes it easier or more difficult to participate in clinical research. 
 Your responses to a list of factors that make it easier or more difficult to 
participate in clinical research that was created by providers, researchers ,and 
advocates. 
The interview will be audio-taped. 
You do not have to answer any questions that you don’t want to. You can end the 
interview and your participation in this study at any time. 
How long will this study take?  
The two interviews should take no more than 90 minutes, with your interview lasting 
about a half hour, followed by your friend or family member’s interview, which will last 
up to one hour. 
What are the risks of being in this study?  
It is very unlikely that participating in this study could cause you harm. However, it is 
possible that some questions or comments may bring up memories of difficult 
experiences with the health care system or a research organization. There is also a risk of 
loss of privacy if a researcher failed to follow the strict rules about confidential 
information, but there are safeguards in place to avoid this. For more information about 
risks and discomforts, please ask Nicole Bouranis. 
What are the benefits to being in this study?  
Participating in the interview may or may not be helpful to you. However, your answers 
may help make it easier to improve access for people with MCI or ADRD to participate 
in clinical research in the future.  
How will my information and data be kept private or confidential?  
When the project is complete, there will be a report of the results.  Your name or 
information that might identify you will not be in the report.  Everyone involved in the 
study will be trained to keep your information private. The recording of the interview will 
be erased once it has been written up, and your name will not appear in any written 
documentation or any other places where the study results are shared. Information from 
this study will be kept on a password-protected computer.  
Will I be paid for taking part in this study?   
Both you and your friend or family member will receive a $25 gift card to your preferred 
grocery retailer at the end of the interview.  





You do not have to be in this research study. You have the right to change your mind 
about being in the study at any time. If you decide not to participate, you will still receive 
the $25 grocery gift card.  Your participation in this study will help researchers find ways 






Who can I contact with questions or complaints about this study?  
If you have any questions, concerns, or complaints at any time about the research study, 
please contact Nicole Bouranis at XXX-XXX-XXXX or Bour4@pdx.edu. 
Who can I contact with questions about my rights as a research participant?  
If you have questions regarding your rights as a research participant, you may contact the 
Portland State University (PSU) Office for Research Integrity at (503) 725-2227 or 1 
(877) 480-4400 or email hsrrc@pdx.edu. The ORI is the office that supports the PSU 
Institutional Review Board (IRB). 
CONSENT 
You are making a decision about whether to participate in this study. By signing below, 
you indicate that you have read the information in this form, have had an opportunity to 
ask any questions and have them answered, and are agreeing to participate in the study. A 
copy of this consent form will be given to you, if you request it. 
Your signature below indicates that you have read the information provided (or the 
information was read to you). By signing this consent form, you are not waiving any of 
your legal rights as a research participant.  
____________________________ ____________________________ ___________  
Name of Adult Subject (print) Signature of Adult Subject Date 
 
INVESTIGATOR SIGNATURE 
This research study has been explained to the participant and all of his/her questions have 
been answered. The participant understands the information described in this consent 
form and freely consents to participate.  
_________________________________________________  
Name of Investigator/ Research Team Member (type or print)  
_________________________________________________ ___________________ 






APPENDIX J: PERSON WITH ADRD CONSENT FORM  
 
Portland State University 
Consent to Participate in Research 
Multi-level factors affecting clinical research enrollment among people with 
Alzheimer’s disease or related dementias (ADRD) 
Study By: Nicole Bouranis, MA, Doctoral Student, Bour4@pdx.edu 
Principal Investigator: Dr. Sherril Gelmon, Dissertation Committee Chair, 
gelmons@pdx.edu 
What is this form for?  
We invite you to participate in a research study being conducted by Nicole Bouranis, a 
doctoral student at the School of Public Health at Oregon Health & Science University 
and Portland State University. This form will explain the research study and the possible 
risks and benefits to you if you decide to participate. If you have any questions, please 
ask Nicole Bouranis. 
Why am I being asked to participate?  
You are a person who has been diagnosed with MCI, Alzheimer’s disease, or a related 
dementia. 
What is this study about?  
This study looks at the different types of factors that affect the ability and motivation of a 
person with MCI, Alzheimer’s disease or a related dementia to participate in clinical 
research. We hope to better understand what helps or gets in the way of a person’s 
decision to enroll in a clinical research study. By doing so, we hope to improve access 
and motivation to participate, increase enrollment, and find a cure, treatment, or 
prevention for Alzheimer’s disease and related dementias. 
What will happen if I decide to participate?  
If you agree to be in the study, you will participate in an interview with Nicole Bouranis. 
Your primary caregiver will also be interviewed. They are welcome to sit in on your 
interview if you wish, but it is important that you are the one answering the questions. 
This interview will take place on [DATE]. During this interview you will talk about:  
 When you noticed signs or symptoms of MCI/ADRD and your ADRD 
diagnosis. 
 Why you are or aren’t motivated to participate in clinical research. 





 Your thoughts on a list of factors that make it easier or more difficult to 
participate in clinical research that was created by providers, researchers, and 
advocates. 
 
The interview will be audio-taped. 
You do not have to answer any questions that you don’t want to. You can end the 
interview and your participation in the study at any time. 
How long will this interview take?  
This interview will take a total of up to 90 minutes. Your primary caregiver will be 
interviewed for up to a half hour. After the interview with your primary caregiver is 
finished, our interview will begin and will last for up to one hour. During your interview, 
you will respond to a list of factors that make it easier or more difficult to participate in 
clinical research. We will discuss your responses to the list during the interview 
What are the risks of being in this study?  
It is very unlikely that participating in this study could cause you harm. However, it is 
possible that some questions or comments may bring up memories of difficult times 
within the health care system or a research organization. There is also a risk of loss of 
privacy if a researcher failed to follow the strict rules about confidential information, but 
there are many safeguards in place to avoid this. For more information about risks and 
discomforts, please ask Nicole Bouranis. 
What are the benefits to being in this study?  
Participating in the interview may or may not be helpful to you. However, your answers 
may help make it easier to improve access for people with MCI or ADRD to participate 
in clinical research in the future.  
How will my information and data be kept private or confidential?  
When the project is complete, there will be a report of the results.  Your name or 
information that might identify you will not be in the report.  Everyone involved in the 
study will be trained to keep your information private. The recording of the interview will 
be erased once it has been written up, and your name will not appear in any written 
documentation or any other places where the study results are shared. Information from 
this study will be kept on a password-protected computer.  
Will I be paid for taking part in this study?  
You and your primary caregiver will each receive a $25 gift card to your preferred 
retailer at the end of the interview.  





You do not have to be in this research study. You have the right to change your mind 
about being in the study at any time. If you decide not to participate, you will still receive 
the $25 grocery gift card.  Your participation in this study will help researchers find ways 






Who can I contact with questions or complaints about this study?  
If you have any questions, concerns, or complaints at any time about the research study, 
please contact Nicole Bouranis at XXX-XXX-XXXX or Bour4@pdx.edu. 
Who can I contact with questions about my rights as a research participant?  
If you have questions regarding your rights as a research participant, you may contact the 
Portland State University (PSU) Office for Research Integrity at (503) 725-2227 or 1 
(877) 480-4400 or email hsrrc@pdx.edu. The ORI is the office that supports the PSU 
Institutional Review Board (IRB). 
CONSENT 
You are making a decision about whether to participate in this study. By signing below, 
you indicate that you have read the information in this form, have had an opportunity to 
ask any questions and have them answered, and are agreeing to participate in the study. A 
copy of this consent form will be given to you, if you request it. 
Your signature below indicates that you have read the information provided (or the 
information was read to you). By signing this consent form, you are not waiving any of 
your legal rights as a research participant.  
____________________________ ____________________________ ___________  
Name of Adult Subject (print) Signature of Adult Subject Date 
 
INVESTIGATOR SIGNATURE 
This research study has been explained to the participant and all of his/her questions have 
been answered. The participant understands the information described in this consent 
form and freely consents to participate.  
_________________________________________________  
Name of Investigator/ Research Team Member (type or print)  
_________________________________________________ ___________________ 










Subject Contact Information: 
 
This study looks at the different types of factors that affect a person with MCI, 
Alzheimer’s disease or a related dementia’s, which I will refer to as ADRD throughout 
this interview, ability and motivation to participate in clinical research. We hope to better 
understand what helps or gets in the way of a person’s decision to enroll in a dementia 
clinical research study. You are a clinician who treats people with ADRD, an investigator 
or research assistant for ADRD clinical research, or an advocate for people with ADRD. 
 
This interview will last approximately one hour. During this interview, we’ll discuss you 
and your organization’s engagement with people with ADRD, policies and funding 
mechanisms that affect your engagement with people with ADRD, partnerships that 
engage with or relate to people with ADRD, how valued clinical research for ADRD is 
within your organization, and your perceptions of what makes it easier or more difficult 
to recruit people with ADRD into clinical research. 
 
You do not have to answer any questions that you don’t want to. You can end the 
interview and your participation in this study at any time. This interview will be 
audiotaped. The recording of the interview will be erased once it has been written up, and 
your name will not appear in any written documentation or any other places where the 
study results are shared. 
 
Do you have any questions before we get started? 
 
Okay, let’s get started. 
1. Describe this organization and your role within it. 
a. Prompt: How does your organization engage people with ADRD? 
2. What policies or funding mechanisms enhance your work? 
3. What policies or funding mechanisms have made it easier or more difficult to 
engage with people with ADRD and/or increase knowledge of research 
opportunities? 
4. What kinds of partnerships are you involved in that relate to people with ADRD? 
Please describe these briefly. 
5. How is this/are these partnership(s) funded? How are stakeholders involved? 
6. Describe your process for informing [recruiting, and enrolling (if organization is a 
research organization)] people with ADRD and their caregivers of research 
opportunities. 
a. Prompt: Has this always been the process? How has that process changed 





7. How high of a priority is clinical research at this organization? 
 
8. What are some factors that you think may facilitate recruitment? 
a. Prompt: examples may include transportation, awareness of opportunities, 
time, etc. 
9. What about factors that impede recruitment? 
a. Prompt: examples may include transportation, awareness of opportunities, 
time, etc. 
10. What are your recommendations for increasing ADRD clinical research 
participation? 
 
Thanks so much for your input; this concludes this interview. As you know, my next 
phase of interviews will be with people diagnosed with MCI or ADRD and their 
caregivers. Would you be willing to help me recruit for these interviews by posting this 
flyer and also sending my recruitment letter to your email list, or specific people that 
would eligible for my interviews? Individuals diagnosed with memory loss need to be 
diagnosed with or in the early stages of MCI or ADRD. They also need to be able to 
speak about their diagnosis experience, living with their diagnosis, and their perceptions 
about clinical research. Lastly, they need to be able to sign a consent form. Both dyad 
members also need to speak fluent English. 
 
Remember, you can follow up with me at XXX-XXX-XXXX or Bour4@pdx.edu. When 
my research is finished, I will contact you again to offer you a summary of my major 








APPENDIX L: CAREGIVER INTERVIEW PROTOCOL  
 
Bouranis Dissertation 
Study ID:  
Participant contact information: 
 
Thank you for participating in my dissertation research. As noted in the consent form, 
this research looks at the different types of factors that affect a person with diagnosed 
memory loss’s ability and motivation to participate in clinical research. You are a 
primary caregiver of someone who has been diagnosed with memory loss. ADRD 
research requires that a person living with MCI, Alzheimer’s disease, or a related 
dementia who participates as a research participant must have a study partner to attend 
appointments with them and make sure they adhere to study protocols. This means that 
your ability and motivation to participate in a clinical research study is just as necessary 
as the person living with MCI or ADRD. 
 
This interview with you will take up to an hour. During the interview, we’ll talk about 
when <person living with ADRD/MCI> was diagnosed, motivations to participate in 
dementia clinical research and factors that make it easier or difficult to participate in 
clinical research. After our interview is over, I’ll interview <person living with 
dementia> for up to an hour. You are welcome to sit in on that interview, but it is 
important that you let <person living with dementia> answer the questions. You can 
provide me with any corrections of facts or clarifications after that interview (by email or 
telephone). 
 
You do not have to answer any questions that you don’t want to. You can end the 
interview and your participation in this study at any time and you and <person living with 
ADRD/MCI> will still each receive the $25 grocery gift card to [PREFERRED 
RETAILER]. This interview will be audio-recorded, and I’ll also jot down notes on my 
clipboard. The recording of the interview will be erased once it has been written up, and 
your name will not appear in any written documentation or any other places where the 
study results are shared.  
 
Do you have any questions before we get started? 
 
Okay, let’s get started. 
 
1. When did you first notice signs of MCI/dementia in <person living with 
ADRD/MCI>? 
2. When did they receive a diagnosis? 





a. Prompt for those who don’t have an answer: Would you describe it as) any 
medical research involving people; b) research that involves drugs or 
medical procedures; or c) research that tests if one drug, device, or 
medical procedure works better than another one? 
b. Have you ever heard of clinical research opportunities? What about 
clinical research for dementia? 
c. What do you think about clinical research? 
4. In our previous conversation, you mentioned that you and <person living with 
dementia> have/have not participated in dementia clinical research. What made 
you decide to participate/not participate? 
a. Prompt FOR THOSE WHO HAVE PARTICIPATED: what was your 
experience like? Would you participate again? 
b. Prompt for all: did you attempt to join other studies but were considered 
ineligible? What happened? 
5. Are there any barriers that made or make it more difficult for you to participate? 
a. Prompt: What were they? 
6. Was there anything that made or would make it easier for you to participate? 
a. Prompt: what would it be? 
7. What makes you not want to participate? 
8. If you could tell research organizations anything to improve research 
participation, what would it be? 
9. I’m going to show you a list of factors that make it easier or more difficult to 
participate in clinical research for dementia. This list was created by local 
providers, researchers, and advocates. Please tell me if you agree or disagree with 
any of these factors and why. 
 
Thanks so much for your input. That concludes this interview, and we’ll get <person 
living with dementia> to begin their interview. Remember, you can follow up with me at 
XXX-XXX-XXXX or Bour4@pdx.edu. When my research is finished, I will contact you 





APPENDIX M: PERSON WITH ADRD INTERVIEW PROTOCOL  
 
Bouranis Dissertation 
Study ID:  
Subject contact information: 
 
Thank you for participating in my dissertation research. As noted in the consent form, 
this research looks at the different types of factors that affect a person diagnosed with 
memory loss’s ability and motivation to participate in clinical research.  
 
This interview will take about an hour. During the interview, we’ll talk about when you 
were diagnosed, motivations to participate in dementia clinical research and factors that 
make it easier or difficult to participate in clinical research. We’ll also discuss your 
answers to the form on factors that make it easier or difficult to participate in research.  
 
You may choose to have <caregiver> with us for this interview, or choose to have them 
not here. If you choose to have them here, it’s important that you’re answering the 
questions, not <caregiver>. The caregiver already answered these questions in their 
interview, and we want to learn about this from your perspective. 
 
You do not have to answer any questions that you don’t want to. You can end the 
interview and your participation in this study at any time and you and <caregiver> will 
still each receive the $20 gift card to [PREFERRED RETAILER]. This interview will be 
audio-recorded, and I’ll also jot down notes on my clipboard. The recording of the 
interview will be erased once it has been written up, and your name will not appear in any 
written documentation or any other places where the study results are shared.  
 
Do you have any questions before we get started? 
Okay, let’s get started. 
1. When did you first notice signs of MCI/ADRD? 
2. When did you receive a diagnosis? 
3. Please describe in your own words what “clinical research” is. 
4. Have you ever been aware of clinical research opportunities? How so? 
a. What about dementia research opportunities? 
5. What do you think about clinical research? 
6. In our previous conversation, you have mentioned that you have/have not 
participated in dementia clinical research. What made you decide to 
participate/not participate? 
a. Prompt FOR THOSE WHO HAVE PARTICIPATED: what was your 
experience like? Would you participate again? 
7. Are there any barriers that made or make it more difficult for you to participate? 





8. Was there anything that made or would make it easier for you to participate? 
a. Prompt: what would it be? 
9. What makes you not want to participate? 
10. Let’s review this form you filled out. This list was created by local providers, 
researchers, and advocates, about factors that make it easier or more difficult to 
participate in clinical research for dementia.  
a. Prompt for each factor: For <factor 1, 2, etc.>, you said you 
<agree/disagree, and …>. Why is that? Is there anything else you’d like to 
add? 
11. If you could tell research organizations anything to improve dementia research 
participation, what would it be? 
 
Okay, that concludes our interview. Thanks so much for your input. Remember, you can 
follow-up with me at XXX-XXX-XXXX or Bour4@pdx.edu. When my research is 







APPENDIX N: LIST OF FACTORS  
 
Bouranis Dissertation      Date: 
Study participant ID (for researcher use only, please don’t fill out): ____ 
 
Directions: Please indicate your level of agreement with each of the following factors 
regarding how they affect one’s decision to join dementia clinical research studies. 
Please circle your answer for each statement. If you have additional comments, 
please write them in the spaces provided on each page. 
 
Factors that Affect the Ability to Join Research 
1. Learning about research opportunities from one’s 
provider. 
Agree Disagree Don’t 
Know 
2. Learning about research opportunities from a 
presentation or from a trusted community leader, 
organization, or group (e.g. senior or cultural center, 
support group, clergy). 
Agree Disagree Don’t 
Know 
3. Learning about research opportunities from flyers, 
newspapers, radio, tv, or social media. 
Agree Disagree Don’t 
Know 
4. If one’s caregiver is interested and able to 
participate. 
Agree Disagree Don’t 
Know 
5. The study staff is willing to be flexible for the 
caregiver’s schedule. 
Agree Disagree Don’t 
Know 
6. Being told about other study opportunities if not 
eligible for an initial study. 
Agree Disagree Don’t 
Know 
7. Options that make it easier to participate (e.g. ride to 
the study site, no site visits). 
Agree Disagree Don’t 
Know 
8. Not receiving a timely and accurate dementia 
diagnosis from one’s healthcare provider. 
Agree Disagree Don’t 
Know 
Please write any additional comments here. 
 
9. The time one needs to spend being in the study. Agree Disagree Don’t 
Know 
10. The distance or inconvenience of traveling for study 
activities. 
Agree Disagree Don’t 
Know 
11. Eligibility criteria that exclude someone from joining 
research (e.g. age, memory scores, history of disease, 
medications, distance from study site). 
Agree Disagree Don’t 
Know 
 
12. Finding out the study won’t start for a long time after 
initially hearing about it. 
Agree Disagree Don’t 
Know 







Factors that Affect Motivation to Join Research 
13. The hope that research will help the person with 
dementia, their family, or society. 
Agree Disagree Don’t 
Know 
14. Being able to contribute to science. Agree Disagree Don’t 
Know 
15. Whether the study builds trust and benefits one’s 
community. 
Agree Disagree Don’t 
Know 
16. The fear of being identified as a person with 
dementia. 
 
Agree Disagree Don’t 
Know 
17. The fear that the study intervention may negatively 
affect one’s behavior or physical abilities. 
Agree Disagree Don’t 
Know 
18. Receiving information about one’s health (e.g. test 
scores, results from scans) or resources (e.g. 
education, support groups). 
Agree Disagree Don’t 
Know 
 
19. Being able to try a new medication. Agree Disagree Don’t 
Know 
20. Receiving regular updates about the study. 
 
Agree Disagree Don’t 
Know 
21. Public awareness/opinions about dementia and 
dementia clinical research. 
Agree Disagree Don’t 
Know 
22. Ability to socialize within research. Agree Disagree Don’t 
Know 
23. The fear that nothing can be done even if one does 
participate. 
Agree Disagree Don’t 
Know 
Please write any additional comments here. 
 
24. Being paid an adequate amount to participate in the 
study (and without affecting benefits). 
Agree Disagree Don’t 
Know 
25. Study recruitment materials (e.g. flyers) that feature 
people who look like the person with dementia. 
Agree Disagree Don’t 
Know 
26. Study staff that look like the person with dementia 
and have a shared socio-historical background or 
other shared connection. 
Agree Disagree Don’t 
Know 
 
27. Being a part of an advisory board that collaborates 
on research. 






28. The relationship or connection between an 
individual and the research staff/research 
organization. 
Agree Disagree Don’t 
Know 
29. Whether the study seems invasive or risky. 
 
Agree Disagree Don’t 
Know 
Please write any additional comments here. 
 
Thank you for your responses! By completing this survey, you are helping researchers 
understand what helps or gets in the way of the decisions made by a person living with 
memory loss to participate (or not) in clinical research.  
